<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31d934e0-04a7-4490-98c0-c83e476eddae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67e2d4f2-164a-4eeb-9c68-86cc2286dd0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e">
        <rdfs:label>Muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <dc:identifier>ECO:0000352</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afaa283f-a1b9-454a-a2a2-6e27db4d9ca9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/253c535d-4b96-41d3-990c-afd5506515b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bfbdd410-9b95-44a9-9184-c217dba0f235"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06c3ce65-a652-4cb4-8990-beb31e18e69b"/>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/103a49db-7117-4995-b5b8-55e7b3a99875"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4020263-978b-425f-aeae-e9a4d277a5fa"/>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/4cbe4c1d-48c6-4b12-bfda-c5c2edaa9acf">
        <rdfs:label>functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e175aa89-e8df-43bd-86fa-1e989d3e3efc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/07bb018f-555b-4e3f-b6fd-b6079c0dce12">
        <rdfs:label>POMT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>Q9Y6A1</ddiem:uniprotId>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26527668-185d-47ba-89e1-25095c2ef077">
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f5429c57-5fc2-43bf-8864-104b0d6dac7e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62db8a40-e084-48ef-b2b4-26fdd08fdd2d">
    <rdfs:label>Methionine synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bcde477c-417a-489c-8abe-9ba050afcf1a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ec4461d-d33d-4562-a3d6-5fba1062ce0b">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/8cfc7fc8-6301-4c4a-ac30-4f6ffee4a0f2">
        <rdfs:label>direct complementation of genetically defective protein+Functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4b6ff9cc-439c-4ab9-bfda-65b06b2b78d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9f50efc-ba20-4dd8-9086-38efdafbf9ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/139a1e75-c416-4270-9102-959fc49a80c8"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48d1e9c7-59e7-4ec0-883f-d036d1930a33"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f33ea64-113e-4a99-b686-49f05a122b36">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short stature</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ddb82f9-7c3c-4f2c-9b45-ca3d69545659">
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <rdfs:label>system B(0) neutral amino acid transporter 1 (B0AT1)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f5d20cff-0ba5-42e9-b3ad-096a777f9c75">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29a74817-368a-49ca-aa0c-28cba2406df1">
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2478c7d2-a3ac-44bb-bbc7-81ddf6e5ed88">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
        <rdfs:label>B3GALNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/114f377e-943d-4c53-8c61-f832d895a38a">
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <rdfs:label>Arginase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc72acb5-0b9f-4849-96e4-5422e94652cc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
        <rdfs:label>ARG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b57750b1-2817-410c-8ed4-162ead4a3dcb">
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <rdfs:label>codanin 1</rdfs:label>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a7889b5-a4a3-439b-b9aa-9e732e1f9ee4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
        <rdfs:label>CDAN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/813759e4-49b4-478c-a9fc-37607e8003d5">
    <rdfs:label>fukutin</rdfs:label>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4702c99-d408-463d-bc5c-c76bcd92237b">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31abcda6-bc22-4dff-b686-08fc70acc2fb">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4cbe4c1d-48c6-4b12-bfda-c5c2edaa9acf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e2f71d0-714d-48bd-8c07-5876dd108044">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/19bc2698-af79-407b-a5cc-653688ec3892"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b51a62c-465d-4612-a3e6-ca845d26cb36">
        <rdfs:label>Metabolic acidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4503c91-ea76-44e7-aa72-58326969c54f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad227345-6a1a-4177-a5aa-6a178f0240e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f19ecf7f-2c89-4a19-8ee0-47d65356babf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Disease progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd23b81e-b258-47ef-b95f-23f506b0e476"/>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f013014a-8616-4c1f-9584-9499623c805e">
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/488cd051-3368-4c7f-87a1-9b1110471210">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5528a879-8b7e-4421-8759-3deec2110390">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
        <rdfs:label>CTNS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/17aceb2b-b79b-4e17-8bb3-53bb02d5726c">
    <rdfs:label>apolipoprotein A5</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a072515-87eb-46a0-9359-7ff642ed32a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
        <rdfs:label>APOA5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7f1a3cc-89e4-40b2-b0f9-96740676deec">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41343e19-dd90-4584-92ec-6d78884cc995">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b023d55-0cc2-48b7-9b99-5f59d9af1fb7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faebf3e5-8f5b-40ee-9c8a-dab43b76fe47">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c">
        <rdfs:label>symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ace1f428-c7e4-4434-9654-a5a70450a0e6"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/909cc698-086f-41b3-b302-54ab21e4e997">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8bb7ea06-2bf0-4bfd-82f8-3eeb3511552c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/721c6750-81c5-4d5e-932a-40009b75f4dc">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <dc:identifier>HP:0040088</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/07a3c9b6-365f-4f8d-afcd-c085a5416dca">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>prosaposin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b07325af-a55b-4648-baa0-ae3b79bd2904">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a7dfb66c-eaa0-401e-81d8-757d10a1f88b">
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f9f29776-de29-41f4-8195-1330b317da1d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
        <rdfs:label>GGT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3027635a-eaee-4493-b1e2-212e90ba8666">
    <rdfs:label>NPC2 protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4dbe6d0c-1797-4fb7-8531-f7d821c00196">
        <rdfs:label>NPC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P61916</ddiem:uniprotId>
    <ddiem:keggEntryId>K13443</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a208e46-7590-42ba-8b12-c84ac9fd83f9">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c">
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Oxidative stress</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b8149b5-2cdc-4fcd-a2d8-3c3366b1a402"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab48bf03-390c-4c12-b208-05053ce81c26"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7957fd2f-aed3-44b5-93dd-ad964872d51e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/db4a085b-87b4-472e-a2a9-971fe856e268"/>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/1a191c16-06c0-42c8-91a1-61eaba1287f7">
        <rdfs:label>functional complementation of a genetically defective protein+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a34b8ffd-efc7-4a04-b24b-174b96967d14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c581726-9efd-4872-8329-563b2cf10fa5">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0025065</dc:identifier>
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22b2288a-57bf-4a24-a50c-b8864895a170">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca514538-9b1f-4faa-86d0-5f02a146b3e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb9c8655-be3b-4b10-9eb3-0f7c4492a077">
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
        <dc:identifier>HP:0025546</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3f216bdb-1122-4623-a843-4c68bb04cf6d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b22d4d43-caef-4ca0-b945-e6232f20aaa9">
        <rdfs:label>BCKDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4db48719-1724-4c9c-840a-0840069daa82">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23ffe525-2704-470d-9af6-b8a98d728cba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
        <rdfs:label>AP2S1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0cab2ddf-483b-4b94-a56d-036d783df576">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa9b0772-96fa-4922-9fa5-188e2429af41">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
        <rdfs:label>MCCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0facffe8-c278-4739-81b9-5ba02e699a30">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
        <rdfs:label>MCCC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/233206a4-6641-43cb-9e66-e610f9ea6baa">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a">
        <rdfs:label>functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe53ace1-7bd1-4e73-809b-ed684e7f6fd8"/>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e54b7bd-f844-468a-91cc-a3ccb414260b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/099b64c4-5ece-4afc-bace-cf187dee35da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
        <dc:identifier>ECO:0001565</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9105a828-9935-413c-b264-dabc02dc3248">
        <dc:identifier>HP:0012444</dc:identifier>
        <rdfs:label>brain atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cff9b067-43f9-4ae0-828c-05969f62474d">
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/de3eea9f-cd5c-4a3f-ad0c-85a628081147">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
        <rdfs:label>ASAH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d2dabd41-e822-4c0d-840b-5e2aa4d7f5e4">
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4678d51-1955-4827-9180-dc9253f6acb5">
        <rdfs:label>SLC7A7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f11bd907-8d33-4dec-ba08-64ef95d38fa6">
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f9301622-3aa5-41e1-a250-4a463c23da9a">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb5a0cc4-46f7-4cb5-90b5-1218bba18b10">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a">
        <rdfs:label>activity modification of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e53cb08c-2258-4899-9ac7-d8eb194ff15f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0684f7e6-c5fe-4bf1-8eeb-e389351161bf">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4633b926-3caa-4b80-8c9b-90d4415b664c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a37a7276-855c-461b-8d2a-a5cd55c81829"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4d44f82e-2633-4dbb-9c78-aaa88181010a">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c343ff8-22f7-43f4-94ed-a1715e4123cd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c911034-e588-4085-bc48-e205aedc7533">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33652cbd-d6a9-4cbe-a80c-49a8e1e414eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4462d8f-a495-4e8f-9c47-c915e5443913">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a401212c-565a-441c-b36b-6221c4d658b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee5c0a0-be4d-4211-9fbb-cbfbe3dbacb3">
        <dc:identifier>HP:0001944</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Dehydration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d964ca49-bd7d-4b65-8db4-2d498d7ea643">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b652ca7e-b9f8-43d6-a7b0-d7f17c46cc52"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4fceab32-d85a-4dc4-8a3e-03b317cb4d1c">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d">
        <rdfs:label>MT-TK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81a42b11-b64e-4e3e-9859-6f33f87fbb8f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e543ff7-2d97-408a-8bec-936c317f5fe2">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>low muscle tone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ce10b4a-2b67-4abe-9058-917b161c1b8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb55e838-1749-4793-a6c2-ce76643cf359"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa3e17e6-50ab-4a12-adae-b3181d7a46f5"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a96c794-6b98-41e2-a226-93e20bc836ce">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4462eb13-753d-4bbb-8c42-c3559deff88f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f5fbe022-cf1c-4b0e-ad7b-18d46afa1875">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b286eac-07e2-4ea6-8f7d-e39d3018b70c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffac4fd8-ceae-4680-83df-54df2c6e57ba">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70d28806-4317-440a-81b9-7dc4bd06422f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a5d0533-57d2-44ae-bd67-11829dd20b2a">
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3332809-01d8-461f-aaf0-0dadd9d7c318"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d2392e41-8aba-43a0-ac0a-7eadc28031dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/081ffae8-2719-4cdc-941b-dd45afd9595b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d224aa7-9cab-43f8-aa3f-10a19ec53409">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a74d6c31-1419-40e6-9401-7e472b17820d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b08758a3-9b83-4536-a470-3535cf699e6c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa672ba7-dcc8-4749-a15a-818e9ab3e56d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5d44f6f-8127-4fa4-9cc8-7b8879096080">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/94304376-02d7-428c-a04e-9b88269c4ba1"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41006fac-3305-43be-abf5-a2342ef34de1">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fbef57b-0d8c-424f-95e2-9b6558d91e16">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d0e6abc-0fe3-4218-a678-d308b03cec8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9174de12-8607-4af9-b4d7-abece01f54c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b72f14cb-7de3-4ed3-b720-90e0fc144069"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57">
        <rdfs:label>Hyperammonemia</rdfs:label>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/453645d8-1c9b-4586-a498-2f072e94a59c"/>
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2486f6fa-3a10-4682-85ab-a044c12849ac">
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/931ddc04-177a-4819-ac90-bd80d5a960bc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
        <rdfs:label>PHKA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b4ece4e3-a0a0-4bd8-954d-0090465cd63e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
        <rdfs:label>SCP2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d87a1111-aa82-43f0-9384-bdea66fe5b57">
        <rdfs:label>ANO5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f528162-79cd-4203-a55c-0e3db9c68614">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5b19c38b-7ff4-4f08-86ed-1ff64adf9d74"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6fa51b4b-c2e1-481c-8f21-fdca80099434"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72a4745b-9972-4601-ae12-5730a89e3ca9"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/60619f04-9c9f-4bae-86ae-fb1fdbe2261f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d9f1b05b-71ac-44bd-86d3-bc4bd50d2c25"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dcaebd26-79bd-4077-9afa-96e7d2d3f3ae"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c058b67a-1fc6-4ef6-b494-70e1bca9694b"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78d41e44-15d3-4800-96fc-92e6e7dd59a0"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/23329cae-4d5d-4514-824f-cb24103ed2dc"/>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c6dc6270-4c43-4f5a-8c77-17f165772666"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c96b379-8bfc-496e-9658-d1da6b63272d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45118d6c-756b-456f-8971-3ecc32cbaf52">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7dfd8f8b-8dfc-48c3-bb78-d8eaa8356323"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58167006-b1aa-41a9-97cd-d8133c867110">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07086de1-39d0-4215-993d-390a249d13ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/443c733b-9f60-4179-a106-74a7efb9b730">
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>low Hb level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9525954-4b8e-446c-ae69-5a296c6ebe5a">
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78d41e44-15d3-4800-96fc-92e6e7dd59a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23329cae-4d5d-4514-824f-cb24103ed2dc">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c6dc6270-4c43-4f5a-8c77-17f165772666">
        <rdfs:label>RPL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6fa51b4b-c2e1-481c-8f21-fdca80099434">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72a4745b-9972-4601-ae12-5730a89e3ca9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
        <rdfs:label>RPS26</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/60619f04-9c9f-4bae-86ae-fb1fdbe2261f">
        <rdfs:label>RPS10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c058b67a-1fc6-4ef6-b494-70e1bca9694b">
        <rdfs:label>RPS17</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5b19c38b-7ff4-4f08-86ed-1ff64adf9d74">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9f1b05b-71ac-44bd-86d3-bc4bd50d2c25">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
        <rdfs:label>RPS7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c96b379-8bfc-496e-9658-d1da6b63272d">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
        <rdfs:label>and</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dcaebd26-79bd-4077-9afa-96e7d2d3f3ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
        <rdfs:label>RPL11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89a148d7-b2f4-4af2-9084-f93cc0e058a0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b51a62c-465d-4612-a3e6-ca845d26cb36"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ab8d757-6071-4ae4-902b-0736be1e951c"/>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1faff951-d0e3-405d-ac41-0ccfa366b42c">
        <rdfs:label>Developmental delay</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2e6ef2f-440d-4e40-8424-9dcc5deb6146">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/636f59e1-b064-4f3d-9ecc-1b47a3ff4cd5">
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:label>Metabolic stress</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/344f692b-11c7-4685-b219-2f705da5f373">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07e146cc-a259-4343-8fdc-2b3b0f4898e1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/253c535d-4b96-41d3-990c-afd5506515b0"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a4d94ef-8087-412a-8084-be569e7df701">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed6463dc-6b45-4243-9a08-07fbcd98c6e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d9ddf1d-a104-45a0-9b19-699c92490a50">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epilepsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca31d84e-903c-4d4d-bbb2-af201ed471bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85c3ec4d-d8a0-4502-9986-948927535fd8"/>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aa75588-2443-4871-9ced-d355eb52ee4b">
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <dc:identifier>HP:0001285</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/acc6e774-5bb3-4b90-ad58-0185e59bdb97">
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd4a2abf-c06a-467b-8c9c-bbb095e25609">
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:label>Growth abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc9347cc-3abb-4d36-981b-38e3b68226cb"/>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74e7c329-9c03-490d-b0a9-157b09b48a0d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63109928-8d1e-4e99-9b01-472ff3b9c7ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/256b2c25-c4a4-401f-b213-a261405abf08">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22b2288a-57bf-4a24-a50c-b8864895a170"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53b59138-a747-46b9-b179-781bbbf01171"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07bb018f-555b-4e3f-b6fd-b6079c0dce12"/>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d2078dd2-f213-4781-a3f2-11a0ddc92fd7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c7581df7-da3b-4a4c-9d02-9d3ad3512051">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
        <rdfs:label>PLA2G6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd31c8c5-b19a-4208-88d0-4fe4fb27b948">
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6680c49a-c2dd-4949-be10-c4f514465455">
        <rdfs:label>PHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4d3991ea-f5ca-4180-b0c8-d87b5f7c4d6a">
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d4702c99-d408-463d-bc5c-c76bcd92237b"/>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>Fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4565d0bc-2123-481a-af1f-ab443b3bc770">
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cb99f976-a911-49dc-a8c8-7198c160ebe0">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/487d5181-6327-4965-8e99-1742ba0cf8cb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b393e2d-f3b8-42a6-9700-cfe87f0851be">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <rdfs:label>neoplastic growth</rdfs:label>
        <dc:identifier>HP:0002664</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f838fae4-f4d8-4675-9ef6-fef5e4196d01">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/017fd858-985d-4889-a745-a9822fc5272c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f6488152-fd03-47b3-b6d2-c8e6e4bfc300"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb680c04-38f1-4397-8d74-58d0a1d2bd9c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b9b917d-3ca3-452f-90d0-1937fabdd990"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1fd8c141-9876-408b-8edb-1e08bc435e8e">
        <rdfs:label>GALK1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7214690a-f120-406b-8f04-2bf5c7c0a05b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5ec0d32b-7895-4f5b-9607-e120a0e64ae8">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6aae5ad-0348-4878-ad43-d873fb37c45a">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f67edb4e-a3c1-4288-9945-31f06f1a5c1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c6059b5-36ee-4ed9-b61b-ce1c7b67940e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/990efb8c-358a-4cef-a6d7-3d1970327d06"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28dc983d-7558-47e1-af1a-c43f1de94e9b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <dc:identifier>HP:0000505</dc:identifier>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b125816-66d0-4276-b6c2-82a3130e8945">
        <rdfs:label>Muscular abnormality</rdfs:label>
        <dc:identifier>HP:0012638</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e2187469-8abb-4afb-bef6-2198b8dd7090"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d651a0af-d89d-485f-acb4-66dfd9035b40">
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e598bf55-6e98-40a8-acc6-8ba6a45fc57e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
        <rdfs:label>LIPC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/71a7a522-3c24-4f19-a499-0b6930cbea52">
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a70cf78a-e8e8-44ed-9c64-ad6f67c38f06">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b585ce09-f8ba-4428-b4ce-775c9a68f769">
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79517926-bbbf-44df-a0d7-a4b66cb4c568">
        <rdfs:label>SLC12A3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0ce7dd53-278c-4cd2-969f-fc6ca568a974">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8acafb45-56e3-42ab-b64e-d2aa106d2b72">
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08adb341-f28b-44f0-b99e-841a5279975f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aadc884-7315-4eb1-8595-f5766981a799">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a8307d1-270e-4397-97cd-6d7f81d7a05b">
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac">
        <rdfs:label>metabolite replacement</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6886fbd7-4a1e-4885-a0f7-22dfb3947d02"/>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f67edb4e-a3c1-4288-9945-31f06f1a5c1b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa91b8aa-5d4c-43ed-960b-5f6aaaa37015">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/496f6406-bdfd-473c-afc4-eb99df48e75d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58497244-f5b5-4797-8e14-b5a8890e5e7f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7abb8498-4720-4b49-a359-0795d16a4333">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4a3cd6f-8839-4294-8151-a55e122c9c45">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:label>Hyperglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f9c4a83-2b72-42d3-9e26-9a25209fd999">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypertriglycridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d9c7c3e-dff8-441d-b30e-53e049d40bed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3078ebb4-c942-4112-9748-f2260c9943d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03357058-05cb-48cf-bed6-1f0d61507195">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a14c0c67-8c73-494b-8713-59c6c6b8bf14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1423001-986d-41ec-9006-f21d88994ae1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/faac7d99-0e23-4eb9-b353-461045162a85"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8da1f64-fcc6-417e-b554-7b175cfa5e53"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b3e40065-6ab6-4a13-bcfa-364a55de0844">
    <rdfs:label>glucokinase-4</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/63bc0e10-fc1d-42a3-b259-5980931d3122">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19dbc9e7-93e9-4583-990a-8359f18bfc61">
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/85c3ec4d-d8a0-4502-9986-948927535fd8">
        <rdfs:label>QDPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c120145b-d9de-492d-9a2a-fd7c695160fa">
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6a072515-87eb-46a0-9359-7ff642ed32a0"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac73d5ed-21f0-46dd-a5ca-97dfb6bcab8e">
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9e64eabf-3e39-450e-86ad-d6f612eae928">
        <rdfs:label>AGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/58ee3d16-f654-4f0e-8341-5560fa148662">
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e81c7f4-72a7-48bc-b53a-114608c837da">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1ea148a5-f651-485a-a7d8-fb710f50676f">
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fae4714b-f165-4bd1-8575-0baf2360dba5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6b3c0df-04da-4e25-88ef-7cb799cd64fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9407b757-02eb-4a09-9715-8d98f4d7e7af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/796f9fc0-43b5-4087-a9e0-a0c41dc409f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4678d51-1955-4827-9180-dc9253f6acb5"/>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a274042e-39cd-40e2-855a-3b92f2f1b2d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/974fe5f2-ef1a-4c46-8fd2-04c93d66aec3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0de56b8-99d7-4913-af47-7eba92e1af00">
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0000793</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ea68154-4342-4acb-8fff-44a99d6bdbf9">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5fa3442-6065-409f-a5cd-ea49ec80990f"/>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10ae5858-969e-4ca0-af87-42eaa7b4ffe6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7531a952-cc62-4b5c-b061-9f9e184e115f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/947ce8b3-f319-43b2-8994-54c406d1d877"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3a53ef1e-5896-43c5-8c4e-0c65e4de6267">
    <rdfs:label>Glycerol kinase</rdfs:label>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d404994b-2c79-45fe-bf2d-ed7832874ff8">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b03a96f-9ea2-4181-8193-0e979724c31d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43cbd1df-9514-46bf-96e3-d48ea01ad050">
        <rdfs:label>CYP27A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/569af763-116b-4187-a92b-878c78ebd8ea">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1fb58c2-b8d8-4b57-98cd-9200b1016e3b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/909cc698-086f-41b3-b302-54ab21e4e997"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a3aa48a-cfe0-4fbd-9be6-fe50e690bac5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <dc:identifier>HP:0003288</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d"/>
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/840a8a15-3e85-412b-816b-ccc25f5a1c57">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3862e98-b1e2-4487-a8f6-684500e2ba00">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56c98853-4272-4c49-98a5-d8a89d14c59c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b9c7322-0312-450d-8fd0-d4b6096d261a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Dementia</rdfs:label>
        <dc:identifier>HP:0000726</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f221346-e637-4919-b7ca-4c0ec899ba7f">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9999347-718c-4f07-9a68-9259d47333d9">
        <dc:identifier>HP:0006958</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa17f7d0-8a43-48e9-9511-394ffc2484ea">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <dc:identifier>HP:0012120</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/511f62c6-8a60-49ac-89ca-5159a84a00e9">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000649</dc:identifier>
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f924adf-eee3-43c9-a447-7dedf464e152">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c209bba8-62a6-44da-b3e1-b2874a24bcba">
        <dc:identifier>HP:0002355</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Difficulty walking</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/718b0cff-29c7-43a5-9fba-0282c9cec251">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>Mental impairment</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95b3fb03-e82c-46c3-942c-b44bc1ea37e8">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Emotional lability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/dae62352-27a0-4817-8100-10eb60f77f30">
        <rdfs:label>functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3bfa35c5-56e8-4dae-94e2-93cc68a80978">
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d7ec55be-4887-4a95-9269-5d362c309dd9">
        <rdfs:label>PRODH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f193ca8-5707-4bce-9be5-0ac8d752fba6">
        <rdfs:label>DPM2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0f4f93a2-0d9f-4c1c-8951-b025720cb3f7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/044b34c1-954d-44d6-b5ea-10e6fefd24d7">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1cdfa8b4-2be4-4bed-822f-1bccac6cf45c">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
        <rdfs:label>MT-CO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12ec2ff9-4d8b-4ab7-b2c8-751cc48a2796">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
        <rdfs:label>MT-CO1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b35f8223-b6fe-4a5e-9522-c9d909720ea3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/99eebdad-079f-40ad-96f7-644997d82cee"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/149a25b0-6bd1-4228-b2a0-f15618f4a2c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da3a4e7f-7f47-446c-8331-67aef7a1f474"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f735b17-fd6b-43f7-9014-463f494df1f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b0dd595-a8ca-4574-9c98-5719bd6990fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9448e67a-296f-48c9-a134-88ec72b08dec">
        <rdfs:label>Hyperurecemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>done</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9711c098-5e07-4a4b-be96-a75bdf714351">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22b15f68-c9f0-443b-aae9-bbdd97e4d421">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <rdfs:label>ferrochelatase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7fed4194-28b4-460f-a2e6-aa303f889af4">
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/19b6b432-2c1e-4d52-be7f-3e91fb2d2dd0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1798f896-09e4-4fe9-b38f-ad0d2adf6a0b">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2cf09954-fe0a-4401-ba01-d7836b30a9a6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5a7c4d5-4410-4262-8898-e62a7159b9dc">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e13a951-22df-4246-8251-0b38356a3d08">
    <ddiem:uniprotId>Q9Y223</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/701cfde7-f962-4b3d-9063-4e06770aebd1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
        <rdfs:label>GNE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12409</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.183; 2.7.1.60</ddiem:ecNumber>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c77e0f87-b8cf-4f18-a888-8f351aa0d9c9">
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/747461ed-f04a-4941-be59-f4c2a080668b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
        <rdfs:label>ATP7A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fbdecf20-42cb-46ae-8073-3e06fd9c2330">
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5ba81ae-3b8b-4658-b7fc-a01c2802f466">
        <rdfs:label>CPT1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0441ad79-3ded-4ef1-80e6-8a628681e009">
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/44991a52-1090-4e53-91f8-87c52314060f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7bb15e0c-6615-4741-99ea-3bb440193eed">
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06c3ce65-a652-4cb4-8990-beb31e18e69b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/103a49db-7117-4995-b5b8-55e7b3a99875">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4020263-978b-425f-aeae-e9a4d277a5fa">
        <rdfs:label>ETFDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8087849a-fd58-4b2c-b89e-9edfc08aee1d">
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/edc1197c-232a-47eb-90c4-2d0e4bbc0d78">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
        <rdfs:label>AASS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UDR5</ddiem:uniprotId>
    <ddiem:keggEntryId>K14157</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.8; 1.5.1.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ad971771-0bc6-4b6c-a11e-659cf073ce92">
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bf032858-3fec-4312-a5aa-78b2dc12ecaf">
        <rdfs:label>GNPTAB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa5b7d78-578f-45ab-9d16-1443dbac0f1e">
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e27fe350-b07a-41a5-aff5-521d6e64a27a">
        <rdfs:label>BCKDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/10615cf2-ca7a-41b3-a620-763d933df868">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8473421-64ea-4dd4-8362-ed03a0f2d347">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001877*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ee3ee75-f39d-45cf-b27d-6aa3cdb0bf04"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/41358b16-a1bc-40a7-9626-ab2ab1dbd82f">
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <rdfs:label>dolichol kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c775547-4168-45dc-998a-8ed879494117">
        <rdfs:label>DOLK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd60c6d7-295f-4264-971f-534ac3b49631">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2338df35-ce83-4558-827c-1f04729006e9">
        <rdfs:label>PTPS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf71048f-46bc-4da6-8c56-3f96e8649968">
    <ddiem:keggEntryId>K21052</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y2B1</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5653aee2-a25a-4d8f-a8eb-40578867bf6b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
        <rdfs:label>RXYLT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/48b2ba04-ffc1-437e-a09c-96572a9f3d7e">
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f7c644a6-882a-4456-a06b-f40444c41661">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
        <rdfs:label>HSD17B4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bbc4cccd-7b76-476f-8cdb-247213c0c899">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/259c72f6-dacc-4a19-8a09-ad96f46f137a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
        <rdfs:label>HADHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3d2f5b5-3d7c-4e41-b43d-706bc3059816">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/55144a39-9bb2-4b71-882d-1c957288e17f">
        <rdfs:label>SLC25A13</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15105</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UJS0</ddiem:uniprotId>
    <rdfs:label>citrin ( protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/49235ab3-8c78-43e2-b6f6-9d218168bfc5">
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4442831c-0d46-48d3-ab0f-52f30cf95a18">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
        <rdfs:label>TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7acf969f-12c9-4d64-97a5-1102aead7cb9">
        <rdfs:label>GCH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/35108e0e-007e-45cb-a7a9-ac6398f21d81">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
        <rdfs:label>SPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d529234-04c8-423a-843c-c8f639cdff30">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32378294-b902-49de-ab73-db4f84c29882">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6458930b-4ca8-435d-b53c-add5d0d09edb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf">
        <rdfs:label>Hypoglycemia</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b51a62c-465d-4612-a3e6-ca845d26cb36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cf8e2ff-56ed-4022-a5a7-98f0ebfa5911">
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <dc:identifier>HP:0008315</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6fccddad-c26d-4f7e-8314-d073bf0ca049">
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/29e08a18-56cd-475f-a7fe-d3d6401b54e9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
        <rdfs:label>PYGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/616a3605-fa6a-4156-aebf-3d8d1843a280">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa27e4c9-1aba-4e13-ab30-9d2bfdae8828">
        <rdfs:label>LBR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e83ca129-ed95-445d-a271-0f263eab05e1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d53f6ae-c8c2-4b52-bf30-ca5752f1b270">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e46f4902-7c7b-4336-a5e7-d5072d6bafe0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8965d2bc-3960-4214-93a9-99dca22ccd38"/>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/77517d5a-c1c1-48f6-8470-f7c70ddd54d2">
        <rdfs:label>symptomatic treatment procedure+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6dd4ab14-da67-47aa-9140-729d135b1ec7">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0451378b-6202-4526-96c0-29aa1fa6adb7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcfaa493-b7b2-4941-afd1-79c4e0fddce6">
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:label>Stroke-like attacks</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/511a071d-3fbe-444a-909d-ae5efe81904d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/543e6ba8-53c3-443d-b6fd-37d754aba89d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a473959-2374-4ec3-978d-6bdc63e249df"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96a4b366-9670-42f4-a771-5714481d125a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4449e153-706b-4bc3-ba24-f954fab145d5"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e262d84-ba81-40c9-840a-adfa57ab9b0d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9903073-f594-47cf-be8c-dc9706ca1806"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e7694e92-2b9e-4475-82da-cffeecf3e6c0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3865a10e-1c1f-47d0-8ba2-1e9f35103f46"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b34143e-135f-4e2b-b0ba-2d2db8b86eb4">
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47025ca1-0524-4df5-adf0-0fe7b20775a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <dc:identifier>HP:0030890</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/588dd572-4ad6-46e3-b486-94fd033333aa">
        <rdfs:label>symptomatic treatment procedure+symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66a896a8-5049-4326-b3f8-71050376f1b2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c378d35d-3d9c-49ac-86af-dc2e7e72cf74">
        <rdfs:label>MYH2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0dd3db9c-449c-4caf-be7f-d6c298606ed7">
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/453645d8-1c9b-4586-a498-2f072e94a59c">
        <rdfs:label>ASL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/984627fb-ea4b-422a-b64b-59258bdd9640">
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c6f7597a-7217-41f5-9534-532d9d1cd026">
        <rdfs:label>PAH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/caf97c33-735c-4419-8437-dd2f6103ca74">
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21957ff5-2d96-4835-a6d2-7bbe0cb518f8">
        <rdfs:label>GNA11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b34fb7c0-b502-41dc-99b2-22b6c645537e">
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71bb1728-d33e-432b-b81d-d352af61f14f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
        <rdfs:label>GSS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glutathione synthetase</rdfs:label>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e910986-8a25-43cc-9a92-f43dbf92d61d">
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a810e094-cbed-4254-af4d-a4744ea3c0ab">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
        <rdfs:label>HAMP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3813adad-e631-4eaa-bb00-a10947c6e983">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
        <rdfs:label>HJV</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ac992ba-8036-481e-99f9-1f9092b54bea">
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <dc:identifier>ECO:0007764</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/774d90be-ca3f-40bc-95af-552dc36782a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef92f84b-3982-4487-ac0d-739c20ba25c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b93bf342-770c-40dd-9e96-f51605b3393f">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:label>Nephropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/44991a52-1090-4e53-91f8-87c52314060f"/>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b58323b5-56bb-4f10-87b8-9b78dce7e417">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/059baf88-2b46-4abb-aa06-21d071b1906e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/34e4385e-c47e-4e3e-a443-2264969185d2">
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <rdfs:label>Sar1b protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/990efb8c-358a-4cef-a6d7-3d1970327d06">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
        <rdfs:label>SAR1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/05b9f29d-cad3-4fdb-b406-3c6559a55a60">
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6237074-e071-4c90-ab0d-702d3f6fa5d9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8600a21f-3caa-44db-8a4f-4f88a0fe2b33">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c7581df7-da3b-4a4c-9d02-9d3ad3512051"/>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3233b23e-ec66-45f9-b8d4-460597f9bfa7">
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b46aff3-b415-41f6-a74c-e013c12686ff">
        <rdfs:label>DAG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
    <rdfs:label>Dystroglycan</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11aea037-0c8a-4a7c-ad98-f2996c3786f7">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/348d1864-5b84-4862-a7d3-12d762b9b2cf"/>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22b2288a-57bf-4a24-a50c-b8864895a170"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8aeca315-56f4-4aec-a187-8df9f8876248">
        <dc:identifier>HP:0001889</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/cdda6fd6-a57f-4b59-bc00-638cd6742f4a">
        <rdfs:label>functional complementation of a genetically defective protein+metabolite replacement</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/45f32b43-1ae5-48f7-a2ae-ef42aa9ec50c">
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c73216e1-b548-40bb-82de-d8ca89c631a3">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2aa6278-9e6f-4f3c-aca1-24b43ce970d6">
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/17d4b5af-1b25-4826-ba0c-64466e264163">
        <rdfs:label>PYGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2897d581-9f44-437d-bcc6-63ac4b601ef2">
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b018cd15-4fee-4b00-8328-117462b522be">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3381284a-865b-4e68-8821-f4f4e3e41693">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/feab8b3c-d92c-43c2-8f3a-9297a28361fc">
        <rdfs:label>LARGE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d87c894f-63fd-4a28-909d-9e224ab7ece6">
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d1275e8-ce45-47b7-9e05-c04b7801e387">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
        <rdfs:label>MLYCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e788fc5-21ec-4a66-aec8-30ac40bc9bba">
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bf98be2c-baff-491a-a522-472fbf1e32bb">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/699d4899-eb53-4c49-819b-7ee5ad9b9047">
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ae621d2-7dd0-4d18-b4b8-82e0d0e0b115">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
        <rdfs:label>AGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ae12b9f8-f530-4770-a4f7-a3dc62688f9b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
        <rdfs:label>ALDH4A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b33905ad-01c1-4316-b223-c8824607fdc1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6d46e540-666f-466d-8de7-830d447faf5c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
        <rdfs:label>FKRP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/454f13fb-3bbf-423b-aead-ca0cbd803cdb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6f93dd9-733d-4ba0-98de-6ece50f501bf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c0dff81-f351-4bd3-86d1-c14f3b65f510">
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cfcdd6b2-da9d-4465-841a-0278a0d63418">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
        <rdfs:label>HMGCL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eae7a752-6ea9-492b-9059-781260cf3d84">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32378294-b902-49de-ab73-db4f84c29882"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf8e2ff-56ed-4022-a5a7-98f0ebfa5911"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d47a101b-3650-49ee-961c-e711a3ec22fb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b2bf000-bc04-4b76-aa85-c20ee41d3424">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
        <rdfs:label>SLC1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 1 member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be08ccd8-a423-431e-b78b-9bdbaac70018">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5efa7745-d5d2-49c7-93a8-b10122d479a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d3e7d54-8f2d-40b6-b253-b332035f3c11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/edc1197c-232a-47eb-90c4-2d0e4bbc0d78"/>
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in our patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ac828fe-87f7-45c5-a36e-b1057ed7e46a">
        <dc:identifier>HP:0010818</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f">
        <rdfs:label>seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/983c68c5-4ce3-4f2d-9a03-1d03de08bb7e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb3b14f7-d0e0-4909-a398-e1ae6e10517a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
        <rdfs:label>HFE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8545a4a6-3231-41af-aa76-a2e8332645e9">
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8285dae-4970-4c6d-84cd-20888ebd77be">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0361fd7c-be74-421d-bcdf-f29c11ce03ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dfbc245c-72a8-48ce-bb06-a132e0df9062"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdec4299-bbb9-4a69-8626-e7e3f1065676">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4100f22b-ee85-495b-a288-fc8d6f39dce8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d519ecaf-6d2d-49bc-9f9d-835f9a391e6c">
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61bcbd07-d3a4-418e-900e-4317d937b3b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d41f58f5-6480-4a2a-80d5-2f61e8a00eb5">
    <rdfs:label>Ferroxidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31bdb5e1-5b6b-4a63-a8ac-1510200f4d57">
        <rdfs:label>CP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c6a7857-18df-4715-b533-e72652d10fa2">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/66f7ffa3-0ac4-4bb5-884a-c28fe87dbd50"/>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6c219a9-80ff-4ca8-b96e-25e14d7cb69a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3700f14e-c53a-4545-9afd-776de7fa4fa3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db304e2d-23ef-4bb4-bd70-0795a6dbf709">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/11b274be-046b-483a-8c94-099561b93739">
        <rdfs:label>MAGED2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b3758fa1-6cf5-460c-8227-9fc906df6070">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/138a4107-6029-45e2-98c9-36508bc7a8a8">
        <rdfs:label>GIF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c378d35d-3d9c-49ac-86af-dc2e7e72cf74"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e674ec90-c825-437c-a76b-388b03f5fbb2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
        <rdfs:label>PIGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57c1f6aa-9b60-4249-b009-fb5ab4227310">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
        <rdfs:label>MANBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/045642d6-249a-408f-9867-d642b5fd6ea0">
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e5ed22e-7837-4e8b-966f-b5aae3414ffa">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67f07b14-539d-429f-808b-92b8d947589c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e58efdac-b25b-4248-9b07-7792e599e7fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3455b1b-c376-483c-82df-58a4ffcd680f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/621593a8-5b45-492f-929d-a7de664d979c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00df4eb1-b039-4d09-bcd5-bd65318a8f71"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c775547-4168-45dc-998a-8ed879494117"/>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcf768e7-4327-4081-abfa-6c4d5b43b0ad">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6f93dd9-733d-4ba0-98de-6ece50f501bf"/>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da32e78e-6dd5-4498-8425-c9645544bee6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8def5f3-3329-45bb-b55f-40b8cc50b667"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22e0fe0c-ea83-4ae6-b79e-fe5c29e9f861">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d604178b-df28-4297-aa69-a7e6d7177e7a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/053793fd-d585-48c9-839b-74bd2c6dd08a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736622</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <dc:identifier>ECO:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5795f84-fabb-4e33-8fb7-caa8581d6e10">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14b70caf-0259-4dd6-9eb9-1408f7e586bf">
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3aadc884-7315-4eb1-8595-f5766981a799"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/3bd23091-f55a-41f2-bc7e-fce60498027c">
        <rdfs:label>dietary exclusion+metabolite replacement</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/827d5e68-b2f5-4e82-864f-c778c2c27d00">
        <dc:identifier>HP:0040086</dc:identifier>
        <rdfs:label>High serum  prolactin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76b0bd58-11b7-4a78-9257-5143ab8c8208">
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010893</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/21ca87ea-d24d-4833-b27f-98e6686bc1ea">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd5e4be8-3524-4956-8f01-4d7f8cea543e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3717972-54fa-4352-b365-8bbaa8805fc3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cfffcf9-596f-4cdd-a684-8c8f07aec003">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Petechiae</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <dc:identifier>HP:0000967</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7e4f595-c04e-4326-b383-103a46ab25fe">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb02cdf5-06a7-4670-8be4-aefb195d3628">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4230c38e-f9df-4cc0-9e89-05bc5080e072">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59c74f06-9c90-4596-a867-6589d9d91dd5">
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9270b9b-a01c-4e8e-a8ce-ee1b7b87b091">
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db8ad232-05a8-4df9-9de2-be01baf3c660">
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3974bf57-9305-4ec4-a46b-dbf2d55c1fae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
        <rdfs:label>ACADSB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc1857b2-7f45-40ed-83c2-9e90290b1879">
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6dca6fa0-d217-4121-bd89-00ba005252c2"/>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/997e3080-23f5-47eb-acc9-c3e2a90a3734">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20d30cfc-e941-4de0-a7f9-6e5e1ee14c73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2b9d974-7f8f-458a-8360-ecd71767b1d6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Scaling Skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9675916f-fb38-4c83-87e0-162835ce2aed">
        <rdfs:label>VX‐like lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8901f20f-76c1-4fa2-9ae2-a186fdd29327">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:label>Itchy skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31111b98-db9a-4fa1-9719-e716f6788bc9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031517*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfb63cbd-cf8a-41a9-8eb3-da007ccdfd6a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythema</rdfs:label>
        <dc:identifier>HP:0010783</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1b681ac-99c0-4b22-8e47-f26a75ba2a20">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad">
        <rdfs:label>functional complementation of a defective protein by inhibition</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4a9ea70-0c1d-485e-a241-f731b9927c5c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/00f890a1-efee-4b2e-9879-a8d0bc01c0ce">
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/955b7c0b-4426-4898-b4b5-2dfc3afbf7c1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
        <rdfs:label>TTPA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d69fb987-b3cd-4bf5-b01f-f512fe08916d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be323d9d-e74e-4207-b774-a9a3b585f817">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/d02fb727-58e6-40ee-abdb-76653c852ecd">
        <rdfs:label>functional complementation of a genetically defective protein+activity modification of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f013014a-8616-4c1f-9584-9499623c805e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/776a76f3-450b-4a6f-8a7b-275a280b42c9">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1798f896-09e4-4fe9-b38f-ad0d2adf6a0b"/>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2e6edcb-7934-464d-b20c-f7d257b44cad">
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a326164-f8c6-4b77-aeec-c70e11675a8f">
        <rdfs:label>PRPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f556840-79ee-45d5-b257-0c7d9437a8e9">
    <rdfs:label>lipase maturation factor 1</rdfs:label>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8da1f64-fcc6-417e-b554-7b175cfa5e53">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a10c67c-d746-4c62-80e3-d9726a323784">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/588dd572-4ad6-46e3-b486-94fd033333aa"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/330fe3e2-5b52-4bf3-b2ab-9686381d2d12">
        <rdfs:label>Abnormal EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2534724a-cee8-4d82-bad2-794c9ee228fa">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b07325af-a55b-4648-baa0-ae3b79bd2904"/>
    <rdfs:label>Prosaposin</rdfs:label>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/27692be2-acf3-4da4-b8d7-9c1669f30ba7">
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5fa3442-6065-409f-a5cd-ea49ec80990f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
        <rdfs:label>GLUL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29496d53-1291-4fb8-abbd-f4710e6137c9">
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa4a54a7-3ab4-4b32-9be7-97df36e69e1c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
        <rdfs:label>CYP17A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/531a0f69-09b3-49c9-8727-64f7d59b86e8">
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca9ac55f-3b2c-4a77-8c6a-a0ffdcca5533">
        <rdfs:label>OAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9950e70-1f4d-4c3e-8d37-3ce7aa5b7a8a">
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96963a5a-c362-4927-aac5-6d97d47d0e5b">
        <rdfs:label>HADH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3bb476c-76ef-42f6-8cc2-b13657217b42">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e2c25f2-c4ec-439e-b6ee-76ef3b76af5e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <dc:identifier>HP:0001677</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e971d71-da2f-4cb5-99fd-437568050e33">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:label>xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/983e24aa-5e38-459c-9272-a1f1933b725d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f1452d9-d411-49ef-96e2-a55b29605891"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1a692f8-e0d2-4edd-9e39-7f915cfdec49">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <dc:identifier>HP:0001681</dc:identifier>
        <rdfs:label>angina pectoris</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e828364-a136-4180-af05-911ed826317d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/859291f1-e6ed-4470-a310-2d06db95fda9"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26fad782-0379-468a-9f8a-fe2c8daa6ed5">
    <rdfs:label>Folate receptor alpha</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/064a995e-7d76-40c2-b017-1283c2a3d578">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
        <rdfs:label>FOLR1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a1cb18c-d76e-428f-9608-31b6c13bdf70">
        <rdfs:label>MAN1B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65b7f4fc-aa43-4804-99b2-05073944f52a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4fcf6bf-43ed-41eb-933f-bc87db0e96c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac7b166a-83ea-4e85-b27d-51c4fb2478a2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7118811e-3446-4258-8962-a1a70fd92ff3"/>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>Dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f5629e4-da64-43e9-aee9-21225a7aa2c4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
        <dc:identifier>HP:0002072</dc:identifier>
        <rdfs:label>Chorea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e66019d-9229-49aa-86bb-2b8c8fb4b835">
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/668ad5d6-73b0-4b93-829e-ac4a7fa590ee">
        <rdfs:label>TFR2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13a7696f-0b8d-4404-94e8-e051e27c7b8c">
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c91c7981-0669-4178-b802-0bf221065529">
        <rdfs:label>MTRR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1cdfa8b4-2be4-4bed-822f-1bccac6cf45c"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2036f79a-5ff2-4479-82ed-0341dbb6c659">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/372d9a18-7172-45f2-a716-60b40b1279e8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
        <rdfs:label>DGUOK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee25a74d-a1fc-4e81-a622-a2e6e1e92b0e">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c">
        <rdfs:label>dietary supplementation</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/469e7dcb-34fc-4015-b2c8-b6bf3f9c87be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c911034-e588-4085-bc48-e205aedc7533"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b369f978-ff6d-4af2-924a-9a403fba4bd5">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c453495f-91cc-4e32-9189-ce263d2dfd90">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70c43c8b-6635-48a1-82e8-1ffe24ca306e">
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Myoclonus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f45c1dd-7df7-47a6-b8a0-459c06cf0d2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1631222-0922-42ea-b5dd-a5ab4de0d9f4">
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06eba4bd-c516-496b-903a-b2b8d56f6d4d">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5871983d-b764-43c5-878a-59736402e646">
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b4ece4e3-a0a0-4bd8-954d-0090465cd63e"/>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1661304d-57d0-42c5-b24a-589f104ab733">
    <rdfs:label>Aprataxin</rdfs:label>
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bfa7b894-b865-4cfd-8cf9-863831477b98">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
        <rdfs:label>APTX</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6c9e510-8f57-45cb-9998-a4aee5c5f6cd">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/62a45e8a-d52f-4d15-bafe-ea759dd59268">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6d875f4-cddf-4625-9bfa-b0dadb3fe341"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/184b164b-4034-45bb-b8d1-ba499027e36b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>hypertriglycernemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7b3a167-071d-4170-8982-ce748981d7b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b70b7f8c-040d-43f9-8c8d-ec5725ef43bf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd5e4be8-3524-4956-8f01-4d7f8cea543e"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/259eecaf-495e-42ca-b1ba-f4fa2c034bfc">
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <rdfs:label>GABA-transaminase</rdfs:label>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b1c59f2-23a1-4003-ac40-f0b53472f110">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
        <rdfs:label>ABAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/10a6cc92-48e4-4b48-9047-01a487553014">
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c81a1b6-0abb-4898-a7dd-db4ca9769a00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
        <rdfs:label>PIGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d70c1c3f-179f-410d-9367-5ecff5851206">
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b787bd36-6ba3-49f7-ac0a-4da9689fa77a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
        <rdfs:label>PHKA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d1cb5de-fa9c-4db2-9e8e-d7ee22df003b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/564dff74-61d7-498a-88e2-178644668113">
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Dysphagia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c209bba8-62a6-44da-b3e1-b2874a24bcba"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f013014a-8616-4c1f-9584-9499623c805e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4cbe4c1d-48c6-4b12-bfda-c5c2edaa9acf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4369028-0d71-4676-8533-954047161744">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d1650b8-e87f-4a0b-8a10-e13233056493">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <dc:identifier>HP:0003530</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Glutaric acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e2f71d0-714d-48bd-8c07-5876dd108044"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d224aa7-9cab-43f8-aa3f-10a19ec53409"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9174de12-8607-4af9-b4d7-abece01f54c9"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/6a96e420-2cb7-4f3d-8a39-1d067cade4b1">
        <rdfs:label>functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4aa988b-225d-4a2d-8af2-6bda862892f4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2dafe1d-ae08-48da-b4b7-d96a50b9f749">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The study was terminated</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5fbe022-cf1c-4b0e-ad7b-18d46afa1875"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f7c644a6-882a-4456-a06b-f40444c41661"/>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3db02cf2-b071-4936-ae27-1bcdf4b0ca99">
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b682c844-f782-4346-b51e-d2530b5c8440">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
        <rdfs:label>GLYCTK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d630111a-7445-4896-824c-7255ffb66ca8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc9347cc-3abb-4d36-981b-38e3b68226cb">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7fbedb0-591a-49ba-8658-23bec6f307a4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/40a9220b-712f-477b-a86b-4d2da22c18d6">
        <rdfs:label>GYS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/415f731c-acc2-4a6c-8dd6-a6883ce1edd2">
    <rdfs:label>thiamine transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c98dcc8c-4423-4a42-9278-0bc469100040">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
        <rdfs:label>SLC19A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/44d2c2a9-3c22-4c3b-ab6d-8bb5b6b45d9f">
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78eea9ce-7f9a-465c-985b-7151d0a7ae26">
        <rdfs:label>BCS1L</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5dde8b4c-af5a-40c9-a86d-ac86083129d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
        <rdfs:label>POMGNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45169bb5-bffe-477e-a294-9a6c297fee02">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e81c7f4-72a7-48bc-b53a-114608c837da"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141">
        <rdfs:label>Seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40af249a-cede-48b9-ba14-00c110cc003c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e49c447-72c9-4da9-9cac-650e67b3136c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c7109a6-3531-4eb8-b124-48c1726ad438">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
        <rdfs:label>B4GAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b190037a-8851-4cd8-af19-f6f42215bbba">
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4dc45a57-9986-4a1b-8246-c61a83434219">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5b9c8f49-8b54-4122-b4f2-4861ce7eb1c2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e262d84-ba81-40c9-840a-adfa57ab9b0d">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
        <rdfs:label>MT-TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e7694e92-2b9e-4475-82da-cffeecf3e6c0">
        <rdfs:label>MT-TL1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f9903073-f594-47cf-be8c-dc9706ca1806">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a473959-2374-4ec3-978d-6bdc63e249df">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
        <rdfs:label>MTTC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/511a071d-3fbe-444a-909d-ae5efe81904d">
        <rdfs:label>MT-TS1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/543e6ba8-53c3-443d-b6fd-37d754aba89d">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
        <rdfs:label>MT-ND6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5927e947-4f39-422f-9095-b0cbf0ef0d00">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
        <rdfs:label>MT-TE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4449e153-706b-4bc3-ba24-f954fab145d5">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
        <rdfs:label>MT-ND5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96a4b366-9670-42f4-a771-5714481d125a">
        <rdfs:label>MT-TQ</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3865a10e-1c1f-47d0-8ba2-1e9f35103f46">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
        <rdfs:label>MT-TS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a382c902-dc28-4545-bc7a-a5ba1e43952f">
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4d44f82e-2633-4dbb-9c78-aaa88181010a"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9ae0857d-3520-48eb-9a9d-4dff6ec17823">
    <rdfs:label>kynureninase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/659a550c-90a2-465f-81b8-82289fd40a09">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
        <rdfs:label>KYNU</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ceb136b9-0399-4314-a7d1-b9f82628f4cb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef5b5795-d7cd-4686-a868-8f1c297c3286">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Study is still recruiting</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544">
        <rdfs:label>direct complementation of a genetically defective protein by gene therapy</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/960cfc7d-f72f-42d8-81ea-bded8f52d194"/>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a07b78f8-c37c-4636-acb5-bddc783ee0a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f96107b-83d5-4a8b-8d21-8b73e9850e4c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf85775b-4959-41ea-9085-c656191babfd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a94e39b4-ea3f-402d-a9f0-68a4f8e34ad7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94d4d776-f00f-49dd-8b1e-fe2a807513b6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c209bba8-62a6-44da-b3e1-b2874a24bcba"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/f75e779b-59a2-4b1a-b636-e6d24923b7f0">
        <rdfs:label>symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/92b9d183-506b-44fd-90f9-fae66bd7d194"/>
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9bb0d198-28aa-45af-a229-92fde51e6e07">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/249000a9-da2e-409b-9373-2de1eef9cba3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0142947-ba7f-43dd-a5d0-b6e0579a2899">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3c06488-0f31-4308-8203-2a10ec149343">
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5955b7da-7916-4c8c-a4e3-6d2318033bd4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>fatigue</rdfs:label>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/033b937a-458b-453d-a5a4-54674b23f3d2">
        <rdfs:label>anorexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <dc:identifier>HP:0002039</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6">
        <rdfs:label>hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/926965ed-c58c-4558-9f7c-0660740b961a">
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56d24cb5-41c8-4c2d-aaf6-097769a364b8">
        <rdfs:label>Poor growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86231424-c661-4074-b43d-a22d63e4c37e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:label>lethargy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/55144a39-9bb2-4b71-882d-1c957288e17f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9174de12-8607-4af9-b4d7-abece01f54c9"/>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47f1e2e9-7748-46f3-bc60-766f8d3d5415">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ae3a062-a992-4535-9747-4ece9d8d0be4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daa36fd8-997c-49b9-987b-fb180223985a">
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0004337*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e1c022e-5315-4235-864e-4c81d5f62f21">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e7f117f-3a2b-46a5-a66a-af2e70562013">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1be2a194-0dab-40b3-8a1d-393d502c82dc">
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/68f8b77e-83ee-4710-b429-f0a237b5d4f6">
        <rdfs:label>OCRL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2836426-8408-4220-94c7-62211f5eb2be">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e6e9531-08b3-44d7-8fcb-6ce69cefe2b0">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:label>irritability</rdfs:label>
        <dc:identifier>HP:0000737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08120c74-228f-4ad3-8c8b-dc8f65668173">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <dc:identifier>HP:0003657</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ee6795d-cc00-4c19-9214-3c7fce877486">
        <rdfs:label>Defected alertness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004372</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69c2ad07-4678-4b35-8917-63322c5debe0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0881876e-b212-4a70-9bdf-84ca8d738981"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b17e14f-a648-44b6-91e1-7629cefc3841">
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6f2a790-1b78-4a37-ba1f-9905ec17ff91"/>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f5baa7c-99fb-4007-8317-89ca1406fd2a">
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd23b81e-b258-47ef-b95f-23f506b0e476">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
        <rdfs:label>GCDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed685e0d-aee9-40ef-a0e2-8189d72c012d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c3332809-01d8-461f-aaf0-0dadd9d7c318">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
        <rdfs:label>AKR1D1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4d93417-69fb-43dc-967e-9ce38376468c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3bf5b155-34c6-4453-9f7e-d861a3b44ec9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99db7c95-5e1b-45f6-8021-c45ceb531a14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86ad1cc5-adcb-43a9-a6d5-0c068007af9e">
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003162</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99a7c7c3-e3cf-4f7d-bdcd-fd8e458278bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1eaa1eaa-d96b-44a6-9cbd-a56cfa0875db">
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c3b228de-08cf-4e92-b8fd-f29f3f84a3ec">
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21e40347-72c8-44cb-bdef-24a5c0216658">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd147033-815a-4aad-a1c2-bff7e639a9ed">
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71a9479e-4532-49bb-90c4-584334b1d672">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
        <rdfs:label>FA2H</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f87db77-7f08-4686-ae11-5adfe84b678e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/856dd3ce-1388-4b68-b360-c43043dfe7b4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>social interaction defect</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0000735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1b9b2bb-0e2f-4281-bfed-3da0e7b5c08d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eefd7f5d-2874-4891-855b-f8ff0db15cff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9249955e-2c9e-4db7-a174-50774a070152"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e513e0ff-601c-4ed0-98af-54ff0fa15d19">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4746ac75-01d4-4354-b0ba-cd19a00dd8ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d0ad4de5-cb8b-416c-b702-4159b5c0ada5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49ada44b-fc8a-4785-9cce-3c3824b0f173">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/398814b5-8824-4585-93b2-918027abd4c1">
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1f136d92-0836-4eca-a3ce-e8b70110313b">
        <rdfs:label>HSD3B7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf0566a5-303d-4d31-9a13-0d3bf05db9be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/768621df-58ef-41dd-a130-6aaf5c3c9b6c">
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:label>Delayed receptive language</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1faff951-d0e3-405d-ac41-0ccfa366b42c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b21735e-2fc0-46a2-b95e-108a97d4b22e">
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89dd4b58-9143-46e5-8788-683469d0f1e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3cd7b14f-ed95-4c31-8161-abc82aa6cfef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0684f7e6-c5fe-4bf1-8eeb-e389351161bf"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/192825c6-76d0-49d2-96ca-2cab60493a3b">
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d0e12841-339e-479f-9558-d5ecbf8b1c3c">
        <rdfs:label>CLN6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ecff698-d211-48b1-8a9e-263ca7b86217">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e5af3d87-ba99-4f2f-8b65-81768b8abde3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6ac26ce-e2c4-4f3e-a1d6-69b5d72745d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c291370-0cd1-42b9-bbab-b72e5a1b968a">
        <dc:identifier>HP:0000939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
        <rdfs:label>Osteoporosis</rdfs:label>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9e64eabf-3e39-450e-86ad-d6f612eae928"/>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a8bd169-68c8-4ca7-b686-710586eb6d45">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa9b0772-96fa-4922-9fa5-188e2429af41"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0facffe8-c278-4739-81b9-5ba02e699a30"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e516f4c-92e2-4236-80b6-bec2c964a028">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/145f6353-ebd5-442c-b10b-efcfb78af397">
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/253c535d-4b96-41d3-990c-afd5506515b0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/44fd526a-b6da-4f9a-96ee-8969c237da26">
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/722c2c1f-ddb3-4d4e-8956-9d4b4c25900c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
        <rdfs:label>D2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b67f4016-5032-4cf1-91dc-289a28f18308">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/adf11c2a-1424-4ed8-92db-e2e5dbcb5f0e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47ae3557-7dc4-4c78-bb46-9bc412e8af1c">
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ace1f428-c7e4-4434-9654-a5a70450a0e6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
        <rdfs:label>ATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/977fb8f6-d273-4d66-8df7-7ff4adbcf576">
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4c7109a6-3531-4eb8-b124-48c1726ad438"/>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/258baca0-81df-4632-acff-c750c12d5920">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfa4bb4c-27e3-4e8f-9e4a-96de4d044cf8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21aedce3-3448-4fc5-8424-f321b9d56855"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/63bc0e10-fc1d-42a3-b259-5980931d3122"/>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc0068f7-ead8-4fac-ba00-0bf7ac7f48bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a286d5c5-4338-45f9-a4de-b6b0ce6e7696"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11b434ff-a577-4dda-8a3c-686bcf83b940">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ee75eb1-4f24-4690-8606-b00219241d3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/040df56d-6865-4ea5-923d-add3f8513528"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07bb018f-555b-4e3f-b6fd-b6079c0dce12"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01e64856-6129-40b5-b72a-ba57269a6038">
        <dc:identifier>HP:0006785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9127c50-6caf-454a-9341-dc003f632f45">
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/57c1f6aa-9b60-4249-b009-fb5ab4227310"/>
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e65a14ac-7e1b-4800-b0fe-2b4a09b5c588">
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a080e21f-4c13-48bf-9e4b-a727a5966014">
        <rdfs:label>POLG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2d5bbdb-bc0d-4938-98e7-f0ff750614ee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d15ed51b-6d28-47f3-991b-2ff9c04a0145">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Memory impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <dc:identifier>HP:0002354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab8be818-5020-4188-9f46-d669382e0d3c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4d443af-3780-4964-af2e-d3fc1cbb2cdf">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a371e84-ea08-44bc-865f-b33619344c6d">
        <rdfs:label>cognitive imapirment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/698727a5-93b1-4cc9-b0a1-8cefb8b6c30e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/769b9cf5-e009-4001-a4a5-4f0c8780331a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bb3b5f2-70a0-465a-b05a-d24d2e8ae3c2">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0001328</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <rdfs:label>Learning impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bcebd71a-957d-4c7a-a0a9-4cd688fcec41">
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ab8d757-6071-4ae4-902b-0736be1e951c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
        <rdfs:label>IVD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15b6563c-84cb-47a3-b1ba-9e57b262a9b6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f003de2-e1d2-4076-ac4b-a93e9459f5bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3e894c3c-84b1-42a0-8342-23cf52e3463c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3206498d-8c8a-4062-a40a-9ea31fe08a05">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff146da1-81e8-4ce1-9e17-e05016af9339">
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ce0cca37-7447-4f92-a723-f83b114b5139">
        <rdfs:label>SLC17A5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6d866f91-fd68-4677-b034-72f4d2ce9407">
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/960cfc7d-f72f-42d8-81ea-bded8f52d194">
        <rdfs:label>UGT1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bc0435a2-7bc9-42ba-bd0c-0eb2bfb79511">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc98ea8c-1451-4f8b-aa10-c85b40590d7e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20e03af5-bbe2-4f55-8517-93d073e347ba">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/54a5125b-d2fc-4d90-8e13-ec4ca1ed4645">
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/139a1e75-c416-4270-9102-959fc49a80c8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
        <rdfs:label>IGF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/229a1b56-b126-4f95-8b45-1ae08de3edbc">
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/722c2c1f-ddb3-4d4e-8956-9d4b4c25900c"/>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2feec52-f6e6-4b84-87ac-bd3862297466">
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f5d20cff-0ba5-42e9-b3ad-096a777f9c75"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2e15cc50-c5a2-44b2-a2ab-45e813977d37">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9156df20-b2d8-471a-9b5a-f9da5e6d503a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a75000dd-3cc7-440e-9d63-8dbdf7459e0c">
    <rdfs:label>battenin</rdfs:label>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2562f7ba-8f0a-4bda-9ab7-50e4348c045f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/090bcea3-18f3-40fb-a26a-ffa2cbe581b3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/90ad31ab-a2c2-40c9-a23f-9a678170ef2b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72be17dd-e953-4521-8891-80d979227a33">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f93af73-878e-4af5-8115-37fb199a95ff">
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a4cad2b-c1a1-417e-aa16-f924222e96a3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
        <rdfs:label>HPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5d3fd1a3-048c-40aa-979f-76c636520c29">
    <rdfs:label>uroporphyrinogen decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8bba1c1-daed-4a31-a9f3-70dc21a6375f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
        <rdfs:label>UROD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8bac6cf8-e234-4e76-8d27-ac797cc210ec">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e0fd840-dd6e-42af-8ab0-656eeef693c5">
        <rdfs:label>Anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36408ac7-9992-4e2e-b432-990285900b1c">
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:label>Spasticity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a0a223b-9e68-43f1-9b15-71715365a242">
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>Impaired renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d060462-e690-4f2e-be76-e277ab1729bf">
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93b76ff6-41c9-45c3-835f-3e4756de393f">
        <dc:identifier>HP:0002395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa17f7d0-8a43-48e9-9511-394ffc2484ea"/>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/dae62352-27a0-4817-8100-10eb60f77f30"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65eb5314-d8d9-485d-96b9-a77d732685c0">
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Haemolysis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f924adf-eee3-43c9-a447-7dedf464e152"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/406e98bb-5138-4174-a3ce-f29694e35cbb">
        <dc:identifier>HP:0031258</dc:identifier>
        <rdfs:label>Delirium</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/223c976e-3a62-4858-8b89-45f7b951dc98">
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/01e388e3-667f-4ad0-9a36-2d66b5c8bde9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
        <rdfs:label>PGM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1fd4585a-0a01-4e73-9fe3-c39081cb6606">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5efa7745-d5d2-49c7-93a8-b10122d479a9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b00acd2-c80c-4f15-89b6-6fdfae82ace4"/>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ada43eb3-aec9-42ab-856d-f659e4f7c19e">
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba972bd4-b23f-4d1f-8760-cd8c69caeccf">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4765ac25-7472-4209-bb73-ac9ddedfbd4e">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4442831c-0d46-48d3-ab0f-52f30cf95a18"/>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7533c56e-ee39-40b8-a9d7-85e2c7ec37ae">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/72c7627c-0a0c-42f7-924e-c8b494d57443">
        <rdfs:label>functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa17f7d0-8a43-48e9-9511-394ffc2484ea"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f924adf-eee3-43c9-a447-7dedf464e152"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33d53024-748d-4ee4-8dfa-f383e2e0babe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4fcf6bf-43ed-41eb-933f-bc87db0e96c8"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14b70caf-0259-4dd6-9eb9-1408f7e586bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/ea15b5b1-0b2d-42fb-b52d-879640a90f8f">
        <rdfs:label>metabolite replacement+symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8f18871-473c-425f-b600-182e28ab2713">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eac96051-3234-4f89-9fc9-4af70d5be8ca"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/37c88fb1-e9e0-402e-a8eb-3cefccdc46e1">
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/85c3ec4d-d8a0-4502-9986-948927535fd8"/>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b570d1e3-4f78-493e-8c89-3a8ff9033ec8">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3260e0ae-fbde-4bb7-a5f7-12ef6d49a4d3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
        <rdfs:label>POLG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dbec482b-8277-4c61-a34b-e6642abbbbbb">
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d25f20fa-c1a2-4358-bf24-9a6f708c750a">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/33eb58e5-4b8c-4afb-874a-edbc2e7a9029">
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ebd3c2a-290a-4df9-97e7-3280e7336737">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GALT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e8ffc07-25d6-4189-bd34-08ce889e30d9">
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9bf6214d-50c5-47fa-bd39-551adb6357b6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
        <rdfs:label>NAGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5d20cff-0ba5-42e9-b3ad-096a777f9c75"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9156df20-b2d8-471a-9b5a-f9da5e6d503a"/>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82dfe3ac-c2d5-4fc4-b6e1-73bb2a417ce8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
        <rdfs:label>LDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6c1ba85-2c4e-471d-b3f8-1ffcdd30b90a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/caed1c2d-5985-4271-b7fd-bf4cdfe939db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afd314ef-b0eb-40a2-b50d-76fcc4458aff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5d625145-4e6f-461c-8664-d1d4e928d1fa"/>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5cd927d-aff5-4c56-820e-c54462609c7b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27d408d9-305c-4dee-925f-2974ebab649a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfa4bb4c-27e3-4e8f-9e4a-96de4d044cf8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e">
        <rdfs:label>hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5eb20719-8e85-4ac3-ac52-29c7a3971f56">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/348d1864-5b84-4862-a7d3-12d762b9b2cf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
        <rdfs:label>FTCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84e01eb2-6261-42cd-bca9-89ed805826b2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c809059f-8960-42f9-a0d8-aee0555c7cbe">
        <rdfs:label>ATN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
    <rdfs:label>atrophin 1</rdfs:label>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a137c102-c5b7-405d-84d5-f315bb00765e">
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b40c247-d9c2-46f0-b98b-c48ca8355bdd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e5c005d0-5eea-4c40-8304-7c6e531b8a32">
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77ff8203-a2ab-4997-8a4c-404f90a4c301">
        <rdfs:label>MAT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cdc508a1-0273-463c-982b-c57830acdf01">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/ea15b5b1-0b2d-42fb-b52d-879640a90f8f"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/407a5684-2b50-419e-9727-11e64dcb47d6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef8b0c00-a7c1-4816-a4fb-3e55765238ef">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>developmental delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8b9a8dd-2849-48b9-bec2-5cfa4d3e04b1">
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df1070b8-c590-4034-a425-fe383e3ba165"/>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2e2919df-bb29-4292-b7af-8005ba9aff75">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7570619d-7152-44e9-a9e4-013711082bb3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/34892a02-5da3-4f2d-acfb-8107b2bf66ff">
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7118811e-3446-4258-8962-a1a70fd92ff3">
        <rdfs:label>HPRT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/986b1b06-f18d-445f-8e02-b56548a543f7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0083aae1-79ef-4613-87c4-4b189b3387f8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c911034-e588-4085-bc48-e205aedc7533"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/29e08a18-56cd-475f-a7fe-d3d6401b54e9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd2b8c77-2077-4fdf-bd5c-69b1c38907b9">
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b00acd2-c80c-4f15-89b6-6fdfae82ace4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
        <rdfs:label>DPYD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/10a049ba-9f6b-47b8-86f8-8a2cbd70e66d">
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/678583fd-fa4c-4e67-aa6a-32ce4b60d404">
        <rdfs:label>DPM3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b73495a2-594f-4bc3-8f9d-6ce374d8c63b">
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df1070b8-c590-4034-a425-fe383e3ba165">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/15eb25dc-6eaf-4d85-9dc5-c9bffaa65e7e">
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/768b61ae-7fa5-438b-8a27-90e98bff80e6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
        <rdfs:label>HMBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1d9076b-7016-4bdf-a2d9-dc7b411b0178">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bbbded45-e5a7-4d98-9e55-a323a8ef18be">
        <rdfs:label>SLC25A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c35b153-7a27-434a-9ec7-4207ed42084a">
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b3f8e5a-888e-4194-8761-e91840ab8aff">
        <rdfs:label>LIAS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/094a56dd-f734-45e5-a487-2b3b93c9337a">
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a8b82f75-3d9a-4fa1-a844-4d208405a34a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
        <rdfs:label>SLC39A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4e555470-26d0-491f-b751-9ca5fd39f646">
        <rdfs:label>POGLUT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4861a6a-a650-4930-a36a-f6f3a3b885ff">
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3e81c7f4-72a7-48bc-b53a-114608c837da"/>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7bd66a0c-2297-448f-8c43-c298c8cc5f03">
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8b23a27-ab0c-4dcc-8bba-296b95f2116f">
        <rdfs:label>OPA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/38baeaa7-4d24-455e-a873-e651a01c86cb">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01e64856-6129-40b5-b72a-ba57269a6038"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ee75eb1-4f24-4690-8606-b00219241d3f"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6d46e540-666f-466d-8de7-830d447faf5c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6a9e9b62-dcab-4892-9d17-e30a4cec5542">
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c3332809-01d8-461f-aaf0-0dadd9d7c318"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6bd68a4b-88f0-4719-90f4-bfc7bdd85dae">
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe53ace1-7bd1-4e73-809b-ed684e7f6fd8">
        <rdfs:label>TPP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83c3b6c6-ffb4-41f9-b967-d8e827b036f9">
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bc0435a2-7bc9-42ba-bd0c-0eb2bfb79511"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c3dcfb9c-562d-4cdd-96c7-1a5f5162a238">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ae12b9f8-f530-4770-a4f7-a3dc62688f9b"/>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87898c03-1dd6-4988-8570-04bd8212e52d">
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/069ce3fc-790d-40ef-a111-ddae973f739c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
        <rdfs:label>LPIN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8fdef8e-270d-4773-be85-5e11949fcd33">
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d64b924e-c3b2-4ff2-8dbc-bfea25acf675">
        <rdfs:label>ACAT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/81db6dfa-ea14-4a09-9148-044a8d0f1603">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67aa678a-b9ce-41d9-9bb0-e791e282c925">
        <rdfs:label>GLB1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <rdfs:label>beta-galactosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/678583fd-fa4c-4e67-aa6a-32ce4b60d404"/>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae42f43d-d19f-451c-b13f-ddb4c53de613">
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a7209044-81d0-4fc0-b7e2-021d565fbea4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0f6f017c-68b0-4732-891d-f36390ddb3c0">
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fa27e4c9-1aba-4e13-ab30-9d2bfdae8828"/>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <rdfs:label>lamin B receptor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da066b5a-809f-4677-a017-feb2a6b492ae">
    <ddiem:uniprotId>P53634</ddiem:uniprotId>
    <ddiem:keggEntryId>K01275</ddiem:keggEntryId>
    <rdfs:label>cathepsin C</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d98085a-8ddf-469b-bb13-11ce18bdc538">
        <rdfs:label>CTSC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.14.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a9695b7-6077-4caa-aada-c72372b336b0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8965d2bc-3960-4214-93a9-99dca22ccd38">
        <rdfs:label>ETHE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/391375f5-13e5-4304-9e9c-b07eb4c89c3d">
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa3e17e6-50ab-4a12-adae-b3181d7a46f5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
        <rdfs:label>MTHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75c1cdd4-8b1b-4f96-b287-709a5fee9b6f">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f9903073-f594-47cf-be8c-dc9706ca1806"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a98ded23-815d-444d-a210-50b8dc21a0c4">
        <rdfs:label>MT-ND4L</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/543e6ba8-53c3-443d-b6fd-37d754aba89d"/>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51ed80e5-70e5-4f57-afde-39e2d2b7548d">
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/edc79d5f-5e1f-4748-ad52-24ea2fbff326">
        <rdfs:label>GATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3147e885-d51d-4d03-8273-82b73566d6f4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/74703d4a-61b0-458e-9133-38bf6471e1f3">
        <rdfs:label>DNAJC5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/258b5e0b-2be9-4d42-8d8c-638a3d6fcda9">
        <rdfs:label>DPM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/091d3b2b-8cc7-4019-9cb5-7300952af13c">
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a76f0a40-5ce5-4f16-b719-87c477696bd4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
        <rdfs:label>LCAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd2d52b0-c604-4aa3-a205-758c4ac02ee2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/99eebdad-079f-40ad-96f7-644997d82cee">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
        <rdfs:label>UMOD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <rdfs:label>uromodulin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6208f2c9-d22a-41c6-b8bf-de42145d78ef">
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b4d13fc4-57fe-4421-b291-18f51fe008fd">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/204fc037-f997-4caa-bed2-02f4aa51c20a">
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f89e23ca-6f98-4aa2-b8f3-97726c04b291">
        <rdfs:label>PHKG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e308249-ca55-4270-a436-3b2a516ebcbb">
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/92b9d183-506b-44fd-90f9-fae66bd7d194">
        <rdfs:label>DNA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/74a77916-f81c-41aa-beb1-1b23f8cf821b">
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3ad0d439-6d8e-45a4-bf6d-d15814fe8332">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <rdfs:label>Ribonuclease H1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d1df534b-b9f1-4f2c-b227-fa9595989edd">
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/596bf85b-cd13-47f4-b60d-d8a3ed24733f"/>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac369538-676f-498e-8a7d-96ed69a9422e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <rdfs:label>Slow recovery</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012823*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c218cc2-c322-4b60-8c05-7d8be60d3cd5">
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e65dc412-0ebc-488a-aca1-602502fb3cdf">
        <rdfs:label>ENO3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
    <rdfs:label>enolase 3</rdfs:label>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87fa762d-c810-4f09-bc65-4fd31f6dae44">
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/960cfc7d-f72f-42d8-81ea-bded8f52d194"/>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f81d68d8-161a-480b-9554-2468bfa17c4e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b488137e-3d98-491a-941f-dba70c4a50c1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
        <rdfs:label>HGD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c47738d-dc46-475e-886d-bc5628493fb1">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a70cf78a-e8e8-44ed-9c64-ad6f67c38f06"/>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fda7eee2-ae8e-49fb-9a79-2da3ee5c2963">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d87a1111-aa82-43f0-9384-bdea66fe5b57"/>
    <rdfs:label>anoctamin 5</rdfs:label>
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0384dc1c-8376-4f5c-a8a3-3dcd9eaca109">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9a1cb18c-d76e-428f-9608-31b6c13bdf70"/>
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f7fe90ad-e1f6-4a20-b850-3291c20e75b2">
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8930a55e-0854-47b5-8986-034bcb84ba76">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4008ccd-4136-4810-938b-8c75c0f4a26d">
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/adf11c2a-1424-4ed8-92db-e2e5dbcb5f0e"/>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/65f75eb7-add2-417c-8f4d-d470eab9b087">
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/66f7ffa3-0ac4-4bb5-884a-c28fe87dbd50">
        <rdfs:label>SGCG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85045015-3f60-4d10-a199-960f50e39c1d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fdb84e8-af85-4034-9719-7b78e0aacc1d">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86ad1cc5-adcb-43a9-a6d5-0c068007af9e"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3bf5b155-34c6-4453-9f7e-d861a3b44ec9"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3ad0d439-6d8e-45a4-bf6d-d15814fe8332"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fbb1f98f-0fe8-4683-a016-dbd5250ee2e0">
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0df5a167-c06b-4d72-9ace-f5bf474914d2">
        <rdfs:label>GAMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/48eb5fe0-ee3b-4592-b103-e4c72f7a3287">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6d46e540-666f-466d-8de7-830d447faf5c"/>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/572dd353-f703-4ac2-b1ea-bfd1d12c3391">
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53629c1c-c22b-40d8-9e4a-78d673e58eb9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
        <rdfs:label>APOB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2fb34972-ce8b-44b9-9e90-c99abd21a07e">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/699e58a8-6116-4551-9375-5e19e8ebdc62">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3bf5b155-34c6-4453-9f7e-d861a3b44ec9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86ad1cc5-adcb-43a9-a6d5-0c068007af9e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1eaa1eaa-d96b-44a6-9cbd-a56cfa0875db"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d25f20fa-c1a2-4358-bf24-9a6f708c750a"/>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b56f2e30-4f01-4470-abb4-93d59cf2cbd3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e01af460-60d4-46cd-a050-6d7614a3387b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
        <rdfs:label>ABCC8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <dc:date>3.10.19</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc833392-85ae-47bb-8d16-e776a68de097">
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af46d7d1-731a-451d-a573-e112080a5e95">
        <rdfs:label>MPI</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/df6f2d43-5e0a-42c2-ba22-ee162eeb49d6">
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5dde8b4c-af5a-40c9-a86d-ac86083129d6"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b46aff3-b415-41f6-a74c-e013c12686ff"/>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e65dc412-0ebc-488a-aca1-602502fb3cdf"/>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19ddd0ae-1b3a-4a15-a144-407efbffaecf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/437460ef-780a-4376-ab57-3af0912076e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/197aa9cf-adba-429e-9c23-b56374f58976"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39c1d1d7-755b-4ab1-9caa-0fd4eb70de74">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56d96ed1-3dea-4b0c-b827-b64b2c3f74a2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0ce7dd53-278c-4cd2-969f-fc6ca568a974"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee2f3c82-fb41-4035-835e-5a3895ab609a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6252942-c38d-4525-bbcd-73f0addefa64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f33ea64-113e-4a99-b686-49f05a122b36"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eda3ddb0-f1d2-4de1-83fc-f3b22ca4904c">
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f6488152-fd03-47b3-b6d2-c8e6e4bfc300">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
        <rdfs:label>RET</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/65e9d5ac-4ecc-43f3-b9f9-912304bdb8c1">
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bfacc159-3628-48d5-8cfd-a3bdf86c8903">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af00b64e-122b-486f-bd50-870f647a5284">
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/09292616-60fd-47e0-93e2-700122510e02">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
        <rdfs:label>FBP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e7985d1-1e30-4372-87ad-1241eaf91e97">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8484d4be-2efc-4ea4-a1ba-0e04d0dcf973">
        <rdfs:label>CUBN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f7cc1c76-5116-4992-b37e-35db5bcc8c85">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
        <rdfs:label>AMN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1f425e51-074a-43df-83d9-a5e9bb2c87dc">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e20d8718-2f72-4e54-abe2-b02132c7588c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73c65ae4-b139-4c40-b01a-69943b196a93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc80c155-ac7c-4cf3-90de-5a3908fd59a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0054c8e9-b230-4eb3-9046-3cda0c83cda5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5efa7745-d5d2-49c7-93a8-b10122d479a9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fae1173c-ff63-4891-804b-2500e9bb09b0">
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c9a01a2-3085-449d-89d9-bfc90f716e1b">
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4e555470-26d0-491f-b751-9ca5fd39f646"/>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5652066-4937-4670-afa6-df3d542e777d">
        <rdfs:label>KRT5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d13a609a-98b0-4f4a-a068-445504d40075">
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8b40c247-d9c2-46f0-b98b-c48ca8355bdd"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cd44b786-204a-4efa-b418-1beb7b51511c">
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49c963d9-0552-4448-b7e3-84ea1fff7892">
        <rdfs:label>ANKH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6656242f-40cc-4ab9-a7f1-833e724634ee">
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a7cf6b9-ae0f-4620-a1df-9556899fcb87">
        <rdfs:label>GLA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <rdfs:label>alpha-galactosidase A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6debf92f-5472-4849-b064-d5c6dbadd1b1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/308147ac-ee1a-43d7-9f72-d53742df1db5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bef031e1-10a8-4620-85da-db1dc26feee5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d9a6f41-2f4e-40b5-80ff-c7a30e6a124b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07ff3c4c-7cfe-4539-91b5-8507b2e31f64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/3e70eeaa-e50e-4029-a9a0-b38bf96880be">
        <rdfs:label>symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68bd371a-0ffe-4e30-a35b-f462dba29cbd">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:identifier>HP:0001250*</dc:identifier>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a080e21f-4c13-48bf-9e4b-a727a5966014"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/990efb8c-358a-4cef-a6d7-3d1970327d06"/>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e6ff1a8-ec02-4695-90a9-f4c35c097006">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3b1fd8c-fe49-487f-bea0-bb98c0efe1c5">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9b419072-8aa8-41cc-9ee7-545522c28d3b">
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1fd8c141-9876-408b-8edb-1e08bc435e8e"/>
    <rdfs:label>galactokinase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67dec868-4d44-4065-87b6-4af1e5beaa6e">
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/00a6c171-5a7d-4af1-bdcf-07aaeafad53a">
        <rdfs:label>RRM2B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2ebb4ae3-134b-4668-9aab-d96a4a77859e">
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2f193ca8-5707-4bce-9be5-0ac8d752fba6"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bdb84f4e-b449-400c-8b6e-6549ca38f06f">
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca5def42-c4f5-40d5-8181-3a6f24d47045">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
        <rdfs:label>CTSA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7fb5bccb-3992-444f-8b9d-a98bc3b36ce4">
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0ce7dd53-278c-4cd2-969f-fc6ca568a974"/>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ad0d6e26-a0d7-4d04-9194-e84e7aadaf79">
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/090bcea3-18f3-40fb-a26a-ffa2cbe581b3"/>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67e722fa-5d0c-46e2-a07b-2c274ad66c32">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d9c7c3e-dff8-441d-b30e-53e049d40bed"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f9c4a83-2b72-42d3-9e26-9a25209fd999"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1423001-986d-41ec-9006-f21d88994ae1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/814add82-9649-4e53-80a9-8a8865bfdf0d">
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79d328a1-106a-4660-9a5f-202461fdc946">
        <rdfs:label>MVK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8b23a27-ab0c-4dcc-8bba-296b95f2116f"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9172bccf-b282-4088-a3d3-7bd0bdea078d">
        <rdfs:label>COG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b0dd79ac-04f1-4b04-8086-05fc33b3cf16">
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9dbb1120-3114-40c7-8f8f-890e7116158b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
        <rdfs:label>SGCA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e603c88-23a4-4f03-a342-7df1768b6041">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edcc86a6-11c8-4cfd-93bc-0d7e068252fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd2bea93-4d0e-41a0-8258-2a50e59f76ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-016-2044-9</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/443c733b-9f60-4179-a106-74a7efb9b730"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58167006-b1aa-41a9-97cd-d8133c867110"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11197ec3-19cf-4a21-87fa-b5d581bd6e42">
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51e35ff0-3cb1-496a-bddd-3233776338eb">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd76ed1a-42a8-4dec-8160-25fdace349c2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e20d8718-2f72-4e54-abe2-b02132c7588c">
        <rdfs:label>AVP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe1ef078-f80c-4f52-9b2b-b8c4ac0d3888">
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5d625145-4e6f-461c-8664-d1d4e928d1fa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
        <rdfs:label>GLUD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eaf671c3-5bc4-4a7b-98b0-bd26db8df0a2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/08e921d4-b388-45be-a45c-9ff926d471c5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
        <rdfs:label>CBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6e87f37a-20cb-454e-82e9-aab036b01482">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8814a9aa-79af-4d95-9af3-45d1a4adb1c3">
        <rdfs:label>LRPPRC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17964</ddiem:keggEntryId>
    <ddiem:uniprotId>P42704</ddiem:uniprotId>
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20a61a53-66da-4c32-8f9a-59c8fa8fc766">
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a97d23f7-8b5e-4f75-aab6-c59a8b3fd9b6">
        <rdfs:label>SERPINA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a4855fe-b1a0-4206-af5c-9ff10eece435">
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4602656a-5840-475a-83ea-5981f2a64a13">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
        <rdfs:label>ABCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/98eaca18-6287-4c1d-a396-4c37e1ca79c1">
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/db4a085b-87b4-472e-a2a9-971fe856e268">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
        <rdfs:label>DHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7949845f-1877-4531-a6a5-09515e69f03f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b652ca7e-b9f8-43d6-a7b0-d7f17c46cc52">
        <rdfs:label>SLC5A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55416c70-9210-4150-8e0a-853acb55402f">
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab8be818-5020-4188-9f46-d669382e0d3c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed448e8a-b143-41fe-ac89-aceeaa8a6082">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/258b5e0b-2be9-4d42-8d8c-638a3d6fcda9"/>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c510a3e6-19fd-455c-9f65-d79bf247eb9c">
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff7bae78-0368-4952-964f-e993f75d939e">
        <rdfs:label>ABHD5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db0d55e6-8749-4843-a644-78b612581ed7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6dca6fa0-d217-4121-bd89-00ba005252c2">
        <rdfs:label>NSDHL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f36618ed-944b-4c37-a281-4f9695c1d11f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c426778-d4de-431f-be4e-84b1db75c7c3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
        <rdfs:label>FUCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9b91e94-f630-47c3-857e-53e32aeb3878">
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba52f356-8701-4a65-ad5a-30e3e82be153">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
        <rdfs:label>FXN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15fc0ceb-f8f5-42f6-9af8-b37c0e8f3524">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/931ddc04-177a-4819-ac90-bd80d5a960bc"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c911034-e588-4085-bc48-e205aedc7533"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/daa0aea2-e549-4184-81e2-87fee541a800">
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c81753c0-0a5a-4ae9-9b62-ed9926bb2da1">
        <rdfs:label>APRT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c6fe167-76b8-457a-9bbc-89eecd5e632f">
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba4bc30c-eba4-403f-89c7-0b214ad3e26f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
        <rdfs:label>PIGN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/441bc6f9-a909-4621-a3ac-31a9f8685826">
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b1e04ed-a5eb-4101-a1b5-175e002233b6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
        <rdfs:label>KCNJ1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1a0cc76c-6d07-44ca-8a21-22f59d0e8a63">
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7093ccec-714a-4ac4-a627-933243325464">
        <rdfs:label>POMGNT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b018cd15-4fee-4b00-8328-117462b522be"/>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59e543e0-51d4-4768-957a-dc571ce72a2f">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01e64856-6129-40b5-b72a-ba57269a6038"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/feab8b3c-d92c-43c2-8f3a-9297a28361fc"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ee75eb1-4f24-4690-8606-b00219241d3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ace1ab8c-efcb-4bff-bb4c-aca5309fae13">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83adf724-8fdc-453b-8f9f-90a01e329c7b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/668ad5d6-73b0-4b93-829e-ac4a7fa590ee"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbe9f6b0-58d8-490c-9b47-21b9680a0671">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/923c987a-767c-4db7-b59b-8438cef7a58b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4636eaa9-0641-42ee-b778-a1ea4ef63598">
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f6aaacb-e832-4856-97c9-2c16bf1de9b7">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5eb05e21-0ba4-40dc-985e-3b5f9f1e62eb">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/596bf85b-cd13-47f4-b60d-d8a3ed24733f">
        <rdfs:label>MT-ND4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0091c719-fd03-451b-a5ee-0a009e46d0df">
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df651a28-e6b3-4d0b-8c1b-c0dfe5a0222c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bf032858-3fec-4312-a5aa-78b2dc12ecaf"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5653aee2-a25a-4d8f-a8eb-40578867bf6b"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b07325af-a55b-4648-baa0-ae3b79bd2904"/>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1a6d6fab-04e8-4ff9-8a6b-94eb7eca6f29">
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33e02c52-9126-42ef-90c2-a3ccb39b8f7d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
        <rdfs:label>AUH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8d928a3-1c62-41f9-bec7-c05399832775">
        <rdfs:label>LDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/82dfe3ac-c2d5-4fc4-b6e1-73bb2a417ce8"/>
  </ddiem:Disease>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d5b99a8c-b68f-4f4d-8119-ad0a8ebabd7a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b9def35-116d-4957-b417-33dce6e5fc4e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
        <rdfs:label>BTD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
    <rdfs:label>biotinidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1058f74a-40e0-4f41-af3f-d17c58eb804c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5892260e-bc5b-4e1c-9f04-e742d231b791">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
        <rdfs:label>CASR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c15a7e26-3b13-4b18-954b-46b2bf654f3f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d67da1b3-32e2-4164-b6a2-357c81f53f95">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
        <rdfs:label>SLC12A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86cf5643-552c-43ca-8043-e394023f9875">
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0575ec98-6a23-4ce7-8046-3b473580b0ef">
        <rdfs:label>PNPO</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/74703d4a-61b0-458e-9133-38bf6471e1f3"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4c8e494-aebd-416e-8ecb-718413277150">
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6611ee6-2d85-4964-808f-f6f28171905f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
        <rdfs:label>PIGT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ae405e8-5dc6-4fa2-84a6-4bd62a26ed77">
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94304376-02d7-428c-a04e-9b88269c4ba1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
        <rdfs:label>APOE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein E</rdfs:label>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/235d9143-0a59-4e46-8f67-e0a7f43a2e9b">
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53004509-282a-4a31-85f2-3e3616d1e588">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
        <rdfs:label>DARS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c996bbac-e8f2-41d2-bc62-d0993bc5c88c">
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9172bccf-b282-4088-a3d3-7bd0bdea078d"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29a2f660-103f-4a01-8e76-ce3ed0348e26">
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1f136d92-0836-4eca-a3ce-e8b70110313b"/>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/31b2f1f1-d2da-42e4-a1c5-81d6270556b9">
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/58db51a7-5188-4b81-b2f4-ee42f7591576">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
        <rdfs:label>MAN2B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4b49c0b8-c200-4950-b374-fd90472327b0">
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
    <rdfs:label>barttin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a755409-270b-4fa8-b6f2-2404bfab3ec5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
        <rdfs:label>BSND</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a28f0df3-a5b0-4d4c-b8ea-f8a41ba9b2c4">
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6886fbd7-4a1e-4885-a0f7-22dfb3947d02">
        <rdfs:label>MTTP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f5ff8407-0ab5-4fc7-9b54-2ba649003d85">
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a9e732f-121f-456f-96bc-29d3595f03ea">
        <rdfs:label>SLC2A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b44cdc75-bcc7-4728-8047-4060bfa80159">
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3260e0ae-fbde-4bb7-a5f7-12ef6d49a4d3"/>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4d5828f-22ae-4739-8cfe-33453e7dba0a">
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/65dfcc2c-2e1c-4051-97d9-4f959f437d8b">
        <rdfs:label>DYSF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dysferlin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f63997c3-f1ef-4380-bacf-33a44a8ed490">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab48bf03-390c-4c12-b208-05053ce81c26">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6186c734-64c8-400d-838f-1ec582ec3b84">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b0a34c70-fff1-43e7-854b-62019773f3b5">
        <rdfs:label>SLC2A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a634fa85-6daf-4223-b481-6f72c2475e4c">
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ab8be818-5020-4188-9f46-d669382e0d3c"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5a91c36d-9c2f-492a-8cf1-36c75d3e5d89">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/616a3605-fa6a-4156-aebf-3d8d1843a280"/>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf56a01e-aef0-4e3f-bfe6-7577b54691d2">
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7acf969f-12c9-4d64-97a5-1102aead7cb9"/>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c6a9250-ae69-434c-b0d3-660b43bda631">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6f2a790-1b78-4a37-ba1f-9905ec17ff91">
        <rdfs:label>PPT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84998008-c371-4f4e-a7de-18a2068d00e1">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e8e3443-295e-4543-b69c-5fc4b9f6aac5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
        <rdfs:label>ECM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06bf04d0-f1a5-4531-a429-12bb974836f1">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5af374b5-a7b0-41d5-b18b-df5091357846">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d259ab72-271d-4719-bf23-bc1b19e51dc4">
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4aeed686-a74e-433a-bce2-1c82028011ad">
        <rdfs:label>TF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>transferrin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8aa2a5c-f721-427c-b421-5e8f1c5675f9">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d3b1fd8c-fe49-487f-bea0-bb98c0efe1c5"/>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d950c881-ebe8-4aa2-8e04-bc4191748323">
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56c98853-4272-4c49-98a5-d8a89d14c59c">
        <rdfs:label>MMACHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1975555-17dd-42d5-91c8-9fcd0410c35c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/28aa8ec3-07b4-4e06-ab03-9ef6322d8cfa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
        <rdfs:label>LMNA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1cfed7b8-c02b-494e-98e6-167e88013865">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a0b0eabd-bed7-4471-b7dd-1150ed5da8a6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ADCK3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c750a0bd-4a0d-46e6-8496-99737d168ca1">
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fa3e17e6-50ab-4a12-adae-b3181d7a46f5"/>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
    <dc:date>4.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f36777c-9b69-4939-aaaa-4e57b3be34fc">
    <ddiem:keggEntryId>K01488</ddiem:keggEntryId>
    <ddiem:uniprotId>P00813</ddiem:uniprotId>
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <ddiem:ecNumber>3.5.4.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/026f5a3c-95b8-48d1-9c32-27f3ef118bf8">
        <rdfs:label>ADA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e0bc23f7-1d31-4f86-8c9e-bad6ad17c429">
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e53cb08c-2258-4899-9ac7-d8eb194ff15f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
        <rdfs:label>L2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a58fabb8-5635-447c-964a-2b6ecee0103e">
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc9570b3-e678-44e0-b53a-649e96a6aa6f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
        <rdfs:label>DNAJC19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9ae25655-a22c-43a4-8505-4a41e613a917">
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5e6605e-738e-4dd8-8020-0cd3a3d9d73d">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8aee7003-e6d3-4a1a-8320-51a19b6ef486">
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e674ec90-c825-437c-a76b-388b03f5fbb2"/>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3bb34dc1-d1f5-48fd-94f0-2b9e54b8361b">
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0c81a1b6-0abb-4898-a7dd-db4ca9769a00"/>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="https://raw.githubusercontent.com/OGMS/ogms/v2019-04-30/src/ontology/ogms.owl"/>
  </owl:Ontology>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fa0a1129-1ccc-45f8-a36c-23e02c7b6831">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6cd732a7-79e9-43d3-b5b8-04a979c640da">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
        <rdfs:label>DHCR24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b2bf000-bc04-4b76-aa85-c20ee41d3424"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b3b473b6-4d5d-4431-b9d2-8a5ed693b713">
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b8d928a3-1c62-41f9-bec7-c05399832775"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/82dfe3ac-c2d5-4fc4-b6e1-73bb2a417ce8"/>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea1f9701-fe03-4772-8bdb-0f8e04e9d4fd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8ff32dd-2c8f-47c9-9701-08712f360f09">
        <rdfs:label>SLC25A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/646fdcca-93a9-4725-ab15-db0c65ffaeaa">
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/65a3f4d8-e305-4b24-9b12-ae109f991206">
        <rdfs:label>DBH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9ede4765-7e18-4f17-bdaf-d46091887ae8">
    <rdfs:label>calpain 3</rdfs:label>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f646d6e8-544a-4290-bb82-bb7e9fa44a00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
        <rdfs:label>CAPN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6feb7f39-2633-41e1-b8e5-b577f6560193">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0239c591-fce1-411c-b661-c6a8e16dd695">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93e5f0a5-9338-4461-a2b1-c132f1530363"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27086147-436c-407c-9621-7089ccff1404">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3147ad6f-f5ea-432e-a182-0880fb59555d">
        <dc:identifier>DB00331</dc:identifier>
        <rdfs:label>Metformin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1318b239-3416-4b03-8849-895be71bcafe"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d218fca-1f53-4ce5-a59f-2d2ec800c31c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c16c9e8c-5d0c-446b-b573-699d1732a704">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Decreased muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9dbb1120-3114-40c7-8f8f-890e7116158b"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6c219a9-80ff-4ca8-b96e-25e14d7cb69a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bc83627-f589-40dc-9ac5-682c0b42ed8e">
    <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
    <dc:identifier>HP:0025201*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aab4a0cb-861b-456a-bc7f-f1d1eb52b836">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b0dddd9-c627-458c-a88d-e18fa219e4ae">
        <dc:identifier>HP:0200114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic alkalosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93b6dfb3-3540-4844-a52d-5cd52c4f3a90">
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <dc:identifier>HP:0000407</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a755409-270b-4fa8-b6f2-2404bfab3ec5"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f34aba8-ef45-433f-8758-ea0e73883616">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a2a35a2-124b-43a4-846d-e7d26d5eeeea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdfc0005-eeb3-464e-a2ff-838835a1ab57">
        <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfe0175b-c659-439f-aead-e1e40cba8e43">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>Hypokalemia</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a2d62e5-145e-47bd-8979-ce7b75e50121">
        <rdfs:label>ER-associated degradation of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcf06710-0af5-4062-9e0a-348b2cdf05fd">
        <rdfs:label>Mislocalization of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21fa99f9-e50f-47de-9579-97411473f0df">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5326d39a-8e9d-4ed8-b17c-2b6f5ec2ead1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f7baf5c-b7e0-4ff3-ba42-42c748d869ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bec9cf6-a8ff-4a5d-83d6-63b4c652de7d">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68edac5a-71ba-4f6d-b07e-539b242d3cb2">
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <dc:identifier>HP:0001712</dc:identifier>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a7cf6b9-ae0f-4620-a1df-9556899fcb87"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbaae0d1-04c7-426b-8c7d-7577cb2c8146">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31a9268f-6980-4495-a981-277e41d2ae57">
    <dc:identifier>DB04075</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2456759c-c067-441c-a473-a5102a80ab80">
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5ae967f-4e3b-4a54-8347-8ccb04d5aed9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7134f16d-e1ee-4691-8556-e174bb40ea58"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1318b239-3416-4b03-8849-895be71bcafe">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f9c4a83-2b72-42d3-9e26-9a25209fd999"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27086147-436c-407c-9621-7089ccff1404"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b5c9b53-7cf9-4991-964d-269532328b11">
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormality of movement</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f">
    <dc:identifier>HP:0002630*</dc:identifier>
    <rdfs:label>Hepatomegaly</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0216987-e777-4cbb-a6fb-d28389dcad67">
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba4bc30c-eba4-403f-89c7-0b214ad3e26f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d9a6f41-2f4e-40b5-80ff-c7a30e6a124b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/825598e1-ad58-46b7-83d8-ef088ea42a65">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/447fb91d-cd55-4be3-89a3-c17647ce29f8">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d613f263-5152-4728-9ce3-16cbe6bf795d"/>
        <dc:identifier>DB09449</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
        <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e009378-edbb-44d1-aada-d24fc50008ee">
        <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
        <dc:identifier>DB14502</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d613f263-5152-4728-9ce3-16cbe6bf795d"/>
        <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa672ba7-dcc8-4749-a15a-818e9ab3e56d">
    <rdfs:label>Lovastatin</rdfs:label>
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/807e2f45-a7ac-4a23-9095-fa2ab611fcc0">
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e6366f4-210c-4bf3-8ea4-ef7bf2cccd34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b08758a3-9b83-4536-a470-3535cf699e6c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a715149c-8445-4c15-9d90-f5e16646bb08">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b62a7452-578a-42a6-ba4a-42a65098961b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b08758a3-9b83-4536-a470-3535cf699e6c"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1898fe5f-9c66-4bb5-a019-72bfc4f682ae"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c9cf5b2-13e3-4a26-8b51-a0f63fa69759"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc1da5c6-9748-4dc7-a1ea-f7c1e84fe29e"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d862554-5b4a-4a76-83cb-7325e032cbbf">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1d799582-a3a6-4d0f-ba3b-1e2197ddade5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b08758a3-9b83-4536-a470-3535cf699e6c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
        <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/160a6374-91a4-424d-8604-013dc606fc62"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d921d021-140a-4e9d-aa47-600b083d86b0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5afa2617-8dca-47f8-9e1a-574ad1a5a3e5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/246d6ed6-b97e-4458-887a-ceb951fd1ceb">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
        <dc:identifier>DB00026</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ce1a705-0ce0-45f4-8dfe-14dc7d13ad52"/>
        <rdfs:label>Anakinra</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91641809-e16e-4c2e-a9fb-3fb150d90bb0"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/325bb5b5-0f7e-457b-8bfb-80486eb06826">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ce1a705-0ce0-45f4-8dfe-14dc7d13ad52"/>
        <rdfs:label>Canakinumab</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa002fcd-63a7-47f8-8d95-50e4e7029433"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
        <dc:identifier>DB06168</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56209dbb-c1aa-49f5-830b-17d647e55443">
    <rdfs:label>Tizanidine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
    <dc:identifier>DB00697</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ee072ec-e17a-48da-8c89-14a80df7b77e">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ad638cc3-f3f8-4de0-990c-f556d40b7683"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a462da46-c1d6-4762-af6e-bd32fb11b57b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76741262-f10d-443b-a736-4834e8df9dc4">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>retarded growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/017fd858-985d-4889-a745-a9822fc5272c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82aad1e0-28e3-4692-bad1-6624b7ff3804">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0003304>I278T</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f838fae4-f4d8-4675-9ef6-fef5e4196d01"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af6e62b-08c5-4090-8c6f-5a9c1c322d57"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00188</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89cd9530-37af-481f-ad66-a9cc20d95bc2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa80325a-7838-4e27-a629-3af43baaf297"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ecc8d8a-f2c1-4cf0-b031-e76bd6077ff8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7450c3fa-99db-49dd-93c4-906f389e7bfb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0565e16e-54f5-48f9-9ba6-6d6b428386a9"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263700"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f838fae4-f4d8-4675-9ef6-fef5e4196d01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Bortezomib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4fb23fe-f261-40c0-85d2-4afae0a28ad2">
    <rdfs:label>Refractory Arthritis</rdfs:label>
    <dc:identifier>HP:0031375</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/01e388e3-667f-4ad0-9a36-2d66b5c8bde9"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fdaf81f4-80c5-44f6-8d0f-95370c1bcaa8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a8b82f75-3d9a-4fa1-a844-4d208405a34a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21ab0f5c-1012-4d80-bc83-50464dfe23c3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>skin inflammation</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ce6fa19-15ea-4275-bae7-e187a526ad5f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb591fb6-5b90-4782-84c0-8bd4057dd951"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/513eca18-8dbd-4b1d-b863-d982e265c69e">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:label>diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5f4e8c0-9440-4509-8765-fa01c8869532">
        <rdfs:label>Alopecia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001596</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ebba2df-2ed3-42e2-9667-3fd256caa7f3">
        <rdfs:label>Agitation</rdfs:label>
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e6e9531-08b3-44d7-8fcb-6ce69cefe2b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/164afb19-3b3c-4da9-b314-28ee4143c4f0">
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>emotional disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/559f5aa0-0bd3-4b34-8378-c6d553928c15">
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/087b357c-6263-4303-9a00-69e6f2bb3981">
    <dc:identifier>DB0084</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/13518389-b182-462a-9191-903f07924f7d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d536e237-6794-480d-96ce-0185a81f563d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97a7a5a3-37ca-4cde-9214-2202ef1d063d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ddda299-1ff2-44c2-aead-67706f8e1b87"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/370bd89d-ee1e-4fe8-9de1-edfd76972eee"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/357904aa-35ec-4515-975f-4b62d46bad99"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fefe6a3c-a4f1-4eb8-babf-297495ddebe1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/722c2c1f-ddb3-4d4e-8956-9d4b4c25900c"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d903784b-9736-4c04-bdf3-b87b09cfac55">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d1ae3b5-6cf1-4c39-9a27-b978f3361e07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1126ea04-8868-4136-a6ae-36a52ed2d653">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/8ffc05a1-5f11-4f5e-86f3-4e6c274d1913">
        <rdfs:label>metabolite replacement + symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ce6fa19-15ea-4275-bae7-e187a526ad5f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d498316-be8d-4905-81ce-f9d6f104ca1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71b16e77-8c87-4599-9684-e888ebbc1667"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e088f87e-5a9f-47fb-90aa-0791dca015ab">
    <dc:identifier>HP:0000821</dc:identifier>
    <rdfs:label>hypothyroidism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbe026da-7463-4e18-ae06-d274d62bb563">
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <dc:identifier>HP:0009830*</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef5fee1d-e0e3-4c64-accc-596757e3a9b6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfb17dd0-dbc1-4fa2-a412-46d7b3582683">
        <rdfs:label>growth impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f33ea64-113e-4a99-b686-49f05a122b36"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17885562-f91f-4976-9a9c-3e08db261a88">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/118ddc4f-8c3a-403d-827f-cf980e8303a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
        <dc:identifier>HP:0002011</dc:identifier>
        <rdfs:label>nervous system abnormalities</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/027d437b-b931-4539-804f-633e8b67fe89">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurologic dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/696fca4f-c39a-4835-8b4c-d43775c51dbd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <dc:identifier>HP:0000488</dc:identifier>
        <rdfs:label>Retinopathy</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d70b529d-0984-4d0c-9c28-b9ba753316f2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc015d81-eb7c-4185-be98-87df98f86aa3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7721d2f5-8219-4d29-92ff-3f1cec71f476"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/488a836c-a225-49ce-8e37-f96f91d5030b">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ae621d2-7dd0-4d18-b4b8-82e0d0e0b115"/>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f7369ec8-d143-4bf5-a2ea-ab53a8344f49">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60c1f563-0953-47c0-af22-7a3a0150c231">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e65a7bca-c3b2-4751-b40e-509b92f99d17"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3067bf0e-90f1-49d7-9953-ff26bf0049a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Recurrent infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56fc0e65-b081-47f0-b02d-34e51dd8de4f">
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>Neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20e03af5-bbe2-4f55-8517-93d073e347ba"/>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4f45fe4-0632-4e67-9fe4-6755a19cd115">
    <dc:identifier>DB01323</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1a4821e-d224-4d10-a7a9-79f3536cfb8a">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40f13438-0ae3-4861-8058-84d233d52ed8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20f34742-b191-412e-849d-6eb1528d661c">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67aa678a-b9ce-41d9-9bb0-e791e282c925"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd9b9b66-5ca0-4870-86da-0790f787ef94">
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89b27164-7eaf-42dd-997e-f3548714ffc2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0b73e6e-878f-4f9d-bdad-8eb16cced690"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/dfbcd5ab-7e10-4a86-87f9-6567448c8c8d">
    <rdfs:label>compensatory complementation of a genetically defective protein</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50ca0dfd-1d35-4375-b98d-f8789c89b428">
    <rdfs:label>Decreased cellular ATP level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011925*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb33b96a-7ca7-442d-9d32-454ca6f6aac0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb28d451-41bd-4ad0-96a6-efa01269c560">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c178836-3b68-4b8a-a5fb-014a0155d26d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5056d4c-2fa1-4bf4-ac23-e19548fa1402">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
        <rdfs:label>No result was accessible</rdfs:label>
        <dc:identifier>HP:0100851</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b8ca2d5-9822-4578-b4e5-11e309c02fa2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9448e67a-296f-48c9-a134-88ec72b08dec"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f735b17-fd6b-43f7-9014-463f494df1f6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70993780-3208-4a52-bef3-4f13ceb72672">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97279320-f903-46d5-bf5a-f80d8e4fc504">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0001513</dc:identifier>
        <rdfs:label>obesity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/403e211f-c4aa-4c24-87b2-a47d616975d9">
        <rdfs:label>hyperlipidemia</rdfs:label>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d31d641c-e553-4594-9e23-979ba783d069">
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <dc:identifier>HP:0000855*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/565ce558-6f22-4485-92cd-6a6cd9cdf076">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:label>lactic acidemia</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d0be932-45ab-4df7-a08c-91eac2b09be5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9525309-65f6-4c58-9f79-441a8119780e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2da55ace-ec33-4038-ac7e-2ff1072a7ef5">
        <dc:identifier>HP:0002149</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:label>hyperuricemia</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23dd5d4d-a2e8-4f6d-8a0f-f73574a0f9d5">
    <dc:identifier>DB00502</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b685bc5-750e-4785-b739-34c73ed34ce4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7d6a40f-762e-4aa2-8821-62b412d1a53d"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/798b083a-6a34-4ba4-9d13-64308e5968a8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Haloperidol</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78b23cf8-0b79-47d2-9288-eb1b3a2d2e31">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2743c4d1-28dc-46d1-87cb-f8eaf69ed5fa">
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>Short Stature</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b07325af-a55b-4648-baa0-ae3b79bd2904"/>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551">
    <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e6c51e9-3180-4c57-9cdb-6a2b25cb4d7a">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c7581df7-da3b-4a4c-9d02-9d3ad3512051"/>
        <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d4baaed-c7a2-4b00-adec-ece3c83dfbf6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:label>parkinsonism</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2047f25-10c1-4397-96b8-d45dd12d956f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95e31b7f-e428-4510-9b0f-243e05f6d7ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77d56c9c-ad03-4622-aa22-4244a8935248">
    <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
    <dc:identifier>HP:0001112</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cb42475-2cad-422f-8997-058368225718">
    <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
    <dc:identifier>HP:0011990</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5eaacc8c-9863-47f6-8744-f4414287c29f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ce6fa19-15ea-4275-bae7-e187a526ad5f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c32e56fc-81c1-4e39-aff2-aa54e918f517">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased ROS formation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22b15f68-c9f0-443b-aae9-bbdd97e4d421"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12970230-200f-4281-b49c-1e3a00330013">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a4a046c-a7e1-43d3-b546-154590cd0020">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a3f6eae-affc-4ba6-804a-d2d16cd21634">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological abnormalities</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf19b3bd-c748-4ba6-994a-c3f5470af27a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e37da3b1-5565-4fc2-b231-f98dc0d6b42f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/957f5f1c-f002-4fc2-b702-1d981130c7ed">
    <dc:identifier>HP:0012449</dc:identifier>
    <rdfs:label>Delayed mylination</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fe06fed-3550-4b6e-bc12-acc22811c80a">
    <rdfs:label>Diabetes</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <dc:identifier>HP:0000819</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6829befd-7888-4dc4-9879-2ea3d33144a6">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002719</dc:identifier>
    <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e605f16-70c0-48ce-a6d0-e4d80e1c6dbb">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72259ed6-e219-420c-88ca-92478a7f7f04">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Chronic kidney disease</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2277b668-6646-4336-9aa4-d595f0df4a37">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f8ee56f-d52c-41bc-bb20-f20bb1a9bc91">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000790</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <rdfs:label>Hematuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9e4cbb0-ebf0-482b-bed1-878f8ded9708">
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
        <dc:identifier>HP:0000010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2fa75b3-ee8a-480b-86f4-4f9c81d1b4bd">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Kidney stones</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c81753c0-0a5a-4ae9-9b62-ed9926bb2da1"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b23507ae-0308-49c3-80c6-bfc460c146a0">
        <dc:identifier>HP:0100518</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:label>Dysuria</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/149a25b0-6bd1-4228-b2a0-f15618f4a2c1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d36f622-d5a6-4ce4-8ccd-4097e2667379">
        <rdfs:label>urolithiasis</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000787</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/593b184b-6e7e-4ca0-945d-5cc9842a66fc">
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>crystalline nephropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be2122af-0b86-43f9-b04d-7a8f9ff63169">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30c993fb-b91f-4273-b938-d6b476d29efe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>thrombocytopenia</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cea46c4f-cc63-484e-8900-f36704bff364">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <dc:identifier>HP:0025547</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5ec0d32b-7895-4f5b-9607-e120a0e64ae8"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ca2f1ef-2239-4cb4-9c79-c313e7ec51fa">
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b37d0fed-4c2b-4d8e-b925-1e76e89e96f5">
        <rdfs:label>anaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499">
        <rdfs:label>direct complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c236408b-6bc3-4934-a190-cbd59310b75f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>Splenomegaly</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1e1642f-5b33-41b6-bdfb-33d9f89653d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/602bfb8f-fb60-4b0e-a4c3-ccc832d61a3e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45ce952e-d0f4-4ee6-ab13-eac7a20f6b2f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
    <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
    <dc:identifier>HP:0012217</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71680fb9-cef0-4487-9d2a-a50fda57c931">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c209bba8-62a6-44da-b3e1-b2874a24bcba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a744d6a4-5848-4855-85ac-9336818f566b">
        <dc:identifier>HP:0100614</dc:identifier>
        <rdfs:label>Myositis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d28536c-1a4a-407b-b997-aff768627d07">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9407b757-02eb-4a09-9715-8d98f4d7e7af"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6d46e540-666f-466d-8de7-830d447faf5c"/>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c6ba068-d63e-4a11-b0f3-acef94a364c6">
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>Rapid progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01e64856-6129-40b5-b72a-ba57269a6038"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27585449-b61c-4718-9bca-b57d13c7401e">
        <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040081</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85f97363-7c7c-4be2-b51e-91547994f977">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>cardiac dysfunction</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dda3f269-ecf2-4e43-9e28-d9e1336a1b5d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/080482ce-b5f7-42ab-a98b-57768bb9aacd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ad82a62-c450-4afb-8c1d-13299a250832"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af07f989-695a-410c-90a5-41ae77fa1e96"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c88958f-26da-4625-aa0c-dc94d80c5a69"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00603</dc:identifier>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43069fea-6a5b-44e8-9a75-d30534da85af">
    <dc:identifier>DB12783</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd18c404-e49a-43c0-9b1d-07a6f507d019">
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6484e092-33d6-480a-bb63-18b40a32aae8"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a2c48a6-ac41-4db9-b91b-8cc87abbf869"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Benserazide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9e9c9ae-46a3-4e85-85cb-4129389f225b">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/778af531-3158-4c87-9b21-c7356b4ac614">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cb99f976-a911-49dc-a8c8-7198c160ebe0"/>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/259c72f6-dacc-4a19-8a09-ad96f46f137a"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
    <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
    <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8b5237c-11ed-418b-a144-19319e87ff7e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a0b0eabd-bed7-4471-b7dd-1150ed5da8a6"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6739fb6-52cf-4fad-be4f-e64f19140adb">
    <dc:identifier>DB01329</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <rdfs:label>Cefoperazone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9727076f-88a1-4f33-a316-52b2959a5553">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/973c5339-2d59-47c6-a061-8f675756c975"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cff3a9d1-6a7e-4316-848d-374b6fbb657c"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ade92ca8-00a1-466d-a856-260feb2df748">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67aa678a-b9ce-41d9-9bb0-e791e282c925"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7644eecf-ae2c-4250-bd35-c3c95345b054">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89b671df-cbb1-492a-b656-99eb311c18b5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a9271d5-afc3-42f1-a85a-f42e47b59573"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75fd871b-2ee7-45b5-8419-ca773d6be6b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58a24a87-1f00-4bfa-8f3c-df0ab95ebc2c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ketosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <dc:identifier>HP:0001946</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/40a9220b-712f-477b-a86b-4d2da22c18d6"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d511ebd4-a051-40e3-9043-f90eaffbc756">
        <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <dc:identifier>HP:0012051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4b12da4-2214-4583-9d1b-d6e8ebe6572c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64452907-4692-4aaa-a868-fcaf75844d11">
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5128e39-c25f-482c-ae27-80dced2a6511">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0100786</dc:identifier>
        <rdfs:label>Hypersomnia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/beaeae42-bf6a-4821-bca7-45371c702be0">
        <dc:identifier>HP:0000952</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Jaundice</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9afa76c2-cc38-4171-b74c-1fa8bd090b5a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8ce967d-b397-4dfd-a593-e014005004a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa6f15d2-89df-4c03-8fda-5bce842c0f34">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da63acb0-39a8-416d-9434-2094730507c7">
    <rdfs:label>Postural tremor</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
    <dc:identifier>HP:0002174</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6549a7a1-8e79-4e70-bc12-78a1e589cd1a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d6ceb86-c9c2-4407-9205-45213248149d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a6ecb1a-7d90-4748-aae5-f7f071466459"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a530071-8075-48b6-b4d7-c20b5137f11c">
        <rdfs:label>affected functional activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8710776-8fef-4496-b304-b09a1d2d46b3">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/234a4ac0-3740-49a7-af21-45aad98bd64c">
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>Decreased plasma carnitine</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4732eabe-b58d-40e6-b16d-3cb0dd06c651">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2a7889b5-a4a3-439b-b9aa-9e732e1f9ee4"/>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23960ea4-5ae2-4d83-9be4-c28eff5c0832">
        <dc:identifier>HP:0003281</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c12de0d9-0600-43fc-a59d-5f90be52902e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a60fbdc-85a0-4538-85d1-c278c0c25b49"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c281ee2-c70b-4388-804e-68b07b762b1c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83e12fa4-e0a2-4b35-9aa4-b889dffdaebc">
        <rdfs:label>Myoclonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e7f117f-3a2b-46a5-a66a-af2e70562013"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35fd9339-df1e-49dc-90a6-dad58a0dd2a8">
        <dc:identifier>HP:0000735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>Impaired social interaction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fd6ecf9-7155-42cc-b08d-ae8284cc705a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Movement disorder</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa3e17e6-50ab-4a12-adae-b3181d7a46f5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80c8bceb-4380-4158-a49a-e3c33bf7c1ef">
        <rdfs:label>astatic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7c9568c-1aef-46ec-ac63-b6d1ff710e21">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
        <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
        <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bcde477c-417a-489c-8abe-9ba050afcf1a"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49290373-f6ef-4b83-aa0a-5ff2a5ed197f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>Anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bef80f0-45c9-44c7-a187-113b4f1a5326">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/440e8a0f-7c6c-4141-b44d-942219ad952c">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
        <dc:identifier>HP:0012594</dc:identifier>
        <rdfs:label>Microalbuminura</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffffeecb-ec71-4992-a1e2-ba0891ec5643">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:identifier>HP:0002907</dc:identifier>
        <rdfs:label>Microhematuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb1114d7-9887-40e4-b55d-8297eee0d77f">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afd9266a-0bf6-47a8-9878-3aee4d403c1e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c852d06-f279-4c5b-8743-6833f6ead59a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/430e3e21-5b10-42e0-8803-a8f60289f82e">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2338df35-ce83-4558-827c-1f04729006e9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2113ea08-cf96-497f-8670-0460477f337a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:label>Low dopamine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1824033b-c027-4dcd-83da-74b4b05db12c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd34dad5-6b33-49ef-981f-8349c0924848"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80f27ce1-6b4a-433a-8121-5f7a24753424">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b56416d5-bfd4-4c16-86f2-a29534164927">
        <dc:identifier>DB01956</dc:identifier>
        <rdfs:label>Taurine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8fc6c003-73e4-441c-89de-18e8cc1acaf8"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93c1d203-1e9c-436f-bf93-70a421770652"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6e6e606-0ec4-426b-a168-3014c5016968">
    <dc:identifier>HP:0005135</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
    <rdfs:label>T wave abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57beba64-a75e-412e-aea0-ecff467679d4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4d35794b-96da-4757-bbcf-3df489b76325">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/953bb473-ed20-4b35-8969-f7f06452ce0d"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adc021a8-de5c-46a9-94a9-08e1f19f1abc"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/575fb37c-e284-49c7-a316-aaa15cfa6208"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a077a9ba-1777-4735-8df4-5453e9b43845"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e3ad3d7-9d7b-4a02-bb7b-41f6bfea1d60"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
    <dc:identifier>DB12536</dc:identifier>
    <rdfs:label>N-acetylmannosamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d4f6e44-684d-4d8c-954c-f53d9b68e540">
    <dc:identifier>HP:0003107*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:label>High desmosterol,cholesterol ratio (Abnormality of cholesterol metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa632dfa-4252-4be8-bd9c-c8b95888f5ea">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ebd6e2b-4016-4fb0-8247-ef3c51a068c8">
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0e0c55d-249d-40cd-acdb-21d61dcc341e"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c72d14a-e4a7-446b-9ae9-e3d8332a09f9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <rdfs:label>Ketoconazole</rdfs:label>
    <dc:identifier>DB01026</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c467bcd-9515-4eb6-8e9a-bf10f7a4836d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe010a9f-32bc-4beb-b9e9-6cfa7648fe5a">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df7b9baf-39bc-4b80-881e-184c177ce245"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/551cbc01-8146-4388-92cd-fa9217c3d322"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8aeb3d3-36e9-47e1-84d5-e754e9329d56"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
        <rdfs:label>Biotin</rdfs:label>
        <dc:identifier>DB00121</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb55e838-1749-4793-a6c2-ce76643cf359">
    <dc:identifier>DB00650</dc:identifier>
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c281ee2-c70b-4388-804e-68b07b762b1c"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5776a97d-d4d9-4613-aa80-0447ae5e9320">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf91abd2-e667-4c70-8b18-0aa08fba5dbd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd33b2a9-4874-4086-8f89-fa196f2fdb24">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1507d156-ec38-4188-af1c-eb8472ec7b98"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65ca935b-3739-4898-89ee-0b07f7aaeaac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f51a2c66-a202-4bb7-b993-d66cbddb75e7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/036a3761-c7a6-4903-afb0-78956f33dc29"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7b527ba-b0a8-46b1-a246-10df229e41c6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46e4f447-0b12-40de-81bd-df57c8e5e015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2c7e6e66-1ca5-4202-b0ca-2d94764f1fb8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c3a7436-b759-4b6e-8ff1-1372173830c8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32bc8a69-e4a4-4350-b241-6ee5e6192fbb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a33e1ec4-6f12-4f5b-8dd9-a70e064a7d9f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db18ded5-f01b-4be3-8c9b-788f58c4197c"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/473923f5-7d78-423b-87dc-84521f4bd498"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aeca315-56f4-4aec-a187-8df9f8876248"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c6fd3d0-7915-495e-9819-4b981f3547b3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7b3a167-071d-4170-8982-ce748981d7b2"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e598bf55-6e98-40a8-acc6-8ba6a45fc57e"/>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/707e62c1-8d20-4a8e-9bd6-6335c5bf9042">
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/540ce34c-87f4-4407-9b19-63c75116f750">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e05fbb1d-7451-42be-b64e-8b2cda0a3329">
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.malacards.org/card/hepatic_lipase_deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97e6cc28-f8d3-4d0b-b099-de0cce802172">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1e1cf973-3af2-4c71-9be6-749444e5fe79">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/806e584a-d01e-47a6-a2b0-28462f25ee5e"/>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB11677</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2fb8523e-a83a-4347-9d30-fad362cd1d6b">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ba1574f-9c00-4d58-bce5-cd588f0e7fa5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab54a6c5-af4f-4402-9358-3ea4d20a5b0a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59bd81be-339a-4162-9381-3099ea7fb987">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abd8bf28-f332-46f0-a333-c23ba8189d35"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d34d14f5-b1eb-42d4-b3e4-705f4d984af2"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263570"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f58035b-c316-4e3b-b307-a9e312d3b767"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6746da2-76e7-4b96-a791-c9eb4463e410">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31fb932d-ccec-4e47-826c-92c5083115e4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4757c44b-c044-43df-a7cc-6fd152766b44"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d34d14f5-b1eb-42d4-b3e4-705f4d984af2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>PMC2676979</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/388b8f6f-402b-4d71-bda0-0d6ef1e0b575">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
        <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d956b54-b839-42c2-8f49-fb11ad0afed8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18e29b6b-9f02-4f8c-91f8-e15651599d1e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/272b6dff-53c7-4deb-bc95-d56e6b2f9c87"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f533a2ef-c6b8-4b60-b1e5-0af3df024da0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/470db80a-96d9-43f0-aea2-80f468622015">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c59331a5-75af-4bc5-b34c-8c6408e701cc"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aba6f615-cd78-4a8a-ae55-695e003cd1ce"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Triheptanoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30b37d8f-a00a-42ec-92be-ab73d715e306">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3337e7bd-42db-4230-bf5e-306f1d4cc797">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
    <rdfs:label>Joint disesae</rdfs:label>
    <dc:identifier>HP:0001367</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5328e27c-89a8-4736-abd6-00a93faa407f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39bf3cad-ca43-487c-82a2-e6917a921243">
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <dc:identifier>HP:0003434</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25e37a37-6301-4b6b-be57-e40e497e941f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/79d328a1-106a-4660-9a5f-202461fdc946"/>
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/156b97b3-7795-40aa-9ed7-6f6a845525e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>Pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cea2b93c-0af2-46df-98d4-4b94377a823e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/570440f7-9a0c-4690-972a-e176284741bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f31f01b6-6687-4532-b0fc-5170a21debb9">
        <dc:identifier>HP:0012649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Inflammation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31ea34b1-be42-4351-bc05-1e97640acbdc">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>Oral ulceration</rdfs:label>
        <dc:identifier>HP:0001945</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9823a038-bd0f-4239-ad69-7c21be01c66e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Fever</rdfs:label>
        <dc:identifier>HP:0001945</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/008f060d-9271-4ca5-a973-9430f14de8da">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal cellular proliferation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
    <dc:identifier>HP:0031377</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/38c08611-f032-412a-935d-a6e358b66d31">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb861352-7e43-4ffa-9069-05d7f01555a9">
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6684e63e-58bd-4d13-bd5d-8d335726c8e7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
    <rdfs:label>NeuAc</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/032a5f38-1e87-4afb-be59-f0489e13a795">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/953bb473-ed20-4b35-8969-f7f06452ce0d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6684e63e-58bd-4d13-bd5d-8d335726c8e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a077a9ba-1777-4735-8df4-5453e9b43845"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca9b44e6-b3e9-4605-81d5-bfadbed3fe33">
    <rdfs:label>Milrinone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13518389-b182-462a-9191-903f07924f7d"/>
    <dc:identifier>DB00235</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21fbd864-1740-4daa-afb0-e6939d1bd8f1">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1172aca1-9a90-4389-917c-923c92535905">
        <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19aeb085-8434-4f8c-8eac-db63c29cb8c2">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/891baef2-5e17-4140-8794-938fd685122d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31cd95df-be3c-40df-9653-b0684989f231"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49290373-f6ef-4b83-aa0a-5ff2a5ed197f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a89b3c7d-46bb-4b76-bd57-69e563b8b088">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa2b82da-6b09-47cb-9c24-9944056745d2">
        <rdfs:label>High ferritin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25b935b5-869e-4879-81fc-c6de1053b3e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <dc:identifier>HP:0003254</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba52f356-8701-4a65-ad5a-30e3e82be153"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/016f65cc-5a00-4459-9cbb-fb1c3d4b833a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/568899cf-ea30-47f0-b956-72c44713cb6b">
        <rdfs:label>Low Frataxin expression level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0684f7e6-c5fe-4bf1-8eeb-e389351161bf"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f9ca3aa-8eff-43ef-897c-9d2f19b59705">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7290e06-1b30-4d9e-ab08-94295da7d94d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/dfbcd5ab-7e10-4a86-87f9-6567448c8c8d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f79624bb-6cb7-4c5e-b571-e04e429cbb62">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Tiredness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a74d6c31-1419-40e6-9401-7e472b17820d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <rdfs:label>Clofibrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ce2a1fd-6790-4635-84e7-8e24f44b6f0e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d224aa7-9cab-43f8-aa3f-10a19ec53409"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc39d0a9-6007-4305-bb06-922346b7f130"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00636</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57904ac1-4d67-4fbb-9579-28d748a09b38">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05a71b1-c61f-4ad4-be7f-0d8c5875c4fd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d224aa7-9cab-43f8-aa3f-10a19ec53409"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5f2b59c-9859-43bb-9e90-11cc8358abe3"/>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14df3d9d-3715-4ac4-9305-6235d17a6442">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d224aa7-9cab-43f8-aa3f-10a19ec53409"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e6366f4-210c-4bf3-8ea4-ef7bf2cccd34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c42fd5ff-ada5-4f47-9c41-f9e710a99c15">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12ddbfca-a800-4e4b-b1bc-df9fd7de8f2e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000531</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <rdfs:label>corneal crystals</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8f2eb05-a757-4c69-a75f-d93727babccf">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1bccd43-50b2-49f2-999d-a0128f921ef9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Photophobia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <dc:identifier>HP:0000613</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef8861ff-04cf-4abb-9cb9-f2d835a9173c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
        <dc:identifier>HP:0003358</dc:identifier>
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e088f87e-5a9f-47fb-90aa-0791dca015ab"/>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0950eb5a-e60e-4d21-bf5c-f2f8862e5c53">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:label>renal function declines</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5528a879-8b7e-4421-8759-3deec2110390"/>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60cf71ac-620f-457b-8eb3-4598d8832e27">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>glomerular damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <dc:identifier>HP:0000095*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56489e74-cc7e-40b5-9d32-f066910dd562">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69c2ad07-4678-4b35-8917-63322c5debe0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86ed0ce6-39b3-4894-96c6-b2e4a017b0f3">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>shorter life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/208df92c-d8a5-40cb-a22b-91580b12de5e">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7e42712-1bc2-4410-a219-56b7ab153666">
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab3cabf8-2758-4899-8be3-b6da9663764d">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <dc:identifier>HP:0010918*</dc:identifier>
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1bc4985e-0d61-47a4-ab0d-705a02322690">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0684f7e6-c5fe-4bf1-8eeb-e389351161bf"/>
    <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aca537b8-76f3-4d21-a568-c1b2077b40ce">
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040144</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a19948d-5ee9-477e-8209-570c30328d91">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <rdfs:label>Leukodystrophy</rdfs:label>
        <dc:identifier>HP:0002415</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6498e053-5386-46e5-a348-482ab7e08744">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4633b926-3caa-4b80-8c9b-90d4415b664c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25bc20ed-6534-4a02-b1ec-1be2657e1bbd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7586c52b-7cf4-4895-bc13-ec0a47ecfa7e">
        <rdfs:label>Scaling</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87a13282-138d-4d9b-85ad-79cae167dff9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a1d91b4-5df9-4834-a1e0-09168726eea9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5f958f2-0fcb-4ded-80af-5971b8481692">
        <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a1aa186-e23b-43d4-8044-a02788d97530">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:label>Ichthyosis</rdfs:label>
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f90982d-4df9-49a2-9385-7e278bc39f48">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <dc:identifier>HP:0001019</dc:identifier>
        <rdfs:label>Erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfb63cbd-cf8a-41a9-8eb3-da007ccdfd6a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4600c1cc-c606-4681-838a-a07130fdc39e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
        <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
        <dc:identifier>HP:0007479*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff7bae78-0368-4952-964f-e993f75d939e"/>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/828c26b4-e0ff-4373-b4e1-bc2af3c02b9e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b957bab-a09f-4fc7-b768-b232c2e0cd1b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a04b132c-5e0c-4bd8-a127-57a8e1d822a5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d56a02a9-ec56-4a60-90cb-a772027b090f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be59f880-a8dd-4044-987f-57ccd4f18a41"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/960cfc7d-f72f-42d8-81ea-bded8f52d194"/>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/798e0f44-5d80-4aee-b7b6-8aa9d4755ef3">
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Abnormality of metabolism</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b12a61e2-cd61-4689-8d0f-e4110b459bf3">
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0012649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc39d0a9-6007-4305-bb06-922346b7f130">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c">
        <rdfs:label>Abnormal liver function</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ec88cfd-c943-4352-9f39-32489a9feb59">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/621593a8-5b45-492f-929d-a7de664d979c"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f6aaacb-e832-4856-97c9-2c16bf1de9b7"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a462da46-c1d6-4762-af6e-bd32fb11b57b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>spasticity</rdfs:label>
    <dc:identifier>HP:0001257</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59e02844-e7e7-4c25-abed-cee78a8fd88b">
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b741c433-9afa-482d-ba06-f1858b13594e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2a7c57c-eab8-405e-8eb3-8412bad9118e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43e9ba75-9199-4fe6-bd76-5fda1d11d945">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Optic nerve damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
        <dc:identifier>HP:0001138</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4589bd8b-abd9-4d37-80b0-c41d7c626930">
        <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6199e113-015d-48f4-a1d3-2e628cb1e859">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b3bb191-10a5-43b7-baf6-d14e77d10075">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eaae1a9c-1099-42bf-80c8-3c331afd96cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa4a54a7-3ab4-4b32-9be7-97df36e69e1c"/>
    <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d145ae47-018c-48db-b94b-08416bc5589e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65c93838-42b7-40c6-9565-2d08dc73f5c8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <dc:identifier>HP:0008282*</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a5bc051-b0b2-4f79-aecc-e843a9763b59">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0008282</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6fa177b1-2dea-4b25-a07b-a225fd1bf995">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5141558-8559-4e67-9811-eadd9740685c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fa3adf3-fafe-4f0e-a24f-19a1c361df82">
        <dc:identifier>HP:0002570</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
        <rdfs:label>increased fecal fat excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2b2e71c-80cd-49d8-b166-05b83a89147b">
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:label>Abnormal enzyme activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c9abf52-89f1-48ee-b31f-79289296723c">
    <dc:identifier>HP:0000570</dc:identifier>
    <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2e941c8-f505-4238-b1af-2771d41ee969">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5">
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/588d649d-4875-4fd5-9276-0fb631fc6aee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/304205f1-8359-4459-a20b-4154073d4344"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25264cc8-e0b8-4dd0-bf7a-309fed0c20ac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11e79c6b-b083-4a27-9ef5-17ae80537f6c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8917778-2ee0-451c-bb7c-2046f09496a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c62b7da2-5f89-4d98-b526-c47c04205077">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>Fat malabsorption</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
    <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5d20cff-0ba5-42e9-b3ad-096a777f9c75"/>
    <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fb9ee9d-cb07-4adf-bf33-e8dbcce9832b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
    <dc:identifier>HP:0001072</dc:identifier>
    <rdfs:label>Elbow skin thickening</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52cc001e-d5e3-47bd-9a6c-d128b442fcf8">
    <rdfs:label>AAV-based gene therapy</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a80a19ae-5406-4b46-a81c-960eb7106360">
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4890d35c-bc4f-4c04-a091-73e7b811c4dd"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a3f6eae-affc-4ba6-804a-d2d16cd21634"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5d7a1c-7fe3-4148-b1c4-4a8c2108131e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be5a2459-27f5-4175-8a12-159713d8f4b5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/468e321a-3d29-41bf-9199-36955e130df2">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:label>Low ATP synthesis</rdfs:label>
    <dc:identifier>HP:0025464</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d995f56d-6204-4c72-b914-064ee1894e7c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4adb8ca6-cdae-49de-933d-dc302eb63a5a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a005a0d4-0a83-4d62-974a-70b16cc2c632"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ec913c0-73d7-4367-9536-e8951e72f758">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Psychiatric disturbance</rdfs:label>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bc00b4b-9cc8-4728-9582-ea3dcc107607">
    <rdfs:label>Fluid retention</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <dc:identifier>HP:0000969</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2e8ecb4-ea9d-49ee-afdb-0f88306bea9f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:label>rickets</rdfs:label>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f5d7a1c-7fe3-4148-b1c4-4a8c2108131e">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>neurotoxicity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a79b0400-2daf-4e57-89af-6dae9569b9fb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>intolerance to sunlight</rdfs:label>
    <dc:identifier>HP:0000992</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff45e633-93b0-4d64-b687-b110abd0ee13">
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:label>myoclonic seizures</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f64150f8-7a6c-452a-8fce-0412d94b3556">
    <dc:identifier>DB00112</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
    <rdfs:label>Bevacizumab</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2c74939-0ab4-4720-99ce-fa8e282966f3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32ac9841-e85f-4766-a070-f16d4c839f10"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e1184d4-3961-4c2b-ab86-88360bda5743"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a27ca96-bc6a-4d9b-bd2a-de4e1332d1ae"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f587e029-1f0e-4e87-a783-fa738e2e9359"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fbfa2df-f136-4b16-b254-e569585abd27">
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>Liver steatosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c798565-ed80-483d-a892-65e56fd3f16b">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9a0035c-cb5b-4a26-8d58-9d665c28c9d3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b0f8e54-60e9-4b2b-be84-c200c79e23de"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9891ad92-7a45-46a7-8b66-3da07887df9e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>electrolytes</rdfs:label>
    <dc:identifier>B05BB01</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d7ec55be-4887-4a95-9269-5d362c309dd9"/>
    <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
    <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1f89eaa-73a3-4705-b429-21c5e873c8c0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a072515-87eb-46a0-9359-7ff642ed32a0"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03357058-05cb-48cf-bed6-1f0d61507195"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/8f719191-8214-406b-b3ed-ca96ccc431cf">
        <rdfs:label>functional complementation of a defective protein by stimulation</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b787bd36-6ba3-49f7-ac0a-4da9689fa77a"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
    <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f646d6e8-544a-4290-bb82-bb7e9fa44a00"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00bae8f3-0c41-49f4-a9a4-1f979b0be10f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:label>EEG abnormality</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33f6a332-c566-45cd-a4ee-0034dd32471e">
    <rdfs:label>Dyslipidemia</rdfs:label>
    <dc:identifier>HP:0003119</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/afea60ec-e61b-4fe1-a639-3c2b38fb859c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3c52a00-0fcd-4bdb-bc15-bac6e7ec66a9">
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/90547738-37e8-4fbc-8b88-90cc5bf553a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e0753407-6349-4379-b0d3-30e0a265869b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85bb696d-fec8-4715-bf50-106a94950535">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Acute attack</rdfs:label>
    <dc:identifier>HP:0011009</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4af0564b-603e-4121-b6ee-7ecfec30739e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/182f3d77-82ff-47e7-ac98-df0a0a2994f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c98ecadb-3ebe-4f42-99b3-fc9d5511dec2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dd23055-c3aa-439f-8f2a-b69f918907b5">
        <dc:identifier>HP:0011031*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3f32a98-8820-44e5-8c40-458d82956fe4">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e16c6b2-19af-4d5c-881d-0dd81873b59f">
        <rdfs:label>High VLDL triglycerides</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e6366f4-210c-4bf3-8ea4-ef7bf2cccd34">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0df5a167-c06b-4d72-9ace-f5bf474914d2"/>
    <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e2c6ed4-ad26-45bb-a41a-be9d93fdf1de">
    <dc:identifier>HP:0001992*</dc:identifier>
    <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5429c57-5fc2-43bf-8864-104b0d6dac7e"/>
    <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
    <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31a7650a-0a77-4531-b7a4-24bbd6e13339">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
    <rdfs:label>Thrombosis</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0001977</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2033930-ef5e-4de8-b364-00eaf2255e5f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c7b1748-aa01-479c-b375-2015873093c7">
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>hypolysinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/471facff-d542-4a32-a960-8af09880d495">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7515f73b-02d7-491f-9d28-b3d35cd29f44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05d0a261-ca29-4a37-914d-700f259064a2">
    <dc:identifier>HP:0003155</dc:identifier>
    <rdfs:label>high serum alkaline phosphatase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/addbd11e-95fc-49d8-8730-d30a1b2b81c7">
    <rdfs:label>Impaired fine motor skillls</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0007010</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d110c349-9a03-415b-8208-11dff8950f4a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c2c0a9f-deed-43b4-8486-43456930cc39">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d855068-1ab7-437b-8517-a087e1aa54c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7211668-1630-499a-bb01-e6ae04f8c8a9">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40a5d6c5-9e1b-4002-a3ae-103ad60c7bab">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e480b3d-bea5-45f1-a6de-aae1fe7c94b6">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f54e879-867f-4cd9-a494-95a2a9d20e6c">
        <dc:identifier>HP:0001976</dc:identifier>
        <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/574f5efb-7cc7-489d-9c34-9a4203ce4c65">
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003645</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaebf7b6-9593-423f-8e61-b9af717248bf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:label>Abnormal aPTT level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55aa1644-c098-47ad-b9ba-6ceae6e22bec">
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b14e6796-3303-4742-8f72-49c64a630542">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>abnormal aspartate transaminase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1724e95-93ac-4212-a692-cb741dfa2c89">
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <dc:identifier>HP:0001976</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4460f6f8-aa08-45dc-b397-2f9d7958c15c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/49c963d9-0552-4448-b7e3-84ea1fff7892"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d657b70-f3d0-404f-b63f-65f322757432">
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:label>swollen joint</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/822d0137-2e54-4c35-b060-4526916309df">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
        <rdfs:label>Arthropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003040</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bdefb16c-cbac-4e06-bca4-73870efe8e28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f8ce8a4-f351-42c2-b2cb-6c14e44c1ed4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae9e679b-9182-4d25-aad9-0265d2a34407">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a55f7668-dbbf-4568-9cd4-c2344b5d2637">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c467bcd-9515-4eb6-8e9a-bf10f7a4836d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee1c6bfa-06e7-4e32-b26f-cf2ddaa8e816">
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>encephalopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cf9cb2b-9468-4df9-b96b-0d0e2040ef9c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
        <dc:identifier>HP:0030178</dc:identifier>
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c8508aa-2a2d-428a-b90c-15ac4ce1e458">
        <dc:identifier>HP:0001347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Abnormal reflexes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c98dcc8c-4423-4a42-9278-0bc469100040"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c00ffe8-5cb5-4617-acf4-fd7299249be9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal movement</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
    <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
    <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/68f8b77e-83ee-4710-b429-f0a237b5d4f6"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b08f367f-7fab-4326-bb75-b9e6f368c1db">
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8a2cd87-1bc5-4867-b081-f640f3c24b98">
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ca84a01-1be9-403a-96f6-f1071978ef0e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/beda787e-4eb6-447e-9a5e-b23840086afa"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e32c92db-90e5-45f2-84c2-cddf08168527">
    <rdfs:label>Ursadiol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <dc:identifier>DB14555</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bee72397-cbb6-42ec-a1ad-754f8c679e26">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2dafe1d-ae08-48da-b4b7-d96a50b9f749"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5fbe022-cf1c-4b0e-ad7b-18d46afa1875"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64f6bf42-ea1a-48fc-a56e-e3665f2b78da"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8a3b38f-80a4-412e-bb7f-ff1a3a0ca6b3">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
        <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/960cfc7d-f72f-42d8-81ea-bded8f52d194"/>
        <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e263c982-c4c5-4ae5-ad7d-62a5f76f8b03">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <dc:identifier>HP:0010836</dc:identifier>
        <rdfs:label>hypocupraemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2478bc0a-df31-4901-8432-a0d5c178872d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a39e735-1fb1-447c-9d27-ab9bc632712d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c225cc9-9904-4e1a-bbd5-87ae3752cf3b">
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fb50998-d994-4467-9bf4-7ea4f3ce8257">
        <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b4a1e7e-3054-42f2-8a9c-5ae891bf6347">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/859291f1-e6ed-4470-a310-2d06db95fda9"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1400c793-f5dd-4768-8ac1-4eca82243f01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf91abd2-e667-4c70-8b18-0aa08fba5dbd">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>cerebral folate depletion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <dc:identifier>HP:0012446</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43593fea-3512-4cb0-9cbc-cf0fd120673b">
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5355cd7e-7302-431a-8d99-3a7f15708ed1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3c05dc2-ed20-4c52-a0db-010a2f19c164"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/997e3080-23f5-47eb-acc9-c3e2a90a3734"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b08758a3-9b83-4536-a470-3535cf699e6c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05a8b335-0b87-4630-8479-8fdfa7b28b03">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <dc:identifier>HP:0031517</dc:identifier>
        <rdfs:label>verruciform xanthomas</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36d6812c-50b4-4259-ad79-3e8f942d9d81">
    <dc:identifier>HP:0011943</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal thiosulfates level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a74259d-a1c1-4259-b0ae-998a907a0d2d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8bba7be3-dcdc-48d7-83f9-ac75f0fb01d6">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2693e49-e078-41c5-8b20-0475ce0a832b"/>
        <rdfs:label>ARC-AAT</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/473923f5-7d78-423b-87dc-84521f4bd498">
    <dc:identifier>HP:0040087</dc:identifier>
    <rdfs:label>Low total RBC folate level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/edb922d8-4f91-4c64-9c66-c41f887a9ace">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25ccfe71-2aeb-40ef-8101-1fdf9588f026">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <rdfs:label>cystoid macular edema</rdfs:label>
        <dc:identifier>HP:0011505</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c7af476-4038-47ed-91fc-ae1555c55ba7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f1e8f326-a187-47c2-a559-6a9bf61cd2b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5dd6f44d-1f13-45f1-968d-e6d8d2130be1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da78f0f6-355e-4fae-a788-10e8341459cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca9ac55f-3b2c-4a77-8c6a-a0ffdcca5533"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c78394ae-2386-4239-b50f-a75470d6ecd8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d73ed534-b648-4f40-93c8-b8eac0f96375">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:label>Growth impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/841571a6-da96-4aba-818e-ec0af3765804">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/477c0f9d-3e65-4bb3-9365-62ee5c7af6d5">
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <dc:identifier>HP:0012100</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
        <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90bb8767-9f75-425a-a13c-a9a0ece9daa2">
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/08e921d4-b388-45be-a45c-9ff926d471c5"/>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e5d7a9bc-6348-4f1d-bf74-b26167c4dc1d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49c886cb-9b46-4cca-87a5-65dfb32910f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28ed244b-4d82-4daa-8be1-88f5daf34edb">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0a34c70-fff1-43e7-854b-62019773f3b5"/>
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02266dcb-18fc-4a62-bf6a-cc9880ce1aca">
        <dc:identifier>HP:0001947</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
        <rdfs:label>Renal tubular acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6226c03-633e-4907-a4f9-01367ec39c7e">
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5ba81ae-3b8b-4658-b7fc-a01c2802f466"/>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/649b791d-5321-4c36-973d-32f5f23b1c15">
        <rdfs:label>neurological damage</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c125475-e1c7-46e6-a685-9409da4ccce9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21aedce3-3448-4fc5-8424-f321b9d56855">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d138b7a-8e3a-4dcc-94b6-51ba209dad5f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8125c10-7128-4940-b617-ca93fc3a77a8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfa4bb4c-27e3-4e8f-9e4a-96de4d044cf8"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5ed4c6e-8be2-439b-93cb-36ce6b9cf009"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a3cf86e-6ee3-4af3-9b0c-e2170888f011">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0003304>R1353H</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240800"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <obo:RO_0003304>E1506K</obo:RO_0003304>
        <obo:RO_0003304>delSer1387</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfa4bb4c-27e3-4e8f-9e4a-96de4d044cf8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01119</dc:identifier>
    <rdfs:label>Diazoxide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4156dcc3-b300-48cc-b0c0-36085bd64390">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c96126c-b2a1-452b-9daa-6b820c0e5f12"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfa4bb4c-27e3-4e8f-9e4a-96de4d044cf8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0003304>S64Y</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0003304>G68V</obo:RO_0003304>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0003304>A456V</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>W99R</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
        <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>M197I</obo:RO_0003304>
        <obo:RO_0003304>V452L</obo:RO_0003304>
        <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e"/>
        <obo:RO_0003304>T65I</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48f1949d-318f-41da-8407-60736725fdc1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fae4714b-f165-4bd1-8575-0baf2360dba5"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/361edaf6-15d0-4385-8633-2a6ec27a9fd6">
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/588d649d-4875-4fd5-9276-0fb631fc6aee"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c243688-aaee-482a-9843-02bcf57e8c65">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f105166-38c5-43ed-9f71-318b2b1faa2a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6644f29e-969a-4255-8361-3f72ecec1757">
        <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5cb60e64-33fd-4a9f-9d2d-802cfb64d49e"/>
        <rdfs:label>Gemcabene</rdfs:label>
        <dc:identifier>DB05123</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7431d2a-9486-4b65-a33e-86a49cf5ed30">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
    <rdfs:label>Hyperparathyrodism</rdfs:label>
    <dc:identifier>HP:0000867</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea4a329f-cd6f-4e82-a071-7a2e83b8d643">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <dc:identifier>DB04931</dc:identifier>
    <rdfs:label>Afamelanotide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1aca77ce-12f8-4b12-94a3-59dc7bb14721">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a80542da-88d1-4afb-b015-1aa8e1b7e12f"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfb63cbd-cf8a-41a9-8eb3-da007ccdfd6a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfa32beb-d7f4-46e4-9bdc-07102b716beb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1bd1476e-0bf0-41e0-9c96-7d42f4a52cec">
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5ec0d32b-7895-4f5b-9607-e120a0e64ae8"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4d917e5-322e-4e36-9cd8-4cc1d56455a9">
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:label>High spleen volume</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e04903d9-c23c-4476-936b-7e53ab1afe27">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8eda31ce-1102-4e7d-ac8a-bb284175a478">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5d93408b-a14d-45a4-b770-30e46ac93257"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30c993fb-b91f-4273-b938-d6b476d29efe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da284125-53b3-4800-b840-56a6015267c0">
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>high liver volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e14c21f7-47c1-405e-b717-94ae118a3332">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/308147ac-ee1a-43d7-9f72-d53742df1db5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e5b9b92-820a-404b-b950-783bd580a75f">
    <rdfs:label>Homocystinuria</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
    <dc:identifier>HP:0002156</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c61df16-42a7-4c8d-b40f-f3f011c278f6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/621593a8-5b45-492f-929d-a7de664d979c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec809593-df92-4f5e-8db7-3d7225d3e411">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c911034-e588-4085-bc48-e205aedc7533"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Failure to thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/024a9db0-d1e4-4140-bc65-c675e511ddff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5326d39a-8e9d-4ed8-b17c-2b6f5ec2ead1"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9bf6214d-50c5-47fa-bd39-551adb6357b6"/>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
    <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9301622-3aa5-41e1-a250-4a463c23da9a"/>
    <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f0011dc-ddec-42d4-98b5-6f66f3ad12e3">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0575ec98-6a23-4ce7-8046-3b473580b0ef"/>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1faff951-d0e3-405d-ac41-0ccfa366b42c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3330b214-895f-4b26-82b3-445158efed6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c73a7a43-6efc-4a0c-b074-b52583d63f9d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b9c96bb-d3a1-4f02-acc7-3c98e794d81f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
    <dc:identifier>HP:0009051</dc:identifier>
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ace8279c-22af-4d57-9020-3dc1bd8c16f0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/559f5aa0-0bd3-4b34-8378-c6d553928c15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8372948-619a-4c19-9f71-fa2f0f22ff80">
        <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e90b72a-2c10-4aae-90fc-822a2cb0d2df">
        <rdfs:label>secondary carnitine deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad86a3cb-dc10-4e99-bce7-35306c7d5a02">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a9c459c-40f9-4d25-8c6f-aae28d5fb1d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d5f50ee-0802-4097-b9ed-90d6433afe8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c28a17d-722e-44e8-a9aa-9a3c850bdf81">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>short stature</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efa54aac-ecbc-4ed1-91a6-9b179301ea69">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e7694e92-2b9e-4475-82da-cffeecf3e6c0"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5927e947-4f39-422f-9095-b0cbf0ef0d00"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec21a7ae-b95b-4ea2-b032-113e4bae29d0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c7cc290-5a40-49df-b64d-e0997f680557"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/002f448d-2277-4f73-ba99-b0d5b9e033b5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <rdfs:label>Malnutrition</rdfs:label>
        <dc:identifier>HP:0004395</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a31fc9c-b8f1-4eea-a320-209a6240523c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Myelopathy</rdfs:label>
    <dc:identifier>HP:0002196</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0a83ddd-9491-4f34-97f8-7d2e2f9f920a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7866c40-5028-423d-98db-314a822be098">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85ab96b9-4f62-447e-a02b-0b51200079ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b51a62c-465d-4612-a3e6-ca845d26cb36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b39e5090-df99-4796-b605-ed4cba0b217d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/322892c2-4132-4fe9-94f3-20b08b233bc4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c31558f9-374b-4091-a0e2-f3d3082e88aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba775b9d-d5d1-4515-a926-34f3ed4d36f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5345ba4a-e8cc-4ec8-bb14-20029081e8b1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dfd10161-8e1f-44ad-908c-3f4466bacda3">
        <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
        <dc:identifier>M01AX</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63d106ae-d5e7-42ce-882f-041d62561a78"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e26be1b8-15cc-405a-9fca-c01d0eff8f4e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f69139de-a7bf-465d-a120-c33502d144dd">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee5482e8-7cc8-4853-9c8a-08c9b2dad1ee">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
        <rdfs:label>Normocytic anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001897</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b38870db-e002-4fa4-b9bb-1eb2b387749e">
        <dc:identifier>HP:0000953</dc:identifier>
        <rdfs:label>Hyperpigmentation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54fb0bd6-56b1-4fe4-aed2-962b5a1a5e46">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe6930a5-cd47-429e-8dee-79bab929b2f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bc82398-c2ad-49d7-a997-3e2e90ddaa4b">
        <dc:identifier>HP:0040126</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low level of serum B12</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3aadc884-7315-4eb1-8595-f5766981a799"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16bdaab9-9a61-4a3d-b5fc-3d34d2e16e99">
        <rdfs:label>Megalobalstic anaemia</rdfs:label>
        <dc:identifier>HP:0001889</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdf91fa6-5902-4ffe-be28-e31667a7a82f">
        <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <dc:identifier>HP:0012120</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8484d4be-2efc-4ea4-a1ba-0e04d0dcf973"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f7cc1c76-5116-4992-b37e-35db5bcc8c85"/>
        <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ca8d4c1-2a35-458e-8e34-e059813c0cbd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8731da9-5d72-47bf-82da-ba0a5c71812c">
        <rdfs:label>Acid regurgitation</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
        <dc:identifier>HP:0002020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc15771c-dcf4-4333-a08f-965a1ef83032">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a7e1990-78eb-46af-b3ed-4d497980e7cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf6e3ea4-2340-44d7-81c6-0858d0fd26c3">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Epigastric pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
        <dc:identifier>HP:0410019</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11e40438-202e-4423-aa9a-3e27ffacc2b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4f53fe7-8866-4a1b-8207-c9870da33913">
        <dc:identifier>HP:0003281</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>high plasma ferritin</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698727a5-93b1-4cc9-b0a1-8cefb8b6c30e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/097b9286-324a-4012-89de-81d94dcd6859">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983e24aa-5e38-459c-9272-a1f1933b725d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04eac582-8385-49c3-a444-83bc02179ef2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/627970a9-2241-42ed-8f08-9469c35d5ab3">
        <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <dc:identifier>HP:0011009</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3">
        <rdfs:label>direct complementation of genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e99976f-1623-43c2-a4b3-7b52599e181a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78ea02d8-cc7e-4290-8e21-85db95548a25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d848e00a-f633-4ae0-afe0-60c2d04e8a8c">
        <dc:identifier>HP:0012217</dc:identifier>
        <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/768b61ae-7fa5-438b-8a27-90e98bff80e6"/>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80b2efba-36c8-4193-8eb7-e646dabdd2c1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b31651d6-a4a8-47d5-a4a8-6a2327b9342a">
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Low IQ</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5e4f83c-25dc-4fd0-a184-c4756afd94f6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Delayed development</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9c5493f-1942-4f52-b4e6-364a51d29488">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baf27ed9-e3a6-4791-a55d-c166838f90a0">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Poor traction response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71eeb15a-01fb-4d08-986c-4a6a59f401c3">
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68fef3e7-2479-4194-a5be-8e9c465402ac">
        <rdfs:label>Brain demylination</rdfs:label>
        <dc:identifier>HP:0007266</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c6d4af7-fc80-45e0-8e17-96e4b3cf5bb2">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Hyperreflexia</rdfs:label>
        <dc:identifier>HP:0001347</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cd60f6b-d984-4524-a997-4410ccd158bd">
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:label>Delayed motor milestone</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d6b0472-996b-4702-b0e1-260a5b30e16b">
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae9032c6-3a72-4f80-b292-37ff780ac4a4">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:label>Irritability</rdfs:label>
        <dc:identifier>HP:0000737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ce89210-3f1d-4edf-91bf-39a553f2b0b4">
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <rdfs:label>Poor appetite</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/007977fc-7b12-4c88-9a89-beeb3593fb02">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f46727a-28b5-4ae1-b9fd-9db6b05f277a">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Abnormal Awake EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/602cc120-f010-472f-8d81-185d027c0108">
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Behavioural abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/957f5f1c-f002-4fc2-b702-1d981130c7ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5c84a57-5aab-4754-8f4f-69f3eedadb20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/208f387c-1a01-499e-a402-0ebac8de06de">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Poor weight gain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ff23844-b191-48fd-9e9a-618058bb5aa4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0011448</dc:identifier>
        <rdfs:label>Foot clouns</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77ff8203-a2ab-4997-8a4c-404f90a4c301"/>
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60440c20-d063-44d6-82ed-8aae17597d33">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9233a7c-16d8-457d-bd40-1d82f895e0da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9fdf572-c965-4b31-b5ec-9c38c62cff58">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a892a7e7-8022-4e49-804b-5901208513c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
        <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa32e695-55d7-4586-9256-cb6c239fd38e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/adcc2a32-a24b-4d1e-9465-5d8b2ff58edf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/588dd572-4ad6-46e3-b486-94fd033333aa"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/022bae1f-9a21-42cd-8fda-8b1ac343a4ec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ee249fd-a962-42cd-8977-4ba3c49f0c87"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/795fc5cf-ad9f-49b7-90e4-e565a873fb9c">
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5033e7f8-607b-4a24-af6b-63fc54149d56">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24f49924-c22d-4cb5-b43b-6578a4a7f5a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21fe2243-f66e-4b9c-bf58-6a915c4d9fef">
    <rdfs:label>Norleucine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6cabc498-1287-4398-abaa-328528bbfc9f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5fb381e-05e5-4f8b-91eb-2d4b19add653"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4574a0b3-8cee-4e73-86ff-27fef8dc460e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22e97e22-6864-4940-8b80-8a5b2222c185"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/099ac911-a445-4b83-87c2-2eb7f4edd750"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6c91d08-94f3-4728-9b39-b7a9fc17bfdd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e7f117f-3a2b-46a5-a66a-af2e70562013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4feac68-4e40-4a4a-99f7-c4c528882ceb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fd6ecf9-7155-42cc-b08d-ae8284cc705a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43cbd1df-9514-46bf-96e3-d48ea01ad050"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61680b72-57f0-4cea-8eae-b89d36e2158b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal gait</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3764d4ca-e140-4e33-9140-d428132c982e">
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:label>Incoordination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1596f45f-1a77-4f5c-9a5f-808c00515b67">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001665</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
        <rdfs:label>chronic diarrhoea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb02cdf5-06a7-4670-8be4-aefb195d3628"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/362ba280-1c0a-4d67-a902-4a033c67c335">
        <rdfs:label>cataracts</rdfs:label>
        <dc:identifier>HP:0000518</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b46bf98-4336-4533-9010-0ef254d4ada9">
        <dc:identifier>HP:0040129</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02c72e1a-994e-48d6-a328-72fe808f16d3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological dysfunctions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5af1ec9d-f43a-464f-ae8c-5e7963c28812">
        <dc:identifier>HP:0001114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Xanthoma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7bbe9ff-925c-4072-8c5d-ba87a5a7ff03">
        <rdfs:label>EEG abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ce10b4a-2b67-4abe-9058-917b161c1b8e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <rdfs:label>Glycine betaine</rdfs:label>
    <dc:identifier>DB06756</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1101df5-3cd8-4216-a1b8-d25c8a93d211">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cbe90ed8-0732-45da-8e6d-5ed5764d8d32"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bafb71e-6cc1-49e2-b2d0-f0d81672b5c8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bb0b514-86de-423b-b67c-45b7ac7a47f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3048e161-854f-41c6-a7db-1e7299f2cf5a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6dd9b37f-d259-44b2-916d-60b18126c6cc"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/883456b8-af7a-46cd-be4e-2ada0b19ef27">
        <obo:RO_0003304>T122K</obo:RO_0003304>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0aa8acc-03c6-42d4-85ae-ba8a02b64e4d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
        <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9e44160-9d29-4c2b-bf4f-1c9eba110014"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/488a836c-a225-49ce-8e37-f96f91d5030b"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bbf9f2f0-54d5-42b9-91ef-f5bce1dbca89"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67b521c4-f858-4092-9dfa-c08955fe7bd7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025463</dc:identifier>
    <rdfs:label>oxidative injury*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e5b87b4-f767-4d75-9952-9d685ecc3a4c">
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63aa0f57-9576-473c-93b3-c511b9fe9edb">
        <dc:identifier>HP:0001252</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
        <rdfs:label>Muscular hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/646fc70b-3bcb-4392-bd01-e12fee2b016f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9b20cbe-2331-46b8-bfed-6e8d79d8bc58"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f45c1dd-7df7-47a6-b8a0-459c06cf0d2b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/581c52bb-7c5d-4be6-9073-eefb89bcdc2c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0750c42c-c1cd-44fc-9ae4-3cce94b8960c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12576e0f-32f2-4f02-9221-0d1f67ed8cf8"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11ee4e98-6477-46cb-af7c-ebbd67f033da">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ccb2159c-cb33-428e-962d-ce446c7837e9">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6b7df3a-a073-4a36-a1b7-c8003b92a977"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d341b6b7-04a1-4722-819a-7f330a72079b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levetiracetam</rdfs:label>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd239556-d32b-4481-ab8f-643f71a78fa5">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0762c52c-d981-4b40-b651-a709645ab8df"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18a6d519-e21d-44d5-9f11-1863cdfae85c">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58778f90-fdf3-4602-9706-1a63a11f70af"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ade1732-6154-4919-990b-e669d24d8ac1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>strabismus</rdfs:label>
    <dc:identifier>HP:0000486</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72be17dd-e953-4521-8891-80d979227a33"/>
    <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d871f20d-be29-4a51-982b-1bb138e7c199">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39f9e68f-87b4-4940-b628-80a2f3932e27">
        <obo:RO_0003304>G666R</obo:RO_0003304>
        <obo:RO_0003304>N1304S</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00edec54-a891-450f-b364-f832b73ce724"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/100311f6-2ea9-49f3-ac73-cf2f292dc218"/>
        <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66be445e-b485-4218-96c1-b62d06e88b48"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/286ab37e-6fd9-4db0-96a7-2639681a85c5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebe9d9a2-8447-4e49-9302-165a33f56fcb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8edda-8c5a-426c-b20c-5f3131a8d67f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
        <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acad1cdb-290d-4a0f-af80-70721d719c7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dc9f268-6cab-483d-8b89-321717d068e5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61f0237e-c76f-45f8-9be1-9433176cc061"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/208f387c-1a01-499e-a402-0ebac8de06de"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/512cd752-4a55-47dc-8c22-16eac02bab09"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0cfccf3-fd8e-40e3-84a5-404be17103fb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/523e8bc6-cfd7-4a70-8573-f81ad463a67d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9915e7ff-64fe-43ba-a9d3-eb45f246255b">
        <rdfs:label>Sucrose</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49aafa34-5e10-4d8d-a0f4-22dca93eb126"/>
        <dc:identifier>DB02772</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5abbe97e-9564-440a-bc46-a5be035ad024">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6022de8-931d-45a7-bd52-660c833943ce">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41343e19-dd90-4584-92ec-6d78884cc995"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d4f6e44-684d-4d8c-954c-f53d9b68e540"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6cd732a7-79e9-43d3-b5b8-04a979c640da"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/195bb022-81b5-4d78-bb0f-e9f4eb413aca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31d90d9d-fde3-413a-9891-e83b03bb5c1a">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>High blood ammonia level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4081c0ae-2dec-4d66-9212-cfad763638a8">
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:label>High plasma citrulline levels</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/e16316f7-3e24-4b61-ac74-7a096655d799">
        <rdfs:label>functional complementation of genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32544025-3d62-477a-9bff-81338d56f946">
        <dc:identifier>HP:0010903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c7c5b7b-2373-4c85-b84b-d7c22ba8a881">
        <dc:identifier>HP:0001298*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/488061cb-0792-4659-8aeb-2c6fa33bc886">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7bfa6a56-667c-409d-b44e-a8f3df4bc122">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef502999-6d4f-462f-8ccf-cffce737ec7e"/>
        <dc:identifier>DB00230</dc:identifier>
        <rdfs:label>Pregabalin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f89e23ca-6f98-4aa2-b8f3-97726c04b291"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8ebc2f3-1ef9-45fa-b4be-e2e027dc4564">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
    <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
    <dc:identifier>HP:0000722</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/162fdc69-7ffb-4d70-9991-411d53201b36">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7118ec07-5cfc-4ecd-a881-15355c8734de">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa911a6a-2687-4a09-bb18-b0a46036e5b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d5e1e8a-ef89-43ba-aa9d-7c345a4f5297">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003797</dc:identifier>
        <rdfs:label>Muscle atrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c333f2f0-9011-41b1-9a74-563448a48f7d">
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscle strenght</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95f29519-6756-4a4a-a04a-6beca79ac5b7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <rdfs:label>Nimodipine</rdfs:label>
    <dc:identifier>DB00393</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c08e4ab7-430c-465f-8301-4f293a6f387f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e5cb6df-54cc-4235-bdd0-1d054b40e5eb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4516abf5-16a3-40db-9d2a-b88cb02add0e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a85029bd-c8ad-4942-bb73-1f81ce4ee489">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9e679b-9182-4d25-aad9-0265d2a34407"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d657b70-f3d0-404f-b63f-65f322757432"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29fc8b44-5f43-43dd-a721-772dbb5688bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/529b5776-e947-4d25-a753-43ee2066a133"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b3793bf-5f75-4bc4-83f4-8093065fa760">
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/146bc7a3-50e4-4900-b485-15bccced3eaf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>High plasma uric acid levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/149a25b0-6bd1-4228-b2a0-f15618f4a2c1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aaa87744-bc85-413f-8d8b-3a49186c2bbc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc39d0a9-6007-4305-bb06-922346b7f130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a07b78f8-c37c-4636-acb5-bddc783ee0a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09e21dd3-e3bd-49d8-87ee-fed0872f9c5b">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4fcf6bf-43ed-41eb-933f-bc87db0e96c8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/382f99a8-ec44-4c83-9de3-7e2e190b5896">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <dc:identifier>HP:0001337</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7a34661-ae56-4a9b-b8bc-53c44db40b62">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a258ac66-1f79-45d1-9a88-2cc8c9d86bd0">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a04cf5e-6c55-4174-9f1a-035ecd11da6c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cac63526-7bcf-4643-8edf-c0110f1d7ea0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b36505d-670c-4c8d-b15f-ba734582401f"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022510X16303495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/216e7c39-b663-4b09-8573-0b77f0619f0b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ecd4343-a7a1-4be5-9226-1a1d3d389f7a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00413</dc:identifier>
    <rdfs:label>Pramipexole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/188dfe9a-1f5c-49c5-a315-9f30c66de212">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffd718c3-e3cb-4a96-b8b3-5047eb99fb98"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5d9f6d6-ec3b-4456-989e-7d1f01069ea2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/093dd37e-9d89-4497-9d70-26710d125257"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
        <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a04cf5e-6c55-4174-9f1a-035ecd11da6c"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/8f719191-8214-406b-b3ed-ca96ccc431cf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcad3147-183d-42e3-ab15-0db7b73136ec"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a1d91b4-5df9-4834-a1e0-09168726eea9">
    <dc:identifier>DB00459</dc:identifier>
    <rdfs:label>Acitretin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25bc20ed-6534-4a02-b1ec-1be2657e1bbd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d18f3214-3189-4ba4-8589-eaaee84560ab">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/247100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9dac309c-19d2-4540-ae04-351049783391"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fb9ee9d-cb07-4adf-bf33-e8dbcce9832b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87a13282-138d-4d9b-85ad-79cae167dff9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/edcea33b-befd-4f61-b06c-4698fdf7c8f9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5022a83-4484-424e-9c33-358e21f9c298"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd69b1bd-c8e7-4f07-9200-b2361a7d6832"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/650eea1f-4882-4ef9-95c5-b903786b6766"/>
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bf70f20-176f-45c8-9284-e66c83428e23"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90322ae9-fa07-431f-af11-303d3010c299">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87a13282-138d-4d9b-85ad-79cae167dff9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71811fdc-8353-4db8-9820-28837415a347"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00ffd927-2fe0-4ce8-8692-b9639b52a255">
    <rdfs:label>High serum total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da3a4e7f-7f47-446c-8331-67aef7a1f474">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d313754d-38a9-4fdf-b815-e19161648a49">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2da55ace-ec33-4038-ac7e-2ff1072a7ef5"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/149a25b0-6bd1-4228-b2a0-f15618f4a2c1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9093d7cf-a826-4340-b888-2bea1ab67460"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d9e0a21-ca38-43d8-a113-d30823d4a251">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9448e67a-296f-48c9-a134-88ec72b08dec"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14b6bc37-36cd-4782-ad5e-9829718ad954"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93602d1d-23af-465c-ac0d-6d54d2134387"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/149a25b0-6bd1-4228-b2a0-f15618f4a2c1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b3793bf-5f75-4bc4-83f4-8093065fa760"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e605f16-70c0-48ce-a6d0-e4d80e1c6dbb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <dc:identifier>DB00437</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c2c9f85-5bd3-410c-a230-323a46df3243">
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:label>low HDL level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07d0dc6a-28cc-45c4-983a-a5d0ce9aadf1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d09ae2d-0a74-4808-9904-cfa994f486d2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <dc:identifier>HP:0003750</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>lack of strenght</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bfa7b894-b865-4cfd-8cf9-863831477b98"/>
        <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f92b9fc2-44f9-4230-abc2-5991b040e70e">
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7acf969f-12c9-4d64-97a5-1102aead7cb9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c0bcf64-51a3-4bbc-8333-f6659b4cd181">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b49a0df-6ffe-4de5-94e2-996f4400ad05">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70b26806-28ce-4aaa-9685-7ff2a83e2dfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa6f15d2-89df-4c03-8fda-5bce842c0f34"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1f03fe1f-81b4-477e-8959-b9036078a425">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b1c59f2-23a1-4003-ac40-f0b53472f110"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b14f3eb-2675-4f5f-b073-1f553881f80a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e74dbcf6-4445-41b9-8d37-8a58f70a2305">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cecb2e47-fa47-4453-853e-c7d3bbd9fcf1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f010cd4d-6320-41fb-b649-67786c066850">
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7522af18-8414-4916-b33b-b56f04445550">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8a8aff3-ad33-4bd4-8458-b46af34a4b9f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025280*</dc:identifier>
        <rdfs:label>Pain in the skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8104e870-f42a-4838-a15d-74dbed4b8896">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/abf9e081-9f0e-47ef-90e5-54888206a2d5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a79b0400-2daf-4e57-89af-6dae9569b9fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a687b508-30a1-4c36-9fe7-aef831a211c1">
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <rdfs:label>orotic aciduria</rdfs:label>
    <dc:identifier>HP:0003218</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eaae1a9c-1099-42bf-80c8-3c331afd96cf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6199e113-015d-48f4-a1d3-2e628cb1e859"/>
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48d1e9c7-59e7-4ec0-883f-d036d1930a33">
    <rdfs:label>Somatotropin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61848e49-daa0-44a8-ad67-7bb66f1891c5">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79230e27-81d4-4e1f-93d9-a59e8c3e2b7e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76741262-f10d-443b-a736-4834e8df9dc4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef5fee1d-e0e3-4c64-accc-596757e3a9b6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d0ecff1-120d-48a8-ba52-87cb072d92f5">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/fcc48fc7-c496-4200-a53c-1a77f2c7f711"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f33ea64-113e-4a99-b686-49f05a122b36"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
        <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4c957e8-fc26-4390-9bd5-76c3f7a11475">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a9130e2-e8ed-4334-bba6-0c7550ac67e4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f33ea64-113e-4a99-b686-49f05a122b36"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78b23cf8-0b79-47d2-9288-eb1b3a2d2e31"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58ed4778-4d5c-445b-8e27-f6505cf3be3a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de461459-097b-476e-a9ff-1bf985ed2c88">
        <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
        <dc:identifier>HP:0012212</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b58323b5-56bb-4f10-87b8-9b78dce7e417"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c27d71f-58a8-4887-ac35-d553340c20b0">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e92a9440-fb92-4516-aa95-9dfb62166e04">
        <rdfs:label>Bradykinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
        <dc:identifier>HP:0002067</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e8f93e5-4835-4e54-a48d-7bb2f01c8672">
        <dc:identifier>HP:0001337</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
        <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3260e0ae-fbde-4bb7-a5f7-12ef6d49a4d3"/>
        <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a4717d8-52b9-45cb-b561-012f98c76bf0">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Rigidity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
        <dc:identifier>HP:0002063</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e942a454-677a-4e6f-8d79-384dfc9d47ea">
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:label>Parkinsonism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42cea71d-8a74-4ca2-952d-6cdd4a9b74dd">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Limb dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5354e50-747c-4d60-8795-3d91d634f013">
        <dc:identifier>HP:0002530</dc:identifier>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Axial dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7aba6fd4-0c4a-4f4f-85f8-312cb2b505af">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:label>Gait abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5f13e87-fb50-4828-9731-eb4bc1b5358c">
    <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c3a7436-b759-4b6e-8ff1-1372173830c8">
    <dc:identifier>HP:0012446</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:label>Abnormal CSF folate level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68c40cad-5286-41e2-b774-2f3fbda3127c">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Oculogyric crises</rdfs:label>
    <dc:identifier>HP:0010553</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2222f4ed-9159-4964-b516-89a7920eb994">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83d8c5ce-de87-4f88-bea0-6a184a4eefae">
        <rdfs:label>failure-to-thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a70cf78a-e8e8-44ed-9c64-ad6f67c38f06"/>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9ae5b65-4f8d-4fb7-9e6c-85eb8664ee3a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>deteriorating pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03052473-af0c-4033-8e3a-60d576e4fbb0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ccb9d0e-3324-415f-813e-fa0a1190d5b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/653f1be7-e3e9-4923-8f14-6981eca17c8e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal developmental milestones</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/176cef88-7cea-4d28-b95a-862e4f53f782">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000164</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
        <rdfs:label>Dental Defects</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b34a1159-9816-465a-a93e-d0aeef98ca35">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:label>Decreased physical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5a88681-9a43-4de6-a8f5-f5efbe6107bf">
    <dc:identifier>HP:0001824</dc:identifier>
    <rdfs:label>Weight loss</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc54e79c-fe1d-4dde-91b8-874e4c11d87a">
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00d7a8a7-679a-4b10-88a7-d107bff56f98">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2345df56-2921-42dd-b630-9d2f50237e86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/069ce3fc-790d-40ef-a111-ddae973f739c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c80492f-d222-4029-8c27-d1f63a31898b">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High triglyceride levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f820b7d2-fc69-4a11-864f-d3886b41e311">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f05a71b1-c61f-4ad4-be7f-0d8c5875c4fd">
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <rdfs:label>Ployuria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b72d802-a9e0-4987-8b33-50db3165751c">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5137a18-7a8e-4121-b89f-96816a7ec000">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
        <dc:identifier>HP:0002360*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a4240e9-4535-44d4-8083-ae7462baef37">
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
        <dc:identifier>HP:0001943*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3bf5b155-34c6-4453-9f7e-d861a3b44ec9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c995c1d6-4dac-4311-b493-1fcf64c04e63">
    <rdfs:label>Low life span (Mortality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0040006*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e46f4902-7c7b-4336-a5e7-d5072d6bafe0">
    <rdfs:label>Metronidazole</rdfs:label>
    <dc:identifier>DB00916</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b588b63f-62fb-404d-8810-2d97383e90c9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa6f15d2-89df-4c03-8fda-5bce842c0f34"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/762bb923-15ca-48e1-bbd1-7dcff5acb927"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/689ee4c0-91ee-4a5b-a06f-c4eadcf26aa8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/513eca18-8dbd-4b1d-b863-d982e265c69e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d53f6ae-c8c2-4b52-bf30-ca5752f1b270"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/781e408b-b0e2-4839-ae06-d1d5a87faa0a">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
        <rdfs:label>CYSTATHIONINURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b4d13fc4-57fe-4421-b291-18f51fe008fd"/>
        <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
        <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e8f93e5-4835-4e54-a48d-7bb2f01c8672"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/854ab568-93db-49c7-8f73-79a8c3a6a4d9">
        <rdfs:label>Cystathioninuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
        <dc:identifier>HP:0003153</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07b32d67-0496-4ab4-a647-cdf29edbe7d0">
        <rdfs:label>High total homocysteine level</rdfs:label>
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00bae8f3-0c41-49f4-a9a4-1f979b0be10f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/addbd11e-95fc-49d8-8730-d30a1b2b81c7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3673e529-233e-4292-9e7d-f8d9d67665b5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aca1c11-12c8-4d1b-9949-48d71a2f9235">
        <rdfs:label>retinal dystrophy</rdfs:label>
        <dc:identifier>HP:0000556</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a93a967-2aa9-41d3-a5bb-58a5b7c30c7d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001874</dc:identifier>
        <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56fc0e65-b081-47f0-b02d-34e51dd8de4f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afb37f15-3fe8-4d25-acaa-a0ab34fc1444">
        <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35b1c968-cf74-4152-80c0-2281ff06f7f3">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <dc:identifier>HP:0002718</dc:identifier>
        <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2768a3b-9a59-460d-98d4-5ef592353f1b">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
        <dc:identifier>HP:0007367</dc:identifier>
        <rdfs:label>CNS damage progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e61f39a-30d4-47e6-9acf-411010d655b5">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>abnormal microtubule assembly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5906a6e3-2b50-4eb4-aa1f-ddde42117ccb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pyruvic acidemia</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95697d2a-b813-4fab-8dfd-5b99b0403cf5">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001888</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
    <rdfs:label>lymphopenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7c5c810-9bda-4288-97f4-488678ac2886">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e1ffcc5-0312-4d47-9147-50156b5f1348">
        <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
        <dc:identifier>HP:0010978</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/431eeb13-51f7-4187-9f77-7ea9e762d422">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c20d38fb-da34-4457-9e8a-aa422c7dedb8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2cb8d6f5-54b9-473a-8a1c-4ddc2f81a8b1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60c1f563-0953-47c0-af22-7a3a0150c231"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3eb79783-6db6-4161-bc56-223ca180dc46">
        <rdfs:label>Low pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b7f33da-dbb7-4fcb-946c-b9c113e27c32">
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0006517</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a66dd9a-2cbe-4aa5-9200-3a703557de6e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/149a25b0-6bd1-4228-b2a0-f15618f4a2c1"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8d8f41e-2304-4986-a1f4-d83e7a611134">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32a3297c-b2a1-4a6e-9181-817283e9b4f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9448e67a-296f-48c9-a134-88ec72b08dec"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc6322b8-2faf-4945-bac7-46c5bd7700ef">
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:label>Speech problem</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55eef6a6-0773-4fc9-b001-3c626d9934c7">
    <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75c6c010-30d2-4592-b987-f54368b4fa24">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2380191c-19b8-463a-936f-192ebe82bade">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Generalized muscular hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>HP:0000750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3bf87ae-e8ae-41c5-9eec-aa699f15bbfe">
        <dc:identifier>HP:0012011</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
        <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42ba6b82-8357-4efe-9ea9-881a4b1ad3e8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Speech and languague delay</rdfs:label>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33d9f3c7-7ae3-4c30-a3dd-df408579f8ef">
        <rdfs:label>Developmental impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ae3a062-a992-4535-9747-4ece9d8d0be4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1491585f-ae26-4ae3-97a3-6c77f074e5fe">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c30e6f30-96e5-4dd8-b298-f7248201a8b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/47f1e2e9-7748-46f3-bc60-766f8d3d5415"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf55e7b6-1abf-4200-9262-dddddd5aaaba"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7762478-85fc-4d19-81d1-08ebe881777c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c374e81d-84d2-4c17-8a7d-fc0fa1c32bff"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00119</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d5a3de0-377a-449e-99b1-f844b6a93f5c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/47f1e2e9-7748-46f3-bc60-766f8d3d5415"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03ec10aa-84db-4a9b-be70-82fd37d74d93"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c30e6f30-96e5-4dd8-b298-f7248201a8b5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c374e81d-84d2-4c17-8a7d-fc0fa1c32bff"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29ec73ed-e99e-41c5-bfcb-d7a9ba824fa3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7762478-85fc-4d19-81d1-08ebe881777c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c70b6300-2847-410c-a63d-cdbb25e0fcf8">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/47f1e2e9-7748-46f3-bc60-766f8d3d5415"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <rdfs:label>Pyruvic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3a6ea28-0467-47e6-b82c-da052f0dd854">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15f80b6c-c1dc-42f2-be20-25b9eb1e1f15">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a31a2104-801b-4a43-aac7-ae087a64370c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c96126c-b2a1-452b-9daa-6b820c0e5f12">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
    <dc:identifier>HP:0001943</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/586b996e-336b-4093-a823-a8c451fd5dff">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/810d4cd0-f7ab-4233-a847-4038183a6393">
        <dc:identifier>DB12839</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e18ab86-f934-4aaf-bb1e-787048e153db"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
        <rdfs:label>Pegvaliase</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2648405a-0049-4c64-9ddf-b61ef25565ee">
    <dc:identifier>DB00321</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
    <rdfs:label>Amitriptyline</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8d57bdc-922e-479b-8392-31f9d7abbbbd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f677b5a-6ca0-4461-a595-69c46966d53c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41498fdf-ebd5-4e0a-90d5-870b5abd1c6e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
        <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7492f9f7-b88a-424e-812e-4b5e68ce56e8">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2eb804b-c0e4-4c05-a8a9-82bab19b0d00">
        <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac71632f-5118-4ab3-8a97-c4586b49544a"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce5655f2-7a8c-430e-b183-d64533443451">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d27487b0-75d0-4455-a80e-d1167a3e6e19">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c2ea9cc-b7eb-49b4-9862-935761fd4e69"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffac4fd8-ceae-4680-83df-54df2c6e57ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1f136d92-0836-4eca-a3ce-e8b70110313b"/>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5020498-c044-48ec-acd7-1245706a398f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8814a9aa-79af-4d95-9af3-45d1a4adb1c3"/>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8c06e02-4a5b-40df-b008-ba2e4b74970a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5444d1e5-a4be-43d5-927a-1f19247681ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/111505d1-e8e1-4def-9621-4864fa2a152f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10ae5858-969e-4ca0-af87-42eaa7b4ffe6">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04c5a145-1e8a-441a-9a25-920a083da24e">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/212c2f86-daea-4075-b085-ae3b8dda00e5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a09ea6a4-4332-483a-a117-e1554ad5cf4a"/>
        <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c38a9756-174c-464c-9203-30344357d1dd">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db2b7c06-6dca-4692-9951-9fcb4cc6c7a6">
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d4ad9a5-bff5-4fc1-92bd-c60ae9e89371"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1ea532a-3d96-4aa7-9f44-eb90d8bc243a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b14f3eb-2675-4f5f-b073-1f553881f80a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <dc:identifier>DB00126</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/152a5075-b81a-46ea-a877-da3d8e2b0d93">
        <dc:provenance>https://www.degruyter.com/view/j/jpem.2016.29.issue-1/jpem-2015-0132/jpem-2015-0132.xml</dc:provenance>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7af185da-c65b-498a-b9de-b5c84e485253"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d98085a-8ddf-469b-bb13-11ce18bdc538"/>
    <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
    <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/daeb618d-5ea0-43d5-9137-5b11a11c4759">
    <rdfs:label>Regramostim</rdfs:label>
    <dc:identifier>DB05386</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8cc34e7c-34b8-4963-8024-6c0915cb098e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4db172a0-0b66-4e0e-96b7-6c9187c4ed29"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b7f33da-dbb7-4fcb-946c-b9c113e27c32"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3eb79783-6db6-4161-bc56-223ca180dc46"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07086de1-39d0-4215-993d-390a249d13ad">
    <dc:identifier>DB00635</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12ed2f7d-5c6d-4607-b597-d74abce98a72">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e78bd70e-0933-4c5c-af05-e248b22ee40c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58167006-b1aa-41a9-97cd-d8133c867110"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e1ed8f7-a6c6-43b8-8c09-659de9ca3ef4"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6044241f-b668-4da2-ac85-090fa978cbb1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab6a4b2b-d5ca-4375-9ca9-ac25d994cc08"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Prednisone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75fbace5-b6fb-4424-8cd6-29e6fab86eef">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a27d794f-9a92-4b96-b941-f5bbb32d1892"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58167006-b1aa-41a9-97cd-d8133c867110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/098754ba-968b-4d8e-bd35-67cf2775eb3b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254b0f28-92cb-4ec1-85e9-862f74f5660b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8ce56d4-7b5a-4f86-88c6-3b56b8512465"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f9194f3-dbb9-40b9-a3bd-34b4fa811495"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58167006-b1aa-41a9-97cd-d8133c867110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bba6f937-8df6-4e26-91fb-7115779d4715"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8199d8c-29cc-450b-9638-f9d5f55f7687"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-016-2044-9</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e7d3b99-7fc2-4b20-b2e4-c6bc5b895edd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7cb4e61-4e40-4c43-bf1a-ca5788bcd8a1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9cf386a6-6791-46e0-ad5c-b9bcbc97991d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58167006-b1aa-41a9-97cd-d8133c867110"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcb5999f-13a5-4cac-bbae-16ed916341f3"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c82e57f1-3f1c-4fa7-9a15-9e7cc426d00b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e159881-0318-49fb-9fb9-e5d1d966489e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/300531f1-f32d-4a16-964d-e69b2dd2515b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95ec471e-a9b4-46f2-9b1c-190c467b7199">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6aeeef9-7f50-417a-978e-3111ffa010e8">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbe74b24-2385-4f15-a0a7-0089d2c8024c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e76504e7-4342-4d17-87c1-41bc22f8230c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0dc6a930-ce0b-4b39-bd98-4da3598f8e1b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f9ca3aa-8eff-43ef-897c-9d2f19b59705"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/891baef2-5e17-4140-8794-938fd685122d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22b2288a-57bf-4a24-a50c-b8864895a170"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b37d0fed-4c2b-4d8e-b925-1e76e89e96f5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
    <rdfs:label>GRACILE SYNDROME</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78eea9ce-7f9a-465c-985b-7151d0a7ae26"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/940c298b-1ad1-4c22-96fa-db64ccc2487d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d447f74e-6069-489d-ad1c-7d954fab14d3">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b53f80c4-d389-47c5-a7e6-0204295e71dd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f8ee56f-d52c-41bc-bb20-f20bb1a9bc91"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b23507ae-0308-49c3-80c6-bfc460c146a0"/>
        <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72259ed6-e219-420c-88ca-92478a7f7f04"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/593b184b-6e7e-4ca0-945d-5cc9842a66fc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d36f622-d5a6-4ce4-8ccd-4097e2667379"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2277b668-6646-4336-9aa4-d595f0df4a37"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9e4cbb0-ebf0-482b-bed1-878f8ded9708"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Febuxostat</rdfs:label>
    <dc:identifier>DB04854</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa002fcd-63a7-47f8-8d95-50e4e7029433">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/217327b0-a3cf-4ceb-9700-1b2cec1a4f82">
        <dc:identifier>HP:0011227</dc:identifier>
        <rdfs:label>Elevated C-reactive protein</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/892ad774-7fc8-4f60-b5f4-6ba56861aefd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/325bb5b5-0f7e-457b-8bfb-80486eb06826"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96bbf30f-b0e2-4381-ba98-90f0fa42af67">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>High serum amyloid A protein</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9823a038-bd0f-4239-ad69-7c21be01c66e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4af9ba05-54bb-408f-a675-9c372486d4e9">
    <rdfs:label>hypersomnolence</rdfs:label>
    <dc:identifier>HP:0100786</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4191684a-8147-4657-b063-edaa37b78986">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a06bca8c-7eef-4f9c-8f57-fe6795c525fa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030532</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/450bb62d-1e45-4f63-82f5-660c1a83b0e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0146db9d-ecbf-4929-ad0f-623a45c0a53a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ddd3291-a5ce-4fb5-b090-ed128d21ef02">
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4503c91-ea76-44e7-aa72-58326969c54f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36408ac7-9992-4e2e-b432-990285900b1c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/286ab37e-6fd9-4db0-96a7-2639681a85c5">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0002344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
    <rdfs:label>Neurologic burden</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d5b8105-9244-4ff8-87f1-21b853998155">
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb3493fb-d156-499f-8a20-8088a2aeecc8">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Elevated Phe level in blood</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6ffed0b-9879-444b-90e4-01c970758ee5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e7f117f-3a2b-46a5-a66a-af2e70562013"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28909f38-2a02-44f4-844a-683d6346ef3f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe6e6ae7-7da3-4533-a517-feee6513ce38">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>High blood ammonia levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af30d76b-23c0-4ecd-8c34-dfaaa905d27b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0aaac067-d14f-4a6e-91e5-8e8e5384aeaf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a2c650a-c011-4112-ac64-6fe255d259e7">
    <rdfs:label>flavanols</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c163bd1-4529-49b4-b3f3-627ae9ca146e">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dd23055-c3aa-439f-8f2a-b69f918907b5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48020f8e-6d14-4c31-9477-3d9c363b7df3"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77ad3d61-ef91-4caa-8f01-5be61ea6a0ae">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
    <dc:identifier>HP:0031951</dc:identifier>
    <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6481c89-5746-4f26-9bcd-d60409096d9c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/156b97b3-7795-40aa-9ed7-6f6a845525e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2fc2378-0d5d-4b83-ad3d-ff9eeff54ef2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79b826d4-810b-4779-846c-def8dacedab7">
        <dc:identifier>HP:0031029</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5a88681-9a43-4de6-a8f5-f5efbe6107bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9915e897-b77c-44df-b936-38a4bbe86046">
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7178ce56-e04b-4a8a-8ec4-dee8c7d6dc42">
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003528</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc7f975e-a3a7-48d6-9e3a-c317192f203f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb680c04-38f1-4397-8d74-58d0a1d2bd9c"/>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ceef865c-25c3-441a-8e74-5a6c944c8185">
        <dc:identifier>HP:0040063</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d2f0728-f4cd-4794-b1d8-c1fdc15aff3f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6778be20-7b98-43d2-83ae-950ddaad0c3e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003199</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c8d1b6d-39c8-48a9-8138-3225cab45c13">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Bone pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
        <dc:identifier>HP:0002653</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd92e643-4a06-4595-bdce-295440b2f5ba">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95d10a75-4fab-4553-bb8e-421edce360bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41be7b1e-0878-4956-ab85-5b86dff8ae69"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc4c0d77-a4ac-4884-9485-55b40bb01228">
        <rdfs:label>orthostatic hypotension</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001278</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/65a3f4d8-e305-4b24-9b12-ae109f991206"/>
        <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
        <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
        <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7268bcfc-ab91-4308-9581-c93c32de6d6e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ef1a246-a35a-4e75-abd7-f0b2e73ed719">
        <dc:identifier>HP:0000479*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95b275a4-ff14-4565-8877-f99a63ea009d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7aea0673-6b24-49ed-8d30-d1b0b37f7b09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84fb0556-7e0d-4266-b488-65cc7e64f351">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:label>Hepatomeglay</rdfs:label>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5803b138-d04f-45d0-8d88-66c44fa35d4c">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f8974c5-8824-4671-ba55-28693a163a40">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31d10fc1-477f-4b7c-8b0d-693252c9a7ca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24e2c24c-11a4-4eab-8444-e3cfb06d89a6">
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <dc:identifier>HP:0010472*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19f64f5a-a017-41b7-8c33-2dd042404c74">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/333c5336-dca3-4a80-9647-5529783ffda6">
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:label>High LDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4001bd1-e54d-4554-8431-6fd303260454">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5bc83627-f589-40dc-9ac5-682c0b42ed8e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7b3a167-071d-4170-8982-ce748981d7b2"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a072515-87eb-46a0-9359-7ff642ed32a0"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c125475-e1c7-46e6-a685-9409da4ccce9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f5960aa4-2921-478d-a7b8-ac6e21f48e98">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6e4864c-1189-4818-bb06-ee5f8cd8b4dc">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0010535*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61730e65-faac-4143-ac63-5ac71f822952">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57fe36b0-056e-4d20-950e-bc39b3e87719">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fc5b844-1493-4d38-80dd-3da68f327e92"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff6bab04-ed87-401d-a854-1c9c993ff6b7">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002111</dc:identifier>
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/adf11c2a-1424-4ed8-92db-e2e5dbcb5f0e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a90c1bb7-693e-4c39-84f6-33371479207d">
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fd62770-d928-4dfd-be48-17b91de195d8">
        <rdfs:label>Six Minute Walk Test</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7309ab27-2b67-45a8-93e2-633fcc189f99">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3babfd6f-7483-4308-a779-ca1215df7414">
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f2175f2-50ef-44c2-96e8-fd3fbefb2e65">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Brain lysosomal storage disease</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63802933-0c7a-4017-a49e-8213304df243">
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38d47a3f-64be-432e-ae3b-6cc9fb7ea113">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2ffc87f-7cf6-48de-b098-ce4fd10bdf5c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9eda0cd-72dc-4213-bd7d-958a47c5ed82">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/993babc1-1608-4825-8424-79fe16fc62da">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f938e159-bdba-4e59-b9cc-9f4f741fd2bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90a605d6-a3c0-404a-9c2f-e295cb517337"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bacfa875-e7d5-4dde-9eba-05f84258c1bf"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c325b740-5332-4b4c-927c-350d2eb43828"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24b24857-c8c7-468d-b775-4177f2641972"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5003485-0ddb-4740-ad00-2a145f0323db">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atrial fibrillation</rdfs:label>
        <dc:identifier>HP:0005110</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0dea70c-a324-44aa-87f6-5ee10c108414">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2edef394-50b5-411d-aec7-7efcad902236"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
    <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
    <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b07325af-a55b-4648-baa0-ae3b79bd2904"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16d75d4f-8061-4175-9030-da39c0b46c52">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1158cac3-b2a0-43bd-ad4f-7bc54b006e15">
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7cb55a06-84fd-48f6-a47f-63f59048a746">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39cf2cfc-9a54-4f36-8892-794dc5ae52ca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe0c37bc-f1b1-43ff-bea1-55a3c8aa33e9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>pain</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fec8e99-6b98-42be-8690-081b332d9043">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiomegaly</rdfs:label>
        <dc:identifier>HP:0001640</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64584735-5a0c-44b3-a95c-324850b7570f">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96b0c0ea-0b23-4c1a-814b-088f0eea80e7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9105a828-9935-413c-b264-dabc02dc3248"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/758f0853-7940-4c81-aae1-2bb15b431831"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8c160387-0d90-446f-b376-bd5e0b6d9d77"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6de1c1d-ff6a-49c0-9f97-983b440c850c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be5a2459-27f5-4175-8a12-159713d8f4b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cerliponase alfa</rdfs:label>
    <dc:identifier>DB13173</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a296600-1608-41a4-8f4c-f37a0004f45e">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e54b7bd-f844-468a-91cc-a3ccb414260b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9105a828-9935-413c-b264-dabc02dc3248"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5a44cb8-f77f-44bc-924b-9209229dc71a">
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1eea345-ba83-407f-be3f-27e5354fad3e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>epilepsy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b58004c9-4415-4d5d-abf6-77c523226839">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1a3e9c9-e67d-47d7-98e7-e2c4338b478d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9cac0b93-7ed3-4b2f-9f40-3f913fb36be7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/407a5684-2b50-419e-9727-11e64dcb47d6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2c0856a-6f57-4ebe-8ae9-6918283e7491">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Progressive emphysema</rdfs:label>
    <dc:identifier>HP:0002097</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7929e2d5-a736-4d59-a846-d09ef95aa2c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e85c6ba-363a-4fa0-95d9-9c4e9a1fcae0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>Low myocardial function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/099955b3-7314-493b-8513-3cff0114f53c">
        <dc:identifier>HP:0003146</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ced936f7-6cda-4161-8600-cf8edcd8be75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e405e31-e0be-4aa6-a126-792c2ea99ac9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56fc0e65-b081-47f0-b02d-34e51dd8de4f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04c996bb-234d-48b1-9844-9720c954aafc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Delayed Growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e54edd4-e5df-4801-9071-e16e481c5166">
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:label>hyperuricaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6e6e606-0ec4-426b-a168-3014c5016968"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/839689b7-1aba-4d1d-b1af-1e3fa467a6ec">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cfcdd6b2-da9d-4465-841a-0278a0d63418"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ddc1aef-77b9-4b62-b227-ae4675623f43">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
        <dc:identifier>HP:0001958</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/7e8ef747-e4c8-4b5a-9882-fb1a62ddfec2">
        <rdfs:label>symptomatic treatment procedure+dietary exclusion</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5cd927d-aff5-4c56-820e-c54462609c7b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9553d89-9c21-4306-ad6d-f710cbb617fb">
        <dc:identifier>HP:0001958</dc:identifier>
        <rdfs:label>Acute decompensation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d85ecc15-a70d-41d5-b1c9-cf86832a4484">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <rdfs:label>ARGININEMIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc72acb5-0b9f-4849-96e4-5422e94652cc"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e710fa12-2488-48b8-b625-f255363be72f">
        <dc:identifier>HP:0000707*</dc:identifier>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5672e62e-3dbe-4a87-8915-a98c4aca2935">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3868b5f-9265-477e-a8b3-683f6879eccb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee031561-e090-43b3-94a7-4389ef33efe4">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <dc:identifier>HP:0010909*</dc:identifier>
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a27ca96-bc6a-4d9b-bd2a-de4e1332d1ae">
    <dc:identifier>HP:0011506</dc:identifier>
    <rdfs:label>choroidal neovascularization</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
    <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc9570b3-e678-44e0-b53a-649e96a6aa6f"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e432619-12df-4be6-bca0-36d14e3392cf">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2eead63-51a0-48ea-8eee-3f56dfdb662f">
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7640ff0a-092f-440f-91f2-f3ac61578edf">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96ff05e6-4f4b-465b-a677-fbb157f773bc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low cell autofluorescence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2562f7ba-8f0a-4bda-9ab7-50e4348c045f"/>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca7aec84-9949-4432-97b5-2ec331b56cb3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
        <rdfs:label>extended G1 interval</rdfs:label>
        <dc:identifier>HP:0011018</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce3f2b88-284e-40ef-856a-494725a5891d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aadb201e-481d-4439-8b72-5247031a323d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8d8cf62a-9e3b-42fa-95c6-33dda7a26165">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35af5b63-e31e-417f-bb9b-835a2798a932">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Excessive Reactive Oxidative System</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/468e321a-3d29-41bf-9199-36955e130df2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82dda832-f4e0-4ee9-a416-fdc2b7ee0976">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/749b7ddc-8d36-4bb2-9f44-be1c8f417eb0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/602bfb8f-fb60-4b0e-a4c3-ccc832d61a3e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be2122af-0b86-43f9-b04d-7a8f9ff63169"/>
    <dc:identifier>DB08876</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
    <rdfs:label>Taliglucerase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08ffe602-b78d-4b44-a2d2-f3e72272cb62">
    <dc:identifier>HP:0100512*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:label>concommitant low vit D level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/836d6aa7-09cc-4038-981a-8b7e4aa1d8f1">
    <dc:identifier>HP:0012405</dc:identifier>
    <rdfs:label>Hypocitraturia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/faac7d99-0e23-4eb9-b353-461045162a85">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5bdb1b7-a7f6-4229-9adc-39774308a252">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1423001-986d-41ec-9006-f21d88994ae1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b239b8be-7c3b-4577-81be-1c29c3e5cd44">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1423001-986d-41ec-9006-f21d88994ae1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d224aa7-9cab-43f8-aa3f-10a19ec53409"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <dc:identifier>DB11133</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a7e1990-78eb-46af-b3ed-4d497980e7cb">
    <rdfs:label>Prokinetic agents</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ca8d4c1-2a35-458e-8e34-e059813c0cbd"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7e1cb00-35f2-46c7-aaa4-88062661280b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9f29776-de29-41f4-8195-1330b317da1d"/>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56489e74-cc7e-40b5-9d32-f066910dd562"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d203c9e-d54f-4fe8-b842-5d482fec7397">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Cataract</rdfs:label>
        <dc:identifier>HP:0000518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5c52ea5-3626-4a5c-bd17-758822f31e4f">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
        <dc:identifier>HP:0000144</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f058e25-6fc6-4338-98a1-e3fd44b80f04">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7093ccec-714a-4ac4-a627-933243325464"/>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01e64856-6129-40b5-b72a-ba57269a6038"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ee75eb1-4f24-4690-8606-b00219241d3f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b1f59b4-7190-4d01-a35c-3e4d4840d328">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e79e7d8a-5334-41b4-aa57-3fb44bc7fd80">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bf5b953-0b8a-482e-a07f-58d5315e53f8">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <dc:identifier>HP:0011015</dc:identifier>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0083aae1-79ef-4613-87c4-4b189b3387f8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c28a17d-722e-44e8-a9aa-9a3c850bdf81"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e792d4a-ed40-4ab7-8d0b-1bffb5755328">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66f58c32-1f01-4fe4-8699-6652e1c16c73">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>weight gain</rdfs:label>
        <dc:identifier>HP:0004324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8710776-8fef-4496-b304-b09a1d2d46b3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac810558-9a25-413b-a673-40adf3916700">
        <dc:identifier>HP:0000127</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>renal salt wasting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee2f3c82-fb41-4035-835e-5a3895ab609a"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/180b2a7c-08e3-4242-9c59-87dfba9bb869">
        <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7024c2a-cc10-4d65-9b68-6fc327bb9083">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b657de2e-16ad-4191-9113-b225a07c76fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17a86540-57ed-4dd1-afce-5a31a458e6fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/960cfc7d-f72f-42d8-81ea-bded8f52d194"/>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25fcc28a-eff8-4fda-8698-af51404cd418">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96891385-9ada-48dd-8cdc-f25b0fc7c1a6">
        <dc:identifier>HP:0003287*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0edce8f9-4d89-43b4-8820-b7bc7a532d0f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypophosphatemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <dc:identifier>HP:0002148</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/099ac911-a445-4b83-87c2-2eb7f4edd750">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:label>Encephalopathy</rdfs:label>
    <dc:identifier>HP:0001298</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c89a152-e54c-45dc-bcf7-a97cdd8f9b79">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08ffe602-b78d-4b44-a2d2-f3e72272cb62"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54eb4f5f-836e-4dcc-af5b-36cda3c7b163">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a05f298-8f32-472b-93ae-41c24b867153">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec1debd4-85ce-4f33-a1ad-ce8a9e2f7839"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
        <dc:identifier>ECO:0000305</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fb74a9e-2153-44f1-8e8e-0fd67a9fc0c5">
        <rdfs:label>mortality</rdfs:label>
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5a88681-9a43-4de6-a8f5-f5efbe6107bf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87c30ec1-13bd-48bb-89c4-1a5e3f86264f">
    <dc:identifier>DB00624</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9d73c46-517b-48b3-be3c-8d547fd04048">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42c9e1dc-e285-4cd5-8a95-5904198c5f73"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d358040-2bef-4f98-9a63-e7ce8427f08d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dddc2cd1-e4da-43ba-8d36-70ab69f0395d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3509ef93-af36-4ec7-858f-c3da333affed"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9379d3d1-1755-4871-828d-12e73bfd7446">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d358040-2bef-4f98-9a63-e7ce8427f08d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b78871be-6fee-415d-858b-990c0c1b5dc9"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Testosterone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad40ad64-a670-4834-a073-b772e9e113d5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ad82a62-c450-4afb-8c1d-13299a250832"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d358040-2bef-4f98-9a63-e7ce8427f08d"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67e2d4f2-164a-4eeb-9c68-86cc2286dd0f">
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75a6840e-5d0b-46f2-9f13-6c3c56b6d1fe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a85be92-aa7c-4387-b25b-f76a4a9c9991">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d9aed90-8273-4a0e-a35f-f4bf461fd6fd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73eac236-4c0b-484a-bbc6-4770ea0414a1">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb02cdf5-06a7-4670-8be4-aefb195d3628"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca537b8-76f3-4d21-a568-c1b2077b40ce"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47a67bfa-0e9c-4691-8945-493bbba05cb5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29763ee0-9d7f-4782-aca5-0cc04e5545a1">
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62fe0e31-996d-49db-a164-ff455ad17d11"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231690"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c317839-3c82-4f61-8534-fe0afa8e3c7e"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/631a8d74-1744-400a-aee1-fcdb6a5bb425">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96891385-9ada-48dd-8cdc-f25b0fc7c1a6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44bdb5f7-db5a-4d12-937d-168b5f6065fd">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e81e18-0144-47fb-9587-bb9879dad992"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fc1e4bf-f3d2-482f-ba89-d736542370be"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/040b491d-9732-4e52-8cc0-9a1a1cc7c0fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0434650f-ce2a-4251-9299-d5f3a40b323a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4aab579-003b-40d4-aae3-f7369fea17c0"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f1596c6-ba47-4f9a-b1ca-0b00a42de94a"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c4d3970-fa91-4936-b9d7-0bc3c4a00ad5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49290373-f6ef-4b83-aa0a-5ff2a5ed197f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef7a4ed6-e69a-4874-8063-ae4eb367ac3d">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Splenomegly</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/649873b1-ec00-4a07-a246-53189f9afc90">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:label>Thrombocytpenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae88601e-a9bd-4e5f-8e4b-ddd35fcc7a74">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>hepatomegly</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79c941d1-d4ca-493e-b7f1-e58b3020493a">
        <rdfs:label>High chitotriosidase level</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c236408b-6bc3-4934-a190-cbd59310b75f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce06811f-22f5-40fe-b490-6c8d51dcc136">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e939de0b-f7c0-41eb-b38c-7ce171de07e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94fb0948-d556-42b7-9308-cb42d7be166b">
    <rdfs:label>Self-injurious behaviour</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <dc:identifier>HP:0100716</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b70b7f8c-040d-43f9-8c8d-ec5725ef43bf">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7fcc2a7-a19a-4579-9521-eb0de24b7915">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7b3a167-071d-4170-8982-ce748981d7b2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53f1ccc3-bdee-4fee-9fc2-55f52b39aaa7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7b3a167-071d-4170-8982-ce748981d7b2"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <dc:identifier>DB01098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c6fd3d0-7915-495e-9819-4b981f3547b3"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5060c482-6ec9-460c-bb81-ba18e8ef70f5">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4001bd1-e54d-4554-8431-6fd303260454"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/647cf890-639d-4776-bdd6-3bd9c2b845a2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19f64f5a-a017-41b7-8c33-2dd042404c74"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4fa61863-722a-411e-b5b5-90b0120322d9">
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3f3be25-a82b-4d2e-8477-c02b93763942">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/190757ae-9544-46a9-b9ba-477cde9fc6f2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2b9d974-7f8f-458a-8360-ecd71767b1d6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8caa2f4a-ca5e-4417-a19a-e6e3434501f8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <dc:identifier>DB07425</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8885670c-8ce3-4bf2-bb69-a526f9c75a1f">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/9d963d77-d37d-484a-8309-07be3a380064"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
        <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6e369d3-d141-481f-bfa4-212b194df3b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddf21aab-e6b4-4c83-a56a-dd5b0d996d14"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Sobetirome</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4204ed33-f39e-44f0-8abe-d763aed1150b">
    <dc:identifier>HP:0012450</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Chronic constipation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9522d46b-4baf-4fd9-b69e-6a79dfc86d5f">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0000841</dc:identifier>
    <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e21b2cb-5814-48ec-b795-67d30e0df87e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b9c96bb-d3a1-4f02-acc7-3c98e794d81f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe6cbc28-3c2a-49b6-a4e5-03d84ebd85dc">
        <rdfs:label>liver fibrosis progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e74dbcf6-4445-41b9-8d37-8a58f70a2305"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/5ab07ebf-8c6b-4ccc-bafb-ecfe13a94e0e">
    <rdfs:label>dietary regime modification</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf3c2f05-6117-4f86-b034-e81ecc6115db">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f98a705-c6e8-4898-8fb8-a9be53b6773b">
        <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e392bb8-245f-4cef-a7e3-ec85696c4396"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd752ed9-e27c-4289-b327-78171a3570dc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/75ecb3f5-d7e1-4d75-b04e-f71f39e33272">
        <rdfs:label>direct complementatoin of a genetically defective protein by gene therapy</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff80535b-9fa1-48da-bf31-d4b5f21b6b84">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/416a8626-22a4-4130-b88f-983f1f33cb44">
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f695180b-abd8-429a-a77a-f8374dda00cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4983c93e-e769-4c43-a0aa-c426bb67256b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16858b40-f006-4ee1-8610-592e6371f1b6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24d71e6b-d847-4eb8-9b8a-e9c5b5a18c58">
    <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f02ee08-bd2f-455d-b579-d87640431a72">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d085b17c-6b7d-49de-8b39-7206679a885d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6577281d-ea98-49fc-b568-ff8d88a393ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02db4f9c-caa0-4665-a2d1-3f0e61e2409d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b4bcbd6-faba-4f22-959b-ca7ee3a91f1a">
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003158</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cc84a57-a121-4012-af4e-8127301fbd2f">
    <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ae614412-c78b-464d-b0fd-7f00e453bebf">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5a7c4d5-4410-4262-8898-e62a7159b9dc"/>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cde7bef7-ad4a-44b3-89c7-3bcea6943e04">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ef8323e-c625-4ed7-975f-57ddce507eab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3a162d3-6978-4829-b7aa-ac1b2fac1ba4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ed68c71-e23e-4a8c-a301-940cb90f5ae7">
    <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
    <dc:identifier>HP:0100712</dc:identifier>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aadb201e-481d-4439-8b72-5247031a323d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e432619-12df-4be6-bca0-36d14e3392cf"/>
    <rdfs:label>Carbenoxolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <dc:identifier>DB02329</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4dbe6d0c-1797-4fb7-8531-f7d821c00196"/>
    <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
    <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
    <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69e07741-5c0a-4754-a174-5c687cfc93e1">
    <ddiem:failedToContributeToCondition>C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26d60d32-a827-4f68-92ec-b855a37d69eb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0003304>C282Y/H63D  heterozygosity or compound heterozygosity</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/081a7588-d408-4afd-8fef-bd76a0262644">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e429081b-a47d-4f7e-851d-8b6a0f52eef3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47b818ee-d74b-4862-819f-e81eb3ffbc06">
        <rdfs:label>Increased serum iron</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e59a9d69-4808-4b09-9af1-dce122c8fda6">
        <dc:identifier>HP:0012465</dc:identifier>
        <rdfs:label>Increased liver iron level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4def6af5-c32a-4150-9e95-4948732deceb">
        <dc:identifier>HP:0012463</dc:identifier>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb3b14f7-d0e0-4909-a398-e1ae6e10517a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
        <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
        <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fb96843-0874-4478-bbd1-81722bb866be">
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d59b519-fda9-4ccf-adbc-0408eafb625b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a27825df-85da-457e-b6fd-6d976eabc434">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <rdfs:label>Muscle inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100614</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4702c99-d408-463d-bc5c-c76bcd92237b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/240d5b02-099e-4b76-bcda-c7cadcebea05">
        <dc:identifier>HP:0003713</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle necrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/431eeb13-51f7-4187-9f77-7ea9e762d422"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52e7bf71-f4fd-45f5-95e1-e0f029b95389">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d4595dd-65e6-4d56-803f-d4a43b068620">
        <dc:identifier>DB00435</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2430c4e-f8d2-4f6d-94ed-dbd4deb29e75"/>
        <rdfs:label>Nitric Oxide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b4869eb-bab4-458d-8de6-f645daa27ee6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/468941df-19a0-4d3c-ac77-0659b5f26caa">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002749</dc:identifier>
    <rdfs:label>bone weakness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613521">
    <rdfs:label>UROPORPHYRINOGEN DECARBOXYLASE; UROD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613521</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8bba1c1-daed-4a31-a9f3-70dc21a6375f"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df6ffd17-9e50-47c4-9144-44df5876ad89">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/774d90be-ca3f-40bc-95af-552dc36782a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b002deb8-6103-4f37-83b1-e138c07ac340">
        <rdfs:label>Abnormal renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b93bf342-770c-40dd-9e96-f51605b3393f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4eb14427-7659-40bb-a69e-54f2adcb1ee2">
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003676*</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
        <dc:identifier>ECO:0005242</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f30a351-d485-48ea-bece-24613dc3a664">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurological malfunction</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17493778-1c5e-4126-a4ba-0dbb8a02e955">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/267761e6-89b6-41f4-bab0-54a053a16c80">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>White matter changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/898bec0f-0951-49b0-a8df-e8d23729f1d3">
        <rdfs:label>dietary exclusion</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2193e6bd-c06f-4f4a-8e5d-69cbf1aaf4d5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/620e3aa0-8eb9-4daf-a906-b04015ea174b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ad6969c-8ca2-46fd-a2dd-1050f212edb0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10d95212-6f01-4598-a38c-dacd25692665">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebbb3b73-cb84-4754-9cf3-4c07a3dbcc4e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5cfcbf2-af5e-4538-a525-fa03cd11ec9b">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90d77ddb-4b1d-41b9-894d-ca35c82d670f">
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eabfd918-13ce-408e-b749-6629b63fd6f7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>low visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/471facff-d542-4a32-a960-8af09880d495"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25ccfe71-2aeb-40ef-8101-1fdf9588f026"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b2c910f-4307-4015-8296-3f3127e4a094">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
    <rdfs:label>pathology in many somatic tissues</rdfs:label>
    <dc:identifier>HP:0000924*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52cfa7ab-e677-4ac6-93da-3750d77a4e93">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40af249a-cede-48b9-ba14-00c110cc003c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29ec73ed-e99e-41c5-bfcb-d7a9ba824fa3">
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8fc359b7-a441-47b9-ad28-723e6e87d2bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4442831c-0d46-48d3-ab0f-52f30cf95a18"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf1dcf94-6960-4289-8d9e-2eb70c5e1df7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7b2f890-0da2-440c-97ae-9bfcfecfec28">
        <rdfs:label>lack of eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5346f0fd-8afd-43e4-b336-32b26ff21d89">
        <rdfs:label>Hypokinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a308d315-b0bc-45fa-9063-063a3e93f3c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <dc:identifier>HP:0003785</dc:identifier>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64dca48d-a1fa-4b89-82e3-838f9e1fbd17">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed mental development</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9170d275-0b2e-4123-b70f-3c7bf5ebdf6c">
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:label>Poor head control</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8f18871-473c-425f-b600-182e28ab2713"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d730e91-c41c-4a6c-bfad-61f9bc4db838">
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49dffdaf-0438-4add-ad5b-28b4fc594369">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/211bda83-e4de-4a80-be08-0c48d3db2398">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>lack of gross motor function</rdfs:label>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de00a910-8843-40f0-9fd1-d442ba94467e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>behavioral abnormalities</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3113bfef-d336-4564-96f1-2567c13f16b8">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc69c393-961f-477d-ac83-33c8c07074a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e3e846a-86b0-48c8-a973-607b479943c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81edd59a-02d3-4e4a-91f4-e70efc7e6cc3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:label>Low ejection fraction</rdfs:label>
        <dc:identifier>HP:0012664</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bac3c7f-a530-4bd7-86cf-134c85dccc83">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <dc:identifier>HP:0005180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be5b073d-82d2-40d4-8ebd-3e79aad37b9b">
        <dc:identifier>HP:0001653</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:label>Mitral incomptence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebbb3b73-cb84-4754-9cf3-4c07a3dbcc4e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ad6969c-8ca2-46fd-a2dd-1050f212edb0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c46c35a-e2d6-4b6f-9953-d8f36f7febaa">
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10d95212-6f01-4598-a38c-dacd25692665"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/791e2824-5f85-4d5f-9855-f3ec6ea31bca">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc1da5c6-9748-4dc7-a1ea-f7c1e84fe29e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10d95212-6f01-4598-a38c-dacd25692665"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Fenofibrate</rdfs:label>
    <dc:identifier>DB01039</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1572752-f160-4aa6-8b79-ceaa9e96680f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4204ed33-f39e-44f0-8abe-d763aed1150b"/>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9170d275-0b2e-4123-b70f-3c7bf5ebdf6c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cffe9c20-8fcc-417d-9337-4a3d8f776df3">
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7859fcf5-611b-4318-9e1b-b1a401d2c8f9">
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <dc:identifier>HP:0000496</dc:identifier>
        <rdfs:label>Defective eye motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06a194eb-8178-4e31-b469-6c0ccadff7f5">
        <dc:identifier>HP:0001283</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Bulbar dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c7581df7-da3b-4a4c-9d02-9d3ad3512051"/>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d848b86-1669-4e47-a0f0-83cc0c80c6b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/468c6852-d1e6-4d1a-a0f1-1fe88ef79925"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/532114a3-d1d4-4f72-998a-6438f9535133">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f2ee76a-eae0-413f-b404-f7fb3e58f288">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33f6a332-c566-45cd-a4ee-0034dd32471e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3ab2db18-1ed2-4234-aba6-16aa5d0bc3f8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00973</dc:identifier>
    <rdfs:label>Ezetimibe</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebec3f6b-f3c7-439d-92bf-7b87bf7b213c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36ebaeff-5cd7-4258-9e36-b78c03335dff">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b217d952-f590-40d3-90f6-18116a8e04b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d69b3d4e-87a3-4b33-af76-3f377b1e2f37">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2269de39-3109-469b-a3d5-0734d07718be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>cognitive deficits</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/58db51a7-5188-4b81-b2f4-ee42f7591576"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6732d2c7-bb6c-44ce-b841-0712435d7878">
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5608a30-910b-469b-8946-48fd78d1fa71">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55e6af57-f2ea-4967-a254-f786a3e16d67">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/791a65c6-b5ed-49cc-b90a-77d8cef98780"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb46a430-e6da-492e-8f74-c2d2b88a73e5">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/908a2445-310c-4107-9a4a-436c20479cf4">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0030878*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
        <rdfs:label>Low FVC%</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a52aa0b9-1383-4357-8e29-9364d3c990e9">
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2170ad0e-665c-45f4-aea6-bedf20834828">
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5befd1e-cf52-41ab-89d1-05b806c9759a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001877</dc:identifier>
    <rdfs:label>NA</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d432f0e-35fe-49a8-8593-ebbfff22ad43">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8930a55e-0854-47b5-8986-034bcb84ba76"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d793440-c0e8-4379-a995-e4f6a2488d55">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfcab91b-a7cf-4418-bd45-d1753bab8cf7">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/267826b3-d5c4-4003-a6f4-351ff444b82a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bd010dd-a88d-47b0-ba6c-38c75e695e6a"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82fd5597-bbc0-44f5-b98c-8ebeed8e4dbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4dfdc92-54b0-4705-b241-d6fac154c34a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25248365-1089-4d86-8d40-52978c6a3f6f">
    <rdfs:label>elevated liver iron concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
    <dc:identifier>HP:0040134</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe5318bb-4210-46c4-8f96-2dbf92951370">
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <dc:identifier>DB00855</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c72010b-cd8a-455a-bba3-85536f145ad2">
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e5b9b92-820a-404b-b950-783bd580a75f"/>
        <obo:RO_0003304>R266K</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05c19b2a-7387-492f-9f72-9bb4dbee0d43"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af6e62b-08c5-4090-8c6f-5a9c1c322d57"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0003304>R125Q</obo:RO_0003304>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd69b1bd-c8e7-4f07-9200-b2361a7d6832">
    <dc:identifier>HP:0012500</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>verrucous lesions</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0daaccbc-2ecf-46a6-ac2b-827f77bb6f1f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/356e6ca5-4701-42bf-8c92-4a453613cab8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8d8d10b-cc8b-422c-80c9-d317b54d4969">
        <dc:identifier>HP:0100036</dc:identifier>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64b43643-471f-4daa-9790-85f4eaa43ea3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a70cf78a-e8e8-44ed-9c64-ad6f67c38f06"/>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://academic.oup.com/jcem/article/95/12/5174/2835157</dc:provenance>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61276396-bed8-49f1-b1ba-f3012e6fb5c3">
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
        <dc:identifier>HP:0006462</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46ec7057-869a-4992-89ab-7708e24486e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <dc:identifier>HP:0003239</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00198-015-3272-1</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9574e5b9-321d-4493-8204-4848c8739133">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc887c95-ebd6-4ea7-a050-750a0d982885"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b00b4601-824f-44db-be32-f38e2a450f12">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <dc:identifier>HP:0003260*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4285b50-a37a-417a-b40b-0c2670abb0a9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <dc:identifier>HP:0001832</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bac8bdd1-85e9-4a47-b964-9015ebb63712">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <dc:identifier>HP:0002756*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/156b97b3-7795-40aa-9ed7-6f6a845525e0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbc11e3f-c8d0-40a9-abff-79e900ec33d0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mobility problems</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <dc:identifier>HP:0001376</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaec78eb-a7f2-4275-a714-976b95cc257d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Abnormal motor function</rdfs:label>
    <dc:identifier>HP:0004302</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4b0ab2f-1ac0-4057-8f2a-7d8d27dc1fd0">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/1e324038-755f-4605-aa7a-3c2394800334">
        <rdfs:label>symptomatic treatment procedure+dietary regime modification</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f19ecf7f-2c89-4a19-8ee0-47d65356babf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/234a4ac0-3740-49a7-af21-45aad98bd64c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26ec64d2-138f-4fc9-aebd-d6588c6ae6a9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:label>steatohepatitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001397</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12576e0f-32f2-4f02-9221-0d1f67ed8cf8">
    <dc:identifier>HP:0002069</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16326d54-796f-4d73-9f7c-e06a0260c6d0">
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f221346-e637-4919-b7ca-4c0ec899ba7f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/72c7627c-0a0c-42f7-924e-c8b494d57443"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97ec4088-1adf-4876-a613-18e3e1a18103">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Lower extremity weakness</rdfs:label>
        <dc:identifier>HP:0007340</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5635106d-bf88-4ae9-a202-ed04080cf942">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02ec64d4-de8b-47c8-bb5b-53633a14fab1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f596495-aaa3-4eb5-87eb-9392aded48b3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
        <rdfs:label>Gait instability</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0002317</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcca5172-a73f-4faf-b9c8-17ec45143946">
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>Neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03ec10aa-84db-4a9b-be70-82fd37d74d93">
    <dc:identifier>HP:0200125</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1598ea8-2b5a-46b3-b502-4d78dae567b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13bb1d25-fd9f-4873-8806-bff029901c13">
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Pruritus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/431eeb13-51f7-4187-9f77-7ea9e762d422"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/156b97b3-7795-40aa-9ed7-6f6a845525e0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e5cb6df-54cc-4235-bdd0-1d054b40e5eb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011021</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
    <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aa38c17-63b0-45b0-8369-319d30ba1e56">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46cb9908-9f16-45f0-aa59-2642dff77dc8">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
    <dc:identifier>HP:0040215</dc:identifier>
    <rdfs:label>Abnormal circulating insulin level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b64feee7-830a-42ca-9637-081986ca3046">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/450bb62d-1e45-4f63-82f5-660c1a83b0e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5af374b5-a7b0-41d5-b18b-df5091357846"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
        <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60b88e00-19e6-4c00-933a-effe4c268dc5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78adfb8d-ab81-47ae-aa2c-c80c6bfaf6e9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum phenylalanine</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/593b3dd2-39d6-4eaf-90e6-ce47cad09ef9">
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c9f6e29-a08f-4abc-a94a-d0f8fc7c6b51">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
        <dc:identifier>HP:0004349</dc:identifier>
        <rdfs:label>low bone mineral density</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/472974b4-19c7-4fbf-8110-83192cc5800c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1b2446a-007e-4196-9450-3bde1690b75d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/468941df-19a0-4d3c-ac77-0659b5f26caa"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e753a58-45f2-4933-93c3-620bb9cbb03e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
        <rdfs:label>bone fructure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002757</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5691a730-d189-4f89-9fb8-b960302fc964">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
        <rdfs:label>low bone formation biomarkers</rdfs:label>
        <dc:identifier>HP:0031429</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4421eaa-a1d6-4eb0-8cbb-e88e84ee41b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46a2a2fd-1f10-4366-a96d-fed9fcbf5b39">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <dc:identifier>HP:0030872</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32acc94a-c896-412f-b08a-177b6788410b">
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <dc:identifier>HP:0001640</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c5850057-aae5-43ab-9ac9-56bbba509051">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a5bce75-f73e-463c-ad61-16dd4b33ca56"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b3f8ee5-6677-4502-8657-b9730a9afa14">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69472036-3643-4a65-ae40-b6cfdc3c101e">
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001714</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/adf11c2a-1424-4ed8-92db-e2e5dbcb5f0e"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84bd0179-247c-46e5-b82c-e36f7b9aa7e8">
        <dc:identifier>HP:0006670*</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95e65b13-2728-4283-9ead-05ea710f30d9">
    <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41e6024a-01b6-4b6c-bb27-79a27e961cef">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41343e19-dd90-4584-92ec-6d78884cc995"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f8c692f-990c-4a93-a284-e13d930de749">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9536dd8-6041-4144-b988-51ea62a7427e">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74958559-ad26-45c1-8e9c-674c9b8bff06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aea41c21-9cdb-4dff-bc4e-c38f47920aaa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b682c844-f782-4346-b51e-d2530b5c8440"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8381aa6f-d8a1-4d7c-9a0e-83319270ce61">
    <dc:identifier>HP:0031851</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
    <rdfs:label>Reduced hematocrit</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3dcdb52-85a2-4eac-9f22-a148effc7f99">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d64b924e-c3b2-4ff2-8dbc-bfea25acf675"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>Abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58a24a87-1f00-4bfa-8f3c-df0ab95ebc2c"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc0068f7-ead8-4fac-ba00-0bf7ac7f48bc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08adb341-f28b-44f0-b99e-841a5279975f">
    <dc:identifier>DB11094</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <rdfs:label>Vitamin D</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c89a152-e54c-45dc-bcf7-a97cdd8f9b79"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ee032b3-47f5-4637-b8b3-1b9b259517f7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6561c18e-e5ec-44db-a7cc-a4b0689bacbb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044915</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9aaff5c7-85ec-49c2-8920-4ccee7e0afd1">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd637b17-7776-4b63-ab79-a146f4402667"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46e92b14-5c26-4214-8c5f-8fd2cf52c9bb">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f33ea64-113e-4a99-b686-49f05a122b36"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b604b645-70b4-4fde-afa0-d6db6a8053a8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96da02a2-23dc-4836-8bba-28b074559ed6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d7db588-e5d6-4f5e-9244-7d9d05d14b71"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/faf84308-5f25-4ccc-8963-90fad8e5fd6e">
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/902b456a-b8e8-4490-9967-f9b2b41e9467"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fb9c390-58be-462c-a552-e63929312a7b">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <dc:identifier>B01</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec3433a0-13cd-49cb-8f5d-7b10363d4148">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cb6a6dc-a608-4eb5-9ec2-93b1677f6f22"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31a7650a-0a77-4531-b7a4-24bbd6e13339"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/089f101d-ae9e-4118-ac69-5e8b3eccc4a2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84fb0556-7e0d-4266-b488-65cc7e64f351"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa889d69-23d6-409f-843c-e7122e2f00c2">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d63f8912-b98e-43ec-ac0f-06e735c07520">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86488b3f-f732-477c-bda0-add667a41631"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0083aae1-79ef-4613-87c4-4b189b3387f8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21da7477-0732-443b-bbdf-219f460ef270">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c239d05-9ee2-4ff6-8bf5-320c50271287">
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0031544</dc:identifier>
        <rdfs:label>High blood malonylcarnitine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/209abe70-9d5b-4439-8dd1-4151bbf8f41b">
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>Failurre to thrive</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0d1275e8-ce45-47b7-9e05-c04b7801e387"/>
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dbd26b6-8de2-46f4-a0b0-25d42ec1976e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0003679</dc:identifier>
        <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efc5fe87-d986-41d5-9527-822bf06fcdfb">
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <rdfs:label>Low endurance</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/349eaae9-12f4-47c0-ad3e-4d04f5ede1dd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b267042-f8f6-4da9-9953-379e08842cbc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000166</dc:identifier>
        <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6342c83-e557-4693-9d8e-81dee86c8337">
        <dc:identifier>HP:0000982</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
        <rdfs:label>Keratoderma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b33d1196-fec1-4220-b05e-44c7c5011e37">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/434275c8-72e8-490c-8f4d-eb048233694b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5206e3e4-ce91-4398-9fdd-ed9c699cd2b0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>dementia</rdfs:label>
    <dc:identifier>HP:0000726</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/908ddbce-f483-4a05-8a58-9d02c42d53cb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35776987-983a-4885-b2d8-50f51b978e46">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/050883b9-57c9-41c1-bacf-3d1d9c52a7a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96155a37-a01e-4b4e-b971-691923846e1c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c22fa375-8a7e-4362-95d8-534841b572cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0004371</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37de00be-d2b9-4691-b6af-acbf4a9d1349">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002062*</dc:identifier>
    <rdfs:label>Pyramidal neuron loss</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69ff7257-7a57-4830-8fec-e92719dbce66">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4746ac75-01d4-4354-b0ba-cd19a00dd8ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7cfdf1b6-6b26-4be5-af0b-2de0e9a48582">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
    <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06eba4bd-c516-496b-903a-b2b8d56f6d4d"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
    <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
    <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b9def35-116d-4957-b417-33dce6e5fc4e"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e7c75f4-4ec7-4ee2-bc10-3ee41bec78fe">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/548ffff0-ed01-4887-b5a0-786f8585547e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f7b2ff7-a219-43f1-9825-9c3414d3f89c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfffd107-d6dd-4f22-9a49-882416c9e9b7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dca1c11b-b065-4018-bd41-cecb3ce3388e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3de019c-42a6-4a7b-9c26-642a9628cc26"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f269219-4374-46b1-b4eb-269e8073d0e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fc8ee83-21ef-4891-b1a5-4b8117bd3d30"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5bc00b4b-9cc8-4728-9582-ea3dcc107607"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09278</dc:identifier>
    <rdfs:label>Activated charcoal</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2627dc2-fa16-4d1d-85c1-1b7cabb1eea1">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbe12df4-6110-4413-90df-26cddc05a073">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7d03d3c-0eaf-4943-ac20-bbf683b9c028"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a06bca8c-7eef-4f9c-8f57-fe6795c525fa"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e36731d2-474f-4fa2-b619-a1ff9197bcdd">
    <dc:identifier>DB03756</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3388ec8-99a0-401d-8776-c26ef03296cd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b571921-3849-45cf-8e14-c69cf63a8490"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2baa57c3-b3f5-44ec-8665-c48b15fa82d8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Doconexent</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2070a48f-31af-44ca-b98a-be1d6a610c73">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e075dc8-eab6-43b6-a9da-0b19981e0c29">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64136ee4-42c3-43f8-8f59-85aa22b9ee9e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54d7831a-4258-4cb0-a785-8328e0e82db8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004818</dc:identifier>
    <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/143ac8cd-2ec4-4667-8593-56b3a0931fa6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012187</dc:identifier>
    <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb591fb6-5b90-4782-84c0-8bd4057dd951">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e787d88f-1907-46ff-a139-d2f49835545a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbc83946-a599-4489-b4ba-bfb95e78d242"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/890bba22-2ab7-44a2-8b8f-41af025b9adf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48369725-0f66-4918-9c17-83e583e6d109"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ce6fa19-15ea-4275-bae7-e187a526ad5f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fdaf81f4-80c5-44f6-8d0f-95370c1bcaa8"/>
    <rdfs:label>Zinc</rdfs:label>
    <dc:identifier>DB01593</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5eaacc8c-9863-47f6-8744-f4414287c29f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/62b01bcb-bb4e-4451-ac3b-76ef492b48d8">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a76f0a40-5ce5-4f16-b719-87c477696bd4"/>
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9a2be94-70cc-4022-8b5f-8d248337c6e6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <dc:identifier>HP:0010979</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/904ab471-b900-4719-9d8c-6273252cfe85">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f1215d9-7876-4527-9519-1dd96d8fac11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cef8256-67f3-4a93-adc7-a7771eb61669">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C  level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b6ca70f-aa4a-4db2-a3d0-66974d8756f2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de36ce12-7fd1-4a20-b58c-1844ee68977d">
        <rdfs:label>Diabetes mellitus</rdfs:label>
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88b04dc7-5658-441c-a8b5-aa767c3f8fdb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/824a5ca8-d592-4b44-9e43-ef02b47a6438"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00b977fe-7bcb-496c-933d-6ab91e9ddf8b">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>unalertness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
    <dc:identifier>HP:0002329</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88ade400-ef15-4134-8596-8fb0b87fa9d7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f5629e4-da64-43e9-aee9-21225a7aa2c4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1f1e1c3-a2ef-42c3-bf4f-550b5b27a8da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75f4085c-5640-4484-9fcf-b9a9f02fe578"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/385c91dd-0b6f-42b2-a016-4de9fcb42f5c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bf1ed66-7e62-4ae2-8b1c-68bab9ad27e3">
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af07902e-7516-4572-8fa2-873fdb386599">
        <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0009587</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e3b83f0-a93f-4627-be2d-121ff81b4f68">
        <rdfs:label>High cermaide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/965b463c-0dd2-4688-a79c-5fac9ef446c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79d692bb-42c4-4f70-b215-906f7066b92c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/de3eea9f-cd5c-4a3f-ad0c-85a628081147"/>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13c52b82-7818-481e-b359-3690de0396a4">
        <rdfs:label>high plasma MCP-1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8193bcdf-864c-46f0-8f23-5562de8467ff">
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal spleen size</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62ab598f-7552-4661-b86e-2045d2b7e3ba">
        <dc:identifier>MP:0020582*</dc:identifier>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/343459f0-c708-4f48-aebf-330cfb03202e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Joint inflammation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b89f1733-83e0-4fce-a485-6b3352327541">
        <dc:identifier>HP:0012647*</dc:identifier>
        <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56489e74-cc7e-40b5-9d32-f066910dd562"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4627a0a1-6cdd-4b91-a8ec-5147480e892f">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
    <dc:identifier>HP:0003800</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7b39bcd-a083-4184-a514-eb9744026cc0">
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbddbc3f-8056-4ef4-9d06-1584dba7c5d3">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14a38f56-9da9-43ad-aaee-c31f51f87575">
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f1e3be2-b58e-493d-be6f-3c8351e0c33a">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>recurrent infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56fc0e65-b081-47f0-b02d-34e51dd8de4f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ece36418-c24f-484a-8af2-75eb78c47346">
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low neutrophil count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87216bb7-52ec-445b-bb0b-c517938d2db7">
        <dc:identifier>HP:0010977</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected phagocytic function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cc84a57-a121-4012-af4e-8127301fbd2f"/>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3b1fd8c-fe49-487f-bea0-bb98c0efe1c5"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1cbb05e-6563-4024-a9c6-6e6c8c7675ad">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa5914ae-19c9-42a2-ad5d-6d86db10cf73">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263*</dc:identifier>
        <rdfs:label>atypical psychomotor development</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17550e48-6257-45b6-88b8-48a8815c871b">
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39146c56-f8f8-492a-adf7-e33c012e9850">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6cbd54f1-15c0-4d37-82ab-163595825523"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5b84443-7fd8-4100-ab98-46a7f615235f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee2f3c82-fb41-4035-835e-5a3895ab609a"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2494ada7-2993-4f42-966e-88b90ed166d2">
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <dc:identifier>HP:0004319</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59842061-f1d4-4fc7-bf3f-3b2aa11826b2">
        <rdfs:label>Abnormal serum renin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0040084</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0ce7dd53-278c-4cd2-969f-fc6ca568a974"/>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/79517926-bbbf-44df-a0d7-a4b66cb4c568"/>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef8b0c00-a7c1-4816-a4fb-3e55765238ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b77e6517-5501-423b-b13c-237244af57aa">
        <rdfs:label>high plasma RAAS activity</rdfs:label>
        <dc:identifier>HP:0000847*</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ce1a705-0ce0-45f4-8dfe-14dc7d13ad52">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4fb23fe-f261-40c0-85d2-4afae0a28ad2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb22afed-dad4-4b85-a336-3c2f00252a68">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Synovitis</rdfs:label>
        <dc:identifier>HP:0100769</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/112973f2-6998-4c86-8675-e40c23789c8b">
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025303</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5afa2617-8dca-47f8-9e1a-574ad1a5a3e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a27d794f-9a92-4b96-b941-f5bbb32d1892">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <dc:identifier>HP:0001369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da78f0f6-355e-4fae-a788-10e8341459cc">
    <rdfs:label>Diclofenac</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <dc:identifier>DB00586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/edb922d8-4f91-4c64-9c66-c41f887a9ace"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24f49924-c22d-4cb5-b43b-6578a4a7f5a7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/795fc5cf-ad9f-49b7-90e4-e565a873fb9c"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51e35ff0-3cb1-496a-bddd-3233776338eb"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4699bb7e-244f-4f21-8070-146e92f911e1">
    <rdfs:label>excessive adventitious movements</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fc5b844-1493-4d38-80dd-3da68f327e92">
    <rdfs:label>Laronidase</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3531c1f-8fdf-47ed-8735-d08ecfdeec03">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/771ff50e-799f-4905-a5f6-9cc9ad5bf320"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30428e82-dc5a-43dc-aaa3-cb1f418466a7"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57fe36b0-056e-4d20-950e-bc39b3e87719"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
        <dc:provenance>https://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/790be26f-2cb9-45cb-91c7-7529b2d9bb44"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/425839ae-8ba6-4161-901c-2ac091b992c4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4a62512-73d1-4330-82b9-730d37f84b84"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1db02bd8-3ac7-4a56-9ace-30bf110f1738"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e261ff9-8e4b-47be-9db0-b304c2c6bb06"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38cb2b1c-89e3-48a3-a030-04488ccd6f79"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cecec11a-b064-45be-8211-35455751eba7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ffa08f7-8703-4737-886f-fa74c6decbbc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ed9de0d-6bc3-4e86-91f3-2a0c8593f61c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/049f1be3-61cd-4240-bda8-8f60835a4b48"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d771805-cef7-4026-b51f-f60f347864d1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19800b2d-6238-437a-99ef-1cac8e2dbd72"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f05c0b4-a890-4089-a37d-6faf1b92f236"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f57243c7-d108-4f11-b620-472d4e6e5042"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f46e416-9dc3-499b-86ff-9896168fa0ba"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49ada44b-fc8a-4785-9cce-3c3824b0f173"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcec433f-8850-49e8-8f7f-ac55faa55a03"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5960aa4-2921-478d-a7b8-ac6e21f48e98"/>
    <dc:identifier>DB00090</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91641809-e16e-4c2e-a9fb-3fb150d90bb0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdeee537-01dd-42f3-aed7-cb69fff9b7cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/246d6ed6-b97e-4458-887a-ceb951fd1ceb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2e47597-302a-4f19-b69d-39142fd10a51">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:label>joint swelling</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9e679b-9182-4d25-aad9-0265d2a34407"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89368a4f-a9a3-48c8-a579-4a8184a90dda">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/880eb3e9-c85d-42c9-956f-9c6aa7b1be6e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bebe5346-772e-4a4a-a598-f1810673373e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1b1228b-7674-4922-a5c0-021f734289ff">
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>motor malperformance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aa9e34c-2be4-4614-ad2d-bf5512b73366">
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a401212c-565a-441c-b36b-6221c4d658b2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32945ebc-6f3f-4cbc-a74a-5294042258d8">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4462d8f-a495-4e8f-9c47-c915e5443913"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f1596c6-ba47-4f9a-b1ca-0b00a42de94a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <rdfs:label>Fructose</rdfs:label>
    <dc:identifier>DB04173</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5a62547-1e3a-443e-b583-e547c5e0d6ae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ae57d16-52ff-4ec7-95d3-f9bf513fcdd6">
        <rdfs:label>Growth retardation</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2cdf322-232c-4d3d-a916-6315bb4aa443">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperuricemia</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16d6947b-b8a3-4ab7-9653-666795529771">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000105</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <rdfs:label>Enlarged kidney</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca0855df-9386-45ce-9404-37615357b83f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7338adff-5692-4b1d-a36c-af16accc218c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c681599-13b2-4a84-941a-e96f91ec55b2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperlipidemia</rdfs:label>
        <dc:identifier>HP:0003077</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1083b05f-e867-4aee-8c0d-e4fa27336e3a">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f572ab3-725b-4a8d-8a51-2eb6b7095913">
        <dc:identifier>HP:0045010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dcca5172-a73f-4faf-b9c8-17ec45143946"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96963a5a-c362-4927-aac5-6d97d47d0e5b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93b90f15-0735-469f-9236-d956c1a8b81b">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0251b4b2-eeb0-4bd6-96cf-19a3d2e69416">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca6e5e54-bc80-46b7-b5e1-783ff15b5de0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bac64f69-133f-4748-b59d-5a92aaedfd86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d2b4f7a-c095-47fb-8944-2be18fcbb606">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypomagnesemia</rdfs:label>
        <dc:identifier>HP:0002917</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f395466-6860-406f-9efe-b79d5c9e6f2d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
        <rdfs:label>chondrocalcinosis</rdfs:label>
        <dc:identifier>HP:0000934</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0c864b7-c07c-468b-a926-7015547ee22f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b51a62c-465d-4612-a3e6-ca845d26cb36"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92218fb7-375c-430a-82c9-971668de0c7d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/fedfde7d-1557-410a-9e45-893ddb3fc996">
        <rdfs:label>functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc44e1bc-f66d-4891-bfe0-9ef67520078e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6b95738-070e-4fa0-a44f-a17e0f590fc0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/560d916d-bf8a-4a28-9948-9815b0523d54">
        <rdfs:label>Brain damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f013014a-8616-4c1f-9584-9499623c805e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e2f71d0-714d-48bd-8c07-5876dd108044"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0484187b-fdd1-4aa1-9b5c-8b5dd33666eb">
        <dc:identifier>HP:0100021</dc:identifier>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <rdfs:label>Cerebral palsy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd548f26-848a-469d-a30a-cfed6b9ff7d3">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae40df65-bd67-4943-a763-a575966e62ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcdb0b2a-7bc2-4073-95fb-d2a2bb58d4fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5e586d8-7a1b-4204-a81a-09b909f9dad3">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Abnormality of immune system physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <dc:identifier>HP:0010978</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666d211a-c701-4f67-a556-3d9162c480c1">
        <rdfs:label>periodic fever</rdfs:label>
        <dc:identifier>HP:0001954</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d75d66d3-c854-462b-be7b-477a1523e829">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4cf845f4-b895-4f2c-819c-fe6c33db7152"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/9d963d77-d37d-484a-8309-07be3a380064">
    <rdfs:label>functional complementatoin of a defective protein by stimulation</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b438a8da-e3e0-4002-abf3-1da587f9a32d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f02807e-c3b8-4438-9610-bcb08c941754">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc801c5e-015a-41da-a119-3e58730de77d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0911caf9-3413-4a9d-a659-246f51756555">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <dc:identifier>HP:0001735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/928e1e5d-90bb-4285-a05f-e6b1d391a1d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af1ec9d-f43a-464f-ae8c-5e7963c28812"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f19ecf7f-2c89-4a19-8ee0-47d65356babf"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/62a45e8a-d52f-4d15-bafe-ea759dd59268"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4feac68-4e40-4a4a-99f7-c4c528882ceb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f80ef44-f7f7-4d31-bb49-6486e3dd286f">
    <rdfs:label>primary low heamoglobin level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0001903*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a23ee965-3fce-4d83-b4fc-769fb601231b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2478bc0a-df31-4901-8432-a0d5c178872d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b568f55f-a08a-4164-8971-3aebb52d52c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6f8302c-3e45-4a49-8101-1bba99606e24"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59be07dd-b959-44d7-bab5-baefd173df5c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a86d0736-7876-4f86-acf9-c2931b836385"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef30b467-54fe-4735-af49-4b755c4bd844">
        <dc:identifier>HP:0010836*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1a191c16-06c0-42c8-91a1-61eaba1287f7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/747461ed-f04a-4941-be59-f4c2a080668b"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/015f9c04-b894-4a9e-9f73-30bb4d741ce6">
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7199446b-e1f0-47e2-81ca-db8f1641cf96">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b488137e-3d98-491a-941f-dba70c4a50c1"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02b3b414-9a4d-4f15-9c8f-fb0c7a6af98d">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c95fef39-275c-46c3-a931-89fb70986579">
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62dde710-f207-4f54-b7d6-734f57132331">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
        <dc:identifier>HP:0001928</dc:identifier>
        <rdfs:label>blood coagulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4a0af20-8c10-444a-9dd2-417b7a075ad5">
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolism abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e590216e-663a-4294-8692-e6cdaf10e40d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>hypoglycaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/228691b4-abd5-4ecf-a516-a860a818aa77">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42d3d2bb-ea81-41bf-a742-ea63e62fbd5c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
        <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
        <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af46d7d1-731a-451d-a573-e112080a5e95"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/690f9449-58b4-43a8-8bb7-fe29148174ae">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
        <rdfs:label>protein-losing enteropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002243</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe25cf70-013d-45d7-9eb8-14f7832177d0">
        <rdfs:label>hypoproteinemia</rdfs:label>
        <dc:identifier>MP:0005567</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1f1c989-15ab-4d2f-8498-2fb69b5a8b19">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <dc:identifier>HP:0000010</dc:identifier>
        <rdfs:label>urinary tract infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b506814-533a-4bfa-8388-b5feddd50490">
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97a7a5a3-37ca-4cde-9214-2202ef1d063d">
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b1e04ed-a5eb-4101-a1b5-175e002233b6"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab7e15bb-2df6-4b95-84eb-673aaf2dcf71">
    <dc:identifier>HP:0002019</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>constipation</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60bcfac4-f67a-4257-8be3-d9ed2527fbab">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/249000a9-da2e-409b-9373-2de1eef9cba3">
        <rdfs:label>Creatine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4210d436-b855-49ec-b744-ae633bbddf0d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9fd39e8-ce06-4aaa-a707-93524847de58"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f826ee2e-a0a2-4710-9089-68e45d2a9944"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f16b4aa-31cf-484c-bb27-187bb4720fb7"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d6be78f-2652-4f6d-a9ab-5319767adf6d"/>
        <dc:identifier>DB00148</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5547069a-cb87-4d44-99d0-3471ee7f7ae1">
        <dc:identifier>DB13191</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d6be78f-2652-4f6d-a9ab-5319767adf6d"/>
        <rdfs:label>Phosphocreatine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3bade43e-01f4-4434-8100-2b48905eb0df"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71fe8b16-5735-4709-a04c-d076786e091f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b2c910f-4307-4015-8296-3f3127e4a094"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba5bf88b-b138-444f-b66f-bba0b65308b2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55eef6a6-0773-4fc9-b001-3c626d9934c7"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d08319e-f447-4937-a369-44fbf91cb27d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da655e67-24e8-4bd1-9d3f-2a5513210f0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e26a7b4-dab0-4898-8335-94eadb4113d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/482fdac7-881c-468a-a866-915ab46a1371">
    <rdfs:label>Paroxysmal movements</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0007166</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca31d84e-903c-4d4d-bbb2-af201ed471bc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5328e27c-89a8-4736-abd6-00a93faa407f"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/807fa17a-1e99-49ab-b521-bff8763d63a2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb726fd6-992b-4352-8369-57318251f666">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phenobarbital</rdfs:label>
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d3cd8d2-d5e0-4819-9bf4-c3e7e886f3c1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d94b9c41-56fe-4e8a-9aeb-796efe423879"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab40f657-33ef-4886-a53f-30400a9f7f6f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f75e779b-59a2-4b1a-b636-e6d24923b7f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aeb7778b-0544-4f9a-a69b-ceb0f9b86f68"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9262a77-61f9-478e-a3c8-935489a4f793">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49dc592d-5e75-4c5f-984f-364694ea55cd">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/861569ff-c98f-4082-b201-acda22bf4f30"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40b95f20-3490-470c-b4db-54a1bae8e759"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7903f487-92a2-45d7-a13c-f0686301c202">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36531a9d-69c4-4fdb-a393-e69aa3edfcb0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>recurrent vomiting</rdfs:label>
        <dc:identifier>HP:0002572</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce03c8d3-240e-4fa0-9133-d3a2d8f6ec42">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3754a9b7-9bcd-4dd7-a5be-9f4955a4f44d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f1d5fc9-a7d6-4d84-a1b1-d30146445b73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a718b54c-e6d6-4b7e-b5cc-f388821f33ba">
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
        <dc:identifier>HP:0002718</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9749d11f-a1ca-4a20-bd7a-d3a63de97968">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56fc0e65-b081-47f0-b02d-34e51dd8de4f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/443f0c1c-1ec6-438d-8938-ed167328a9e3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
    <dc:identifier>HP:0004348</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c05fdd8f-84d9-435c-af24-e7dbb686f892">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc69c393-961f-477d-ac83-33c8c07074a2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8b9b98b-a892-4806-8e3b-a0c16eab7489">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48dfa75b-3919-4cf5-bfb2-f38378e87856"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/478ff81b-cc01-442e-a3ee-3ef207e95849">
        <rdfs:label>Developmetal delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2419a78a-03c2-4ed0-a6d2-b95d292d3692">
        <dc:identifier>HP:0012664</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:label>Reduced ejection fraction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b83dfa11-0b56-4c37-b19c-f2eb1f1391fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d126c424-2405-455e-9797-6f778e6f75ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2bc9193-0b86-4aed-aa54-9c1ebe42ed38">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:label>Cardiomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae3f6e32-9256-436d-ad42-9840e28b105c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abormal liver size</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93a5932d-6ab8-4245-9465-3e2a40d591cb">
    <dc:identifier>DB12528</dc:identifier>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f931f24f-7791-48a5-b40f-f8a2019d5006">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4aa38c17-63b0-45b0-8369-319d30ba1e56"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f19ecf7f-2c89-4a19-8ee0-47d65356babf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/613b3dc0-4cb5-4a4d-95c6-bdc31cca55cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12422fef-374c-4209-91ec-c6c502330b3f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70c5a01d-6704-43be-89aa-368106a5246b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3067bf0e-90f1-49d7-9953-ff26bf0049a2"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9749d11f-a1ca-4a20-bd7a-d3a63de97968"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b89359f-2265-4aae-89d9-bc42d75a097b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>Abnormal immune function</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0010978</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/026f5a3c-95b8-48d1-9c32-27f3ef118bf8"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c1ba5dd-c462-4382-bf21-9aec33e8cd63">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c364901-455a-4e69-a41a-eccc10afeb21"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9284564-da42-4a5b-80e5-0b8135e2ca87">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal number of b cells</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
        <dc:identifier>HP:0010975</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/721c6750-81c5-4d5e-932a-40009b75f4dc"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b5ba9a4-9956-4848-a684-49a792fbd04c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01d5e182-8936-4d6e-b572-dcf5bca095f2">
        <dc:identifier>HP:0003738</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb0b3b38-52fb-48ca-a6f1-98927e861986">
        <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0009020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d262474-0803-47fe-87fa-5d45e83e1d57">
        <dc:identifier>HP:0003690</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
        <rdfs:label>Limb muscle weakness</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
        <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7570619d-7152-44e9-a9e4-013711082bb3"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a14c3027-09ac-4015-9ff3-39d7fabe838c">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Muscle cramps</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
        <dc:identifier>HP:0003394</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c10e59c1-b63d-4a8a-8f15-5d63d704db23">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc1b5812-f7b6-43d2-9027-8f82f0b4c929"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e891a03-f9fa-4664-b2c9-15864ba4cdc2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/902b456a-b8e8-4490-9967-f9b2b41e9467">
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa91b8aa-5d4c-43ed-960b-5f6aaaa37015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fd8e695-282e-4dfd-bf40-caf499943019">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <rdfs:label>Tretinoin</rdfs:label>
    <dc:identifier>DB00755</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7477dab2-81ee-4b78-a822-04e15dd5ddc1">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b17c78f1-2fe4-4734-8545-53ab19a87661"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95093a0b-060a-4678-bb95-c76cc8130e0c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa76922c-a0c1-42d2-a263-8238fb607036"/>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/156ddb54-5dca-49a4-86e6-a15f8d32c52c"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f34b2732-f9ad-4ba2-8bd8-701f83aca20a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>abnormal liver function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93c1d203-1e9c-436f-bf93-70a421770652">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff80535b-9fa1-48da-bf31-d4b5f21b6b84"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80f27ce1-6b4a-433a-8121-5f7a24753424"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc67ab51-2b15-4f6a-b1d0-0cd46328ed1c">
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4503c91-ea76-44e7-aa72-58326969c54f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36408ac7-9992-4e2e-b432-990285900b1c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a887f254-d867-4526-ac77-ef156366f64a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:label>mitochondrial dysfunction</rdfs:label>
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a286d5c5-4338-45f9-a4de-b6b0ce6e7696">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9853c297-d9ae-4e75-88da-73fee0c352f8">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc0068f7-ead8-4fac-ba00-0bf7ac7f48bc"/>
        <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a15778df-0cba-491f-8a60-699be0004fb2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/872f4968-914b-4d83-a404-44ce1ea12380"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/236752a8-ee7c-4123-99c0-84b914aae337"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09341</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3dcdb52-85a2-4eac-9f22-a148effc7f99"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dc77d70-d4ce-4ccb-ba21-51f6ec876d90">
    <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
    <dc:identifier>HP:0003287*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b057608-5467-418c-9cba-7828c2325817">
    <dc:identifier>HP:0000822</dc:identifier>
    <rdfs:label>Hypertension</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39ed13e8-b9fe-4b4c-abfb-215999a89805">
    <rdfs:comment>The phenotype has been reported in association to treatment with baclofen as</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
    <dc:identifier>HP:0001945*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
    <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a97d23f7-8b5e-4f75-aab6-c59a8b3fd9b6"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f11ff90b-2598-4648-bf9d-8181e71ac032">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fbfc23e6-cf75-496d-a7ce-2d18182b9d72">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/592f69e7-806c-4685-84fa-e71bcc140ebd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea022030-ce8f-4688-ac41-e47917d91c21">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f7baf5c-b7e0-4ff3-ba42-42c748d869ce">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/024a9db0-d1e4-4140-bc65-c675e511ddff"/>
    <dc:identifier>DB05018</dc:identifier>
    <rdfs:label>Migalastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21fa99f9-e50f-47de-9579-97411473f0df"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c68a57c-fae5-477c-bc82-0a56b0f4e574">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63117bcd-b3b9-4d8b-92bb-e83b5177c37d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d55e6e16-bc1c-4b41-8104-a324c0a7f7cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33f6a332-c566-45cd-a4ee-0034dd32471e"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d7b7390-da59-4b1c-b7c5-363e71bba158">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f00b3a91-2627-475f-ac33-f2ddbb636ca4">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2308a23-5187-48cc-9bf6-7564efcb36ed"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16841060-8d5e-4368-8122-0acaa77088ad"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ab6f569-7cf7-46d5-a6dc-4e32667eb801"/>
        <rdfs:label>Eliglustat</rdfs:label>
        <dc:identifier>DB09039</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5434fb7f-d84b-4bc5-be33-9afc4140de21">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/137afc80-df02-4cb7-a881-c86622750289">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High serum triglyceride</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edec2061-62f9-42cd-be8b-8f97f555c1c5">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/670ff9a9-3ff5-43f0-aaaa-7b5252259cab">
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4356e6e4-67d1-4ec0-b3cc-d4e1e86d2245">
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0031798</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e828364-a136-4180-af05-911ed826317d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3564e8f5-d4e6-4119-a4a7-047afd40efc1">
        <dc:identifier>HP:0003362</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00ffd927-2fe0-4ce8-8692-b9639b52a255"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6064a12c-822c-4f31-8bde-7c49e5ba6f34">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faa3b450-775d-4c4b-b1cd-761393406ec8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000709</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <rdfs:label>psychosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c809059f-8960-42f9-a0d8-aee0555c7cbe"/>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6261b620-e268-4266-a493-bb6111574900">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f22c59ba-af2f-412f-a594-9ac3890802f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e7283d0-6197-4664-8398-7bb4966a824e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dadbb235-3ba1-4281-8404-7963b0010de9">
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>Salt wasting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ae57d16-52ff-4ec7-95d3-f9bf513fcdd6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51719e08-c99d-41f3-929e-051abf63f48e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f1e2d97-f3ca-459c-88df-06a20dbdedec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79bc5186-a365-47de-9595-14ded316663a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deleterious prognosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c9e2d35-18d5-45fe-859b-ad0a031b8319">
        <rdfs:label>Decreased life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/410e777d-521c-4eb6-a758-ef84becd563c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d0854a1-e8be-4da2-b23f-875be35c036c">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/817c3778-828b-4a2c-bec6-3f6ef09b5952">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002333</dc:identifier>
        <rdfs:label>Abnormal neuromotor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/0312d040-59d3-4890-aa0d-0753916228c3">
        <rdfs:label>direct complementation of genetically defective protein by gene therapy</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc582278-0e70-44cd-8bdb-163754582870">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4cb54174-680f-4ba3-bd75-d5cd9d14157c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31207750-7da7-4f41-a377-78cf0876e8a7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0004144</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
    <rdfs:label>Drawing inabiliity</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/370bd89d-ee1e-4fe8-9de1-edfd76972eee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/087b357c-6263-4303-9a00-69e6f2bb3981"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
    <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0e12841-339e-479f-9558-d5ecbf8b1c3c"/>
    <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0e41145-5221-4421-b446-9e3734937462">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6181e130-a5cd-4719-9b12-9cb535d2a86d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
    <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
    <dc:identifier>HP:0000972</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d921d021-140a-4e9d-aa47-600b083d86b0">
    <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fbef1c9-0e7c-45b3-8ba4-1c70a655c12f">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da373bb4-25e6-407a-8fd7-0306f2967c24">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e87ef113-2fed-4345-b7f9-f64c205b36a9"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6782f703-9d74-401a-9474-3669e424428c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/373bdf97-f8d0-46f4-a007-803282beff0e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/193ec30c-93d2-469f-8c21-e9bb9e7b9eb5">
        <rdfs:label>Abnormal reticulocyte count</rdfs:label>
        <dc:identifier>HP:0004312</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14577a88-4971-49d3-94cc-a059551389b6">
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
        <dc:identifier>HP:0025548</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/138a4107-6029-45e2-98c9-36508bc7a8a8"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50c3eae4-d348-4196-add2-f9479dfca7f1">
        <dc:identifier>HP:0100502</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
        <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2440458-d320-40b7-9abd-eb80cbb2d9bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
        <rdfs:label>Low Hemoglobin concentration</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <dc:identifier>HP:0020062</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/295cfcd3-3840-4024-8a78-b2110d5d0998">
    <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
    <dc:identifier>MP:0011598</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74a5ccf3-9902-4bdf-8d14-c80bf34b9924">
    <dc:identifier>DB00376</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ee072ec-e17a-48da-8c89-14a80df7b77e"/>
    <rdfs:label>Trihexyphenidyl</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b52c2edb-a3a5-4870-8892-ef087c13f9ba">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e204a313-32f9-4737-b5d2-787f0be53eed"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/382f99a8-ec44-4c83-9de3-7e2e190b5896"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/927ce464-9f18-44f7-a973-4c24934a8648">
    <dc:identifier>HP:0040006*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6cc346b0-914e-4a79-b055-de30ae31d4cc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36d6812c-50b4-4259-ad79-3e8f942d9d81"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c156d17-9748-4f60-9a19-d3c4236411aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/738dce9c-059d-4ac0-a0df-ee294fb3573b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/762bb923-15ca-48e1-bbd1-7dcff5acb927">
        <rdfs:label>functional complementation of a genetically defective protein,functional complementation of a defective protein by inhibition</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf1b1201-8528-4eb6-9144-68321df0d137">
    <dc:identifier>HP:0002180</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neurodegeneration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff06fd79-4960-4e4d-9da5-cf48402b2a03">
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cca7c07-46e0-490f-a122-5500898b27e5">
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
        <dc:identifier>HP:0002960</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd352662-6686-459c-83e0-42ec2d90dab0">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>dermatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10fe55a1-48f8-4b03-8acd-1a260c1b8481">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <dc:identifier>HP:0004325</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Low weight</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b89359f-2265-4aae-89d9-bc42d75a097b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55f00304-7489-46e6-a08d-7be4455e10db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d2fec20-2a6e-401a-9877-164ca084d910"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95697d2a-b813-4fab-8dfd-5b99b0403cf5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7b0144e-8abc-47eb-b278-09eebc510b39">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4472f53c-ace0-476c-a1d4-955e3056e5ef">
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:label>Hemolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56fe673f-6498-4748-8869-469e994ba282">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8964ab3-8ff7-4813-bb5e-dde7be919974">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
        <dc:identifier>HP:0001879</dc:identifier>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00df4eb1-b039-4d09-bcd5-bd65318a8f71">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ec88cfd-c943-4352-9f39-32489a9feb59"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c61df16-42a7-4c8d-b40f-f3f011c278f6"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1e1e0abd-c439-4421-9c71-cc94074b95e1">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46668266-6007-48c7-b426-0e4234803f72"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d8a4e80-fecb-4e89-95c3-d3b3edb0c52e"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b831fd14-05e1-4ebe-82f8-a69bda5126d9"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00bae8f3-0c41-49f4-a9a4-1f979b0be10f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/621593a8-5b45-492f-929d-a7de664d979c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1db1547c-a203-4f20-8105-4f127872b5ac">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/621593a8-5b45-492f-929d-a7de664d979c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b4869eb-bab4-458d-8de6-f645daa27ee6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccdd5eb3-d425-4819-a3e1-ad45bdff5ab2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01080</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b305751-5e3e-4616-8476-8bb79ba73ba1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adc021a8-de5c-46a9-94a9-08e1f19f1abc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <rdfs:label>Rimmed vacuoles</rdfs:label>
    <dc:identifier>HP:0003805</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/111ea73d-28af-4f84-8cb8-8b811cc36cba">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/274f6f50-f70d-4207-8a1b-c1dae2e608da">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/630a6f24-cb58-4e0c-8dfa-0aab7456d105"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21086a03-de43-4c78-901b-80ca79f76073"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
    <dc:identifier>A11E</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfcbd661-a2f9-4b4c-90d9-fc753d69ced0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Self-injurious Behavior</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c60300d-847b-44d0-a4e8-e112f66a6b85">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b51a62c-465d-4612-a3e6-ca845d26cb36"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcec433f-8850-49e8-8f7f-ac55faa55a03">
    <rdfs:label>low quality of sleep</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4d395b5a-c8a3-4512-892d-0f3ac00bbd37">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4001bd1-e54d-4554-8431-6fd303260454"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68a5e8f5-b802-45ef-82f0-51a38258748d">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL-C</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/deb1c93b-743a-46b1-ad0e-47bbec9b3041">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/329594bd-60ee-44e9-a755-65e3b603c93b">
        <rdfs:label>High total plasma cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/588d649d-4875-4fd5-9276-0fb631fc6aee"/>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d14d2b70-9e04-4684-a7d2-4f4531687844">
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f70b428e-557b-46b6-9c17-4a13bf4dc35b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12e9606d-edd8-4d99-979c-9a118ebf07e7">
        <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48968ad7-3df7-4dae-8ef3-5139bf917304"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8d09e85-a690-4154-9025-0af76b2567ce"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB15066</dc:identifier>
    <rdfs:label>Givosiran</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/512cd752-4a55-47dc-8c22-16eac02bab09">
    <rdfs:label>Neurological abnormalities.</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3db8e91a-9bc7-469f-a80b-278b2634a426">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010876*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
    <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ab03456-e68d-42ed-93c1-c80fd0c611fb">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/62a45e8a-d52f-4d15-bafe-ea759dd59268"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/c1401d7f-49c6-40c3-b547-4283b2a0a2ad">
        <rdfs:label>functional complementation of a defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/537fcb0c-2c5c-4ed1-a6b3-16f83cad7ae5">
        <rdfs:label>decreased cholesterol absorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
        <dc:identifier>MP:0002647</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/971f7365-11cf-42d0-97f6-531c91afd5e2">
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
    <dc:identifier>DB02209</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/553a9667-8a26-4b33-be8c-8974130f6bad">
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-013-9660-9</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79defd26-86c0-4b53-8564-c6713cf8720d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcd06666-50ac-4f7a-a9f7-fc1fbf4cd6b8">
    <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
    <dc:identifier>HP:0008347</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a0bb546-8d01-44f6-a179-a485254e75ed">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f72e8d1-cc4a-4a09-8d5a-de7fa1070d7a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca2a6be0-299e-44b1-a45e-571e24b16556"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0691b59e-c158-4f23-9f32-6ffb8723727d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03277959-b3e9-45cf-bdab-18fe3220de70">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ccb3fea-594e-40df-98eb-2911bc547486"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0f73c3b-27c7-4c9e-ac87-7d7544980a84">
        <dc:identifier>HP:0040087</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:label>Abnormal Folate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/345a323a-3822-465a-9ac9-a2692ae99ea1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7bd8e12e-0454-4107-b08e-69b64d2abe49"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/601cfbfe-ae59-42ad-943b-20fa5356a91d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4fcf6bf-43ed-41eb-933f-bc87db0e96c8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d2b5f4a-5213-4399-a57f-4087dcd85c5c">
        <rdfs:label>Receptive language delay</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296f819d-4be2-4d47-a6b8-c1e8d2f582ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8a80c3c-c638-4836-a921-be642e8c1f37">
        <rdfs:label>unalertencess</rdfs:label>
        <dc:identifier>HP:0002329*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef8b0c00-a7c1-4816-a4fb-3e55765238ef"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e260c96-5512-4bfc-9714-2156ea57633f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8d5886a-a5cb-4d4d-8de6-0a25788f5f78">
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04fb05da-7116-477e-946e-f718dd4e4234">
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a687b508-30a1-4c36-9fe7-aef831a211c1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d6fa621-21aa-4088-bf64-6875da3ef799">
        <rdfs:label>hyperproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
        <dc:identifier>HP:0002152</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c7b1748-aa01-479c-b375-2015873093c7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/adf1a73a-e52f-4646-a500-6ac89445efb9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afaa283f-a1b9-454a-a2a2-6e27db4d9ca9"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b72f14cb-7de3-4ed3-b720-90e0fc144069"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7515f73b-02d7-491f-9d28-b3d35cd29f44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8d5886a-a5cb-4d4d-8de6-0a25788f5f78"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d63774f-1c62-4eea-9c25-0d418263623a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/038fef85-8eed-4373-9eea-400c9bf94a36">
        <dc:identifier>C09</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1f78da3-a9d7-4254-8551-d0e3bf544ff3"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
        <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/013ba298-7272-4bc0-852d-d3f72f7d077a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ad4ac2c-116a-403f-a3c2-435d44a1af00">
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64f0b6e9-2904-4ff4-a536-23f345b3f94f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7eba2633-55e1-4d06-87fb-f8c60cf2f03d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/03ceab51-fa37-45bd-b46f-f02315b13020">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad76d1b0-f156-4b95-bee4-50814d3bbc14">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c2d6dce-08c3-44ca-9860-9d8918b75603"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c2c0a9f-deed-43b4-8486-43456930cc39"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cb42475-2cad-422f-8997-058368225718"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19c8edda-8c5a-426c-b20c-5f3131a8d67f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d871f20d-be29-4a51-982b-1bb138e7c199"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5596f44-f34e-4897-bca0-96860c81ea89">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc80c155-ac7c-4cf3-90de-5a3908fd59a8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cfd3abd-ff29-4474-81e0-5ccb7304d1e2">
        <rdfs:label>Polyurea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08c09366-b2db-41d7-9d0a-2544dc7298ee">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/112973f2-6998-4c86-8675-e40c23789c8b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d9fed67-96b8-425d-bae7-a5156d13f176">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0fca2bd-7489-4510-b133-19e5aedf20e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9e679b-9182-4d25-aad9-0265d2a34407"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c0c6e79-96d1-41a6-ac73-36838ab91b38">
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>Growth failure</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50c7191d-3d30-4455-a375-d9bda2c8c82d">
    <dc:identifier>HP:0001954</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Periodic fever</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac37598f-3d32-4382-b30a-99604a5b4c10">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12ddbfca-a800-4e4b-b1bc-df9fd7de8f2e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69c2ad07-4678-4b35-8917-63322c5debe0"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5528a879-8b7e-4421-8759-3deec2110390"/>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ab6decb-a6dd-4dd9-8e4d-37baa4ad7044">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008993</dc:identifier>
    <rdfs:label>Increased intraabdominal fat</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe6aea51-df34-465b-8598-c76dca58e306">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34245b91-216d-4443-8647-e353c523102c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f08d64-f1d8-41e0-9184-173d11730009">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
        <dc:identifier>HP:0500014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4af717a6-47bc-4585-985d-c5c54b844ce0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5abbe97e-9564-440a-bc46-a5be035ad024"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a697b1ec-8d18-4875-8cfd-a73179b80afe">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f041e464-3930-49e0-be74-4036eb4ee982">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdbfe5d9-94c2-43f8-8681-6fce8179aa7d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Bile flow defect</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ae5d6ee-99f4-4a3f-bb54-7b2b35c879bd">
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06937772-ab91-45a1-892f-8d00619ab9c9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/792ad115-7cc5-4bac-b553-e9c779412517">
        <rdfs:label>Atypical bile acid synthesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5fbe022-cf1c-4b0e-ad7b-18d46afa1875"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/122bf30c-2099-4b85-9528-81b8e337e2fb">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <dc:identifier>HP:0500014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/307d822b-a4bf-42be-9bf2-b84438ec2e02">
        <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b47491ec-cd2e-48e0-8a6b-e87fd8bd6651">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>biochemical abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c77c1a72-0a86-43fc-8c5d-56d05dc7becc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fecec2a-3541-4f69-bbd0-0c4b503929be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic epilepsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cb9e2f2-dbc7-47bc-9816-1402f7534910">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa679168-f067-4f42-9880-9ee1b5c7e6f3">
        <rdfs:label>Lithium citrate</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da30e6ad-80b0-44a0-9f16-7d8b5494129b"/>
        <dc:identifier>DB14507</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/608177fc-c9a8-4923-8643-7bea9b0e8464">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44d1ad5d-b51f-4679-bc6e-c5ff269df0e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b657a961-b885-4e0f-98aa-7338ff1cd13f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4627a0a1-6cdd-4b91-a8ec-5147480e892f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51b47858-28ce-4a55-85cd-f6bc598c681c">
    <dc:identifier>HP:0012477</dc:identifier>
    <rdfs:label>Voice tremor</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1e8f326-a187-47c2-a559-6a9bf61cd2b9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/edb922d8-4f91-4c64-9c66-c41f887a9ace"/>
    <rdfs:label>Ethoxzolamide</rdfs:label>
    <dc:identifier>DB00311</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe4990c1-df15-4dce-ad51-51ab2862019d">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff0f1cbd-5b4e-408c-bcf0-d1680ef40ca6">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
        <dc:provenance>https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-alfa-reduced-the-rate-of-clinical-decline-of-children-with-cln2-disease-a-form-of-batten-disease-300635669.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad63f43c-c419-40f9-81e6-f1f8d63c2e1e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54661f68-2566-48a8-a724-3ae6573b66a4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>recombinant human tripeptidyl peptidase-1 (rhTPP1)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/249793bb-b678-4a57-84a5-8ab3e6379dd1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/caed1c2d-5985-4271-b7fd-bf4cdfe939db"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e5ed22e-7837-4e8b-966f-b5aae3414ffa"/>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2678786f-2ba3-469e-b844-18cc3d6c4c9d">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bd3a7c9-bf9e-4bbf-8a59-c84bde9e90d6">
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0473af77-54e1-44dc-b03f-3da3fdfc68cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30c993fb-b91f-4273-b938-d6b476d29efe"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd412827-c15b-4106-b423-b67ec535419f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>splenomegaly</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f80ef44-f7f7-4d31-bb49-6486e3dd286f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9522d46b-4baf-4fd9-b69e-6a79dfc86d5f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5dbeec45-fb59-407b-af78-fcf5a21936cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30b02f95-33ee-48ed-8421-59384bd19e8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ced57d6-aadf-478d-a1d2-2551b602c46f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6535a0cb-d894-4a92-830d-15501368ba2d">
        <rdfs:label>Abnormal Fukutin function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87cb5e51-37df-434f-828f-49b607fb252a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8833bd30-8bcf-4960-a0b6-ec95a04ea7d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dc4fd60d-ee2d-471a-87e0-12e02f94ae71">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9270b9b-a01c-4e8e-a8ce-ee1b7b87b091"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd7bda0b-2fbe-4bfa-a2c0-ccb5acdba856">
        <rdfs:label>Abnormal facial expression</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
        <dc:identifier>HP:0005346</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60ca7b65-eb1a-420f-8797-6737df6ec0a1">
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d61cc523-1274-4dd5-9fd6-39d2288e87fa">
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6326d17c-1f37-488f-babe-650fbf9c7819">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012075</dc:identifier>
        <rdfs:label>Personality disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b21735e-2fc0-46a2-b95e-108a97d4b22e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5f58baa-9e8e-46c6-9b34-dbf3702d64ef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb10c195-8936-4629-848d-ab3ab03d6cc8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebd85445-2ea4-45e4-9eb6-457fbde78342"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45395689-ab14-49b7-9e43-be096b1d4a39">
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e1ed4f8-1ba5-418d-ae99-1510f3ec0b06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/707af5af-f4c5-44ed-bb7f-db3c8aaf8bbd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0312d040-59d3-4890-aa0d-0753916228c3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abd7dd57-efb9-4875-a569-c3b4ee95e2da">
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84aba42c-9fd3-41a4-b8a9-a86ba5507ac2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58d40ebc-dcd2-4119-a570-578eac40e901">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d7d38d3-16a5-4ecb-bedd-05d18e9e11ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/116bf674-2963-439e-8091-c20118874836"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffd718c3-e3cb-4a96-b8b3-5047eb99fb98">
    <rdfs:label>Behavioural Disability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e511314-7f43-4fbd-ae60-19cc11915c3c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13bad817-7952-4d59-91cd-f6ce6129c9ec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/010df0dc-4ce6-4146-ba6e-55731624187d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a01347a-f748-4973-903b-e7c2e49be0c7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Oxidative Stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S075333221630645X</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35b763cc-3967-4a1d-a518-82bbd5db9f26">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7862cde5-25ef-4548-ae35-ea9e9d9bb342">
        <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>MP:0012604*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f5d5ba0-148d-4704-920e-2143c135f848">
        <dc:identifier>HP:0011118*</dc:identifier>
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f31f01b6-6687-4532-b0fc-5170a21debb9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77f5b38d-6a26-4794-99a8-5efb72c7c6fb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
        <dc:identifier>HP:0025460</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b0419f6-38fd-4c41-a8bd-749d5c322230">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e701a2c8-c110-4573-8ef5-b3116309b02e">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:label>abnormality in bone mineral density</rdfs:label>
        <dc:identifier>HP:0004348</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30c993fb-b91f-4273-b938-d6b476d29efe"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7b0144e-8abc-47eb-b278-09eebc510b39"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/deef7469-8e2a-4bb0-8af3-f1b7bdd0ad90">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>growth faliure</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b37d0fed-4c2b-4d8e-b925-1e76e89e96f5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8eda31ce-1102-4e7d-ac8a-bb284175a478"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c8d1b6d-39c8-48a9-8138-3225cab45c13"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c05e58f3-ce51-4106-80fb-d61e292567ac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
        <dc:identifier>HP:0010885</dc:identifier>
        <rdfs:label>avascular osteonecrosis</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ed68c71-e23e-4a8c-a301-940cb90f5ae7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a3a3f8b-3663-4807-b34b-5f284fd6d70c">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
    <dc:identifier>HP:0001013*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ab8f336-795c-4f4a-a2cf-7f078deaaaec">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bfb1560c-5ecd-45db-83fe-dc210364382b">
        <dc:identifier>DB00111</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
        <rdfs:label>Daclizumab</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3ea3afa-28d6-466f-b097-f93b0cf9da29"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3299be4-cc14-4132-8080-ae0355b9cc39">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <dc:identifier>DB01219</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ee072ec-e17a-48da-8c89-14a80df7b77e"/>
    <rdfs:label>Dantrolene</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d761ad8-a840-4397-bc9a-d4504457b0a6">
    <rdfs:label>Decreased red blood cell production</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
    <dc:identifier>HP:0012133*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d415c1cc-d0cf-45ea-bb7a-6be573caaa36">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9407b757-02eb-4a09-9715-8d98f4d7e7af"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d31a835b-2ac5-400c-b95e-4a743d740931">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41f9aefa-4439-4dc9-a24b-c2b21d626c8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/666d211a-c701-4f67-a556-3d9162c480c1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/022bae1f-9a21-42cd-8fda-8b1ac343a4ec"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2a7c650-a647-4d20-aceb-1be2cdbf19ca">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>abnormal plasma lipids levels</rdfs:label>
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0186e51-6ce8-4524-ad4c-011ac894dd0e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23924caf-5e85-4af1-ade3-2a6157df0746">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>abnormal mental status</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85bb696d-fec8-4715-bf50-106a94950535"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe0c37bc-f1b1-43ff-bea1-55a3c8aa33e9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49b4483d-ded2-4799-abd0-46063f910987">
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>hypertension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f94e682-0fc5-47c2-a78a-9172c405f6a7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
        <rdfs:label>tachycardia</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f8974c5-8824-4671-ba55-28693a163a40"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
    <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
    <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3260e0ae-fbde-4bb7-a5f7-12ef6d49a4d3"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fb5a1bc-ddd8-466b-baaf-a6deafa8d0bf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f38d607b-089b-4797-ac9c-38311c5bf779">
        <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <dc:identifier>HP:0003141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/62a45e8a-d52f-4d15-bafe-ea759dd59268"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0003304>R219K</obo:RO_0003304>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c243688-aaee-482a-9843-02bcf57e8c65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/361edaf6-15d0-4385-8633-2a6ec27a9fd6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a41cfa1c-2e57-4679-8dd9-0c32186489f1">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>high serum ferritin concentration</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4100f22b-ee85-495b-a288-fc8d6f39dce8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f92b9fc2-44f9-4230-abc2-5991b040e70e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc4fd60d-ee2d-471a-87e0-12e02f94ae71"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b733d3b4-433f-4024-90b6-e9f33d75ef64">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ecba524b-5e0d-4293-8136-6d6727888ee5">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e942a454-677a-4e6f-8d79-384dfc9d47ea"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b5fe69a-413e-4619-9d2c-e1eb48bcc4a3">
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d432f0e-35fe-49a8-8593-ebbfff22ad43"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83b21151-8453-490d-a80a-0d1f7da1af8f">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e942a454-677a-4e6f-8d79-384dfc9d47ea"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61b4e135-24c3-4358-95d4-797a0520fc01">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e942a454-677a-4e6f-8d79-384dfc9d47ea"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02aeab36-8b5a-4311-be4b-6bfda79e763c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc66f0ed-de35-423d-931c-179fdca15976"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0954fee9-5416-4e03-8fcd-1e47fd0a7148">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d4baaed-c7a2-4b00-adec-ece3c83dfbf6"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ce49b7c-6c58-4c03-a0cb-f0305bcd6b8e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2a4331c-227e-4e84-bb5e-12d1881ce12f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f90e7ab4-b890-4443-9daa-c6ba1a9030bf">
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/482fdac7-881c-468a-a866-915ab46a1371"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec4299-bbb9-4a69-8626-e7e3f1065676"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fd6ecf9-7155-42cc-b08d-ae8284cc705a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c27d71f-58a8-4887-ac35-d553340c20b0"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3428658b-602f-49ab-8359-28ba8df34c15">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eab78ea1-035a-4657-a7e5-52d3138f4eed">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa44260c-076d-4025-b803-d775d5a74289">
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb576816-3cd5-4b92-bc1e-353462d2fbde">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50c7191d-3d30-4455-a375-d9bda2c8c82d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/859291f1-e6ed-4470-a310-2d06db95fda9">
    <dc:identifier>DB01076</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5434fb7f-d84b-4bc5-be33-9afc4140de21"/>
    <rdfs:label>Atorvastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3eec3bc4-5e55-43e5-8073-24cb8bc89534">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e83a583-48a3-4a43-a220-19c94843cba2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e828364-a136-4180-af05-911ed826317d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c225cc9-9904-4e1a-bbd5-87ae3752cf3b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5060c482-6ec9-460c-bb81-ba18e8ef70f5"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89e2d1f5-e349-4a9b-9dea-a2ee14cb7cd7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77d56c9c-ad03-4622-aa22-4244a8935248"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a06bca8c-7eef-4f9c-8f57-fe6795c525fa"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2478c7d2-a3ac-44bb-bbc7-81ddf6e5ed88"/>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3086fa93-1bd2-4b8a-aa5b-701d25a9bd03">
    <dc:identifier>HP:0001250</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:label>Decreased niacinamide level</rdfs:label>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f3c71df-59cc-4f2c-8f98-ec45edab42ef">
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c8a77ab-aa11-447c-8d37-a5f7a0090833">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88b04dc7-5658-441c-a8b5-aa767c3f8fdb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fe06fed-3550-4b6e-bc12-acc22811c80a"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85ab96b9-4f62-447e-a02b-0b51200079ec">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44296518-5a07-4209-8213-6c0894eaba2c">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7866c40-5028-423d-98db-314a822be098"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b854cf9c-e77f-4c79-bfdd-00e7e2954c3c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09154</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b93aa084-3e9b-4dfd-a409-8859365c26e4">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba43a517-7ff1-44e3-a2d3-548b82d20454"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7866c40-5028-423d-98db-314a822be098"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Sodium citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aab69bd6-a18e-480e-ae6c-cb5973a373e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4442831c-0d46-48d3-ab0f-52f30cf95a18"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7acf969f-12c9-4d64-97a5-1102aead7cb9"/>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/35108e0e-007e-45cb-a7a9-ac6398f21d81"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8ebc2f3-1ef9-45fa-b4be-e2e027dc4564"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/413338be-eb95-4b28-884b-476f5f930ade">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2427971d-6da1-425b-8e1b-f6b8379d2580"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2373adf2-4be0-4cc1-a641-a88112268008">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
        <dc:identifier>HP:0000716</dc:identifier>
        <rdfs:label>Depression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fec46c38-a6d0-472d-a9dc-f78abfb32838">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <dc:identifier>DB14002</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1b73360-b8bc-4304-87c0-cc06fcda7ac5">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c91046b-8e79-4cf9-9303-faad251e2344"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7de1c75-81d0-49a7-919b-6d87ed252906"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e46dc25e-afb5-47ef-bab9-f4adff6cd6f9"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8711fd6f-8f48-4071-b7f7-f29fdc3f4f9c">
    <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45beebd8-de44-42d6-a107-7985c15b238d">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fa177b1-2dea-4b25-a07b-a225fd1bf995"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a5bc051-b0b2-4f79-aecc-e843a9763b59"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dd9b37f-d259-44b2-916d-60b18126c6cc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0012279</dc:identifier>
    <rdfs:label>Low plasma serine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d8283a9-cb41-41eb-934e-f54a2ff4d1bc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>Fine motor impairment</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85b4334d-a355-4c5e-b4b0-760256465c36">
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/396757aa-e565-47e6-8605-b2298213b64f">
        <rdfs:label>scaling</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/703e9bb7-e9f2-4572-bded-35ac94e0ec45">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:label>erythema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/828c26b4-e0ff-4373-b4e1-bc2af3c02b9e"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f269219-4374-46b1-b4eb-269e8073d0e9">
        <rdfs:label>Pruritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a1aa186-e23b-43d4-8044-a02788d97530"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1fb58c2-b8d8-4b57-98cd-9200b1016e3b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07d0dc6a-28cc-45c4-983a-a5d0ce9aadf1"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/358c64cf-4a2f-44fb-9359-af5a8a8b4838">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87540e88-6849-409a-b5ac-51e7fd55da1e"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b40286ac-f03d-458e-9063-6ccc930ce65b">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16a553fd-b25c-4298-a889-a860755d86da">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09270</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61dd26c7-7ce2-4b89-a354-91df6a860150">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/539a1840-1ac8-4ca0-bf1f-9d3f2c3e698a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17ab09dc-9aac-4c56-90ce-c0166e01bd8a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81aa723f-9fb2-41f1-9071-bf4e8d463133"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ce31e07-500d-412a-8cd2-8774dbbd7fa4">
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d48e3316-e85b-4dc5-8a2e-649e22496860"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/77454566-ac01-49e1-b47b-644376f2b28f">
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc42be06-6674-44ad-b8c5-05f0770ffd58"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce1ebbb5-a7bc-4e50-8958-4c8b21349da0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66e5e1f0-4809-4c58-a4ee-2ad2870e730a">
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93664edb-7616-4139-aad1-a59976f8c6ea"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/253c3e50-67bd-47d9-981e-4f3c82008df0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/edd08b49-f5fb-4485-bb94-e56f8de7a03b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f27511a-2cc9-41aa-a5bf-13ec4f6e29ae"/>
        <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aba6fd4-0c4a-4f4f-85f8-312cb2b505af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
        <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/744d03d3-f0ea-4858-a276-855a18bd6bdf"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1cdeb84-82cf-4052-8f66-57e05cfbbc0a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc6322b8-2faf-4945-bac7-46c5bd7700ef"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb295284-e278-423a-aff4-464168629616"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70c43c8b-6635-48a1-82e8-1ffe24ca306e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db49e8a3-8308-4b0f-b245-dc7c5a62dd7a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31207750-7da7-4f41-a377-78cf0876e8a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/382f99a8-ec44-4c83-9de3-7e2e190b5896"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f1596c6-ba47-4f9a-b1ca-0b00a42de94a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3149ed75-7985-4498-b709-82668f05378a"/>
        <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
        <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
        <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e9dcc36-4706-4df1-a9a4-6e7ba483baef">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/621cf4a7-82da-4323-bef7-2744032fbbc5"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4aab579-003b-40d4-aae3-f7369fea17c0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca5def42-c4f5-40d5-8181-3a6f24d47045"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05058665-f1e8-4328-a907-b0efd8444ddc">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91305216-e23e-4afc-af16-0dbdba80c11d">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
        <dc:identifier>DB00213</dc:identifier>
        <rdfs:label>Pantoprazole</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8e84724-2189-44a0-b52e-fd7eaecb3944"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb79b0d5-8740-4e2d-b543-b2da99514244">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/112973f2-6998-4c86-8675-e40c23789c8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d673927b-7af3-4081-a3c4-3687e35c845e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ec5a4dd-69ae-46ed-bb0d-f479af3018b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad63f43c-c419-40f9-81e6-f1f8d63c2e1e">
    <rdfs:label>neurological disease</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1a3e9c9-e67d-47d7-98e7-e2c4338b478d">
    <dc:identifier>DB00147</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <rdfs:label>Pyridoxal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5a44cb8-f77f-44bc-924b-9209229dc71a"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0000bc0-9f6c-4b6e-b573-b397f0787063">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d9c7c3e-dff8-441d-b30e-53e049d40bed"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e16c6b2-19af-4d5c-881d-0dd81873b59f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e6366f4-210c-4bf3-8ea4-ef7bf2cccd34"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87d979f0-bf24-442c-8dc3-10d7101db7e9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3084698-5a3d-477b-832e-5897707712df">
        <dc:identifier>HP:0007346</dc:identifier>
        <rdfs:label>Subcortical calcification</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/186dba5b-912d-40d7-bb92-742a722193e6">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
        <dc:identifier>HP:0002135</dc:identifier>
        <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/dfbcd5ab-7e10-4a86-87f9-6567448c8c8d"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f13ac7e4-a5d8-4504-a6d7-325ea3ee2c84">
        <rdfs:label>Seizure</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/89dd4b58-9143-46e5-8788-683469d0f1e0"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d04b7bb2-caf5-49b2-bf67-fae7560009fb">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/786a4a87-f44c-44b7-89bb-c5f65da43432">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/2cfc12e5-5806-4730-bf41-c38892776126"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9976154b-9d74-4e6e-bd43-a1dd1866ce03"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff80535b-9fa1-48da-bf31-d4b5f21b6b84"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3454844b-a95d-4631-854b-ac6f0ed3b006"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48140560-78e1-44f6-95b7-a791c6da0a1a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <dc:identifier>A11EB</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9015455-2997-432f-92bf-b9197284e799">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc39d0a9-6007-4305-bb06-922346b7f130"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f003de2-e1d2-4076-ac4b-a93e9459f5bf"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3dbc1c7d-a561-4351-93b2-f6e848ee3543">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c1fdaa8-d54e-44b2-9477-d9c6beb2d8c6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c1e4d12-8e8d-4fe1-9639-ff7de6ebfee1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af418504-c24a-4582-a078-2f1a1489dd19"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6a981641-0af2-41d3-834b-3f211332ded9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeb9920b-5f88-4d90-9a3b-f0b514cd0038"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00065</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <rdfs:label>Infliximab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e384279-7848-4e6f-b056-1101f177e9ee">
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7412dc3-1ad8-4e87-a33e-c3dcaf908485">
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ae8f62b-c3e7-4daf-8969-f81499592b05"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a579fb1d-81e4-4b8e-81ca-aec16a963271"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/86f5d3b3-5318-4bc8-b9f7-0e71ae9cab43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b94d9d81-a5d8-4199-8a87-cf439e62d0b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c18c39d1-eae5-412e-ab1a-bc12ea048ee7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0271df8-eff8-4554-811a-c23884315ba2">
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/513f5d87-3e7b-422f-8de5-71afc4c0948d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8860c86e-c29b-4f37-a66c-902b047b5f5b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Large central visual field defect</rdfs:label>
    <dc:identifier>HP:0001129</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0955ea1f-49e4-4fed-9f97-60056e841021">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ce30a9b-3232-4286-9e54-7796bfb3453f">
        <rdfs:label>progressive leukodystrophy</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0002415</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/825a10c6-dd86-4fb7-8113-6d4bb571be1f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>cardiomyopathy</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26a5c989-9836-4d65-8e97-6c105dad75e8">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
        <rdfs:label>paralysis</rdfs:label>
        <dc:identifier>HP:0003470</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d27b81b2-aca4-40e7-aa1a-a1be9dc593a4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <dc:identifier>HP:0006670</dc:identifier>
        <rdfs:label>Impaired myocardial contractility</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9fcd3ce-5090-4feb-801f-9b13c3bb187b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac1a0d6e-22a5-4e0e-8879-301b78999eef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1f78da3-a9d7-4254-8551-d0e3bf544ff3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8d63774f-1c62-4eea-9c25-0d418263623a"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4adefdfb-66eb-4351-876b-372a00bd2153">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24b24857-c8c7-468d-b775-4177f2641972"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f31df870-1081-4a9d-89e3-92d991dedf94">
        <dc:identifier>HP:0001638</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiomyopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57cde1c9-77fc-4422-9056-92ac895e3f4a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5015f398-4cc1-4243-bcae-3f43d606d354">
        <rdfs:label>Sebelipase alfa</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
        <dc:identifier>DB11563</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcae2dc5-4524-4437-9cf1-cb0cfeff561c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5f0426e-4cba-437b-ba20-cdb648e2f5b2">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d604178b-df28-4297-aa69-a7e6d7177e7a"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f27511a-2cc9-41aa-a5bf-13ec4f6e29ae">
        <dc:identifier>HP:0002066</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:label>ataxic gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54102f5f-b494-4bba-9d4e-9e192ca4d347">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbb61e6a-991c-4cfe-be07-89216c9f9945">
    <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6708388-cfff-412f-9860-4752ee3e0cf5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a61d272-ac9d-4e9c-8e87-b329c5857620">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46fa8dc8-4cbf-41ae-b6c8-d8bab27825c6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfe0175b-c659-439f-aead-e1e40cba8e43"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2e91324-c913-413c-9878-cf99a079bffa">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6261b620-e268-4266-a493-bb6111574900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417300086</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eff0e6d7-5b8c-42a9-836a-618b408b12b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>behavioural disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad227345-6a1a-4177-a5aa-6a178f0240e8">
    <rdfs:label>Baclofen</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc67ab51-2b15-4f6a-b1d0-0cd46328ed1c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ddd3291-a5ce-4fb5-b090-ed128d21ef02"/>
    <dc:identifier>DB00181</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6278903-e671-47fd-8557-bd40e482973e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b135d2b-d046-4108-aac7-0130d441b02f">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2d7c761-c19b-4e9d-8b2b-865060559367">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/deb38279-33ca-4db9-9036-114d78922cde"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/5ab07ebf-8c6b-4ccc-bafb-ecfe13a94e0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/825a10c6-dd86-4fb7-8113-6d4bb571be1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87540e88-6849-409a-b5ac-51e7fd55da1e">
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0f64c39-ea63-403d-96eb-bc61aeccd976">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44e2f007-f6fb-438b-8dee-f8036916f226">
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c5a73ae-3692-45b1-8b1a-a955780837dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b00a7185-fcbb-477a-a2e8-834e2877b31e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4bf9436-c7ae-42f2-b3b7-3d0f049881b3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d6b25bb-2e7e-4aef-bf84-c7348b20fdb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7905f83-0727-4beb-a9dd-101a429bd0d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a233f746-6876-4ccb-ace1-aa0ac4d90f3b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36be566c-3bd6-41e9-8a34-9361ad0d4d46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
        <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/19b6b432-2c1e-4d52-be7f-3e91fb2d2dd0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da99ec96-6848-4e70-afd0-9a3d4e0934b0">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>NO revealed clinical benefit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29fb3e0c-61bd-423b-892d-2c40aafe6c26">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fedc14dd-97fc-4838-8fc3-c9e241a9b55b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>lactic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603358"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5cb60e64-33fd-4a9f-9d2d-802cfb64d49e">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/28aa8ec3-07b4-4e06-ab03-9ef6322d8cfa"/>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13632c8f-a511-4866-a36f-bd3f82a79d1d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:label>Hepatic steatosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f105166-38c5-43ed-9f71-318b2b1faa2a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81aa723f-9fb2-41f1-9071-bf4e8d463133">
    <dc:identifier>HP:0012040</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corneal Oedema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eae3e312-a64e-4996-b43f-36549f5dbbdc">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/190bd53a-c510-4f1d-bfe4-982941f48bd5">
        <rdfs:label>Salicylic acid</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01676cdf-33e8-4942-873c-e666c55ad794"/>
        <dc:identifier>DB00936</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78967320-2670-41e8-a68a-60bd95ba7faa">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Macular cystoid changes</rdfs:label>
    <dc:identifier>HP:0008028</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa3770f2-5dc1-46c5-b4ec-73208a0b700e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2494ada7-2993-4f42-966e-88b90ed166d2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59842061-f1d4-4fc7-bf3f-3b2aa11826b2"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1092451b-c348-4606-ac3d-1f79b86b1693">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89eb12b2-1846-4a6d-bbd7-9aa58dd49d45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56890293-3b5f-4f36-ba07-59d8614f9183">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <dc:identifier>HP:0002900*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f22c59ba-af2f-412f-a594-9ac3890802f9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6064a12c-822c-4f31-8bde-7c49e5ba6f34"/>
    <dc:identifier>DB00334</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <rdfs:label>Olanzapine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2e91324-c913-413c-9878-cf99a079bffa"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffa4715f-764f-465d-87fe-71f141b04aaa">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003073</dc:identifier>
    <rdfs:label>Hypoalbuminemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05c19b2a-7387-492f-9f72-9bb4dbee0d43">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe5318bb-4210-46c4-8f96-2dbf92951370"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/965d4a0c-5c83-435b-b3aa-cb775e71c867">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ebd3c2a-290a-4df9-97e7-3280e7336737"/>
        <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c2c0a9f-deed-43b4-8486-43456930cc39"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb579af9-d2a9-4395-a0f9-61511067e5f0">
    <dc:identifier>MP:0003354</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Astrocytosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70cb3107-4f63-471f-97ff-2a391df48970">
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>neuropathy</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a76f0a40-5ce5-4f16-b719-87c477696bd4"/>
    <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/dd2d8b2b-1089-495a-98b7-45e05f433512">
    <rdfs:label>functional complementatin of a genetically defective protein</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8d32737-bc14-4e01-8a68-6df747b16a8e">
    <rdfs:label>Abnormal exercise physiology</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <dc:identifier>HP:0009020</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ba3fff9-ba89-44d5-9763-eac1aad11597">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3539754c-cca0-412c-95b9-95e4bdc17d4c">
        <rdfs:label>Diminished intellectual abilities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1165136c-a186-418e-b295-21aba72fb51f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50b558df-1dd3-4101-98ee-77f16bc8e0ff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff45e633-93b0-4d64-b687-b110abd0ee13"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0fbf99a-222c-44c8-a030-8c33463d296b">
        <rdfs:label>inability to walk</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002540</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fa83b27-2c2c-41b7-8594-932bd4932e1d">
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a887f254-d867-4526-ac77-ef156366f64a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/659a550c-90a2-465f-81b8-82289fd40a09"/>
    <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
    <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcae2dc5-4524-4437-9cf1-cb0cfeff561c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c4ee9d3-6870-44f4-9b1f-f8c3e11243b2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/cholesteryl-ester-storage-disease</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33f6a332-c566-45cd-a4ee-0034dd32471e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57cde1c9-77fc-4422-9056-92ac895e3f4a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03e1fb20-bb4b-486e-937b-6f9d72ddac43">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>hypertriglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/03700ebf-6956-4fcc-a6a4-b1fd481b7db0">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a4cad2b-c1a1-417e-aa16-f924222e96a3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/642c5c18-cf04-4717-957d-b51ed8350cf5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59e51714-fe9b-4ce7-8a24-823165e1f91c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0edce8f9-4d89-43b4-8820-b7bc7a532d0f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b26d813-f7f6-4bca-a924-a2d364a992cd">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0045082</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <rdfs:label>Decreased body mass index</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9233a7c-16d8-457d-bd40-1d82f895e0da">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b8a8df1-1b58-4892-8eaa-b9d2849a1175">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3067bf0e-90f1-49d7-9953-ff26bf0049a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28b79bfc-7671-41da-a307-9939db10811d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6829befd-7888-4dc4-9879-2ea3d33144a6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301835"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ab2ba8c-045e-4cfd-ad0a-c7a14d2df5ac"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60440c20-d063-44d6-82ed-8aae17597d33"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/898f3080-1d82-407b-96d8-9f4e03883e12"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d27b83d6-c0d2-4f13-9a57-c1cc7ecfc4ad"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f96e6bfd-5873-4574-8ef7-57106f707e16"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80b2efba-36c8-4193-8eb7-e646dabdd2c1"/>
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc7622d7-6f40-411a-abe7-8e54f6f03b65">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60440c20-d063-44d6-82ed-8aae17597d33"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34b3c74e-6405-4820-a86b-e403d42b92b4"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc4f90af-c64f-4a8f-95ba-da5bc222c9d5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60440c20-d063-44d6-82ed-8aae17597d33"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94fb0948-d556-42b7-9308-cb42d7be166b"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e02bde1c-86fa-4b1c-82e8-7affcad3b49d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ademetionine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed4f4a3d-0e53-41cc-9aa6-301b598d8634">
    <rdfs:label>L-Cysteine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <dc:identifier>DB00151</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ee0c7b7-a6dd-4d2f-bf1a-c650da068dd0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a959fbeb-49cd-400c-aa7d-d05e95e7e6b2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13ebc7dc-075c-4349-969c-6aed2d0f0703"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f8d0a6d-ea33-4766-b4ee-87c7fcff12dd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54d7831a-4258-4cb0-a785-8328e0e82db8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
        <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
        <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e674ec90-c825-437c-a76b-388b03f5fbb2"/>
        <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/afd9266a-0bf6-47a8-9878-3aee4d403c1e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ba0b3af-7e14-4acc-95b6-0b90d468d11b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92b07a6c-a2d3-4e01-a6b0-0509d164ce51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7eb8e3e0-95fb-4f54-9d19-68b86537033d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd474d3b-ad72-4ae5-a1c2-9b69c3d3e404">
        <dc:identifier>HP:0000565</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
        <rdfs:label>esotropia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ade1732-6154-4919-990b-e669d24d8ac1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af418504-c24a-4582-a078-2f1a1489dd19">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0000559</dc:identifier>
    <rdfs:label>Corneal scar</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b73045f4-d4f3-41cb-8fc3-d518539a2171">
    <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0012535*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/940af391-4582-41d3-a670-3b3073560244">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022510X16303495</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da63acb0-39a8-416d-9434-2094730507c7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1060255-9e16-4176-a84c-e5ef3ae87701">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/265aefb5-2c53-45af-973f-291ae41183e2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
        <dc:identifier>HP:0030186</dc:identifier>
        <rdfs:label>Kinetic tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e92a9440-fb92-4516-aa95-9dfb62166e04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/429657fd-c6ca-46a7-bdee-aa0353f24110">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e553d13-8bb9-41c1-afa5-82f064b53b4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb161655-3b0b-4af6-a61b-18d6fe05e3f2">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/62a592d7-b229-452b-94b9-d63586f1a60e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1db4dc99-8032-4a53-88f5-7667dcfce2f6"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ca0dfbd-ca3d-432c-a018-4ff612eaa409"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62d9e696-c558-4083-84dd-acccfb8f56ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b94d9d81-a5d8-4199-8a87-cf439e62d0b9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56890293-3b5f-4f36-ba07-59d8614f9183"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7721d2f5-8219-4d29-92ff-3f1cec71f476">
    <dc:identifier>DB01025</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d70b529d-0984-4d0c-9c28-b9ba753316f2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
    <rdfs:label>Amlexanox</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3813adad-e631-4eaa-bb00-a10947c6e983"/>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a810e094-cbed-4254-af4d-a4744ea3c0ab"/>
    <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14087166-6187-4a71-a8d1-aa66d9ba8c73">
    <rdfs:label>abnormal hepatic function tests</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8aeb3d3-36e9-47e1-84d5-e754e9329d56">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb10a688-9971-4981-93d1-791b9690c3a7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mitochondrial proliferation in the muscle.</rdfs:label>
        <dc:identifier>HP:0003200</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c467bcd-9515-4eb6-8e9a-bf10f7a4836d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f96e6bfd-5873-4574-8ef7-57106f707e16">
    <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e92aa2c-2b8b-4a31-b36a-f007535d559b">
    <rdfs:label>Cardiac hypertrophy</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1dd9be5-c028-4402-9e25-dfe8e113e70b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>proteinuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
    <dc:identifier>HP:0000093</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac7b166a-83ea-4e85-b27d-51c4fb2478a2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/601cfbfe-ae59-42ad-943b-20fa5356a91d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61b4e135-24c3-4358-95d4-797a0520fc01"/>
    <dc:identifier>DB00190</dc:identifier>
    <rdfs:label>Carbidopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09e21dd3-e3bd-49d8-87ee-fed0872f9c5b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41e10f11-1dc2-4ebe-8a6d-ce0bbcbb0784">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec4299-bbb9-4a69-8626-e7e3f1065676"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4fcf6bf-43ed-41eb-933f-bc87db0e96c8"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adef8c59-fc16-42b0-adda-ac087bce0897">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
    <dc:identifier>HP:0100614</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27f15591-54dc-4841-b66d-cc0e894921e0">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6927cc79-e711-4773-a95e-04b9b1533a8f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a274042e-39cd-40e2-855a-3b92f2f1b2d2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/962fdfe0-71bf-4f3e-89af-8cf2fa3f818d">
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f4fe280e-24f9-4f75-a65f-8b03c03709e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fe74d0c-aa4b-48da-9cc2-21a481143472"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19a58275-5491-4e1d-8a35-4e37b9685748">
        <dc:identifier>HP:0100660*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0974e00-37da-485c-ab96-b1551cdb6e79">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/997e3080-23f5-47eb-acc9-c3e2a90a3734"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d9aed90-8273-4a0e-a35f-f4bf461fd6fd">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28132e62-a39a-4b6d-9f1c-afb42b59a519">
    <rdfs:label>low cerebral creatine</rdfs:label>
    <dc:identifier>HP:0025051</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d2f0b89-8fb1-47b4-85bd-7694456ec6da">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bdac777-c667-4ab5-aedb-f5e9ef386ccc">
        <rdfs:label>Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/002f448d-2277-4f73-ba99-b0d5b9e033b5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/188f04dc-981b-4e7f-accf-6e0b41c701ed">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004325</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:label>Low weight,growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08442be9-a80a-449f-b66a-6162ad6d21e4">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c243688-aaee-482a-9843-02bcf57e8c65"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d9c7c3e-dff8-441d-b30e-53e049d40bed"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3466f49b-e8d8-4e63-b8e6-fe3210b058c6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
    <rdfs:label>Propranolol</rdfs:label>
    <dc:identifier>DB00571</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c23def19-8e65-40c8-b2d6-9b083bc89b9c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12393f3b-3373-4917-bb46-0869d7d7d13d"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39e00bb0-2fe0-4661-a45e-f1db57d5713b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb738444-42db-4374-8f2e-baeb5375bb2f">
    <rdfs:label>PL-induced cytotoxicity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2edb1724-9805-4697-b61a-7825882362cf">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://pubs.acs.org/doi/abs/10.1021/bi1008112</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bdd06ae-adf2-49db-884b-521532e72184">
        <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49f7076b-3447-4482-b598-fd0e18ff58c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5c83ac7-4e88-42d6-b741-90c24d49f365"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c317839-3c82-4f61-8534-fe0afa8e3c7e">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
    <dc:identifier>HP:0002013</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14df90fb-e02b-4626-b469-7d6f15f2138e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c87e793e-d584-4e73-a00b-0d24f3878723">
        <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3acff8eb-5fdf-4a3e-8be1-fb40b6acd0c6"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bfbdd410-9b95-44a9-9184-c217dba0f235">
    <dc:identifier>DB00145</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3bca9946-9b98-4076-b3d2-e2b0f1772362">
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9aabb9d8-b1c5-4750-b58b-34312e775ed4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/145f6353-ebd5-442c-b10b-efcfb78af397"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/253c535d-4b96-41d3-990c-afd5506515b0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <rdfs:label>Glycine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5ae10bf-c0a9-4832-b248-41f437df5f1f">
        <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
        <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/488a836c-a225-49ce-8e37-f96f91d5030b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/253c535d-4b96-41d3-990c-afd5506515b0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57c2119b-bc10-4505-b5d9-2bfc6ff219ae">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
    <rdfs:label>Increased creatine kinase activity</rdfs:label>
    <dc:identifier>HP:0003236</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3cac268-12a7-4b5e-b632-66fd88bcb8de">
    <rdfs:label>Vitamin K insufficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001892</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b944e1f-5155-45fd-8baf-a2965b69ec50">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5892260e-bc5b-4e1c-9f04-e742d231b791"/>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
        <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c580c96-78af-4bf2-b6c4-375706ef6a3b">
        <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
        <dc:identifier>HP:0004732</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64830d3c-8130-4184-8342-530b6435597f">
        <rdfs:label>Polydipsia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <dc:identifier>HP:0001959</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c45f49d5-cbac-4a72-b75a-ddf48204bf34">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56ac239a-7098-4666-ac4b-e7188f36e80c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c4f6f2d-68f5-494d-b346-5e8d0afc3056">
        <dc:identifier>HP:0003072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <rdfs:label>Hypercalcemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/680acdd9-7722-4c28-814f-99c8b60f690a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb3285dd-43a0-4c5d-9733-f17f87751759">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60ac1d78-66d4-4e62-85dc-a0176bc9ad0d">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/955b7c0b-4426-4898-b4b5-2dfc3afbf7c1"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5b8dc1-8c19-4873-882f-9934dfb2311f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <dc:identifier>HP:0001251</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Ataxia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c71e910-74a7-4c3f-8b7c-f1f58203b67b">
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100513*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87ebbc42-a484-4a71-b153-aaed61d6eadf">
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/588dd572-4ad6-46e3-b486-94fd033333aa"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0737ca1-a913-4c4d-9cad-2ef8f08214b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc1b1bba-53d0-4af4-83de-99f1cf68cd5b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24998f2f-90bb-4a14-b6db-bc2d2c9e1a99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30670524-7ac2-4ae1-af48-3cf9b1fd8af0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78967320-2670-41e8-a68a-60bd95ba7faa"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/afaa283f-a1b9-454a-a2a2-6e27db4d9ca9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4a0ba5d-64a2-4486-85e3-9527ae732aa2">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72fc8bb6-6516-410a-97a4-b61269fbc4ae"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9cafa69-b4b2-4ac6-9931-9591575f96db">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606175"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85f97363-7c7c-4be2-b51e-91547994f977"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56489e74-cc7e-40b5-9d32-f066910dd562"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4394cd86-4a31-4412-a6f9-b8787b437588"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/756111bf-9a05-49e5-a29e-c9f33c8cf3db"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ace8279c-22af-4d57-9020-3dc1bd8c16f0"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/babb2dc1-a56e-4873-85ac-786fc816c7d9">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236795"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b49cf86f-1668-4923-98cb-cd2e0a5281cb"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e28467ee-8b9c-458a-8db8-ed632d253127">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e90b72a-2c10-4aae-90fc-822a2cb0d2df"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3be1ce46-d2c9-4764-a22c-2327c75587f0"/>
        <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb6727ab-dcd8-49b3-839a-3edb87d9b03b">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8407c2cc-162c-481e-8b51-bf22b2df62ed"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4b0ab2f-1ac0-4057-8f2a-7d8d27dc1fd0"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8af2c12-1390-42e8-879b-eb753d79d502">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04fb05da-7116-477e-946e-f718dd4e4234"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70bc9c43-4103-43d9-b1a0-ab3057756487">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/727efb21-fb72-45ef-9cc7-01c8b5437468"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dcd06666-50ac-4f7a-a9f7-fc1fbf4cd6b8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cb971cc-0ed1-4fe0-96d0-c522f201f200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb738444-42db-4374-8f2e-baeb5375bb2f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/607de0ec-6743-448c-82e7-94617aa3b708">
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6eb91fb-f8f2-4513-b09e-77c9f0c5f22f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43c9e6ea-a481-4f1d-85f0-3d4095f22544">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d71eb05-e3d0-42f0-a613-95033fcbfbfb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/559f5aa0-0bd3-4b34-8378-c6d553928c15"/>
        <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/2-methylbutyrylglycinuria</dc:provenance>
        <dc:provenance>https://www.newbornscreening.info/Parents/organicaciddisorders/2MBC.html#4</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8ca7b9e-3a6d-4923-ad95-9e56b1283e8c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64452907-4692-4aaa-a868-fcaf75844d11"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/841571a6-da96-4aba-818e-ec0af3765804"/>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e74c37a1-af5f-4c27-b44c-d147f336cf0b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b72d9af-3199-4fd0-9530-3e8fb1f791d6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4aab579-003b-40d4-aae3-f7369fea17c0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25ba604a-1db0-467a-ba1d-ce01cb2b761c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c125464-06ca-4cf2-991f-192e814e6eeb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dbc42d78-657e-4ffd-a47d-3dd52715e271">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250950"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b5c9b53-7cf9-4991-964d-269532328b11"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42a994b9-b217-4672-ade6-319f79ec9e4d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04c996bb-234d-48b1-9844-9720c954aafc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25fcc28a-eff8-4fda-8698-af51404cd418"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1bc4985e-0d61-47a4-ab0d-705a02322690"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73ba082c-8f99-4fe1-89ae-2b619feb514b">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67b521c4-f858-4092-9dfa-c08955fe7bd7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b55b3ee4-7256-4f58-91f6-2e4b6f08629f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdb7372c-b477-4bdd-a449-a1e18e886b43"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd45e18f-1f31-4714-8d92-6c6c4772544c"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600721"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cac0b93-7ed3-4b2f-9f40-3f913fb36be7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fa83b27-2c2c-41b7-8594-932bd4932e1d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7450c3fa-99db-49dd-93c4-906f389e7bfb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
    <dc:identifier>HP:0012187</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a62b29c9-6c74-4027-9304-4f6d9b4ecda1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e1d376f-8a23-4a45-b430-fe4718a33cc7">
        <rdfs:label>Vasculitis</rdfs:label>
        <dc:identifier>HP:0002633</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7b39bcd-a083-4184-a514-eb9744026cc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26ec7b87-0045-45d2-8d09-706b9a772227">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/827f77e4-a39b-4282-887c-9102e5c7c976"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4500106-8202-4e05-a499-e13e9f8310c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <dc:identifier>HP:0031799</dc:identifier>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <dc:identifier>ECO:00055442</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2c77379-0898-453b-bf49-b35650ef80e0">
        <rdfs:label>Arterial pluque</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <dc:identifier>HP:0002621</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fd93374-cbe7-4a8a-9cdf-d0cdc59dc1d8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:label>Fatty liver</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/946ce39b-6b32-4546-a64f-b9bd52474aa0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4746ac75-01d4-4354-b0ba-cd19a00dd8ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b87ae90-cecc-42b3-b3ff-929e0154c643">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
    <rdfs:label>neurodevelopmental delay</rdfs:label>
    <dc:identifier>HP:0012758</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63109928-8d1e-4e99-9b01-472ff3b9c7ed">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6fd61e60-7fbb-4b5b-893e-dab8f3e3fb0e">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30b37d8f-a00a-42ec-92be-ab73d715e306"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0003304>R229W</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca6553f-e344-4401-8af4-cb135fd91394"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/dd2d8b2b-1089-495a-98b7-45e05f433512"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca667e04-e055-4db1-bbf1-3c9038bf01dd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1355360f-d1a2-4a6a-ae95-b4c633d763de"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd625e40-2d6e-44fb-acd4-94ce29d4e1db">
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-013-9660-9</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21fbd864-1740-4daa-afb0-e6939d1bd8f1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/781e408b-b0e2-4839-ae06-d1d5a87faa0a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9e9c9ae-46a3-4e85-85cb-4129389f225b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/154d1a29-3f00-4e75-ac0f-058e88869ddc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0025660-1181-40ef-a5b0-c50d00f6222c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f1596c6-ba47-4f9a-b1ca-0b00a42de94a"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/601a0b23-d67c-411d-aa51-9e6fec88adbd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e743130-68a1-493e-abb4-eeba281f884a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f13ac7e4-a5d8-4504-a6d7-325ea3ee2c84"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/872d6878-9940-4160-873e-afa133f4d9a1">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af6e62b-08c5-4090-8c6f-5a9c1c322d57"/>
        <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1101df5-3cd8-4216-a1b8-d25c8a93d211"/>
    <dc:identifier>DB00165</dc:identifier>
    <rdfs:label>Pyridoxine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ad87856-622f-4653-a4c3-942e8c3be839">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1428ae48-db39-41ec-b923-8f95da00b28c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00f713ba-3904-4923-8e43-f89a414b6947">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
    <dc:identifier>DB00988</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13518389-b182-462a-9191-903f07924f7d"/>
    <rdfs:label>Dopamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af0328a9-e8a7-49dc-9dd8-b236ffcb0e55">
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79c3c080-5469-4ad2-9140-3709c865fbee">
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/749b7ddc-8d36-4bb2-9f44-be1c8f417eb0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d8cf62a-9e3b-42fa-95c6-33dda7a26165"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <dc:identifier>DB11981</dc:identifier>
    <rdfs:label>Elamipretide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec199da3-de27-4c5e-a1f8-50144c083099">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a982f649-31c9-4f88-ac1f-f94b93a7c9b1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82dda832-f4e0-4ee9-a416-fdc2b7ee0976"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b14f3eb-2675-4f5f-b073-1f553881f80a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22109b05-6c77-40a1-ba31-75ec648cc710"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6429ec9-3d9d-4155-bb4d-3a291f2f1e5f">
    <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
    <rdfs:label>Low tumor response rate</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9a3b4ef-75bc-479f-a404-28b2cf3edc1c">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98619345-3e13-4d53-ac56-fabffce4a3b2">
        <dc:identifier>HP:0012321</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
        <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c31558f9-374b-4091-a0e2-f3d3082e88aa"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d284653-eaab-4483-81af-c29e00a67e25">
        <dc:identifier>HP:0040144</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b8ff32dd-2c8f-47c9-9701-08712f360f09"/>
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/836d6aa7-09cc-4038-981a-8b7e4aa1d8f1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca537b8-76f3-4d21-a568-c1b2077b40ce"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c0f4c75-d92b-468b-ab55-ddf79e11229e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9aba3d03-477a-45c8-912d-902072453138">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0011123</dc:identifier>
    <rdfs:label>Dermatitis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d24c77a2-e569-419d-abda-d20ad7e10bae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f818a3dd-cf9a-4e56-babc-1c879a8c3450">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>Cardiac dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/baa835a9-1b41-4552-8015-2853e5909dc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1400c793-f5dd-4768-8ac1-4eca82243f01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0434650f-ce2a-4251-9299-d5f3a40b323a">
        <dc:identifier>HP:0003546</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <rdfs:label>Exercise intolerance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93664edb-7616-4139-aad1-a59976f8c6ea">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
    <dc:identifier>HP:0012433</dc:identifier>
    <rdfs:label>abnormal interactivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/790be26f-2cb9-45cb-91c7-7529b2d9bb44">
    <rdfs:label>dyspnea at rest</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
    <dc:identifier>HP:0012763</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7992b44-0ee5-41f4-865f-8de043b10a28">
    <dc:identifier>DB06667</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d10b96b-d2f7-4cc0-8449-a1be825d12da">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8fddd35f-d43a-408e-b71d-457d0a17dd06"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2508531a-0b1d-41a3-a96f-21b66d2e3e72"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d9676b8-2f17-497b-bc84-86656403d053">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/de205b5e-898b-412d-85ab-58a20b81aada"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fe07572-f98e-402f-8f5a-1b0dc3b254b1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8fddd35f-d43a-408e-b71d-457d0a17dd06"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaab948a-9236-4559-bb8d-df0147e94972">
    <rdfs:label>Abnormal growth</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
    <dc:identifier>HP:0001507</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f4bd841-a43e-44df-9604-67962bf85a90">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aeca315-56f4-4aec-a187-8df9f8876248"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a31fc9c-b8f1-4eea-a320-209a6240523c"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f596495-aaa3-4eb5-87eb-9392aded48b3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2303433e-7bdc-4c2f-9e80-d697b618b723">
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:label>Elevated blood homocystine</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93b90f15-0735-469f-9236-d956c1a8b81b"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b9c7322-0312-450d-8fd0-d4b6096d261a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
    <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
    <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71a9479e-4532-49bb-90c4-584334b1d672"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f13bac8-c322-408b-9e2e-9b9c02ff4a2e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbef57b-0d8c-424f-95e2-9b6558d91e16"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c81a1b6-0abb-4898-a7dd-db4ca9769a00"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/930b5dd7-f0ad-466d-b7cf-174df8b4f422">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b29327ff-659c-4101-8181-bdc8ad816d5d">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
        <rdfs:label>Lamotrigine</rdfs:label>
        <dc:identifier>DB00555</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0fff3d3-5f23-4f73-a916-c2e78de0a271"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bda53ead-ae16-472a-b1d6-9aafb490e29c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
    <rdfs:label>abnormal coordination of movements</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011443</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3700f14e-c53a-4545-9afd-776de7fa4fa3">
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d218fca-1f53-4ce5-a59f-2d2ec800c31c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2427971d-6da1-425b-8e1b-f6b8379d2580">
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aab69bd6-a18e-480e-ae6c-cb5973a373e3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04ed4bf5-0930-4242-843e-972df5215034">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
    <dc:identifier>HP:0002353*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3868b5f-9265-477e-a8b3-683f6879eccb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d85ecc15-a70d-41d5-b1c9-cf86832a4484"/>
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/160a6374-91a4-424d-8604-013dc606fc62">
    <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8def5f3-3329-45bb-b55f-40b8cc50b667">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea5e8dd8-4216-4c8c-beec-5a69a217a30e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a254c86-ff38-49db-b5e2-35badda4ca5b"/>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da32e78e-6dd5-4498-8425-c9645544bee6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95e65b13-2728-4283-9ead-05ea710f30d9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/deaab464-f734-4409-9973-16dd1b60d06a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Brexanolone</rdfs:label>
    <dc:identifier>DB11859</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63d106ae-d5e7-42ce-882f-041d62561a78">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfe0175b-c659-439f-aead-e1e40cba8e43"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5345ba4a-e8cc-4ec8-bb14-20029081e8b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9d733e8-bd64-4ea2-af02-2d04827f1bb1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
        <dc:identifier>HP:0003566</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08f434ff-4df1-47e8-9108-e07e83055bc6">
        <rdfs:label>High calcium excretion in urine</rdfs:label>
        <dc:identifier>HP:0002150</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21957ff5-2d96-4835-a6d2-7bbe0cb518f8"/>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3807bf02-0753-4fa7-a969-a3e21300fc8b">
    <rdfs:label>High serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8241293c-905d-4316-a1d5-038aeb31e906">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6556694-6cad-4693-a4bf-1215bc7b7a8c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>pruritus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/d89188d3-8253-4bcf-a592-674a6b1688e0">
        <rdfs:label>???</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1061c08-c2f3-4d36-a5ca-c89663e92a78">
        <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
        <dc:identifier>HP:0012202</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/152e2867-c129-4f94-bf39-6f5134e6ee26">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>hyperbilirunbinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8f416c2-0ed4-40eb-9fbf-b058daf45890">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94b1fba3-7aff-40cc-b22a-cd2fe7f9e795"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d27487b0-75d0-4455-a80e-d1167a3e6e19"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d0a261-ca29-4a37-914d-700f259064a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
        <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4602656a-5840-475a-83ea-5981f2a64a13"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6667521-c82f-40a5-9b6d-d84543a02eb3">
        <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5022a83-4484-424e-9c33-358e21f9c298">
    <rdfs:label>Hoarseness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001609</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80f4024e-5529-4dad-b14e-d52b281a3f13">
    <dc:identifier>MP:0013277</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
    <rdfs:label>abnormal fasting glucose</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8681660f-2bf3-40a1-b882-d8151e7424c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87144371-0788-4ac0-88e5-013090259752">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f24e8ee-6b65-43ab-8323-dc5f07d7664c"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a8de991-c372-4287-a288-c4b6d8188263"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f8fd563-172b-4eb4-b6b6-1fee9502aae8">
        <dc:identifier>HP:0000739</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anxiety</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/895fd5ed-58cc-4663-a3d3-ef11b3026482">
        <dc:identifier>HP:0003808</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
        <rdfs:label>Abnormal muscle tone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Spa</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7521ca0-5b91-4551-a43f-51d7b2160f45">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
    <rdfs:label>diarrhoea</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0002014</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49862f5e-f9bd-4b31-a1e0-f997df2fc8f8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <dc:identifier>HP:0001943</dc:identifier>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Low serum ICFBP level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b97e5473-ec06-4a85-966f-6e072721b234">
    <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
    <dc:identifier>HP:0008064</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/807994c1-bda1-4754-916d-1ebe332e1240">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/713dd7a9-1db6-412f-97c7-d66b541a9d03">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d4b85b2-3953-49a1-a04e-513cf996297c"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40ecc46f-2bc2-42f3-914c-59fd8f5dbdd0"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00396</dc:identifier>
    <rdfs:label>Progesterone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b84d8614-9d39-47ac-b544-3e1de2e43210">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e955d6c-bbe3-4787-b8f5-9057d135930f">
        <rdfs:label>Hydrocortisone</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f21a048d-7c58-41aa-b525-c81b35d850c1"/>
        <dc:identifier>DB00741</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd06ee52-ad84-4932-a74d-ff3159ec5f23">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ebfc2857-00b4-417f-8505-1fcfd9bac9a9">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0efd4c2e-d5bd-442a-8629-71f8b668a8f2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa2b82da-6b09-47cb-9c24-9944056745d2"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e04903d9-c23c-4476-936b-7e53ab1afe27"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <dc:identifier>DB13257</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a875ec8e-dcad-4f6d-a659-09a9e5217d1f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bdac777-c667-4ab5-aedb-f5e9ef386ccc"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b540a38-30d3-425e-af6e-4f744fdfed9f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Perioral dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
        <dc:identifier>HP:0040181</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5f4e8c0-9440-4509-8765-fa01c8869532"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6760329c-e661-4f23-b881-c052979a70ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00e00b0d-c8ac-4d80-86ab-f8e6c9907529"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49601dd4-ea94-4e74-88e7-17eafd3fbf6b">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b54d425a-746a-480f-8157-9302dc167899">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <rdfs:label>Ecopipam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55186692-e5bd-41d9-b283-221ca2dc2c12">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfcbd661-a2f9-4b4c-90d9-fc753d69ced0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9993a36a-de05-4bbc-8276-ad1e7560fdf1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB12273</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3bade43e-01f4-4434-8100-2b48905eb0df">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07847dad-4d61-4270-af62-e35abe44a70a">
        <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011025</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bdc8172a-e194-4e13-a868-d2ea0523e911">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5547069a-cb87-4d44-99d0-3471ee7f7ae1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/129f3718-d9de-40df-a9f5-44688a7162b1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <rdfs:label>Vasopressin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7efba3b3-5bc2-4af8-9177-3204571a9aa4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/812d45c3-7185-4dc7-905e-5bd338d43a23"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e7ca84a-d30a-4259-94a1-1b869c4635a1"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eac81578-0332-445f-828d-360acee2f0d7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00067</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d19548d-b17e-43a3-a028-a0abaa980790">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22037a81-6976-4e7f-9be8-218389738dc1">
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Apo B protein level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98922c70-f9f4-4cc4-a295-a20c3ea6db5b">
        <rdfs:label>low HDL-C level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c2c9f85-5bd3-410c-a230-323a46df3243"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/580dbc36-65fb-4d44-8e40-be847c9e1f8e">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
        <dc:identifier>MP:0003193</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eebca7d0-99cf-4f70-a38b-642c05cc2dff">
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:label>low APO A level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a2b8317-9271-4d71-ae7a-343273f70e2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/714aa4c5-3d50-4284-81dd-d4791025425e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/295cfcd3-3840-4024-8a78-b2110d5d0998"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1dd9be5-c028-4402-9e25-dfe8e113e70b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28a81fd6-ff1d-42ad-89b8-e8c7e728e56a">
        <rdfs:label>dyslipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0003949</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2a7c650-a647-4d20-aceb-1be2cdbf19ca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6b12e57-55a6-4534-abc7-3b6a3f3e17a0">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05f72ca3-494e-4abd-9184-fd102457cb39">
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e0f9d50-2eed-4f2e-b08a-93e88003f660">
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/487ff6d7-0653-4c0b-8165-57c145bb3fbe"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/249900"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f4d3896e-06cd-41a7-958d-97ceb2db538c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5efa7745-d5d2-49c7-93a8-b10122d479a9"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42bd695b-9133-4b60-b6d3-bc07c5a0f870">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4bce0e8-6469-4072-9337-685255696654">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/278f208d-f5c3-4ffb-93f0-041001d61ee8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08fece22-631b-4b1f-b3e8-ea93c5e20787"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80f4024e-5529-4dad-b14e-d52b281a3f13"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Albiglutide</rdfs:label>
    <dc:identifier>DB09043</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8028c2e-06db-47e3-8a86-95afaab7a09d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb02cdf5-06a7-4670-8be4-aefb195d3628"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2955ad53-0dc3-41a5-b3aa-ac30a148223c">
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d8283a9-cb41-41eb-934e-f54a2ff4d1bc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e3ad8d6-bc1b-4088-9697-0e5d65afdbbc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:label>Poor swallowing</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf1b1201-8528-4eb6-9144-68321df0d137"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/915a9a15-e914-4048-b3ec-ae8872c7c296">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/deaab464-f734-4409-9973-16dd1b60d06a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cfc769ca-7434-45d8-8171-641e8a3ace19"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bd58fc5-286d-4648-b81c-16d89a882eeb">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dde73f74-f929-43ec-87e4-e28c4249aee4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001392</dc:identifier>
        <rdfs:label>Liver injury</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe6aea51-df34-465b-8598-c76dca58e306"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71811fdc-8353-4db8-9820-28837415a347">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
    <rdfs:label>Periodontitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000704</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8541f64-ef8c-47ce-99f3-f2c0456cf246">
    <dc:identifier>HP:0004359</dc:identifier>
    <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c8d3a20c-21da-412c-b1b1-df852f89d390">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/4ec81c4d-2410-4bc5-b9c0-829546b50344">
        <rdfs:label>functional complementation of a genetically defective protein + symptomatic treatment procedure</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6aeeef9-7f50-417a-978e-3111ffa010e8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abc8340f-fc66-41bf-a6f5-def716c359aa">
        <rdfs:label>Abnormal gait</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d27487b0-75d0-4455-a80e-d1167a3e6e19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f67edb4e-a3c1-4288-9945-31f06f1a5c1b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/553678f1-c0c0-40f4-b3c3-8cefe9e8f1d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/effa450a-fd09-4c20-af38-3320d7067d89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80a3626f-dd53-43ed-a7e3-cb9a6a32b838">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <rdfs:label>Osteopenia</rdfs:label>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19800b2d-6238-437a-99ef-1cac8e2dbd72">
    <rdfs:label>conjunctival irritation</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0030953</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62fe0e31-996d-49db-a164-ff455ad17d11">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Bacterial glutric acid production</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94f9e4b6-e7ef-488b-aa87-428e6183287f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <dc:identifier>HP:0006279</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27fae055-1de8-4b97-bcdc-538b4a3a0836">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48a8974e-56cf-4d58-9b2a-4127efdf83c6">
        <dc:identifier>DB00159</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5051dd3a-7c03-411e-a8f9-fee8f94b8dbd"/>
        <rdfs:label>Icosapent</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b1028522-c742-4caf-a0d3-b8fa5965f8c3">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa08f5ca-940e-47e1-ba88-08c1fd38aa3b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3db8e91a-9bc7-469f-a80b-278b2634a426"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d761ad8-a840-4397-bc9a-d4504457b0a6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27e8b6d8-a63c-4cb5-b773-b68f5061e0ef"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3ed529f-ab83-4666-b4a8-eead194f7f12"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>L-Leucine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <dc:identifier>DB00149</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1e841c10-11fa-4b25-8205-502e053c9a84">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97ac81f9-c58e-4d6e-84a1-06bf9a35ec06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21829337-123e-4356-b633-8f155052e6cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6887f81a-d4be-4c6b-907d-ff931df4be84">
        <rdfs:label>high fasting triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ddba7ef0-fed7-422a-a9c9-1046df5daffd">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27f5efa5-aff5-4870-92e4-ea1ae3a404cb">
        <rdfs:label>Fish oil</rdfs:label>
        <dc:identifier>DB13961</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9bc0a900-9fac-4b9e-9a81-749a83aafad3"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54661f68-2566-48a8-a724-3ae6573b66a4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe4990c1-df15-4dce-ad51-51ab2862019d"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6e34287-8fe3-4ec0-8b2a-6fa2d22885ba">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0daaccbc-2ecf-46a6-ac2b-827f77bb6f1f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/deb38279-33ca-4db9-9036-114d78922cde">
    <rdfs:label>high protein diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6278903-e671-47fd-8557-bd40e482973e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df8c0109-08b4-4fba-acdb-e4109aa4c401">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3938354c-ec44-4b8d-af89-c2d26fb713b0">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b057608-5467-418c-9cba-7828c2325817"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b0fc274-8958-4b5f-86fb-d6b0cc8ae24f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1805c702-2c36-447e-b219-c7f726eefbab"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Pioglitazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <dc:identifier>DB01132</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5af6e62b-08c5-4090-8c6f-5a9c1c322d57">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0012379*</dc:identifier>
    <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16841060-8d5e-4368-8122-0acaa77088ad">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7059ea65-6f87-44cb-bb30-6bb7bbeb79ee">
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d7b7390-da59-4b1c-b7c5-363e71bba158"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9201a68-f0b5-4e81-9b6c-ce3cf57717a2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/443c733b-9f60-4179-a106-74a7efb9b730"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1e10eb5-2663-44b3-8429-6e324b601dbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d9f3b5a-b2f8-4d52-97b8-2ff8e4ea39af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1bef80f0-45c9-44c7-a187-113b4f1a5326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb7cfc83-df1f-49ec-874f-5539e4af8cab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74c0c630-284a-4d3f-b73c-0e7ebc17c6e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <dc:identifier>HP:0010553</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/487ca2c0-fe62-401d-b16d-ad1c788038f3">
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f2047f25-10c1-4397-96b8-d45dd12d956f"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa6f15d2-89df-4c03-8fda-5bce842c0f34"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b940e095-cd0a-4ace-b594-2646f4f06c8c">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <dc:identifier>HP:0002459</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9170d275-0b2e-4123-b70f-3c7bf5ebdf6c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39dc9193-42c1-46a6-8934-784497798a75">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa6f15d2-89df-4c03-8fda-5bce842c0f34"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9170d275-0b2e-4123-b70f-3c7bf5ebdf6c"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/429657fd-c6ca-46a7-bdee-aa0353f24110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74c0c630-284a-4d3f-b73c-0e7ebc17c6e0"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b940e095-cd0a-4ace-b594-2646f4f06c8c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/487ca2c0-fe62-401d-b16d-ad1c788038f3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5fb381e-05e5-4f8b-91eb-2d4b19add653">
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <dc:identifier>HP:0008344</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f10eeb5-d497-440a-b4eb-052700655caf">
    <rdfs:label>Low IQ score</rdfs:label>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b36505d-670c-4c8d-b15f-ba734582401f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>behavioral disability</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71b16e77-8c87-4599-9684-e888ebbc1667">
    <rdfs:label>Linoleic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1126ea04-8868-4136-a6ae-36a52ed2d653"/>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43a4dc1d-10d6-4abc-85b6-0b0d22dfce88">
    <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c37cc9b4-57e7-4858-bde7-a60fd6ab95af">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bac543fb-ea4d-4bc4-801e-dfa20ac4b77e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum osmolality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b4bcbd6-faba-4f22-959b-ca7ee3a91f1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05a71b1-c61f-4ad4-be7f-0d8c5875c4fd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8add2af-775e-4b8e-85f6-6374c970953f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96ff9f4b-827b-41f5-8fbd-0c4323fd7f0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ab6f569-7cf7-46d5-a6dc-4e32667eb801">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d7b7390-da59-4b1c-b7c5-363e71bba158"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c236408b-6bc3-4934-a190-cbd59310b75f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1bef80f0-45c9-44c7-a187-113b4f1a5326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5ec0d32b-7895-4f5b-9607-e120a0e64ae8"/>
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/443f0c1c-1ec6-438d-8938-ed167328a9e3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f7b2ff7-a219-43f1-9825-9c3414d3f89c">
    <dc:identifier>HP:0000992</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>Photosenstivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f533a2ef-c6b8-4b60-b1e5-0af3df024da0">
    <rdfs:label>EEG with focal spike waves</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
    <dc:identifier>HP:0011197</dc:identifier>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66648191-0d56-44da-9c41-1fb2fe2efbff">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/855272fc-4109-445d-8915-29d1d4be33f4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9e679b-9182-4d25-aad9-0265d2a34407"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
        <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d31176fa-ea59-4767-b73a-05ff48071a56"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a27d794f-9a92-4b96-b941-f5bbb32d1892"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Colchicine</rdfs:label>
    <dc:identifier>DB01394</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c125464-06ca-4cf2-991f-192e814e6eeb">
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba77e313-21b7-4276-a145-4f169c95c829">
    <dc:identifier>HP:0012030</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal urinary steroid level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/129b488c-a9e9-49b0-8567-add99f0a3074">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff80535b-9fa1-48da-bf31-d4b5f21b6b84"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc904b33-af09-4626-9a46-5ad82ce84a4e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8906584e-899a-41d1-b5b9-f1f366ae7ef7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0368271-a416-443a-bfe5-6fe479851777">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <rdfs:label>Bromocriptine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f23770a2-8dda-4c35-9013-38b93b401109">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b940e095-cd0a-4ace-b594-2646f4f06c8c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dfee4dd-e600-4ee2-ba77-a592db9d4df6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c11908e-e18d-4ca1-b20f-827b206b576f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68c40cad-5286-41e2-b774-2f3fbda3127c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9170d275-0b2e-4123-b70f-3c7bf5ebdf6c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e5a47c8-8547-4df3-9ffb-267e42ffadb0"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a5255a8-894c-470d-8f40-c6af82fd4a59"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18da7944-80ba-4245-a3ec-59d4d0a2299e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/281f029b-5579-427c-ad5b-f135906e50b6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/311f7a89-1cbc-4d0b-87e4-d391d279bdfb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01200</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/063f14fa-016f-4bb3-906c-d054a78ba033">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8b940f4-9d65-4ba0-9b06-510eb0e2fda6">
        <rdfs:label>Poor eye contact</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/750826ad-eacf-4ad9-8978-36888729bfe8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8c7fd582-6767-4e56-90ad-70f22eb3120c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95b3fb03-e82c-46c3-942c-b44bc1ea37e8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d94b9c41-56fe-4e8a-9aeb-796efe423879">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0738c69-6bb4-4789-a2a9-392bcd5890ec">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e970890d-b4be-45b5-9f7c-fd8c8093a6fa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf19b3bd-c748-4ba6-994a-c3f5470af27a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe157c11-ae23-4bba-a80f-4c2b4d0a5db5">
        <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2269de39-3109-469b-a3d5-0734d07718be"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a38581fc-4660-4c5a-a9c9-9d286ca6a15f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/503baa53-1882-4480-a8ce-75fdeaf88d9d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34e459e4-736f-4383-b9f0-0e79a090043b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9aba3d03-477a-45c8-912d-902072453138"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72971a2c-0aaf-4286-badb-53448dbca572">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c91c7981-0669-4178-b802-0bf221065529"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e78bd70e-0933-4c5c-af05-e248b22ee40c">
    <rdfs:label>dysphagia</rdfs:label>
    <dc:identifier>HP:0002015</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/830b2c16-d5f9-4766-b0d8-9914f32b9602">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78001d9e-1922-4b0b-8b01-cdaa6fcdad74">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <dc:identifier>HP:0003165</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54bf7d6f-a1ee-4014-a253-ebd17432ae40">
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
        <dc:identifier>HP:0003072*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c45f49d5-cbac-4a72-b75a-ddf48204bf34"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48283160-7617-4978-a686-fbd61091f85d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
        <rdfs:label>low calcium urine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003127</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/23ffe525-2704-470d-9af6-b8a98d728cba"/>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f77685e2-2ee2-4f1a-8941-c448415a0641">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ff75c6b-8b2e-4cd6-bb8a-fd52f4584256">
        <dc:identifier>HP:0005961</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Low plasma arginine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14087166-6187-4a71-a8d1-aa66d9ba8c73"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d072c27d-1b77-40a4-b656-e0e22cee7a2a">
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <rdfs:label>Acute hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9174de12-8607-4af9-b4d7-abece01f54c9"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ca324de-6787-40de-81f5-04aa020085e6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6c06fc4-39ee-440c-9bf2-2270961bd1b4">
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/701cfde7-f962-4b3d-9063-4e06770aebd1"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/795b044a-bf26-46a1-acde-2bb59b6af9b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7b4d948-3694-4500-824a-e7c852dfdc42"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac2904d5-a061-448b-92ab-6af6b0156903">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e709a3c-0ed2-47cf-ad35-148338fd9adf">
        <rdfs:label>tachypnea</rdfs:label>
        <dc:identifier>HP:0002789</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87cb5e51-37df-434f-828f-49b607fb252a"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa29e659-3fe4-4a4d-aeae-c67f38e02963">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>congestive cardiac failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4dc45a57-9986-4a1b-8246-c61a83434219"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5141558-8559-4e67-9811-eadd9740685c">
    <rdfs:label>Orlistat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d145ae47-018c-48db-b94b-08416bc5589e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45beebd8-de44-42d6-a107-7985c15b238d"/>
    <dc:identifier>DB01083</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df7b9baf-39bc-4b80-881e-184c177ce245">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c467bcd-9515-4eb6-8e9a-bf10f7a4836d"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e7f117f-3a2b-46a5-a66a-af2e70562013"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4fa2f7e5-17ee-487d-b755-97e5c38bae0d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04ff0584-9b82-45c8-8cb5-5e84b019bb38">
        <dc:identifier>N05A</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/175745c6-ac7e-45cd-8dd8-446cbcd2e5f9"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c98ecadb-3ebe-4f42-99b3-fc9d5511dec2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4af0564b-603e-4121-b6ee-7ecfec30739e"/>
    <rdfs:label>Nifedipine</rdfs:label>
    <dc:identifier>DB01115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba3bfdbd-1d75-485a-916a-8bca259f612c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/49c963d9-0552-4448-b7e3-84ea1fff7892"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/386ce69e-71e6-4d51-94a7-5dfcb93cba74">
        <rdfs:label>acute arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8d9fed67-96b8-425d-bae7-a5156d13f176"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f826ee2e-a0a2-4710-9089-68e45d2a9944">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bb0d198-28aa-45af-a229-92fde51e6e07"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c3af28c-db5a-42d2-bf3a-4f98c5dc29d3">
        <dc:identifier>HP:0003648</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high lactic acid level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f470fb25-71b2-4f75-aada-ca8f78ae890d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92fa5b73-a402-460e-862f-e47f621cff9b">
        <dc:identifier>HP:0010919*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea4e90f7-8d03-4a0c-b560-b509bd661375">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36a0b866-055e-4fe9-b39e-3268051e9dc1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e5b9b92-820a-404b-b950-783bd580a75f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe0abc09-fcd6-4ca8-9e8a-86ec6d681ca7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e99c88a4-e725-4cad-a528-7c76b465ed4b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/942c1e09-e42e-40ad-86e5-b177b1075415">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/794408d0-93af-4971-9b2e-7e4660c981a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d23704bd-c4bb-4f30-8db6-fb47c94d3db5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Developmental abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
    <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e8e3443-295e-4543-b69c-5fc4b9f6aac5"/>
    <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24213435-4054-44e7-9956-46441f55a45c">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
    <rdfs:label>Hypomyelination</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0013438</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc1b1bba-53d0-4af4-83de-99f1cf68cd5b">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <dc:identifier>L04</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87ebbc42-a484-4a71-b153-aaed61d6eadf"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4331bb34-f057-4bb9-ad12-e47f58d50dc8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3233f4fa-8752-41aa-94e4-3572b791e801">
        <dc:identifier>HP:0012187</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63117bcd-b3b9-4d8b-92bb-e83b5177c37d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32dae1b4-c9d0-4f9c-a1e0-6794a34ff080">
    <dc:identifier>HP:0001877</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
    <rdfs:label>low RBC count</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5996e0bb-0597-484f-ad6b-19cf8cc8a9b6">
    <dc:identifier>HP:0002311</dc:identifier>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
    <rdfs:label>incoordination</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d8f5bb3-9688-4e17-97b7-fa07ebbcf9ec">
    <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>done</dc:identifier>
    <rdfs:label>Hypertriglycerdemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bd210e3-fefa-454f-996f-7746beff595e">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e04f6ed-e035-4569-a65e-2a65991796e4">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ee6ada3-7fd9-478e-8fe7-9d609b92dcbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f161b79a-291f-4a75-90f8-01b90144a3a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02158c0d-3c0c-46c3-8f82-e6e7ffc11d4c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d903784b-9736-4c04-bdf3-b87b09cfac55"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efc92855-af53-4c4a-99fa-97c81e3dd538">
        <rdfs:label>sleep cycle disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b018e78-9adb-4d1c-a991-ea3e4beda783">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8860c86e-c29b-4f37-a66c-902b047b5f5b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/512491f4-9f78-4a4e-82f4-6f323bf45dce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/38bb610f-1569-4e5e-9a31-bbc6fb8e5e2d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0dea70c-a324-44aa-87f6-5ee10c108414"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/515a0570-36de-482b-866b-b8503c341743">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/468e321a-3d29-41bf-9199-36955e130df2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e02b03a0-5333-4c77-b0ac-65adeb2b949c">
        <dc:identifier>HP:0000648</dc:identifier>
        <rdfs:label>Optic atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/645bbf35-dc68-45a9-89f4-f9300b41525a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2dffbd9-e3f3-43d1-af36-ed691a4e979e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a06bca8c-7eef-4f9c-8f57-fe6795c525fa"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/601a0b23-d67c-411d-aa51-9e6fec88adbd">
    <dc:identifier>HP:0003547</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003547</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33c76f61-8da3-495a-8a13-9c3e11730979">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eac429a4-01fc-48e7-9e04-7cf1e93229cd">
        <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
        <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
        <dc:identifier>DB04159</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b72c2ee-1dec-4b9b-b6d0-d2751645f26e"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/756111bf-9a05-49e5-a29e-c9f33c8cf3db">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0100543</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:label>cognitive impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf5cb5b8-f857-431a-ba1d-96dfaadc1d0c">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698727a5-93b1-4cc9-b0a1-8cefb8b6c30e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9808c63-5f0f-48ca-9ac3-053c2823f063">
        <dc:identifier>HP:0001931</dc:identifier>
        <rdfs:label>hypochromic anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4aeed686-a74e-433a-bce2-1c82028011ad"/>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd5ad52a-3a8a-43e5-a0c6-4e765ff3148f">
    <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/796f9fc0-43b5-4087-a9e0-a0c41dc409f4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89a68f7f-163c-4ae4-8bd7-3d75234f7e9d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9407b757-02eb-4a09-9715-8d98f4d7e7af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab9e0d45-6a70-4f7a-b863-16684a7bf0c4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Prednisolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d415c1cc-d0cf-45ea-bb7a-6be573caaa36"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71680fb9-cef0-4487-9d2a-a50fda57c931"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <dc:identifier>DB00860</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e46dc25e-afb5-47ef-bab9-f4adff6cd6f9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0030390*</dc:identifier>
    <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1dca887-44ee-4954-8ef1-6c747cf73138">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/909cc698-086f-41b3-b302-54ab21e4e997"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24d71e6b-d847-4eb8-9b8a-e9c5b5a18c58"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebe9d9a2-8447-4e49-9302-165a33f56fcb">
    <dc:identifier>HP:0012759*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69c6adf7-f766-48f3-ab9c-6ef21c3c62e8">
    <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001712*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3d2e467-9cfe-4086-b53d-83435ebf2957">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/997e3080-23f5-47eb-acc9-c3e2a90a3734"/>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/513f5d87-3e7b-422f-8de5-71afc4c0948d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a7209044-81d0-4fc0-b7e2-021d565fbea4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/010df0dc-4ce6-4146-ba6e-55731624187d">
    <dc:identifier>DB14307</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <rdfs:label>Green tea leaf</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e511314-7f43-4fbd-ae60-19cc11915c3c"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d97e1b9a-62a1-4ffc-9cd5-b8d5e6ef0486">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08fece22-631b-4b1f-b3e8-ea93c5e20787">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <dc:identifier>HP:0040217</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3806317-819d-4119-8fb6-359bcb70329c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <dc:identifier>HP:0040300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c60c562-e373-46e5-a638-8f92f5d90a08">
        <dc:identifier>HP:0000287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high facial soft tissue volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80f4024e-5529-4dad-b14e-d52b281a3f13"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d2d7926-2d96-49b6-bda4-11911fc62bc9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dccbed26-b0b7-41cd-8377-5dad8d6453e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e37da3b1-5565-4fc2-b231-f98dc0d6b42f">
    <rdfs:label>Tocopherol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12970230-200f-4281-b49c-1e3a00330013"/>
    <dc:identifier>DB11251</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8f4d743-b8a2-4b52-ab1c-b183c7810bda">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf19b3bd-c748-4ba6-994a-c3f5470af27a"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2269de39-3109-469b-a3d5-0734d07718be"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0738c69-6bb4-4789-a2a9-392bcd5890ec"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c30e6f30-96e5-4dd8-b298-f7248201a8b5">
    <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6db9ddf8-1ac4-4b1d-bcb3-74527e6fcd9e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
    <rdfs:label>disability(Functional motor problems)*</rdfs:label>
    <dc:identifier>HP:0004302*</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cecb2e47-fa47-4453-853e-c7d3bbd9fcf1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f03fe1f-81b4-477e-8959-b9036078a425"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e21b2cb-5814-48ec-b795-67d30e0df87e"/>
    <dc:identifier>DB00877</dc:identifier>
    <rdfs:label>Sirolimus</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d27f3565-d41f-4059-875d-3e971a08a4de">
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ce25046-55cb-49bb-8f7b-0837ed4cfd28">
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>Oedema</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f968b012-fc47-4a54-87fb-4f4879a1895a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b244e23c-339a-4f8b-947f-bb6d161bda55"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/37998eba-3ad5-4d43-bf43-5ea8f4153616">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4af9ba05-54bb-408f-a675-9c372486d4e9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00bae8f3-0c41-49f4-a9a4-1f979b0be10f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78e8cfd4-fb40-494d-8141-ec6496ad38ea">
        <dc:identifier>HP:0000657</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Oculomotor apraxia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9270b9b-a01c-4e8e-a8ce-ee1b7b87b091"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1faff951-d0e3-405d-ac41-0ccfa366b42c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00b977fe-7bcb-496c-933d-6ab91e9ddf8b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4699bb7e-244f-4f21-8070-146e92f911e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5dcd685-65eb-4ae6-bd37-78262ed08eff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8aad4c83-2a7e-4788-91b3-ec66fa284a04"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dccbed26-b0b7-41cd-8377-5dad8d6453e9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <rdfs:label>Metreleptin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d97e1b9a-62a1-4ffc-9cd5-b8d5e6ef0486"/>
    <dc:identifier>DB09046</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f24e8ee-6b65-43ab-8323-dc5f07d7664c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8681660f-2bf3-40a1-b882-d8151e7424c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
    <dc:identifier>DB00829</dc:identifier>
    <rdfs:label>Diazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/053793fd-d585-48c9-839b-74bd2c6dd08a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5f0426e-4cba-437b-ba20-cdb648e2f5b2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df7e52a2-b11c-4e76-a1f4-e038f0109d2e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/148377f1-66eb-4d3f-9549-8bd459adb92a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5dbeec45-fb59-407b-af78-fcf5a21936cf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4870f86-2458-4efb-abd9-c22e447c5dce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d604178b-df28-4297-aa69-a7e6d7177e7a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/b01f18fc-c924-47b5-9782-21279ccf83e0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70cb3107-4f63-471f-97ff-2a391df48970"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00419</dc:identifier>
    <rdfs:label>Miglustat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07c832a9-4a59-414f-a8a2-f0c57f310c3f">
    <dc:identifier>HP:0003362</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2109bdd-4ae7-4649-b46a-1d19661df69f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e71497d4-7404-4be6-9824-506198b8956a">
        <rdfs:label>Probucol</rdfs:label>
        <dc:identifier>DB01599</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf1b7ac2-01d9-4c6f-b9d5-8a6f88346d85"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37a488d3-be80-45f8-aae5-e8640ce6e7d8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <rdfs:label>Tazobactam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e5d07cd-cf15-4d33-84a8-da6415b693f1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cff3a9d1-6a7e-4316-848d-374b6fbb657c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c84068ad-6232-44f6-a0db-0d2b90f86053"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01606</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3226c019-6805-47bc-ba5a-0621e4b54aad">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88e8ca38-d858-4495-9489-61d58456b0c5">
        <dc:identifier>DB00458</dc:identifier>
        <rdfs:label>Imipramine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5ff5bee-0eea-4517-a4e8-00feb5ec5176"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db49e8a3-8308-4b0f-b245-dc7c5a62dd7a">
    <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
    <dc:identifier>HP:0001336*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fc8ee83-21ef-4891-b1a5-4b8117bd3d30">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hepatotoxicity</rdfs:label>
    <dc:identifier>HP:0000989</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9eead25-7f70-4569-a598-e14c780f7c59">
    <rdfs:label>fine motor dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007010</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95325baf-176c-4623-a3a3-1d035d3f1722">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26ec64d2-138f-4fc9-aebd-d6588c6ae6a9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18393cfc-95b6-47ff-84b8-3af177ea7baf">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e7ba1ec-3008-4118-9181-bf37f6fd8a56">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55494656-8bb4-4ff1-81af-0beeafe00a6b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23926b59-fde3-49d8-9957-2d1d95f0a99f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b305c52a-bf7f-4105-9525-5fa2365fe803"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <dc:identifier>DB00034</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ad82a62-c450-4afb-8c1d-13299a250832">
    <rdfs:label>Puberty and gonadal disorders</rdfs:label>
    <dc:identifier>HP:0008373</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/005d3a6d-d6f4-4418-93e0-741d49651416">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/143ac8cd-2ec4-4667-8593-56b3a0931fa6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/891baef2-5e17-4140-8794-938fd685122d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46433609-65eb-4fa0-887f-42ec25a0a316">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/034104a3-2217-4203-9328-72bbd88960c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fbe4aafe-fe7c-48e4-bf4b-1943f2561d01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53004509-282a-4a31-85f2-3e3616d1e588"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6c6e6ab-f19b-4777-8224-255522e40420">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
        <dc:identifier>HP:0002066*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/341358bf-b65a-428d-b429-f0eae85cfef8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c995c1d6-4dac-4311-b493-1fcf64c04e63"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/568f60d4-0e6d-424a-9199-c6799372d6b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e97fa4a-b2e3-43d1-a633-780802b196fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2345df56-2921-42dd-b630-9d2f50237e86">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <dc:identifier>DB08834</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc54e79c-fe1d-4dde-91b8-874e4c11d87a"/>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bdfe0a6b-bfbb-48b4-914f-a49e65e63581">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e11979d-69d7-42ef-b2b4-1c7e2b09f8aa">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <rdfs:label>glomerular proteinuria</rdfs:label>
        <dc:identifier>HP:0000100</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d6b1153-cab4-4444-ba86-28ff9f0e3499">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3daf4cbb-c65c-451e-b011-9d3a001c6b29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/679b9089-08fb-4af7-9fa9-2de29b62b045">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:label>Albuminuria</rdfs:label>
        <dc:identifier>HP:0012592</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8833bd30-8bcf-4960-a0b6-ec95a04ea7d3">
    <dc:identifier>C03</dc:identifier>
    <rdfs:label>DIURETICS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac2904d5-a061-448b-92ab-6af6b0156903"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04ab218a-bd05-4be4-b58c-beee75725945">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de6d3048-4b4f-40ff-bb56-5aeaefece42b"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8c3ad1c-d2b3-4d99-a16f-6d7fc3161581"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ced57d6-aadf-478d-a1d2-2551b602c46f"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1799d069-a66b-4ebc-b76f-b9dba11505df">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0000002</dc:identifier>
    <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/808412f7-53e1-4f83-aeee-ed1cf04d094e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a8b9b98b-a892-4806-8e3b-a0c16eab7489"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b057608-5467-418c-9cba-7828c2325817"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e02bde1c-86fa-4b1c-82e8-7affcad3b49d">
    <rdfs:label>Aggressive behavior</rdfs:label>
    <dc:identifier>HP:0000718</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8c7fd582-6767-4e56-90ad-70f22eb3120c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/063f14fa-016f-4bb3-906c-d054a78ba033"/>
    <rdfs:label>Fluoxetine</rdfs:label>
    <dc:identifier>DB00472</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0736cda-9935-47f2-a990-34803b9fc6eb">
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa9dbe22-e791-4ac2-8209-b4bcdc970d61">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/17d4b5af-1b25-4826-ba0c-64466e264163"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c209bba8-62a6-44da-b3e1-b2874a24bcba"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/8f719191-8214-406b-b3ed-ca96ccc431cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a14c0c67-8c73-494b-8713-59c6c6b8bf14">
    <dc:identifier>DB01306</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1f89eaa-73a3-4705-b429-21c5e873c8c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <rdfs:label>Insulin Aspart</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2de8cc73-3955-47d9-a684-a6a554b907ca">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02ec64d4-de8b-47c8-bb5b-53633a14fab1">
    <dc:identifier>A11EA</dc:identifier>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16326d54-796f-4d73-9f7c-e06a0260c6d0"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a5bce75-f73e-463c-ad61-16dd4b33ca56">
    <rdfs:label>Gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4421eaa-a1d6-4eb0-8cbb-e88e84ee41b1"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c475fa2c-64d1-4091-9f49-0ca991b3ed67">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41343e19-dd90-4584-92ec-6d78884cc995"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d983150-6be2-40d7-9609-612591cdfd5a">
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e94ec49f-b826-46b7-b442-6e9f33adac1a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c0c6e79-96d1-41a6-ac73-36838ab91b38"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2cdf322-232c-4d3d-a916-6315bb4aa443"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dfbc245c-72a8-48ce-bb06-a132e0df9062">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6e34287-8fe3-4ec0-8b2a-6fa2d22885ba"/>
    <dc:identifier>DB00360</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60ca7b65-eb1a-420f-8797-6737df6ec0a1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d5b8105-9244-4ff8-87f1-21b853998155"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60b88e00-19e6-4c00-933a-effe4c268dc5"/>
    <rdfs:label>Sapropterin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5eefb80-ba55-4931-9a31-1915235c01d4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63aa0f57-9576-473c-93b3-c511b9fe9edb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b21735e-2fc0-46a2-b95e-108a97d4b22e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c0c6e79-96d1-41a6-ac73-36838ab91b38"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f37bfbe-4d54-450a-afd9-65ad96e5fb51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-012-9506-x</dc:provenance>
        <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93e1c6ca-9fcf-4c19-b4ff-0f3f587b2966">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b21735e-2fc0-46a2-b95e-108a97d4b22e"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
        <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
        <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0121293a-14ec-41c1-a250-311f8e3724f2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9dfe0f70-c935-4322-a1c2-6b0ecb51dc75">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58e539b5-dec6-4679-91ff-006273e93716"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edcc86a6-11c8-4cfd-93bc-0d7e068252fa"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91876e16-60dc-444d-91b6-b4543534f8a6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
    <dc:identifier>DB00098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc0cdc80-05c3-4f57-8681-5c150486a171">
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>growth delay</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2cf3933-8977-42bb-8e4f-005075082377">
    <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
    <dc:identifier>HP:0002630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/772e9068-1c36-4edc-9ea1-22680c08bf28">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/086baa2f-23b8-48e3-866d-316c41901e40">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6fdf1ba7-f67b-42c7-a25b-4cfd6931199c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2373adf2-4be0-4cc1-a641-a88112268008"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54072383-9c08-4719-aae2-d0feb69f86f5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7bcae814-2a38-4786-be23-7f5a6744288a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39701c0a-0448-4f52-a016-d23ea50ed44d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e55102b-c2b6-488d-872e-cc5cec4c3c51">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Low muscle mass</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5ff5bee-0eea-4517-a4e8-00feb5ec5176">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26bfea71-cea8-402b-b46a-31f3da1d5651"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/588dd572-4ad6-46e3-b486-94fd033333aa"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9e3b2ac-fd38-4899-98f0-f8299d68bf46">
        <rdfs:label>Diabetic polyneuropathy</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0001271</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3226c019-6805-47bc-ba5a-0621e4b54aad"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c852d06-f279-4c5b-8743-6833f6ead59a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7c9568c-1aef-46ec-ac63-b6d1ff710e21"/>
    <rdfs:label>Eculizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f8d0a6d-ea33-4766-b4ee-87c7fcff12dd"/>
    <dc:identifier>DB01257</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ef8b194-0ae7-424b-9f98-ca3625a626b7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93378e99-9186-4944-901c-b53d05145018">
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a50c806-7636-4c89-8f80-954eaebad50c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f34b2732-f9ad-4ba2-8bd8-701f83aca20a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab6a4b2b-d5ca-4375-9ca9-ac25d994cc08">
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
    <dc:identifier>HP:0000467</dc:identifier>
    <rdfs:label>neck muscle weakness</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54657026-3241-49e6-b073-874e7d2e87c7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25248365-1089-4d86-8d40-52978c6a3f6f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c12de0d9-0600-43fc-a59d-5f90be52902e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d27b83d6-c0d2-4f13-9a57-c1cc7ecfc4ad">
    <dc:identifier>HP:0004369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>low levels of purines</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e24d2a9-880e-4986-9939-325b4b88a5a9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd352662-6686-459c-83e0-42ec2d90dab0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5206e3e4-ce91-4398-9fdd-ed9c699cd2b0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7521ca0-5b91-4551-a43f-51d7b2160f45"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/588d649d-4875-4fd5-9276-0fb631fc6aee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2019216/pdf/archdisch01582-0040.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7aaeba3-5dce-4156-9692-2edfefd42183">
    <rdfs:label>Poor fine motor skills</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0007010</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5316767c-5592-4b1c-8e95-d8900e29b165">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
    <rdfs:label>Retinal degeneration</rdfs:label>
    <dc:identifier>HP:0000546</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6d875f4-cddf-4625-9bfa-b0dadb3fe341">
    <dc:identifier>DB00175</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fb5a1bc-ddd8-466b-baaf-a6deafa8d0bf"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/928e1e5d-90bb-4285-a05f-e6b1d391a1d8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ab03456-e68d-42ed-93c1-c80fd0c611fb"/>
    <rdfs:label>Pravastatin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7aea0673-6b24-49ed-8d30-d1b0b37f7b09">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7268bcfc-ab91-4308-9581-c93c32de6d6e"/>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <dc:identifier>M02AA</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9eb33cf1-41d1-4bf1-af0f-c5d264c80c3d">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79bc5186-a365-47de-9595-14ded316663a"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dadbb235-3ba1-4281-8404-7963b0010de9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee2f3c82-fb41-4035-835e-5a3895ab609a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/927ce464-9f18-44f7-a973-4c24934a8648"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41b65e68-e09b-4804-9ddf-6653c4d21b52">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d6ceb86-c9c2-4407-9205-45213248149d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8710776-8fef-4496-b304-b09a1d2d46b3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7a2df6d-b822-4302-b321-cc5415628028">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Increased urine output</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4bd90df-9127-400a-a822-fafe7d3c4e0c">
    <rdfs:label>Low HDL-cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a556d70b-30d3-4526-ac2a-91858e0ab02c">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d27487b0-75d0-4455-a80e-d1167a3e6e19"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26ec64d2-138f-4fc9-aebd-d6588c6ae6a9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7515f73b-02d7-491f-9d28-b3d35cd29f44">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2033930-ef5e-4de8-b364-00eaf2255e5f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
    <dc:identifier>DB00123</dc:identifier>
    <rdfs:label>L-Lysine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04fb05da-7116-477e-946e-f718dd4e4234"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90d77ddb-4b1d-41b9-894d-ca35c82d670f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07e68714-89bd-440a-8e85-720be27ffca8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100725</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
    <rdfs:label>skin thickening</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1236c634-0010-4f5f-b240-e17387e23198">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/006a7c7a-25be-4da4-9e00-d27801dddc9f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
        <dc:identifier>done</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10485fb0-3189-4d34-ab8e-a996e3e44151">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b02d5c04-a5ee-414f-a885-a66f819e6fe4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4b1d1b6-3c5b-44d0-86a6-5f2d3ff2f59e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d2b4f7a-c095-47fb-8944-2be18fcbb606"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/034104a3-2217-4203-9328-72bbd88960c1"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241200"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71cbc3b3-7367-4061-850b-b1b9d78b5bc4">
    <dc:identifier>DB00232</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
    <rdfs:label>Methyclothiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13518389-b182-462a-9191-903f07924f7d"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
    <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c73216e1-b548-40bb-82de-d8ca89c631a3"/>
    <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57db16b8-37fd-499b-acdc-23cecff9cfa1">
    <dc:identifier>MP:    ....</dc:identifier>
    <rdfs:label>overall survival( premature death)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
    <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e523d46a-92e7-4ba6-813b-78c33f9fa45d">
    <rdfs:label>mitochonic acid 5</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fdbf46c-9974-40d7-9b1e-6ac82d52805e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50ca0dfd-1d35-4375-b98d-f8789c89b428"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff80535b-9fa1-48da-bf31-d4b5f21b6b84"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef345ff1-7a3e-420d-8237-4efe303938db"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d1a8cc4-0977-4eb3-b20c-7158e8d2a464">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lower limb pain</rdfs:label>
    <dc:identifier>HP:0012514</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfa32beb-d7f4-46e4-9bdc-07102b716beb">
    <dc:identifier>HP:0000992</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>Cutaneous photosensitivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5f7014a-77b9-4d72-b546-7c213a078c54">
    <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
    <dc:identifier>HP:0003077*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b105fd8-1c3d-48b6-baa4-e27a7a02c7f7">
    <dc:identifier>DB01325</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <rdfs:label>Quinethazone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ae31e253-27ab-44b0-a3b8-544ca568327e">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ffae80b-fbcd-470a-9348-702c77ae3734"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/165b6b09-fc5d-4938-97af-1769659fecee"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa76922c-a0c1-42d2-a263-8238fb607036">
    <rdfs:label>Difficulty breathing</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002098</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eac96051-3234-4f89-9fc9-4af70d5be8ca">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8fc359b7-a441-47b9-ad28-723e6e87d2bb"/>
    <dc:identifier>DB01037</dc:identifier>
    <rdfs:label>Selegiline</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01676cdf-33e8-4942-873c-e666c55ad794">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f083760-52e4-4848-a976-f6aac22fea52">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66897cf6-2f0d-47cc-9485-9942fdadb1fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eae3e312-a64e-4996-b43f-36549f5dbbdc"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6181e130-a5cd-4719-9b12-9cb535d2a86d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/865337a8-3c65-4c80-9462-323a95db861f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a47e1c83-b232-4401-bac2-bb88128f2ba5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e7ad88d-8621-4eca-a270-b5282ebc199a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b08fe47-5c24-4b99-bdc7-ae3ddfa3c711">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
        <rdfs:label>Hyponatremia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002902</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee147154-77bf-4651-922c-57c9d57e76a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d8f5bb3-9688-4e17-97b7-fa07ebbcf9ec"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c0c6e79-96d1-41a6-ac73-36838ab91b38"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9448e67a-296f-48c9-a134-88ec72b08dec"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6c3cf4e-bd4b-4b60-96d7-04bc2e182b22">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29164d27-ffcf-496e-9944-5314363dffac">
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>involuntary movements</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d4baaed-c7a2-4b00-adec-ece3c83dfbf6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f4fe280e-24f9-4f75-a65f-8b03c03709e4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5b8dc1-8c19-4873-882f-9934dfb2311f"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04bd4b5d-7c02-42ba-bdce-4e7d7733d0f0">
    <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/baa835a9-1b41-4552-8015-2853e5909dc1"/>
    <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
    <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9444ea1-193c-419b-9c90-ee8824d1510f">
        <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b542534-34ed-4fc5-9bf8-019ecaf4847b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <dc:identifier>HP:0004359*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b305c52a-bf7f-4105-9525-5fa2365fe803">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18393cfc-95b6-47ff-84b8-3af177ea7baf"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3bcaddd-170f-4f15-ab96-32342835b304">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/925b7c3f-bf94-49c3-985c-f3561fd7d397">
        <dc:identifier>HP:0002155*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79c73aca-41da-479e-bdae-b0ed5edc36e9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8eaecb94-dd0b-4875-9244-3fec7feb1841"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b78e67c-6b89-4d6d-a5c1-d64b248ada01">
    <dc:identifier>HP:0012535</dc:identifier>
    <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9629ff0f-4245-4908-9821-6177c667c3ca">
    <dc:identifier>DB05990</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7fea1e4a-c53f-4e3a-862f-e7fd34da9bfa">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13632c8f-a511-4866-a36f-bd3f82a79d1d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6081eae1-4da3-445e-88cb-09e08389f2df"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5f7014a-77b9-4d72-b546-7c213a078c54"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Obeticholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3daf4cbb-c65c-451e-b011-9d3a001c6b29">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdfe0a6b-bfbb-48b4-914f-a49e65e63581"/>
    <rdfs:label>Spirapril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <dc:identifier>DB01348</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4dafee37-1a65-43ac-8b91-33f5f6d08a0c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39ad295e-8a6f-4323-aca6-2ebb670495e5">
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e58efdac-b25b-4248-9b07-7792e599e7fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea9421d5-7c35-461d-b8ae-055e6ebca3bc">
    <dc:identifier>HP:0002344</dc:identifier>
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7448828-65fb-4e3d-8b8d-be38ecee9b14">
    <dc:identifier>HP:0040087</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:label>Abnormal serum folate</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ca4df98-7114-4bbd-8145-2b26356f7460">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002872*</dc:identifier>
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eee0ab42-8ca8-4c85-a332-2429d7f56559">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06349146-48b7-4378-b611-339f0c8fbce7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70667afc-22ad-4927-ac66-839c41ce9036"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ba569cf-db88-4dfe-8764-13ed95f7638a">
        <rdfs:label>Rickets</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002748</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e2187469-8abb-4afb-bef6-2198b8dd7090">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c70db816-3e3b-4d74-8328-8e5c34524c16">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5316767c-5592-4b1c-8e95-d8900e29b165"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0891584915002671</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56327c8b-c5fc-4c2d-8f5b-56b6d3303282"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb7cde19-d899-4a38-8ebd-7cbb7c622b91"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39bf3cad-ca43-487c-82a2-e6917a921243"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17885562-f91f-4976-9a9c-3e08db261a88"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95325baf-176c-4623-a3a3-1d035d3f1722"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3673e529-233e-4292-9e7d-f8d9d67665b5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1083b05f-e867-4aee-8c0d-e4fa27336e3a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c203f38-011e-4d95-95da-1a55de778d99">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9749d11f-a1ca-4a20-bd7a-d3a63de97968"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a9eac6e-4a47-40c0-ae54-5c54e436c9ef"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00163</dc:identifier>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e53e8efe-9323-4f96-9fbe-563a6862deaf">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a3f6eae-affc-4ba6-804a-d2d16cd21634"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb3285dd-43a0-4c5d-9733-f17f87751759"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1956873c-f784-4c11-907d-a39fbc46e93e">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae40df65-bd67-4943-a763-a575966e62ee"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83670053-70b1-4076-a9bc-04e12f4e9090">
        <dc:identifier>HP:0004387</dc:identifier>
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2679db3-3dc8-4e7a-924b-031d1e812258">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c681599-13b2-4a84-941a-e96f91ec55b2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6044241f-b668-4da2-ac85-090fa978cbb1">
    <rdfs:label>dysarthria</rdfs:label>
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30f57f99-b14b-43ec-a883-b0a1d970dc06">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75bf35c7-2364-4c16-ae24-30db0992c045">
        <dc:identifier>HP:0012238</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d14d2b70-9e04-4684-a7d2-4f4531687844"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68a5e8f5-b802-45ef-82f0-51a38258748d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d9c7c3e-dff8-441d-b30e-53e049d40bed"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/802c29e8-fa01-4945-a2cc-495caeb504bb">
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
        <dc:identifier>HP:0012238</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/deb1c93b-743a-46b1-ad0e-47bbec9b3041"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a3a3f8b-3663-4807-b34b-5f284fd6d70c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/956b9472-af6d-41d5-812b-d08f0b4d9c0e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58dbec4c-17ce-4d09-b32f-c70a2f0920a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/580fd404-0e13-4d6a-9724-5eb299bd39f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a68ca17-5bc7-4412-85dd-334b23b2224a">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/8f719191-8214-406b-b3ed-ca96ccc431cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6e8c2ee-7fc5-4e96-857f-411a87a6fc73">
    <rdfs:label>Inositol</rdfs:label>
    <dc:identifier>DB13178</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63c407b3-e0be-4ddc-aa61-42a3d96ac187">
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/361329f4-3e2c-411c-bfa0-599b742d5f20"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f30a351-d485-48ea-bece-24613dc3a664"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f899bb2e-fb37-42fd-ad74-89785faacfab"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/320d4840-eddb-4d5a-aad0-8f34c69a49cf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neuronal vacuolation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43e19c26-6022-4ada-8824-f562ba998c9b">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dd23055-c3aa-439f-8f2a-b69f918907b5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-017-2365-3</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698727a5-93b1-4cc9-b0a1-8cefb8b6c30e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c18c39d1-eae5-412e-ab1a-bc12ea048ee7">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8e70453-f0da-483b-b93c-edec29e3663f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b94d9d81-a5d8-4199-8a87-cf439e62d0b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0271df8-eff8-4554-811a-c23884315ba2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86f5d3b3-5318-4bc8-b9f7-0e71ae9cab43"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <rdfs:label>Potassium chloride</rdfs:label>
    <dc:identifier>DB00761</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a33e1ec4-6f12-4f5b-8dd9-a70e064a7d9f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
    <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
    <dc:identifier>HP:0025454*</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c88958f-26da-4625-aa0c-dc94d80c5a69">
    <rdfs:label>Amenorrhea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67aa49ff-e49e-4cdf-9211-f42dadf1aa7c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5af3d87-ba99-4f2f-8b65-81768b8abde3"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbb61e6a-991c-4cfe-be07-89216c9f9945"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b854cf9c-e77f-4c79-bfdd-00e7e2954c3c">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
    <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
    <dc:identifier>HP:0004364</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8fc6c003-73e4-441c-89de-18e8cc1acaf8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb670510-b62e-4d6e-a05e-1b052735ac47">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <dc:identifier>HP:0012103</dc:identifier>
        <rdfs:label>mitochondrial toxicity*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
        <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
        <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c81a1b6-0abb-4898-a7dd-db4ca9769a00"/>
        <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80f27ce1-6b4a-433a-8121-5f7a24753424"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc6f4886-0ee6-4ddb-a964-4fd17857aace">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0762c52c-d981-4b40-b651-a709645ab8df">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Epileptic seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57ce030a-2973-4265-b6de-1b6aa783c2d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01286287-ea8f-47db-a543-9f66d71debee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04ed4bf5-0930-4242-843e-972df5215034"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80a57ef9-a814-4695-bc30-e002fcdc5378">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002453*</dc:identifier>
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f19785ac-825f-4a0b-b8ac-686e1c6238e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52e6a5b-02d1-472f-88c3-be64c85d95e3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f67edb4e-a3c1-4288-9945-31f06f1a5c1b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5316767c-5592-4b1c-8e95-d8900e29b165"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f5d3d2b-c41c-46de-99ed-d067ff1ff632">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2626ae6-35e2-461a-881f-c5fe007d3b6d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66c3e9f4-d62c-40e5-b56f-ba82d2e40e6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06904f9c-69d6-4a65-be55-170cc6bd284e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f741859a-8fb0-4ed9-a680-24d3997ff224">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/489848bd-bd91-4e28-8efa-0f88dba966c1">
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Defected bile flow</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/887dc0e4-788d-49e4-ad0a-1a2ce3c536fa">
        <dc:identifier>HP:0001394</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cirrhosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdbfe5d9-94c2-43f8-8681-6fce8179aa7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5fbe022-cf1c-4b0e-ad7b-18d46afa1875"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/897bd3f9-c684-4791-a0b2-f5d88420784c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ae5d6ee-99f4-4a3f-bb54-7b2b35c879bd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd5ad52a-3a8a-43e5-a0c6-4e765ff3148f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8d59524-2acf-4556-b0a6-9e9f9d573e77">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6aeeef9-7f50-417a-978e-3111ffa010e8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11db456e-c390-4fce-ae6d-df349233b633">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51ed7079-73eb-4477-b3c5-605f7b300b44">
        <rdfs:label>Atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9bc0a900-9fac-4b9e-9a81-749a83aafad3">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ddba7ef0-fed7-422a-a9c9-1046df5daffd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0774c0bf-451e-4af8-8cf1-5d01f612fc2c">
    <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51341e41-ca36-47ca-95f0-e9f036bed6b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/540099ae-808d-41ae-9ad0-6c6a34817700"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3086fa93-1bd2-4b8a-aa5b-701d25a9bd03"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd7b6863-ce2b-4a18-9b9e-2ad5cc9ab328">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39ed13e8-b9fe-4b4c-abfb-215999a89805"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04647f4d-985d-44a2-b5f8-9ef35d4f14e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd41c5df-59bd-4ece-91f0-ead1295013c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9fd39e8-ce06-4aaa-a707-93524847de58">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bb0d198-28aa-45af-a229-92fde51e6e07"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f1596c6-ba47-4f9a-b1ca-0b00a42de94a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>exercise intolerance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1206689-1291-4c04-8ad5-e9ec968d6b48">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0312d040-59d3-4890-aa0d-0753916228c3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b599a8a2-1ed4-44b6-8cef-7e5a09340558">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aae94b20-415b-4cc1-8bf0-a55424e4e77a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3260e0ae-fbde-4bb7-a5f7-12ef6d49a4d3"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61d30668-e857-4418-8571-0c8193821fdd">
    <rdfs:label>Proximal tubular dysfunction</rdfs:label>
    <dc:identifier>HP:0000114</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fbe4aafe-fe7c-48e4-bf4b-1943f2561d01">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46433609-65eb-4fa0-887f-42ec25a0a316"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5563783-f409-4af6-ba90-d34fd2082015">
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82d8ae4b-a52b-470e-bb7b-7c162ccb0b32"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/034104a3-2217-4203-9328-72bbd88960c1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b0dddd9-c627-458c-a88d-e18fa219e4ae"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba593ba5-0241-4697-bda7-0cf4a9f25245">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/034104a3-2217-4203-9328-72bbd88960c1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ca4df98-7114-4bbd-8145-2b26356f7460"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4b1d1b6-3c5b-44d0-86a6-5f2d3ff2f59e"/>
    <rdfs:label>Acetazolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b78871be-6fee-415d-858b-990c0c1b5dc9">
    <rdfs:label>Low serum testosterone levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:004017</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9e44160-9d29-4c2b-bf4f-1c9eba110014">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Misfolded AGA</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6472e89c-a3c5-49a1-ad92-5e32be98f535">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2c0856a-6f57-4ebe-8ae9-6918283e7491"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3067bf0e-90f1-49d7-9953-ff26bf0049a2"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db11be42-edb4-41d0-b37b-c7fce292073b">
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Decreased lung function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7beb1b39-7b51-4a52-8318-eb3310753004">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea441aaa-7c9a-4dc0-a50e-badf5806472f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42c9e1dc-e285-4cd5-8a95-5904198c5f73">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
    <rdfs:label>decreased male libido</rdfs:label>
    <dc:identifier>HP:0040306</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c67335e3-3208-4bf5-9e31-d6f69b4366d5">
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eefd7f5d-2874-4891-855b-f8ff0db15cff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce1ebbb5-a7bc-4e50-8958-4c8b21349da0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
    <rdfs:label>Low energy level</rdfs:label>
    <dc:identifier>HP:0003473</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3012f613-cd62-4735-9581-78887ed67a7d">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de36ce12-7fd1-4a20-b58c-1844ee68977d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88b04dc7-5658-441c-a8b5-aa767c3f8fdb"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3bfd16d-e8cb-44ab-ab07-e2ee03c86b16">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04ac32e0-14ca-4ae6-90de-11bfb918d6f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a603d56a-54df-4c45-8b8e-48fd533c5c1b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb579af9-d2a9-4395-a0f9-61511067e5f0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/062e308c-8ae4-4b6d-96cb-b81e7fe891b4">
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adef8c59-fc16-42b0-adda-ac087bce0897"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
        <rdfs:label>FUCOSIDOSIS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c426778-d4de-431f-be4e-84b1db75c7c3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cecb6297-c98d-4c03-b03a-0356bac3596a">
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13eb8fd9-044c-4e6d-a7b5-f24105173a7d">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <dc:identifier>MP:0000880</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37de00be-d2b9-4691-b6af-acbf4a9d1349"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c0f4c75-d92b-468b-ab55-ddf79e11229e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa3c5258-ac39-4a67-85c1-403f37064f27">
        <dc:identifier>HP:0100709</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oligodendrocyte loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/320d4840-eddb-4d5a-aad0-8f34c69a49cf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c89c91e7-601c-4f35-9b07-ee44ae64cab2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
        <dc:identifier>HP:0100708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Microgliosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16d93b7d-e4e4-42e0-b36f-4a4d48317814">
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <dc:identifier>HP:0002446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24213435-4054-44e7-9956-46441f55a45c"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f46e416-9dc3-499b-86ff-9896168fa0ba">
    <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a005a0d4-0a83-4d62-974a-70b16cc2c632">
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29af24a4-3ae0-44d3-89ff-263b73fcdaa7">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f7e9dcd-06f8-4363-bbe5-494fa50b7e7c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4adb8ca6-cdae-49de-933d-dc302eb63a5a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d995f56d-6204-4c72-b914-064ee1894e7c"/>
    <rdfs:label>Risperidone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/09292616-60fd-47e0-93e2-700122510e02"/>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/974a8313-dab7-44c9-be76-f626c663dcf1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87e09281-eacf-42a7-befc-77332f473843">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28132e62-a39a-4b6d-9f1c-afb42b59a519"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bda53ead-ae16-472a-b1d6-9aafb490e29c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba6e3ceb-6745-4aa2-9bfd-9b8a7347c67c">
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bb49578-5b94-46cb-a10e-36a5452dd5ec">
        <rdfs:label>low brain creatine phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/006addbc-65ac-40ae-b6a7-7434e822b4af">
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4746ac75-01d4-4354-b0ba-cd19a00dd8ba"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d9ddf1d-a104-45a0-9b19-699c92490a50"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de00a910-8843-40f0-9fd1-d442ba94467e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a254c86-ff38-49db-b5e2-35badda4ca5b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high intraneuronal GSL storage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd468c6c-075f-49b3-87d9-e41bfeebab66">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73f4ea70-8194-44c9-96a6-38c34d8f6109">
        <dc:identifier>HP:0008765</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>auditory hallucinations</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ecc867b-c365-4d12-8618-2b8b7fd65feb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc515b8e-fe39-4282-8271-28987f4cf030"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09d6ebd6-dc02-4571-b7ef-365b2401c592">
        <rdfs:label>elicited hyperactivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000752</ddiem:url>
        <dc:identifier>HP:0000752</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b665f91-88d6-4014-a978-ff0015424edd">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/861569ff-c98f-4082-b201-acda22bf4f30">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
        <dc:identifier>HP:0011167*</dc:identifier>
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6611ee6-2d85-4964-808f-f6f28171905f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e58efdac-b25b-4248-9b07-7792e599e7fe"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/578384da-f0bf-4653-a742-b6966bda1131">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003713</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:label>fiber necrosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4394cd86-4a31-4412-a6f9-b8787b437588">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>fasting ketogenesis</rdfs:label>
    <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/152ef11d-2bc4-4cc3-b74f-07f50f5d2d6a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57db16b8-37fd-499b-acdc-23cecff9cfa1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d2f0728-f4cd-4794-b1d8-c1fdc15aff3f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d21a8b07-3b5f-4127-a40d-ff9b255ded56">
        <rdfs:label>phospholylation of RET</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6429ec9-3d9d-4155-bb4d-3a291f2f1e5f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/934feac2-3029-428b-ae9b-ee2cd661f742">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33e3012a-9841-4f91-a1ee-47d73b70b43c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7178ce56-e04b-4a8a-8ec4-dee8c7d6dc42"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/adfe6264-2f72-489c-b65e-e270061f6f0f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/f50f5ca1-88ad-48a0-854c-56d7be80791c">
        <rdfs:label>symptomatic treatment procedure+Dietary exclusion</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d9c7c3e-dff8-441d-b30e-53e049d40bed"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ba1574f-9c00-4d58-bce5-cd588f0e7fa5">
    <dc:identifier>HP:0003326</dc:identifier>
    <rdfs:label>Myalgia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
    <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
    <dc:identifier>EC0:0007121</dc:identifier>
  </ddiem:Evidence>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/696f2970-569f-4c5c-8908-a499b2a93793">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f968b012-fc47-4a54-87fb-4f4879a1895a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4ebe7ea-de38-4245-ab9e-b0ab279eff48">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
        <dc:identifier>HP:0004910*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3070e726-ac68-4b0c-8bf5-8bdc0bbcaa32">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002521</dc:identifier>
    <rdfs:label>Hypsarrhythmia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d2392e41-8aba-43a0-ac0a-7eadc28031dc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cfdf1b6-6b26-4be5-af0b-2de0e9a48582"/>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6c91d08-94f3-4728-9b39-b7a9fc17bfdd"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1ca8d94-530c-4516-80cd-e6680a8f8edb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba77e313-21b7-4276-a145-4f169c95c829"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13bb1d25-fd9f-4873-8806-bff029901c13"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a237ce2-20f0-4b7d-a1fa-95590e7f7e37"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5f13e87-fb50-4828-9731-eb4bc1b5358c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e16316f7-3e24-4b61-ac74-7a096655d799"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0e1a4c9-6570-44aa-8f13-05fe444680c9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffac4fd8-ceae-4680-83df-54df2c6e57ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ef8b194-0ae7-424b-9f98-ca3625a626b7"/>
    <dc:identifier>DB06777</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76efde02-069a-4352-8944-de1009f10825">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70061e55-430f-4c53-8628-008c21423297">
        <rdfs:label>Mesalazine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
        <dc:identifier>DB00244</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/130575c0-e2ea-40f4-9ad6-65b6a116a49d"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c7478ad-47cc-446f-826d-5e788e27f075">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/786a4a87-f44c-44b7-89bb-c5f65da43432"/>
    <dc:identifier>B02BA</dc:identifier>
    <rdfs:label>Vitamin K</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22109b05-6c77-40a1-ba31-75ec648cc710">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18560de8-9959-462d-8904-06defee17ee8">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f4888a3-8d30-4b48-96b4-d0551717988c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/903af1d9-4758-4ea2-a84a-a13c2a3dcacb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2743c4d1-28dc-46d1-87cb-f8eaf69ed5fa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6680c49a-c2dd-4949-be10-c4f514465455"/>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95e31b7f-e428-4510-9b0f-243e05f6d7ed">
    <rdfs:label>Pergolide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e6c51e9-3180-4c57-9cdb-6a2b25cb4d7a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb7cfc83-df1f-49ec-874f-5539e4af8cab"/>
    <dc:identifier>DB01186</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f94b98f2-aea2-41c6-9d74-d1ce86eee2ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0271df8-eff8-4554-811a-c23884315ba2"/>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8d9fed67-96b8-425d-bae7-a5156d13f176"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a05f554d-8dde-4e70-976a-bf3b6b541596">
    <rdfs:label>inflammation</rdfs:label>
    <dc:identifier>MP:0001845</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d7a8298-e101-41ca-9500-1fd01063aaf5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d22fc4a6-63b5-4034-a60e-2a611ef3f4e9">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7291329-9453-4213-b0d4-25578905445f"/>
        <rdfs:label>Retrovirus</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7300c2c1-0d39-4940-940e-f18713ab1a98">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb5c70d-a3c7-4e2d-aaef-ff8b24c8e05e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49862f5e-f9bd-4b31-a1e0-f997df2fc8f8"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6644d2c7-2ab4-4258-93aa-4bdf7f9568b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f8b362a-704c-4cd0-8708-6d7ee4cbc5d6"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/97083adb-7e49-4085-a4ae-52bd0c95bd21">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5cd927d-aff5-4c56-820e-c54462609c7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/031547eb-d527-43dd-9323-d3728af3428e">
    <rdfs:label>Increased muscle lipid droplets</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab54a6c5-af4f-4402-9358-3ea4d20a5b0a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal cardiac function</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba368dd4-9f38-4531-acb7-8b7ce98cacee">
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7cc719a-dba4-472c-b2cb-56163022793f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30a0a5b6-5405-4579-b1f7-b2d70d87d309"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3807bf02-0753-4fa7-a969-a3e21300fc8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e405e31-e0be-4aa6-a126-792c2ea99ac9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
    <rdfs:label>Pantothenic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7929e2d5-a736-4d59-a846-d09ef95aa2c0"/>
    <dc:identifier>DB01783</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d89149c7-3420-43ef-b4ab-c104cdb96a9c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5efa7745-d5d2-49c7-93a8-b10122d479a9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/914c2e2e-2ae6-4bf8-861c-8626864637a8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8b09be2-0e26-4d29-8ce8-867601a76d97">
        <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0011925</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eac81578-0332-445f-828d-360acee2f0d7">
    <dc:identifier>MP:0001426</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>polydipsia</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c3ced7a-16ad-4f8b-84bf-f40325821666">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f3d5ae3-6ee2-462e-b373-a057d29db529">
        <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e240126-1eed-4580-b98a-6a07d6aeeb3c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc1a9085-9d5a-4147-a9b5-f9d32b417419">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8af6894f-534b-4b9d-bc4d-42135d36baab">
        <dc:identifier>HP:0008344</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7344385-dad5-4800-af02-012597864d59">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80a3626f-dd53-43ed-a7e3-cb9a6a32b838"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edcc86a6-11c8-4cfd-93bc-0d7e068252fa"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6782f703-9d74-401a-9474-3669e424428c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
    <dc:identifier>HP:0003452</dc:identifier>
    <rdfs:label>High serum iron</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93d3bcdd-2204-480f-844e-83998d86ef54">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:label>Renal rickets</rdfs:label>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21829337-123e-4356-b633-8f155052e6cf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e841c10-11fa-4b25-8205-502e053c9a84"/>
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaf206e8-7936-4ba0-b7e9-91359d0f020d">
    <rdfs:label>impairment of reference</rdfs:label>
    <dc:identifier>HP:0100753</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d55e6e16-bc1c-4b41-8104-a324c0a7f7cf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <rdfs:label>Cholestyramine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4331bb34-f057-4bb9-ad12-e47f58d50dc8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c68a57c-fae5-477c-bc82-0a56b0f4e574"/>
    <dc:identifier>DB01432</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13ebc7dc-075c-4349-969c-6aed2d0f0703">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed4f4a3d-0e53-41cc-9aa6-301b598d8634"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07ff3c4c-7cfe-4539-91b5-8507b2e31f64">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aed6ac2f-f5d8-4c83-a025-8b2c31632f55">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77ad3d61-ef91-4caa-8f01-5be61ea6a0ae"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d9a6f41-2f4e-40b5-80ff-c7a30e6a124b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e23c6eb5-8426-4e22-857b-5fcc35f9dd6e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d9a6f41-2f4e-40b5-80ff-c7a30e6a124b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00776</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0216987-e777-4cbb-a6fb-d28389dcad67"/>
    <rdfs:label>Oxcarbazepine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a5255a8-894c-470d-8f40-c6af82fd4a59">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0368271-a416-443a-bfe5-6fe479851777"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/140abd68-0707-45a3-ac2f-485d7f0875c9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edcc86a6-11c8-4cfd-93bc-0d7e068252fa"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f19ecf7f-2c89-4a19-8ee0-47d65356babf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47a67bfa-0e9c-4691-8945-493bbba05cb5">
    <dc:identifier>HP:0002275</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor motor coordination</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71bc9a7d-0098-44be-9fa3-8c3fa1c479eb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff7555c8-fb71-4e7b-9f97-47a3f3bb8d99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a2282239-ed1f-4091-a211-c6f6188aed9f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32dae1b4-c9d0-4f9c-a1e0-6794a34ff080"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b779172e-82d3-481b-b5d5-0e4196bfdad5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa6f15d2-89df-4c03-8fda-5bce842c0f34"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9170d275-0b2e-4123-b70f-3c7bf5ebdf6c"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74c0c630-284a-4d3f-b73c-0e7ebc17c6e0"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b940e095-cd0a-4ace-b594-2646f4f06c8c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9caf04dd-f822-47aa-9bbb-aa31dab7b977">
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70d0cfd5-a277-4163-849c-0bd3801170c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e8f138be-f7eb-413a-916f-b2cdce35adb2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da30e6ad-80b0-44a0-9f16-7d8b5494129b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cb9e2f2-dbc7-47bc-9816-1402f7534910"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4147bd1f-4dc2-4519-9e2e-6365e968a9a5">
        <rdfs:label>psychotic  disorder</rdfs:label>
        <dc:identifier>HP:0000725</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417300086</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3257f499-2885-4b95-963c-c4eb81a91b3e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/034104a3-2217-4203-9328-72bbd88960c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25ccfe71-2aeb-40ef-8101-1fdf9588f026"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77c7238d-d157-4c29-89d4-d06e6b20543a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3320963-0cb7-448d-81fe-23e45d902686"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b55db75-5c38-4130-b82b-913eaeeb53c6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2478bc0a-df31-4901-8432-a0d5c178872d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec5f85af-bbb0-4d1c-9c86-73fa25ad2b34">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e12c1b92-1abd-4aaf-b5f9-c02f69b569f1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/790e4444-7327-4cb8-9212-4a6bc8215b4f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48020f8e-6d14-4c31-9477-3d9c363b7df3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a2c650a-c011-4112-ac64-6fe255d259e7"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba43a517-7ff1-44e3-a2d3-548b82d20454">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:label>Acidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb0fd844-4db3-4861-ab4d-ff2d27a6c1f4">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00d45463-dfd6-4535-b00d-8505cbaf86be">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <dc:identifier>HP:0000002*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e09a305-a1d6-45aa-a7d9-d8339ad518fe">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>hypoglycemic seizures</rdfs:label>
        <dc:identifier>HP:0002173</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c579487-ff4d-406c-bc13-2c8e684a068c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9b20cbe-2331-46b8-bfed-6e8d79d8bc58">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <dc:identifier>DB14681</dc:identifier>
    <rdfs:label>Cortisone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e5b87b4-f767-4d75-9952-9d685ecc3a4c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a181747c-d756-4d30-b078-9339bc69e903">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3eec3bc4-5e55-43e5-8073-24cb8bc89534"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
    <rdfs:label>Torcetrapib</rdfs:label>
    <dc:identifier>DB06281</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e0c7de2-d020-4b2d-ab77-c9260423388e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040084</dc:identifier>
    <rdfs:label>Abnormal circulating renin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d4ad9a5-bff5-4fc1-92bd-c60ae9e89371">
    <dc:identifier>HP:0003688</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
    <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9315bf50-b5a3-4d0c-94cf-3bbe4680814b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49f7076b-3447-4482-b598-fd0e18ff58c9"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3337e7bd-42db-4230-bf5e-306f1d4cc797"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aa1812f-01a1-48e9-95c5-aafc8f253922">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73738507-ae1d-47ed-a85d-a3954e4c99d2">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>ochronosis</rdfs:label>
        <dc:identifier>HP:0030764</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a326164-f8c6-4b77-aeec-c70e11675a8f"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/710aae0c-e401-4ce0-8d7d-ef714dccf6c3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11b274be-046b-483a-8c94-099561b93739"/>
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee2f3c82-fb41-4035-835e-5a3895ab609a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca88dcef-c15f-4c53-a68f-96cb65565699">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e7c9c1e-6ae5-48d8-937c-df96df5e9ce0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96891385-9ada-48dd-8cdc-f25b0fc7c1a6"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63cb2871-c3e0-4525-89fc-ba23c667267e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/344e7da9-dba5-461b-9881-6a1f3eb2cbf0">
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f404ad2e-dc06-4cdb-943f-4607aa8a1a1f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1c65c5c-6ed9-4d6d-8068-de8e06b3dae5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d63f8912-b98e-43ec-ac0f-06e735c07520"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8fddd35f-d43a-408e-b71d-457d0a17dd06">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7992b44-0ee5-41f4-865f-8de043b10a28"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aba6f615-cd78-4a8a-ae55-695e003cd1ce">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <dc:identifier>HP:0011013</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd637b17-7776-4b63-ab79-a146f4402667">
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/adcc2a32-a24b-4d1e-9465-5d8b2ff58edf">
    <dc:identifier>DB14644</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9fdf572-c965-4b31-b5ec-9c38c62cff58"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53e5e5f9-3294-42aa-a96d-c8b17c2a911d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/450bb62d-1e45-4f63-82f5-660c1a83b0e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1929261e-fa4a-4eb8-9027-5d09bb4ca6cc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e2f71d0-714d-48bd-8c07-5876dd108044"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00b977fe-7bcb-496c-933d-6ab91e9ddf8b"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3f2d51d-3020-47de-9bb1-64a14765fe5d">
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f8c692f-990c-4a93-a284-e13d930de749"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55db331b-cc57-4394-ace4-34ad168372a4">
        <rdfs:label>Abnormal EEG results</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54f6ac36-45dc-4a68-a764-205d572c7ca3">
        <dc:identifier>HP:0030980*</dc:identifier>
        <rdfs:label>Low CSF glutamine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38949e41-f58d-4630-a6ec-31b67d38f275">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
        <rdfs:label>Lack of emotional expressions</rdfs:label>
        <dc:identifier>HP:0030213</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b886fdf-3f53-474d-9314-5e9bd38ae1e7">
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <dc:identifier>HP:0030980</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/372d9a18-7172-45f2-a716-60b40b1279e8"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33652cbd-d6a9-4cbe-a80c-49a8e1e414eb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec809593-df92-4f5e-8db7-3d7225d3e411"/>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28a04214-df68-465f-b4f8-043b143ff087">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb96e0ef-a296-4bd8-8091-13a408435a9d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/946eb98e-38d7-4cec-b951-873ac9b6fb82"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c291370-0cd1-42b9-bbab-b72e5a1b968a"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7f3bb1f-3fac-4246-8772-406819f14a9b"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a758139-b00e-4801-b201-845cdf30c9ef"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
    <dc:identifier>DB00282</dc:identifier>
    <rdfs:label>Pamidronic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8db3656-c3ef-4c47-9cd3-216f4e236ae8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc69c393-961f-477d-ac83-33c8c07074a2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b58323b5-56bb-4f10-87b8-9b78dce7e417"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610198"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b83dfa11-0b56-4c37-b19c-f2eb1f1391fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81edd59a-02d3-4e4a-91f4-e70efc7e6cc3"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/794408d0-93af-4971-9b2e-7e4660c981a9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe0abc09-fcd6-4ca8-9e8a-86ec6d681ca7"/>
    <dc:identifier>DB6756</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c59331a5-75af-4bc5-b34c-8c6408e701cc">
    <dc:identifier>HP:0004359</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <rdfs:label>abnormal fat metabolism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0e0c55d-249d-40cd-acdb-21d61dcc341e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:00011911</dc:identifier>
    <rdfs:label>Cutaneous abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94c36957-45a5-4ce1-aad0-9b1c2d9ad1d9">
    <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001507*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fe07572-f98e-402f-8f5a-1b0dc3b254b1">
    <rdfs:label>No result is  added</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27d408d9-305c-4dee-925f-2974ebab649a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1021ecf-abc9-44f3-a9c6-f75e13aba5d8">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0434650f-ce2a-4251-9299-d5f3a40b323a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5cd927d-aff5-4c56-820e-c54462609c7b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/839689b7-1aba-4d1d-b1af-1e3fa467a6ec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97083adb-7e49-4085-a4ae-52bd0c95bd21"/>
    <dc:identifier>DB01914</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9be5bc75-3c90-4a93-8ec8-c11e7c1d46c3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5cd927d-aff5-4c56-820e-c54462609c7b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <rdfs:label>D-glucose</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f965034-c509-426e-b189-d63c77e452c8">
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0e0c55d-249d-40cd-acdb-21d61dcc341e"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/997e3080-23f5-47eb-acc9-c3e2a90a3734"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1b681ac-99c0-4b22-8e47-f26a75ba2a20"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b08758a3-9b83-4536-a470-3535cf699e6c"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9093d7cf-a826-4340-b888-2bea1ab67460">
    <rdfs:label>gouty arthritis</rdfs:label>
    <dc:identifier>HP:0001997</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dd56478-54d5-4d76-adf2-1adecd62a2fd">
    <rdfs:label>Exfoliative erythema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <dc:identifier>HP:0001019</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/beda787e-4eb6-447e-9a5e-b23840086afa">
    <rdfs:label>purified recombinant human -GalWT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b08f367f-7fab-4326-bb75-b9e6f368c1db"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d48e3316-e85b-4dc5-8a2e-649e22496860">
    <dc:identifier>HP:0001941*</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:label>high-anion gap acidosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ed66f58-6be4-4015-8b0b-9c1a3b7b5276">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002529</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
    <rdfs:label>Neuronal death</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63e90731-473b-46fa-b132-74ae1543236f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/791a65c6-b5ed-49cc-b90a-77d8cef98780">
    <dc:identifier>DB12374</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <rdfs:label>Velmanase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d69b3d4e-87a3-4b33-af76-3f377b1e2f37"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/592f69e7-806c-4685-84fa-e71bcc140ebd">
    <dc:identifier>DB14872</dc:identifier>
    <rdfs:label>Lucerastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f11ff90b-2598-4648-bf9d-8181e71ac032"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9707bdb-b0dd-4a82-afb9-a1bc8444030e">
    <dc:identifier>HP:0011042</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acad1cdb-290d-4a0f-af80-70721d719c7b">
    <rdfs:label>Rapid disease progression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/722c2c1f-ddb3-4d4e-8956-9d4b4c25900c"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
    <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
    <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f16b4aa-31cf-484c-bb27-187bb4720fb7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bb0d198-28aa-45af-a229-92fde51e6e07"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfbbdb5a-02a2-4480-b15e-4989bc51ccfb">
        <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
        <dc:identifier>HP:0002071</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0451378b-6202-4526-96c0-29aa1fa6adb7">
    <rdfs:label>Idebenone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/86fa2af5-7259-4eb1-a774-28c0dd8a1a8d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c9abf52-89f1-48ee-b31f-79289296723c"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02aeab36-8b5a-4311-be4b-6bfda79e763c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5b8dc1-8c19-4873-882f-9934dfb2311f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/675eb5fb-4021-4cf9-8028-1a109048276d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6d45f24-f2f0-4a74-8cc5-c0498d24320c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5dfc090-1101-4ac0-9f01-9f45213b5b7c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69c6adf7-f766-48f3-ab9c-6ef21c3c62e8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/155011bf-a03f-406d-a330-d80ad73fce5a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50fcfd7b-7655-4578-a44c-8774e39116a9"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89e2d1f5-e349-4a9b-9dea-a2ee14cb7cd7"/>
    <dc:identifier>DB09081</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/914c2e2e-2ae6-4bf8-861c-8626864637a8"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
    <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
    <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a9e732f-121f-456f-96bc-29d3595f03ea"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
    <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41f9aefa-4439-4dc9-a24b-c2b21d626c8b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/97e78a7d-66fd-4f4f-a45b-c317d1fd4fe1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d31a835b-2ac5-400c-b95e-4a743d740931"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Azathioprine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d415c1cc-d0cf-45ea-bb7a-6be573caaa36"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <dc:identifier>DB00993</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ebcfaa48-94e4-436b-9e12-cb605178cc01">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5a86cfe-76ec-43e2-b4be-dc759f10b56c">
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf1b1201-8528-4eb6-9144-68321df0d137"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14804f8f-5524-4fd2-8971-f399fdf20a28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80759576-6cc3-4cb4-b506-7ec73b371c0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2145ca39-e8e8-4a25-86f6-fc2323f853ac">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae32b270-eabd-4ede-a982-4acc9ea66a11">
        <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7d13607-78da-4600-873e-257a16ebe192"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb3f9620-87e9-4359-9941-8d65ec14965e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e04f6ed-e035-4569-a65e-2a65991796e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/696fb572-1e93-4c3d-98ec-d3702fb35d3c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/355e572f-b3fd-4254-94e0-b463e4e7decc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd616b85-42f0-434e-aa55-68d205b08fc6">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
    <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
    <dc:identifier>HP:0040085</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d0e6abc-0fe3-4218-a678-d308b03cec8b">
    <dc:identifier>DB06819</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd04b47d-a0e1-4e40-ac14-af103166a4f3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbef57b-0d8c-424f-95e2-9b6558d91e16"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a05a0208-97b8-43fc-861c-ee8db8ef9bb1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbef57b-0d8c-424f-95e2-9b6558d91e16"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97661e98-1fdb-4a21-8e2d-5a680a24ce57"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dba8cd15-229f-4880-a4e0-389ab4514a01">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5786ab17-532f-433f-98b5-cff33cca9e59"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fbef57b-0d8c-424f-95e2-9b6558d91e16"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8af6894f-534b-4b9d-bc4d-42135d36baab"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f13bac8-c322-408b-9e2e-9b9c02ff4a2e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f19fd5b9-9484-4173-864b-07c240ae3c01">
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/771ff50e-799f-4905-a5f6-9cc9ad5bf320">
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:label>impaired Visual acuity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bbf9098-544e-4f8a-a3bb-d3539ee8ed57">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b571921-3849-45cf-8e14-c69cf63a8490">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:label>metabolic acidosis</rdfs:label>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc79aa4f-601e-4cc5-8eb3-0c6682549486">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8d32737-bc14-4e01-8a68-6df747b16a8e"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6db9ddf8-1ac4-4b1d-bcb3-74527e6fcd9e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/209a4c8f-0c2d-4823-9ddf-14097b25fa0b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c84d3964-3662-4e06-b728-f03b567475c8"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1db02bd8-3ac7-4a56-9ace-30bf110f1738">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>pulmonary regurgitation</rdfs:label>
    <dc:identifier>HP:0010444</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab9e0d45-6a70-4f7a-b863-16684a7bf0c4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0004295</dc:identifier>
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ad9115f-6f75-4f39-8b58-06ca4144379c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61108f0a-7192-449f-a518-97f3f7470d65">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Serotonin deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <dc:identifier>HP:0003117*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2373adf2-4be0-4cc1-a641-a88112268008"/>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7d03d3c-0eaf-4943-ac20-bbf683b9c028">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2627dc2-fa16-4d1d-85c1-1b7cabb1eea1"/>
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/812d45c3-7185-4dc7-905e-5bd338d43a23">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/129f3718-d9de-40df-a9f5-44688a7162b1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc801c5e-015a-41da-a119-3e58730de77d">
    <rdfs:label>Heparin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b438a8da-e3e0-4002-abf3-1da587f9a32d"/>
    <dc:identifier>DB01109</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b9b917d-3ca3-452f-90d0-1937fabdd990">
    <dc:identifier>DB05294</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <rdfs:label>Vandetanib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6481c89-5746-4f26-9bcd-d60409096d9c"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2512865-d605-4a30-87b3-6a40d43452f7">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1bef80f0-45c9-44c7-a187-113b4f1a5326"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f3c71df-59cc-4f2c-8f98-ec45edab42ef"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffffeecb-ec71-4992-a1e2-ba0891ec5643"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ccfb9eb-3cbe-4f7f-9c33-48cd1d73f395">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <rdfs:label>Granulocytopenia</rdfs:label>
        <dc:identifier>HP:0001913</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aeca315-56f4-4aec-a187-8df9f8876248"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1faff951-d0e3-405d-ac41-0ccfa366b42c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b47b6eaa-4bdc-4b38-b460-eeb698d8a19b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23714122-0509-41e1-8204-4968dc31431b">
    <rdfs:label>Motor function impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002275</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61f0237e-c76f-45f8-9be1-9433176cc061">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0025373</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
    <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d855068-1ab7-437b-8517-a087e1aa54c3">
    <rdfs:label>Galactose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/965d4a0c-5c83-435b-b3aa-cb775e71c867"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d110c349-9a03-415b-8208-11dff8950f4a"/>
    <dc:identifier>DB11735</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/788300ce-e162-4f10-bcee-c443b0a45be4">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
    <rdfs:label>Kidney failure</rdfs:label>
    <dc:identifier>HP:0000083</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd2bea93-4d0e-41a0-8258-2a50e59f76ba">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/140abd68-0707-45a3-ac2f-485d7f0875c9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dfe0f70-c935-4322-a1c2-6b0ecb51dc75"/>
    <dc:identifier>DB00091</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7344385-dad5-4800-af02-012597864d59"/>
    <rdfs:label>Ciclosporin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb86562b-16fa-45fa-921f-083619423d3b">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7cb55a06-84fd-48f6-a47f-63f59048a746"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/90547738-37e8-4fbc-8b88-90cc5bf553a2"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3c52a00-0fcd-4bdb-bc15-bac6e7ec66a9"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18a98bf7-f11a-4505-a9bc-d3dab3e40300">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5955b7da-7916-4c8c-a4e3-6d2318033bd4"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03052473-af0c-4033-8e3a-60d576e4fbb0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/539a1840-1ac8-4ca0-bf1f-9d3f2c3e698a">
        <rdfs:label>muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/756111bf-9a05-49e5-a29e-c9f33c8cf3db"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c759aff-f5f2-4408-8eb0-58068d1e93c1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004348</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:label>Defect of bone mineralisation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b57223e8-9328-4f17-86b6-e97043cbfaa4">
        <dc:identifier>HP:0000002</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>delayed growth(stature)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08da8e4a-0d9e-4142-bcca-447039d9c7f4">
        <rdfs:label>gross motor dysfunction</rdfs:label>
        <dc:identifier>HP:0007015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0aff404b-9b08-4999-833f-633e0d66b8cb">
        <rdfs:label>poor skeletal mineralization</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006462</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2e8ecb4-ea9d-49ee-afdb-0f88306bea9f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32993be3-b180-4288-976a-1db7fb03683d">
        <dc:identifier>HP:0002093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
        <rdfs:label>respiratory insufficiency</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc0cdc80-05c3-4f57-8681-5c150486a171"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9eead25-7f70-4569-a598-e14c780f7c59"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3ea3afa-28d6-466f-b097-f93b0cf9da29">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ab8f336-795c-4f4a-a2cf-7f078deaaaec"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5befd1e-cf52-41ab-89d1-05b806c9759a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a2a35a2-124b-43a4-846d-e7d26d5eeeea">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <dc:identifier>DB05134</dc:identifier>
    <rdfs:label>Tanespimycin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aab4a0cb-861b-456a-bc7f-f1d1eb52b836"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/357ef4e6-a7e1-4de3-909d-63aa873c857a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad40ed7-01b6-42b1-9214-dcef772e8f84"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98d87bf2-c063-4765-8c29-e8d2b657ded7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/699a8c55-bd58-486e-b14e-784dda70787d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaf206e8-7936-4ba0-b7e9-91359d0f020d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2faf739c-e530-4a89-a38d-66dae5c7f737">
        <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432805003657</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8711fd6f-8f48-4071-b7f7-f29fdc3f4f9c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73caf8ae-54c3-41dd-8ed2-9cc346ceec0e">
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:label>working spatial memory impairment*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/13651f5c-bff2-4843-8095-0dea7c373ce3">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ef1a246-a35a-4e75-abd7-f0b2e73ed719"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78967320-2670-41e8-a68a-60bd95ba7faa"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aaf5fa55-91f2-4aaa-a3a9-6d40d8b33f42">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3504a948-07e7-41a3-a5c4-b81afe314925"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a06bca8c-7eef-4f9c-8f57-fe6795c525fa"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6458930b-4ca8-435d-b53c-add5d0d09edb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a2ecad5-bb75-4cf2-8ebb-6727802b0fe6">
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61d30668-e857-4418-8571-0c8193821fdd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28ed244b-4d82-4daa-8be1-88f5daf34edb"/>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c60300d-847b-44d0-a4e8-e112f66a6b85"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7bbf9098-544e-4f8a-a3bb-d3539ee8ed57"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0c864b7-c07c-468b-a926-7015547ee22f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29fb3e0c-61bd-423b-892d-2c40aafe6c26"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbc12955-6445-4aa5-868f-c6a1ab840a03">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e46cf0b8-7651-40dc-94c3-669f9b866a9e">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e45eb5f-b2e7-4f9c-89a5-adbae59336b5"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
        <rdfs:label>Calcitriol</rdfs:label>
        <dc:identifier>DB00136</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2308a23-5187-48cc-9bf6-7564efcb36ed">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d7b7390-da59-4b1c-b7c5-363e71bba158"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b734cf8-f841-48dd-b80f-5b43d1f1520e">
        <rdfs:label>abnormal glucocerebroside level</rdfs:label>
        <dc:identifier>HP:0003656</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30c993fb-b91f-4273-b938-d6b476d29efe"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cea46c4f-cc63-484e-8900-f36704bff364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49ada44b-fc8a-4785-9cce-3c3824b0f173"/>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92ff6092-7f7b-4fb9-9f0f-263e88c1b31c">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b4399ff-f77a-4c53-a76f-9728aaa8aebe">
        <dc:identifier>HP:0002181</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
        <rdfs:label>Brain oedema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b72eb506-c9cb-4072-aa07-b208e645ee7a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72c695c1-da17-413d-a164-829166751ac0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5997791f-e729-45c1-9721-58182eec91cf">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:label>Abnormal walking distance</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/738dce9c-059d-4ac0-a0df-ee294fb3573b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6cc346b0-914e-4a79-b055-de30ae31d4cc"/>
    <rdfs:label>Neomycin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
    <dc:identifier>DB00994</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68e5b581-34e3-46d8-8ac0-27a0e5ab39e9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43c14e7d-f5ff-4192-b869-b592686c421f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53861ecb-e4b1-40b5-8680-c55cb4dafbbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aa527a5-ad72-43a2-a032-f029da23acfb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>Growth Failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c681599-13b2-4a84-941a-e96f91ec55b2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e15b2621-0a9c-4f36-9d9f-f9a5e84d43e7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <dc:identifier>HP:0002180*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72fc8bb6-6516-410a-97a4-b61269fbc4ae">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal muscle physiology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48dfa75b-3919-4cf5-bfb2-f38378e87856">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/808412f7-53e1-4f83-aeee-ed1cf04d094e"/>
    <rdfs:label>Captopril</rdfs:label>
    <dc:identifier>DB01197</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c05fdd8f-84d9-435c-af24-e7dbb686f892"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9c4e64c-4327-4fbd-ae97-cbb39b9dd776">
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3fed21bc-ca42-4996-a1e6-e8b38a30b5fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a1747cd-7faa-4d3c-9b77-e766b04100e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e12fa4-e0a2-4b35-9aa4-b889dffdaebc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e45eb5f-b2e7-4f9c-89a5-adbae59336b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/642c5c18-cf04-4717-957d-b51ed8350cf5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7431d2a-9486-4b65-a33e-86a49cf5ed30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93d3bcdd-2204-480f-844e-83998d86ef54"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0edce8f9-4d89-43b4-8820-b7bc7a532d0f"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbc12955-6445-4aa5-868f-c6a1ab840a03"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/175745c6-ac7e-45cd-8dd8-446cbcd2e5f9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/413338be-eb95-4b28-884b-476f5f930ade"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0406effe-320a-4ef1-bc56-90ce97a00e27">
        <rdfs:label>Complex partial seizure</rdfs:label>
        <dc:identifier>HP:0000718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e02bde1c-86fa-4b1c-82e8-7affcad3b49d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ebba2df-2ed3-42e2-9667-3fd256caa7f3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4fa2f7e5-17ee-487d-b755-97e5c38bae0d"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2280bd6b-5368-4e89-98bf-802ffd7b09ed">
        <dc:identifier>HP:0000718</dc:identifier>
        <rdfs:label>Generalized convulsion</rdfs:label>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/903af1d9-4758-4ea2-a84a-a13c2a3dcacb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18560de8-9959-462d-8904-06defee17ee8"/>
    <rdfs:label>Complex Carbohydrates</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36ccca8c-3578-45e0-ac19-6511b3983584">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/197c385c-e740-4e43-be5d-a38d28de68d3">
        <rdfs:label>high Lactic acid</rdfs:label>
        <dc:identifier>HP:0003648</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/762bb923-15ca-48e1-bbd1-7dcff5acb927"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8563d67d-6a18-4a9b-9c72-31a014c31827">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d15bdb02-ebfb-422a-8f48-a6d0a00953a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca5d72c7-dd7b-4c0c-9075-21b76ca049cd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2b2e71c-80cd-49d8-b166-05b83a89147b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aea41c21-9cdb-4dff-bc4e-c38f47920aaa">
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9536dd8-6041-4144-b988-51ea62a7427e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <dc:identifier>DB09539</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3504a948-07e7-41a3-a5c4-b81afe314925">
    <dc:identifier>DB00620</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13651f5c-bff2-4843-8095-0dea7c373ce3"/>
    <rdfs:label>Triamcinolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/890bba22-2ab7-44a2-8b8f-41af025b9adf">
    <dc:identifier>HP:0001738</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
    <rdfs:label>pancreatic dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4757c44b-c044-43df-a7cc-6fd152766b44">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:label>rhabdomyolysis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66238906-711d-4a27-9df2-52abc5ab93d5">
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720f6c44-a181-4458-b396-9771632c7e8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec4299-bbb9-4a69-8626-e7e3f1065676"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b21735e-2fc0-46a2-b95e-108a97d4b22e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed5a8004-fb9c-438a-b50e-6b8fdd854fa6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Intellectual disability</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d275d60d-0479-4f21-b09f-d800e8df3a21">
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
        <dc:identifier>HP:0002188</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5c84a57-5aab-4754-8f4f-69f3eedadb20"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84bc73fe-5adb-4fc3-9ee6-69d3b0c1abf0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d1a8cc4-0977-4eb3-b20c-7158e8d2a464"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5997791f-e729-45c1-9721-58182eec91cf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/baa00c68-7037-4361-80a6-7aa537ee8478">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fc664ac-9c18-4ee2-bb3c-5c3f10d35e02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1eaa1eaa-d96b-44a6-9cbd-a56cfa0875db"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aee733b9-b90f-46d8-9f96-a548f537478e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2289c75-cc74-4deb-84af-e5b7fc3d3052">
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <dc:identifier>HP:0011023</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/267d467f-0d5e-485e-a887-ac603ae45ca7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No result was added</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/689ee4c0-91ee-4a5b-a06f-c4eadcf26aa8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
    <rdfs:label>high EMA levels</rdfs:label>
    <dc:identifier>HP:0003219</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19cb4e7a-d6c5-4313-8f32-cb1e83108dc8">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4001bd1-e54d-4554-8431-6fd303260454"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4bd90df-9127-400a-a822-fafe7d3c4e0c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c125475-e1c7-46e6-a685-9409da4ccce9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07c832a9-4a59-414f-a8a2-f0c57f310c3f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983e24aa-5e38-459c-9272-a1f1933b725d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c374e81d-84d2-4c17-8a7d-fc0fa1c32bff">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
    <rdfs:label>Elevated serum lactate level</rdfs:label>
    <dc:identifier>HP:0002151</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7291329-9453-4213-b0d4-25578905445f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e04f6ed-e035-4569-a65e-2a65991796e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d7a8298-e101-41ca-9500-1fd01063aaf5"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c12f063a-0b6f-4656-92de-8670670ed61f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>subclinical hypothyroidism</rdfs:label>
    <dc:identifier>HP:0000821</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e18ab86-f934-4aaf-bb1e-787048e153db">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f19fd5b9-9484-4173-864b-07c240ae3c01"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c6f7597a-7217-41f5-9534-532d9d1cd026"/>
        <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/586b996e-336b-4093-a823-a8c451fd5dff"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58497244-f5b5-4797-8e14-b5a8890e5e7f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c78394ae-2386-4239-b50f-a75470d6ecd8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21da7477-0732-443b-bbdf-219f460ef270"/>
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e94ec49f-b826-46b7-b442-6e9f33adac1a"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6226c03-633e-4907-a4f9-01367ec39c7e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/195bb022-81b5-4d78-bb0f-e9f4eb413aca"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2208c7c-4cb7-463d-9b2a-05150dcb7a5f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11fcf246-1e2f-480d-9624-78539d39911b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc0cdc80-05c3-4f57-8681-5c150486a171"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01e1ab93-307d-4569-b8f1-7d7337cf069c"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf840c6-bc4d-44fd-8664-30892f085da1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a13da295-a090-418e-94a9-07a7ce1f5ad3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db486564-f278-4d03-93b9-fd1504209487"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef8b0c00-a7c1-4816-a4fb-3e55765238ef"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d2f0b89-8fb1-47b4-85bd-7694456ec6da"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee147154-77bf-4651-922c-57c9d57e76a0"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/13744bf0-2544-44df-b482-1561b23f57fa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/308147ac-ee1a-43d7-9f72-d53742df1db5"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de188149-4673-40d9-bd19-c69d82955507">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c062fa82-3256-4c9a-a860-6867cf2acd65">
        <rdfs:label>No Studies were done on this drug.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac75d9fb-8991-48db-a702-6992b12e6ba1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb3477ae-7383-4645-9af5-0e8a3f6b940f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7dfd8f8b-8dfc-48c3-bb78-d8eaa8356323">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb994244-d775-4a81-abea-c56816b6376d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8381aa6f-d8a1-4d7c-9a0e-83319270ce61"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/443c733b-9f60-4179-a106-74a7efb9b730"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45118d6c-756b-456f-8971-3ecc32cbaf52"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01233</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <rdfs:label>Metoclopramide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b958058c-c435-4c7a-98e9-465ec1822839">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c12f063a-0b6f-4656-92de-8670670ed61f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c5e960a-7950-4dd8-a319-1a69a91bb8cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72c4ffe7-a689-4c02-8d77-4437204e89f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
    <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
    <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba972bd4-b23f-4d1f-8760-cd8c69caeccf"/>
    <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44001326-1038-4cbb-a604-6a4c64bff88c">
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40af249a-cede-48b9-ba14-00c110cc003c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed6463dc-6b45-4243-9a08-07fbcd98c6e7">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3205df0-6c17-4117-bb42-1fc68f48c09d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ea4b0ec-5f32-4357-bc2b-5f95f7efcb61"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa9dbe22-e791-4ac2-8209-b4bcdc970d61"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c77c1a72-0a86-43fc-8c5d-56d05dc7becc"/>
    <rdfs:label>Valproic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0736cda-9935-47f2-a990-34803b9fc6eb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8b5237c-11ed-418b-a144-19319e87ff7e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75c6c010-30d2-4592-b987-f54368b4fa24"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab40f657-33ef-4886-a53f-30400a9f7f6f"/>
    <dc:identifier>DB00313</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b305751-5e3e-4616-8476-8bb79ba73ba1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c178836-3b68-4b8a-a5fb-014a0155d26d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb33b96a-7ca7-442d-9d32-454ca6f6aac0"/>
    <dc:identifier>DB04076</dc:identifier>
    <rdfs:label>Hypoxanthine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e06caf8-9ec6-4ea2-a156-0e90b6fdf9de">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c291370-0cd1-42b9-bbab-b72e5a1b968a"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/797f4fd3-87c2-4631-a7ad-bcee1bb55c86">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84063437-8460-4ca0-b32f-39fd6ac23bf7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5af3d87-ba99-4f2f-8b65-81768b8abde3"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c325b740-5332-4b4c-927c-350d2eb43828">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/993babc1-1608-4825-8424-79fe16fc62da"/>
    <dc:identifier>C04</dc:identifier>
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f05c0b4-a890-4089-a37d-6faf1b92f236">
    <dc:identifier>HP:0010535</dc:identifier>
    <rdfs:label>Sleep apnea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a37a7276-855c-461b-8d2a-a5cd55c81829">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1bc4985e-0d61-47a4-ab0d-705a02322690"/>
    <dc:identifier>DB03147</dc:identifier>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c74ec41-38a1-467a-b3b7-98cf06edcc89">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Low cerebral creatine content</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
    <dc:identifier>HP:0012113*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aca6553f-e344-4401-8af4-cb135fd91394">
    <rdfs:label>Clonic contractions</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49c886cb-9b46-4cca-87a5-65dfb32910f6">
    <dc:identifier>DB00133</dc:identifier>
    <rdfs:label>Serine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90bb8767-9f75-425a-a13c-a9a0ece9daa2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/300531f1-f32d-4a16-964d-e69b2dd2515b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c82e57f1-3f1c-4fa7-9a15-9e7cc426d00b"/>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/764c4a7c-e9d6-46a2-9ed2-18218abb116f">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20b5657f-4607-4553-8e93-9a4fa25a535c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5dddb876-ad41-42a4-b6ac-80d070bd1b08">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c04ec885-fbca-4531-9e38-f28e8f0661f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d604178b-df28-4297-aa69-a7e6d7177e7a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23714122-0509-41e1-8204-4968dc31431b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23553ec5-6371-4a1c-9808-009e09b52bad">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da32e78e-6dd5-4498-8425-c9645544bee6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e15b2621-0a9c-4f36-9d9f-f9a5e84d43e7"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c236408b-6bc3-4934-a190-cbd59310b75f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a39e735-1fb1-447c-9d27-ab9bc632712d">
    <dc:identifier>DB09130</dc:identifier>
    <rdfs:label>Copper</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8a3b38f-80a4-412e-bb7f-ff1a3a0ca6b3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64136ee4-42c3-43f8-8f59-85aa22b9ee9e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2070a48f-31af-44ca-b98a-be1d6a610c73"/>
    <rdfs:label>Gene therapy *</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94b1fba3-7aff-40cc-b22a-cd2fe7f9e795">
    <rdfs:label>Rifampicin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <dc:identifier>DB01045</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8241293c-905d-4316-a1d5-038aeb31e906"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b17a229d-e0a3-4a10-8929-2ba5810af43e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d874a66-e18f-41b8-bfcd-66b9c33a33ac">
        <rdfs:label>Congestive heart failure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbe026da-7463-4e18-ae06-d274d62bb563"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94f9e4b6-e7ef-488b-aa87-428e6183287f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9174de12-8607-4af9-b4d7-abece01f54c9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c43b9fec-7048-4ee5-9beb-27abbe6eb9c6">
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Stroke-like episodes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6eb03f68-1947-4151-9e01-7837d63f8f47">
    <dc:identifier>DB01345</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
    <rdfs:label>Potassium cation</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/462af571-b156-4d71-adc6-e991d4914b9a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb675716-38e6-4bc1-b7bf-8cf764a39f63"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53411398-b503-4a01-8009-02f7f5da8617"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b377e0e1-9737-41ef-afaf-842ccc28f06b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e03ec7b-bda9-4109-9a5d-88e4f302d5c2">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26c42546-18a4-44be-b24e-22c1534452bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef3122af-118f-43e1-82a2-c607bba33bd3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4738b1b-6994-4964-8baa-60fdfc2afed7">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Abnormal mental status</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a6b59d8-0e16-4c8a-897a-d95761af6040">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45ce952e-d0f4-4ee6-ab13-eac7a20f6b2f"/>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a38eecb-d7da-48fd-a8fd-b11df28690fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6dbc0080-07b0-412b-86d9-56e6ba59024d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93e5f0a5-9338-4461-a2b1-c132f1530363">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <dc:identifier>DB00480</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6feb7f39-2633-41e1-b8e5-b577f6560193"/>
    <rdfs:label>Lenalidomide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b90c8a74-cdd5-4175-9ae9-b0f5402432d5">
    <dc:identifier>HP:0025521</dc:identifier>
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/effa450a-fd09-4c20-af38-3320d7067d89">
    <dc:identifier>DB01022</dc:identifier>
    <rdfs:label>Phylloquinone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7303938d-0ace-4a04-ae07-abcd954a6172">
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3cac268-12a7-4b5e-b632-66fd88bcb8de"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/553678f1-c0c0-40f4-b3c3-8cefe9e8f1d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6389111e-cec8-4e3d-865f-036ab924a844"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8d3a20c-21da-412c-b1b1-df852f89d390"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d0ad4de5-cb8b-416c-b702-4159b5c0ada5">
    <rdfs:label>Benzoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b403742-a819-4945-a250-905b6763fa52">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4746ac75-01d4-4354-b0ba-cd19a00dd8ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/974a8313-dab7-44c9-be76-f626c663dcf1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/946ce39b-6b32-4546-a64f-b9bd52474aa0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69ff7257-7a57-4830-8fec-e92719dbce66"/>
    <dc:identifier>DB03793</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33e02c52-9126-42ef-90c2-a3ccb39b8f7d"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b244e23c-339a-4f8b-947f-bb6d161bda55">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/696f2970-569f-4c5c-8908-a499b2a93793"/>
    <dc:identifier>DB01324</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d27f3565-d41f-4059-875d-3e971a08a4de"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9891ad92-7a45-46a7-8b66-3da07887df9e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <rdfs:label>Renal salt wasting</rdfs:label>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8898046d-9a34-41fd-b24e-730ea9faf893">
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/673df764-6a2b-47a2-a03a-e03a2eaeaecd">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26177f4-ddc0-4dd0-9f2e-afcad74e93db"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e19621ab-9bb7-4610-b0f5-3dfbffbc991f"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaab948a-9236-4559-bb8d-df0147e94972"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b73045f4-d4f3-41cb-8fc3-d518539a2171"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/050d26ae-7916-4684-85c1-c5da333e5070"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dc77d70-d4ce-4ccb-ba21-51f6ec876d90"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d61cc523-1274-4dd5-9fd6-39d2288e87fa"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/b8c6fe59-3638-407a-bb67-1665a311caf3">
    <rdfs:label>Dietary supplementation</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/575fb37c-e284-49c7-a316-aaa15cfa6208">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <rdfs:label>Amyloid deposition</rdfs:label>
    <dc:identifier>HP:0003216*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34c11fe3-a918-4170-a18a-2415d194dc73">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601776"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab7e15bb-2df6-4b95-84eb-673aaf2dcf71"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca6e5e54-bc80-46b7-b5e1-783ff15b5de0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e771f9cd-9478-4887-b705-85c7fd39f735">
    <rdfs:label>rAAV-PPCR</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfa69f91-b831-4e17-8aad-9edfd083c8e1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b609fa61-1fb1-410e-8a6e-a4bb27e54e4a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97b62666-7b14-42d0-b5a6-d9cdfa0916d5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/375684ed-26e7-4aa3-9fe1-5136bf858378"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56baeb13-34a3-4ed1-a33d-5ff036a877c8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5996e0bb-0597-484f-ad6b-19cf8cc8a9b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/818f858f-5040-463c-9a18-5488dd211499"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e261ff9-8e4b-47be-9db0-b304c2c6bb06">
    <rdfs:label>brain ventricular dilatation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
    <dc:identifier>HP:0002119</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/130575c0-e2ea-40f4-9ad6-65b6a116a49d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3754a9b7-9bcd-4dd7-a5be-9f4955a4f44d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72db2adf-4fa1-4342-8d55-09210c7d86ed">
        <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
        <rdfs:label>Neutropenia with IBD</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76efde02-069a-4352-8944-de1009f10825"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6c84218-2cac-4899-a422-9fd791bee06d">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b83e697a-62e9-4e5d-b0c9-a06646d90baf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8ff800d-6e94-4c55-a029-d72cc1c5296c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87a13282-138d-4d9b-85ad-79cae167dff9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4802fc77-33e4-49e6-8e70-2f46f07b739b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Palmoplantar keratoderma</rdfs:label>
        <dc:identifier>HP:0000982</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71811fdc-8353-4db8-9820-28837415a347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42471d48-2aee-48f0-b714-11bec3f354cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74970341-42d1-44ee-8ce5-286314dc1a69"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b7f1fcc-c96b-439c-8e8f-433aa74bddee">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c32c13a0-d146-482e-9319-11327349a474">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Proteinuria</rdfs:label>
        <dc:identifier>HP:0000093</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9a2be94-70cc-4022-8b5f-8d248337c6e6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b002deb8-6103-4f37-83b1-e138c07ac340"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63e90731-473b-46fa-b132-74ae1543236f"/>
    <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b58323b5-56bb-4f10-87b8-9b78dce7e417"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc1b5812-f7b6-43d2-9027-8f82f0b4c929">
    <dc:identifier>DB02053</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b5ba9a4-9956-4848-a684-49a792fbd04c"/>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2693e49-e078-41c5-8b20-0475ce0a832b">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a74259d-a1c1-4259-b0ae-998a907a0d2d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/093dd37e-9d89-4497-9d70-26710d125257">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <rdfs:label>High prolactin level</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0000870</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/210f4e8a-e70a-4038-a1e5-760bedd58510">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/89dd4b58-9143-46e5-8788-683469d0f1e0"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/dfbcd5ab-7e10-4a86-87f9-6567448c8c8d"/>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7448828-65fb-4e3d-8b8d-be38ecee9b14"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39cf2cfc-9a54-4f36-8892-794dc5ae52ca">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16d75d4f-8061-4175-9030-da39c0b46c52"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb86562b-16fa-45fa-921f-083619423d3b"/>
    <rdfs:label>Agalsidase beta</rdfs:label>
    <dc:identifier>DB00103</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b92a0bd-25c0-4e98-a0e5-ef76906e5439">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/909cc698-086f-41b3-b302-54ab21e4e997"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5906a6e3-2b50-4eb4-aa1f-ddde42117ccb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/565ce558-6f22-4485-92cd-6a6cd9cdf076"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e81c7f4-72a7-48bc-b53a-114608c837da"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55d9914d-351f-4c5f-821b-150f28e6bbc1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93071eee-6bcc-40fc-aa95-6aeab7a748c1">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Deep venous thrombosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
        <dc:identifier>HP:0002625</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b86c9eaf-8700-49a9-80b6-68709a412ed1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34a81ee8-9f31-4df6-9556-c54e2e4aa7d6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abd8bf28-f332-46f0-a333-c23ba8189d35">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>defective heart function</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/111505d1-e8e1-4def-9621-4864fa2a152f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5020498-c044-48ec-acd7-1245706a398f"/>
    <dc:identifier>DB03766</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <rdfs:label>Propanoic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c84d3964-3662-4e06-b728-f03b567475c8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
    <rdfs:label>Ramipril</rdfs:label>
    <dc:identifier>DB00178</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc79aa4f-601e-4cc5-8eb3-0c6682549486"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88b47a90-d191-4ccb-bcd5-267bb8e76685">
    <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
    <dc:identifier>HP:0031884</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a6ecb1a-7d90-4748-aae5-f7f071466459">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6549a7a1-8e79-4e70-bc12-78a1e589cd1a"/>
    <dc:identifier>DB00035</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41b65e68-e09b-4804-9ddf-6653c4d21b52"/>
    <rdfs:label>Desmopressin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d2fec20-2a6e-401a-9877-164ca084d910">
    <dc:identifier>DB14712</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
    <rdfs:label>Elapegademase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff06fd79-4960-4e4d-9da5-cf48402b2a03"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62d9e696-c558-4083-84dd-acccfb8f56ed">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb161655-3b0b-4af6-a61b-18d6fe05e3f2"/>
    <rdfs:label>Amiloride</rdfs:label>
    <dc:identifier>DB00594</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6db69c20-daff-42ad-97de-7be560372ae9">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78dc8cc8-9be1-4b59-af58-18daeb10cec5">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>DNA hypermethylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fd93374-cbe7-4a8a-9cdf-d0cdc59dc1d8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79636cd1-8046-4ac0-93ce-364c66ebfda2">
        <rdfs:label>Liver fibrosis</rdfs:label>
        <dc:identifier>HP:0001395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5e6605e-738e-4dd8-8020-0cd3a3d9d73d"/>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fbfa2df-f136-4b16-b254-e569585abd27"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41343e19-dd90-4584-92ec-6d78884cc995"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea441aaa-7c9a-4dc0-a50e-badf5806472f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6472e89c-a3c5-49a1-ad92-5e32be98f535"/>
    <dc:identifier>DB05481</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3c05dc2-ed20-4c52-a0db-010a2f19c164">
    <rdfs:label>Glycolic acid</rdfs:label>
    <dc:identifier>DB03085</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43593fea-3512-4cb0-9cbc-cf0fd120673b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0aa8acc-03c6-42d4-85ae-ba8a02b64e4d">
    <rdfs:label>Unstable AGA enzyme</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb48cf12-9256-416c-afac-31926d03a7ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254ad050-fe2d-440f-a3a4-4798b048ef24"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/b8c6fe59-3638-407a-bb67-1665a311caf3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/675eb5fb-4021-4cf9-8028-1a109048276d">
    <rdfs:label>Nystagmus</rdfs:label>
    <dc:identifier>HP:0000639</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6561c18e-e5ec-44db-a7cc-a4b0689bacbb">
    <rdfs:label>schizophrenia</rdfs:label>
    <dc:identifier>HP:0100753</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e782ec0e-9f1a-4f40-88bc-8968ae1666bd">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d27a3d3-f29a-44b8-9d8d-6d0cd65da062">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/286bc6e9-eaac-4f92-a871-71c2861afcbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/008f060d-9271-4ca5-a973-9430f14de8da"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4210d436-b855-49ec-b744-ae633bbddf0d">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79c3c080-5469-4ad2-9140-3709c865fbee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bb0d198-28aa-45af-a229-92fde51e6e07"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b40c247-d9c2-46f0-b98b-c48ca8355bdd"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01636fdf-a296-4603-9687-349e8b9408ed">
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83adf724-8fdc-453b-8f9f-90a01e329c7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbe9f6b0-58d8-490c-9b47-21b9680a0671"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac71632f-5118-4ab3-8a97-c4586b49544a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a1df32b-acf9-4b37-a199-b570b5508ddb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7492f9f7-b88a-424e-812e-4b5e68ce56e8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0fff3d3-5f23-4f73-a916-c2e78de0a271">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/930b5dd7-f0ad-466d-b7cf-174df8b4f422"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40af249a-cede-48b9-ba14-00c110cc003c"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b3f8e5a-888e-4194-8761-e91840ab8aff"/>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b72f14cb-7de3-4ed3-b720-90e0fc144069">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04fb05da-7116-477e-946e-f718dd4e4234"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b165b6d-46c1-4f08-8404-08c28d50c1ff">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/669bb511-2dd6-47fa-aa2e-07a6acbcc6e6"/>
        <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/099ac911-a445-4b83-87c2-2eb7f4edd750"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9174de12-8607-4af9-b4d7-abece01f54c9"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e16316f7-3e24-4b61-ac74-7a096655d799"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c545ab5-890a-437e-acd9-c39f4381e551"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>L-Arginine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f77685e2-2ee2-4f1a-8941-c448415a0641"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b17a229d-e0a3-4a10-8929-2ba5810af43e"/>
    <dc:identifier>DB00125</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6279dc44-c682-4c95-88d1-507ff27de8be">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14e9bd2a-96f1-42e8-80b2-09d49ca44e0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c60afad-c0c8-4159-bb3e-4346b8dee424"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14b70caf-0259-4dd6-9eb9-1408f7e586bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/ea15b5b1-0b2d-42fb-b52d-879640a90f8f"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8574a254-9bdc-497b-a39a-fa0fa1958030">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5eeaaa51-c62e-4a3b-8c36-25b9147a4d62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/570440f7-9a0c-4690-972a-e176284741bd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25e37a37-6301-4b6b-be57-e40e497e941f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <rdfs:label>Tocilizumab</rdfs:label>
    <dc:identifier>DB06273</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b18c4c91-8bd6-45b0-a27f-d2b3bd3e5a6f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a27d794f-9a92-4b96-b941-f5bbb32d1892"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cea2b93c-0af2-46df-98d4-4b94377a823e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4a9ea70-0c1d-485e-a241-f731b9927c5c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3f32a98-8820-44e5-8c40-458d82956fe4"/>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/794e0240-2b6d-4162-898b-759dde682a84">
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f2a1366-9fdb-48e9-ac88-44b4e9c95146"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07e68714-89bd-440a-8e85-720be27ffca8"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf028570-87f2-45da-bea8-433697a1d187"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a05f554d-8dde-4e70-976a-bf3b6b541596"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b97e5473-ec06-4a85-966f-6e072721b234"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc7b5bdd-965c-471b-8a92-5b2c9a8cd2db">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
        <rdfs:comment>The drug has been reported to be unbeneficial in one patient .</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0565e76-6a7c-4769-a060-da36eb49c04f"/>
        <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
        <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef8b0c00-a7c1-4816-a4fb-3e55765238ef"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcd1606e-e378-4dc3-9a99-82f394a390b7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2679db3-3dc8-4e7a-924b-031d1e812258"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb576816-3cd5-4b92-bc1e-353462d2fbde"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6ba1409-ae1e-4b24-adc9-d938ed8fdbab">
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
    <dc:identifier>HP:0010832*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ca63edc-d224-4163-b444-5d2bd9488db8">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31bdb5e1-5b6b-4a63-a8ac-1510200f4d57"/>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2164b09b-b971-4ff3-9c97-98110431bbd2">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>high brain and liver iron stores</rdfs:label>
        <dc:identifier>HP:0003281*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a41cfa1c-2e57-4679-8dd9-0c32186489f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa50ba14-3818-452f-b41f-f04cb6cd00af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f5b31da-2d87-42f6-b101-3880740f10fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4a4593ef-a362-49dc-b672-08bc9ebe02ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e7ad88d-8621-4eca-a270-b5282ebc199a">
    <rdfs:label>Sodium acetate</rdfs:label>
    <dc:identifier>DB09395</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/865337a8-3c65-4c80-9462-323a95db861f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/551cbc01-8146-4388-92cd-fa9217c3d322">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00bae8f3-0c41-49f4-a9a4-1f979b0be10f"/>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c467bcd-9515-4eb6-8e9a-bf10f7a4836d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3070e726-ac68-4b0c-8bf5-8bdc0bbcaa32"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8407c2cc-162c-481e-8b51-bf22b2df62ed">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <dc:identifier>HP:0001992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Organic aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94a2be75-2639-4c75-b92f-b86e68565d8d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <dc:identifier>HP:0000964*</dc:identifier>
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f7d13607-78da-4600-873e-257a16ebe192">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d51f13ea-e727-40f6-ac6f-0bfa9d9196eb">
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <rdfs:label>Atherosclerosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2145ca39-e8e8-4a25-86f6-fc2323f853ac"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32ac9841-e85f-4766-a070-f16d4c839f10">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000504</dc:identifier>
    <rdfs:label>abnormal central vision</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08aff1fa-2257-41b6-a07a-5ff53934847b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/190b3a62-bd6f-4062-a875-544305a9ea8a">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3ecf0b2-fb55-467e-b759-3441e2cc77aa"/>
        <dc:identifier>DB00999</dc:identifier>
        <rdfs:label>Hydrochlorothiazide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a1747cd-7faa-4d3c-9b77-e766b04100e8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9c4e64c-4327-4fbd-ae97-cbb39b9dd776"/>
    <rdfs:label>Piracetam</rdfs:label>
    <dc:identifier>DB09210</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5b5d848-667b-4f53-b58b-ea9e6f7c3592">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/099ac911-a445-4b83-87c2-2eb7f4edd750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a94e39b4-ea3f-402d-a9f0-68a4f8e34ad7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/539a1840-1ac8-4ca0-bf1f-9d3f2c3e698a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/de205b5e-898b-412d-85ab-58a20b81aada">
    <rdfs:label>direct complementation of a genetically defective protein+symptomatic treatment procedure</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3acff8eb-5fdf-4a3e-8be1-fb40b6acd0c6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14df90fb-e02b-4626-b469-7d6f15f2138e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601780"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4a62512-73d1-4330-82b9-730d37f84b84">
    <dc:identifier>HP:0002500</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>brain MRI abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a48fd2e7-e1cb-405c-b1be-cb3ae718a482">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e26fe58f-3c14-4245-8154-b041b8596b3c">
        <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/422d8c9a-6c55-4cd6-b050-9eab2f6e3df7"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b57152a0-c685-486b-8441-88e3bc00d98b">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39c1d1d7-755b-4ab1-9caa-0fd4eb70de74"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d67da1b3-32e2-4164-b6a2-357c81f53f95"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/437460ef-780a-4376-ab57-3af0912076e5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79981f5c-1efc-4888-9a81-a6886e871d1f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90a605d6-a3c0-404a-9c2f-e295cb517337"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6eeab08-e21e-4ed4-9a07-8261764a391c">
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <dc:identifier>HP:0003111</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bd010dd-a88d-47b0-ba6c-38c75e695e6a">
    <rdfs:label>pathogenic exon trapping</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19400b99-d1b7-403a-bb93-0ec8065a548f">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0010918</dc:identifier>
    <rdfs:label>low intracellular cysteine*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1baca804-7130-40cd-9e3a-94c3f2d4f823">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92b07a6c-a2d3-4e01-a6b0-0509d164ce51"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/275ad08c-2132-4845-a55c-95272cee9d26">
        <rdfs:label>Delayed motor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40ecc46f-2bc2-42f3-914c-59fd8f5dbdd0">
    <dc:identifier>HP:0008222</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Female infertility</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0565e76-6a7c-4769-a060-da36eb49c04f">
    <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/216e7c39-b663-4b09-8573-0b77f0619f0b">
    <rdfs:label>hyperprolactinemia</rdfs:label>
    <dc:identifier>HP:0000870</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f54388b-4df1-46ed-8be4-296a75e83f38">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffdc08e0-fbac-4046-a10d-714fd1ecd2e6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:label>spastic bladder</rdfs:label>
        <dc:identifier>HP:0005340</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/431eeb13-51f7-4187-9f77-7ea9e762d422"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0025660-1181-40ef-a5b0-c50d00f6222c">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/355e572f-b3fd-4254-94e0-b463e4e7decc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb3f9620-87e9-4359-9941-8d65ec14965e"/>
    <rdfs:label>Ad-hBUGT1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b0dd595-a8ca-4574-9c98-5719bd6990fe">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bdfc7875-06a1-4005-ad3d-cee00f9b3085">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb42e556-cfc0-483f-abd5-1d54715592c9"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f735b17-fd6b-43f7-9014-463f494df1f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Probenecid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <dc:identifier>DB01032</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b8ca2d5-9822-4578-b4e5-11e309c02fa2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba775b9d-d5d1-4515-a926-34f3ed4d36f7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9a3b4ef-75bc-479f-a404-28b2cf3edc1c"/>
    <rdfs:label>Potassium Citrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93f9c611-c606-43db-919a-f64365a8baf4">
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c31558f9-374b-4091-a0e2-f3d3082e88aa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/035b6148-cd24-46d1-b7e9-17c0eeb73320"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfe0175b-c659-439f-aead-e1e40cba8e43"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09125</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e19621ab-9bb7-4610-b0f5-3dfbffbc991f">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Neurological abnormalties</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5dfc090-1101-4ac0-9f01-9f45213b5b7c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003678</dc:identifier>
    <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6252942-c38d-4525-bbcd-73f0addefa64">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e792d4a-ed40-4ab7-8d0b-1bffb5755328"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5b84443-7fd8-4100-ab98-46a7f615235f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9eb33cf1-41d1-4bf1-af0f-c5d264c80c3d"/>
    <rdfs:label>Indometacin</rdfs:label>
    <dc:identifier>DB00328</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/710aae0c-e401-4ce0-8d7d-ef714dccf6c3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edcea33b-befd-4f61-b06c-4698fdf7c8f9">
    <dc:identifier>HP:0000962</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
    <rdfs:label>hyperkeratosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/157b2e0c-4a13-42a9-bfe2-62eddf93b510">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec029e4-0e8c-46e4-b68f-fc6b2423bc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/909cc698-086f-41b3-b302-54ab21e4e997"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ed66f58-6be4-4015-8b0b-9c1a3b7b5276"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c936c70a-f645-430c-b4a2-385eed945e37">
    <dc:identifier>DB01124</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0864a4a-aa3a-4f3d-ada2-8d13f6604e19">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb2b47a7-c0d2-48fc-9cb0-d975e7e4d71a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
        <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb4b1ca1-7957-4644-810d-c3c036c2006a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Tolbutamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2430c4e-f8d2-4f6d-94ed-dbd4deb29e75">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2de8cc73-3955-47d9-a684-a6a554b907ca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aca37f37-8ec9-408e-b2f7-ab97b1b507e7">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>endothelial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49b4483d-ded2-4799-abd0-46063f910987"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52e7bf71-f4fd-45f5-95e1-e0f029b95389"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e92aa2c-2b8b-4a31-b36a-f007535d559b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f4799bd-506b-4c30-980c-ecb27361e9aa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>http://www.malacards.org/card/hepatic_lipase_deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f8974c5-8824-4671-ba55-28693a163a40"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613521"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/834950b9-3666-4df4-b8a4-6b3b7082870e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low pancreatic zymogens</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b7c4e1f-1a65-479a-8380-9f71d38bf0bd">
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002574</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84063437-8460-4ca0-b32f-39fd6ac23bf7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <rdfs:label>Cholecalciferol</rdfs:label>
    <dc:identifier>DB00169</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e06caf8-9ec6-4ea2-a156-0e90b6fdf9de"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/402f7a7d-c0e0-456b-8f37-76d824e77a0f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/ec17770b-f616-482a-9d67-b3ef9a1e0f5c">
        <rdfs:label>symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7531a952-cc62-4b5c-b061-9f9e184e115f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b14f3eb-2675-4f5f-b073-1f553881f80a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/872f4968-914b-4d83-a404-44ce1ea12380">
    <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
    <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70284ddb-e966-4f30-a2ca-6b7f83681da1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b610b6e-96b4-42ed-9f9e-b0a8237bc8b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b660461c-bdc6-403d-afd6-1d00b6f0f73a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db18ded5-f01b-4be3-8c9b-788f58c4197c">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:label>Low 5-MTHF level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/422d8c9a-6c55-4cd6-b050-9eab2f6e3df7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24a0254a-ba63-49a0-ab9c-885710843af2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a48fd2e7-e1cb-405c-b1be-cb3ae718a482"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613027"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7cc34911-7dbe-4a88-a57b-5660f5f62e8c"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00edec54-a891-450f-b364-f832b73ce724">
    <rdfs:label>Appendicular hyoptonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0012389</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cff3a9d1-6a7e-4316-848d-374b6fbb657c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
    <rdfs:label>Abnormal inflammatory response</rdfs:label>
    <dc:identifier>HP:0012647</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc887c95-ebd6-4ea7-a050-750a0d982885">
    <dc:identifier>DB06285</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/356e6ca5-4701-42bf-8c92-4a453613cab8"/>
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24b24857-c8c7-468d-b775-4177f2641972">
    <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/993babc1-1608-4825-8424-79fe16fc62da"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04ab218a-bd05-4be4-b58c-beee75725945"/>
    <dc:identifier>C07</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1f78da3-a9d7-4254-8551-d0e3bf544ff3"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bba6f937-8df6-4e26-91fb-7115779d4715">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:label>low quality of ife</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46fa8dc8-4cbf-41ae-b6c8-d8bab27825c6">
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <dc:identifier>DB11098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6708388-cfff-412f-9860-4752ee3e0cf5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b72c2ee-1dec-4b9b-b6d0-d2751645f26e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a462da46-c1d6-4762-af6e-bd32fb11b57b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ad8e4d5-cdc2-461c-b01f-c78b966d4826">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:label>abnormal motor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b78e67c-6b89-4d6d-a5c1-d64b248ada01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fdb84e8-af85-4034-9719-7b78e0aacc1d"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33c76f61-8da3-495a-8a13-9c3e11730979"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1938a0b7-c97f-4276-af84-43479537320a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/022bae1f-9a21-42cd-8fda-8b1ac343a4ec"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3067bf0e-90f1-49d7-9953-ff26bf0049a2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/769b9cf5-e009-4001-a4a5-4f0c8780331a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3f61296-e1e9-469e-bd15-89bea4f2d3a1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698727a5-93b1-4cc9-b0a1-8cefb8b6c30e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dd23055-c3aa-439f-8f2a-b69f918907b5"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11e40438-202e-4423-aa9a-3e27ffacc2b4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf5cb5b8-f857-431a-ba1d-96dfaadc1d0c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43e19c26-6022-4ada-8824-f562ba998c9b"/>
    <dc:identifier>DB00746</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3048e161-854f-41c6-a7db-1e7299f2cf5a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:label>High total homocysteine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6389111e-cec8-4e3d-865f-036ab924a844">
    <dc:identifier>HP:0001892</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
    <rdfs:label>Bleeding tendency</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7d6a40f-762e-4aa2-8821-62b412d1a53d">
    <rdfs:label>hallucinatory-paranoid state</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
    <dc:identifier>HP:0011999*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e7ca84a-d30a-4259-94a1-1b869c4635a1">
    <dc:identifier>HP:0001959</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <rdfs:label>thirst</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0a8569d-6fd6-4dea-b2ee-8c315b33444c">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
    <rdfs:label>enanthate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73df4c53-cd17-4b96-8799-62303443ce90">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88085a1d-52b8-457e-93fd-583c478b06dd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
        <rdfs:comment>The drug has been reported to be unbeneficial in one patient .</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea2da973-054d-46f4-a9b2-6d14c4b19e95"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>CHEBI_32362</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d6be78f-2652-4f6d-a9ab-5319767adf6d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/539a1840-1ac8-4ca0-bf1f-9d3f2c3e698a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03798154-31e1-4469-b0d0-05525fa35668">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Low developmental score</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f10eeb5-d497-440a-b4eb-052700655caf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be5a2459-27f5-4175-8a12-159713d8f4b5">
        <rdfs:label>cognitive dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e3dbdbc-953e-43c7-86a2-62c6a7355df4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>psychomotor retardation</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b87ae90-cecc-42b3-b3ff-929e0154c643"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/edc79d5f-5e1f-4748-ad52-24ea2fbff326"/>
        <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61dbe6ef-a0b8-48dc-9516-e3fd7caa5003">
        <rdfs:label>communicative skills abnormalities</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
        <dc:identifier>HP:0002474*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af0328a9-e8a7-49dc-9dd8-b236ffcb0e55"/>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0cb70d0-a635-4410-975f-d40101e92414">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>language impairment</rdfs:label>
        <dc:identifier>HP:0002463</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c74ec41-38a1-467a-b3b7-98cf06edcc89"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af5efde5-e1e1-46eb-bef1-a00acfdd9157">
        <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60bcfac4-f67a-4257-8be3-d9ed2527fbab"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/827f77e4-a39b-4282-887c-9102e5c7c976">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a62b29c9-6c74-4027-9304-4f6d9b4ecda1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36be566c-3bd6-41e9-8a34-9361ad0d4d46">
    <rdfs:label>Interferon beta-1a</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <dc:identifier>DB00060</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4bf9436-c7ae-42f2-b3b7-3d0f049881b3"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b657a961-b885-4e0f-98aa-7338ff1cd13f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/608177fc-c9a8-4923-8643-7bea9b0e8464"/>
    <dc:identifier>DB03227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8eaecb94-dd0b-4875-9244-3fec7feb1841">
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3bcaddd-170f-4f15-ab96-32342835b304"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f1d5fc9-a7d6-4d84-a1b1-d30146445b73">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <rdfs:label>Filgrastim</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ce03c8d3-240e-4fa0-9133-d3a2d8f6ec42"/>
    <dc:identifier>DB00099</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b72d9af-3199-4fd0-9530-3e8fb1f791d6">
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0200125</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53629c1c-c22b-40d8-9e4a-78d673e58eb9"/>
    <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
    <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c160387-0d90-446f-b376-bd5e0b6d9d77">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64584735-5a0c-44b3-a95c-324850b7570f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1b2446a-007e-4196-9450-3bde1690b75d">
    <rdfs:label>Setrusumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <dc:identifier>DB14778</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/593b3dd2-39d6-4eaf-90e6-ce47cad09ef9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a31a2104-801b-4a43-aac7-ae087a64370c">
    <dc:identifier>DB11672</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3a6ea28-0467-47e6-b82c-da052f0dd854"/>
    <rdfs:label>Curcumin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39ea95b1-5320-44b7-9e21-e27b96d8978c">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001336</dc:identifier>
    <rdfs:label>myoclonuic Jerk</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3509ef93-af36-4ec7-858f-c3da333affed">
    <rdfs:label>decrease muscle strenght</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e240126-1eed-4580-b98a-6a07d6aeeb3c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43a4dc1d-10d6-4abc-85b6-0b0d22dfce88"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c3ced7a-16ad-4f8b-84bf-f40325821666"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc42be06-6674-44ad-b8c5-05f0770ffd58">
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Mitochondrial myopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
    <dc:identifier>HP:0003737</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56d96ed1-3dea-4b0c-b827-b64b2c3f74a2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <dc:identifier>DB14500</dc:identifier>
    <rdfs:label>Potassium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b57152a0-c685-486b-8441-88e3bc00d98b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1503f15-6966-41f7-b65e-e2c8426a2df9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39c1d1d7-755b-4ab1-9caa-0fd4eb70de74"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfe0175b-c659-439f-aead-e1e40cba8e43"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/580fd404-0e13-4d6a-9724-5eb299bd39f6">
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/956b9472-af6d-41d5-812b-d08f0b4d9c0e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd1acfff-673c-4629-a828-2205779ab8ec">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c624596b-ae8f-4f83-b0a8-ae12770613c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6879344-4a29-4bac-bcbe-a232548f5f53"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8541f64-ef8c-47ce-99f3-f2c0456cf246"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57c2119b-bc10-4505-b5d9-2bfc6ff219ae"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e02e6a7-25bf-4378-8194-04696d86abcd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/5ab07ebf-8c6b-4ccc-bafb-ecfe13a94e0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa44260c-076d-4025-b803-d775d5a74289"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49e4baa9-5c33-4096-a7f2-314162675b40">
        <rdfs:label>high creatine kinase</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/825a10c6-dd86-4fb7-8113-6d4bb571be1f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32817b88-7e1c-4af0-aa93-5d5db4106642">
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c6059b5-36ee-4ed9-b61b-ce1c7b67940e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f19785ac-825f-4a0b-b8ac-686e1c6238e3"/>
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca96a316-2234-4a9b-b309-804a33064ce3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f67edb4e-a3c1-4288-9945-31f06f1a5c1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a79f738-0092-4a04-9296-08e213f95393"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a74a7203-8414-4396-a06a-6916e7594cc7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2cf3933-8977-42bb-8e4f-005075082377"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <dc:identifier>DB00162</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f21a048d-7c58-41aa-b525-c81b35d850c1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b84d8614-9d39-47ac-b544-3e1de2e43210"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9707bdb-b0dd-4a82-afb9-a1bc8444030e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e0c7de2-d020-4b2d-ab77-c9260423388e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b057608-5467-418c-9cba-7828c2325817"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd616b85-42f0-434e-aa55-68d205b08fc6"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96bd1ee4-174c-4348-9045-d27535c3b756">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3345333-6cfb-4bc6-b24f-4b76e53940b2">
        <dc:identifier>HP:0004396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <rdfs:label>decreased appetite</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b571921-3849-45cf-8e14-c69cf63a8490"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e2c6ed4-ad26-45bb-a41a-be9d93fdf1de"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3154d6a5-16d5-449f-b86d-9699bee10531"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b622d0ec-addd-4a3b-9311-6343bd7888f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90a605d6-a3c0-404a-9c2f-e295cb517337">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04ab218a-bd05-4be4-b58c-beee75725945"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b57152a0-c685-486b-8441-88e3bc00d98b"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
    <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
    <dc:identifier>C09A</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/993babc1-1608-4825-8424-79fe16fc62da"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99db7c95-5e1b-45f6-8021-c45ceb531a14">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b72d802-a9e0-4987-8b33-50db3165751c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef3122af-118f-43e1-82a2-c607bba33bd3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e03ec7b-bda9-4109-9a5d-88e4f302d5c2"/>
    <rdfs:label>Lorazepam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <dc:identifier>DB00186</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6879344-4a29-4bac-bcbe-a232548f5f53">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd1acfff-673c-4629-a828-2205779ab8ec"/>
    <rdfs:label>Modified Atkins diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58e539b5-dec6-4679-91ff-006273e93716">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012410</dc:identifier>
    <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/744d03d3-f0ea-4858-a276-855a18bd6bdf">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Neurological abormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86488b3f-f732-477c-bda0-add667a41631">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/089f101d-ae9e-4118-ac69-5e8b3eccc4a2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
    <dc:identifier>DB00509</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63cb2871-c3e0-4525-89fc-ba23c667267e"/>
    <rdfs:label>Dextrothyroxine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72c4ffe7-a689-4c02-8d77-4437204e89f5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <dc:identifier>DB00451</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b958058c-c435-4c7a-98e9-465ec1822839"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1113ce50-4ac5-4387-bfeb-8461ed1400f2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4c5e960a-7950-4dd8-a319-1a69a91bb8cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e088f87e-5a9f-47fb-90aa-0791dca015ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levothyroxine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6b7df3a-a073-4a36-a1b7-c8003b92a977">
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d341b6b7-04a1-4722-819a-7f330a72079b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d1ae3b5-6cf1-4c39-9a27-b978f3361e07">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02158c0d-3c0c-46c3-8f82-e6e7ffc11d4c"/>
        <dc:identifier>DB00909</dc:identifier>
        <rdfs:label>Zonisamide</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccb2159c-cb33-428e-962d-ce446c7837e9"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fefe6a3c-a4f1-4eb8-babf-297495ddebe1"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f45c1dd-7df7-47a6-b8a0-459c06cf0d2b"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3455b1b-c376-483c-82df-58a4ffcd680f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b699cfc-8a3a-4ce4-9ddc-9e6ed9b68127"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/064af469-cefc-4d8d-83c2-77898e876322"/>
        <dc:identifier>DB01068</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b665f91-88d6-4014-a978-ff0015424edd"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dafee37-1a65-43ac-8b91-33f5f6d08a0c"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab40f657-33ef-4886-a53f-30400a9f7f6f"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccb2159c-cb33-428e-962d-ce446c7837e9"/>
        <rdfs:label>Clonazepam</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd34dad5-6b33-49ef-981f-8349c0924848">
    <dc:identifier>DB01247</dc:identifier>
    <rdfs:label>Isocarboxazid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/430e3e21-5b10-42e0-8803-a8f60289f82e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f171f2eb-91e2-492a-8659-652eb88b6a93">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002917</dc:identifier>
    <rdfs:label>Hypomagnesemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/923c987a-767c-4db7-b59b-8438cef7a58b">
    <rdfs:label>hepcidin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01636fdf-a296-4603-9687-349e8b9408ed"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52521b4e-b521-47eb-82c3-3b33b3bd3409">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3692a44-c628-48de-8589-9220627dc8f7">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003117</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1956423b-2b6e-4502-92ca-4f51e8f07ae3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec4299-bbb9-4a69-8626-e7e3f1065676"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf55e7b6-1abf-4200-9262-dddddd5aaaba">
    <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5d9f6d6-ec3b-4456-989e-7d1f01069ea2">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Movement Disability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/064af469-cefc-4d8d-83c2-77898e876322">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39ea95b1-5320-44b7-9e21-e27b96d8978c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7aaeba3-5dce-4156-9692-2edfefd42183"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51b47858-28ce-4a55-85cd-f6bc598c681c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e58efdac-b25b-4248-9b07-7792e599e7fe"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f1a15fa-f039-42c6-a195-575ff8981bc0">
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Poor intelligibility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c04ec885-fbca-4531-9e38-f28e8f0661f6">
    <rdfs:label>cyclodextrins</rdfs:label>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/764c4a7c-e9d6-46a2-9ed2-18218abb116f"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1805c702-2c36-447e-b219-c7f726eefbab">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df8c0109-08b4-4fba-acdb-e4109aa4c401"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1428ae48-db39-41ec-b923-8f95da00b28c">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <rdfs:label>somnolence</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1fda405-0c2a-4460-93a1-5bdba337989c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/992e5aa8-5197-4f2c-a02a-3d158a510ad7">
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cef7a0d9-8e91-4084-b630-24724f0308b5">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0003343</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
        <rdfs:label>GSH deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f9cbe2b-abbf-421e-b8ae-0d7f651f8db7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac12a0ae-b551-49a2-a253-95abadcce14a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19400b99-d1b7-403a-bb93-0ec8065a548f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5051dd3a-7c03-411e-a8f9-fee8f94b8dbd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1423001-986d-41ec-9006-f21d88994ae1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10d95212-6f01-4598-a38c-dacd25692665"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27fae055-1de8-4b97-bcdc-538b4a3a0836"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2baa57c3-b3f5-44ec-8665-c48b15fa82d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e36731d2-474f-4fa2-b619-a1ff9197bcdd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f9c4a83-2b72-42d3-9e26-9a25209fd999"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78ea02d8-cc7e-4290-8e21-85db95548a25">
    <rdfs:label>rh-HMBS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04eac582-8385-49c3-a444-83bc02179ef2"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d34d14f5-b1eb-42d4-b3e4-705f4d984af2">
    <dc:identifier>HP:0003326</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>muscle pain</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49aafa34-5e10-4d8d-a0f4-22dca93eb126">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f1596c6-ba47-4f9a-b1ca-0b00a42de94a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/523e8bc6-cfd7-4a70-8573-f81ad463a67d"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dca1c11b-b065-4018-bd41-cecb3ce3388e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>Abnormal liver function test</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dfee4dd-e600-4ee2-ba77-a592db9d4df6">
    <dc:identifier>HP:0002375</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>hypokinesia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b49cf86f-1668-4923-98cb-cd2e0a5281cb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001941</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:label>acidemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1677a8f9-6391-476f-b926-0f858a08b257">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30eb81e9-7d2b-4067-bf4d-83523bf06491">
        <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/094b0855-9e7f-47bc-bd9a-25607f91bb46"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/788300ce-e162-4f10-bcee-c443b0a45be4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49b4483d-ded2-4799-abd0-46063f910987"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1dd9be5-c028-4402-9e25-dfe8e113e70b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00542</dc:identifier>
    <rdfs:label>Benazepril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d05db93d-7628-47d6-86f2-1c9beb8d3bd1">
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dafeb67-ce58-4104-b7f4-5fd2632a1ff7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941*</dc:identifier>
        <rdfs:label>acidotic crises</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e58720e7-a682-481c-aa64-e2360c225ea6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45fe2ba9-6997-483b-b6ae-66a19bd053cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53145565-c528-43f3-bd75-00f0e1c3cae8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low COX content and activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df72f826-1a62-4af5-8b10-27f94c1fc823">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
    <dc:identifier>HP:0002028</dc:identifier>
    <rdfs:label>Chronic diarrhea</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/758f0853-7940-4c81-aae1-2bb15b431831">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <dc:identifier>HP:0002540</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>loss of ambulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0cfccf3-fd8e-40e3-84a5-404be17103fb">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Abnormal brain electrical activity</rdfs:label>
    <dc:identifier>HP:0002353</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6ac26ce-e2c4-4f3e-a1d6-69b5d72745d8">
    <rdfs:label>Calcium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67aa49ff-e49e-4cdf-9211-f42dadf1aa7c"/>
    <dc:identifier>DB01373</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0881876e-b212-4a70-9bdf-84ca8d738981">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c42fd5ff-ada5-4f47-9c41-f9e710a99c15"/>
    <dc:identifier>DB00847</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc8febc9-5d6d-4e33-a08d-af2ace6584e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69c2ad07-4678-4b35-8917-63322c5debe0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63c4ed5d-4e67-4e15-8804-0ac3cc26cb81"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cysteamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac37598f-3d32-4382-b30a-99604a5b4c10"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66a232af-8c35-43ae-a2cf-90ab3545b322">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69c2ad07-4678-4b35-8917-63322c5debe0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea9421d5-7c35-461d-b8ae-055e6ebca3bc"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e6de909d-0bb3-411e-85e9-fe61b469108a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8c3ad1c-d2b3-4d99-a16f-6d7fc3161581">
    <rdfs:label>Heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/529b5776-e947-4d25-a753-43ee2066a133">
    <dc:identifier>DB00563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <rdfs:label>Methotrexate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a85029bd-c8ad-4942-bb73-1f81ce4ee489"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ebe3c66-a551-4940-a17f-cf4177500f94">
    <dc:identifier>DB01001</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/944c44b0-177a-40ed-ba96-f0fc340d545a">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f19ecf7f-2c89-4a19-8ee0-47d65356babf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ab6decb-a6dd-4dd9-8e4d-37baa4ad7044"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ba5bdf8-60ae-496c-9b13-f454261fb23f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a607a17c-2dde-4a06-9381-fe8e5b3ef6e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
    <rdfs:label>Salbutamol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e26a7b4-dab0-4898-8335-94eadb4113d0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71fe8b16-5735-4709-a04c-d076786e091f"/>
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/197aa9cf-adba-429e-9c23-b56374f58976">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <rdfs:label>Spironolactone</rdfs:label>
    <dc:identifier>DB00421</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b57152a0-c685-486b-8441-88e3bc00d98b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9f50efc-ba20-4dd8-9086-38efdafbf9ab">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <rdfs:label>Mecasermin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/031f7be4-c6ff-474e-9436-1c605353f811">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3dd01c09-3e9c-4437-b602-01c3d86bb7a0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7673cae4-387f-4390-ad64-89033f26a680"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d57be4a-cf98-4c8f-a8c7-86fd9c23127d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4b6ff9cc-439c-4ab9-bfda-65b06b2b78d3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b0fc274-8958-4b5f-86fb-d6b0cc8ae24f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bacf3a2b-5290-4f58-8fb7-a4dc75cd2455"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46cb9908-9f16-45f0-aa59-2642dff77dc8"/>
        <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b26d813-f7f6-4bca-a924-a2d364a992cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b90c8a74-cdd5-4175-9ae9-b0f5402432d5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1799d069-a66b-4ebc-b76f-b9dba11505df"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a975cea0-4b10-4be3-96e8-ae93522e1df2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01277</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad638cc3-f3f8-4de0-990c-f556d40b7683">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56209dbb-c1aa-49f5-830b-17d647e55443"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ec25a61-87db-4173-98a2-066fd8fcf994">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ee072ec-e17a-48da-8c89-14a80df7b77e"/>
        <rdfs:label>Amphetamine</rdfs:label>
        <dc:identifier>DB00182</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3299be4-cc14-4132-8080-ae0355b9cc39"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74a5ccf3-9902-4bdf-8d14-c80bf34b9924"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05310b22-2989-417c-9376-f117ad50466c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
        <dc:identifier>DB12537</dc:identifier>
        <rdfs:label>Benzodiazepine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ee072ec-e17a-48da-8c89-14a80df7b77e"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b31b9b1-e10f-43a6-bbdb-114a9c2bcdb9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9dc43b04-a7ae-40dc-91f3-f112ed851001">
        <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
        <dc:identifier>DB12351</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f81bd20a-61f3-4fa6-9120-b477cb76bd8a"/>
        <rdfs:label>Siagoside</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1507d156-ec38-4188-af1c-eb8472ec7b98">
    <dc:identifier>HP:0012335</dc:identifier>
    <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20d30cfc-e941-4de0-a7f9-6e5e1ee14c73">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f965034-c509-426e-b189-d63c77e452c8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0974e00-37da-485c-ab96-b1551cdb6e79"/>
    <dc:identifier>DB04540</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3d2e467-9cfe-4086-b53d-83435ebf2957"/>
    <rdfs:label>Cholesterol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c20d38fb-da34-4457-9e8a-aa422c7dedb8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7c5c810-9bda-4288-97f4-488678ac2886"/>
    <rdfs:label>Amcinonide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d59b519-fda9-4ccf-adbc-0408eafb625b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1598ea8-2b5a-46b3-b502-4d78dae567b5"/>
    <dc:identifier>DB00288</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f54388b-4df1-46ed-8be4-296a75e83f38"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb3477ae-7383-4645-9af5-0e8a3f6b940f">
    <dc:identifier>DB11635</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de188149-4673-40d9-bd19-c69d82955507"/>
    <rdfs:label>Tocofersolan</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e392bb8-245f-4cef-a7e3-ec85696c4396">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/267d467f-0d5e-485e-a887-ac603ae45ca7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bf3c2f05-6117-4f86-b034-e81ecc6115db"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5f68eee-eda4-460d-87e0-d52783884a9c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84248d17-8209-4e6d-91c6-cf4885aab46e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0be20901-8de3-4ade-a0c9-fd5005795219"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05a71b1-c61f-4ad4-be7f-0d8c5875c4fd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6eb91fb-f8f2-4513-b09e-77c9f0c5f22f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:label>High urinary malonic acid</rdfs:label>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0012120</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e87ef113-2fed-4345-b7f9-f64c205b36a9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fbef1c9-0e7c-45b3-8ba4-1c70a655c12f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2508531a-0b1d-41a3-a96f-21b66d2e3e72">
    <rdfs:label>Trial is no longer available</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3be1ce46-d2c9-4764-a22c-2327c75587f0">
    <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7eba2633-55e1-4d06-87fb-f8c60cf2f03d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/013ba298-7272-4bc0-852d-d3f72f7d077a"/>
    <dc:identifier>DB00951</dc:identifier>
    <rdfs:label>Isoniazid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc1da5c6-9748-4dc7-a1ea-f7c1e84fe29e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>Increased plasma triglycerides</rdfs:label>
    <dc:identifier>HP:0002155</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
    <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
    <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8755231b-8c3b-46bb-8fd9-2a3102d7070d"/>
    <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
    <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df651a28-e6b3-4d0b-8c1b-c0dfe5a0222c"/>
    <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c1e4d12-8e8d-4fe1-9639-ff7de6ebfee1">
    <dc:identifier>HP:0007663</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Decreased visual acuity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cac63526-7bcf-4643-8edf-c0110f1d7ea0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>movement disability</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ffa9c4d0-56fa-44c4-a83a-a0880cf81b41">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f233fd36-3235-448d-841d-1a317fa1c7d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f303bc6-de43-4fde-8fe5-37771802150c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5da1431e-1846-42ce-b56e-92c801db1e86">
        <rdfs:label>abnormal muscle function</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8bb7ea06-2bf0-4bfd-82f8-3eeb3511552c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <dc:identifier>DB00166</dc:identifier>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/157b2e0c-4a13-42a9-bfe2-62eddf93b510"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1dca887-44ee-4954-8ef1-6c747cf73138"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b92a0bd-25c0-4e98-a0e5-ef76906e5439"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b17c78f1-2fe4-4734-8545-53ab19a87661">
    <dc:identifier>HP:0002086</dc:identifier>
    <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c7cc290-5a40-49df-b64d-e0997f680557">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <dc:identifier>A11</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/efa54aac-ecbc-4ed1-91a6-9b179301ea69"/>
    <rdfs:label>VITAMINS</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb6438d8-6938-425b-ba83-e3addee96a2e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/022bae1f-9a21-42cd-8fda-8b1ac343a4ec"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3067bf0e-90f1-49d7-9953-ff26bf0049a2"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e8e044b-0555-440a-bb72-d508c96e0d8d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/baa835a9-1b41-4552-8015-2853e5909dc1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/578384da-f0bf-4653-a742-b6966bda1131"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4aab579-003b-40d4-aae3-f7369fea17c0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/031547eb-d527-43dd-9323-d3728af3428e"/>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/539a1840-1ac8-4ca0-bf1f-9d3f2c3e698a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f820b7d2-fc69-4a11-864f-d3886b41e311"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/036a3761-c7a6-4903-afb0-78956f33dc29">
    <rdfs:label>White matter alteration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002500</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50b558df-1dd3-4101-98ee-77f16bc8e0ff">
    <rdfs:label>Perampanel</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <dc:identifier>DB08883</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ba3fff9-ba89-44d5-9763-eac1aad11597"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ab2ba8c-045e-4cfd-ad0a-c7a14d2df5ac">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Noctornal difficulty breathing</rdfs:label>
    <dc:identifier>HP:0002098</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1db4dc99-8032-4a53-88f5-7667dcfce2f6">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb161655-3b0b-4af6-a61b-18d6fe05e3f2"/>
    <dc:identifier>(DB00328</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59e51714-fe9b-4ce7-8a24-823165e1f91c">
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03700ebf-6956-4fcc-a6a4-b1fd481b7db0"/>
    <dc:identifier>DB14573</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30670524-7ac2-4ae1-af48-3cf9b1fd8af0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87ebbc42-a484-4a71-b153-aaed61d6eadf"/>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <dc:identifier>S01EC</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41498fdf-ebd5-4e0a-90d5-870b5abd1c6e">
    <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca21d37d-dfcb-4b38-b299-9f7d44507361">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/97b0115a-fb94-4faf-bb32-9796241d01c0">
        <rdfs:label>functional complementation of a genetically defective protein+symptomatic treatment procedure+symptomatic treatment procedure+functional complementation of a genetically defective protein</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1dcd147d-17ec-49f4-8297-e794207c0a42">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3d710f0-be6d-4a08-9887-3a4931a5b9bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa638a0-b821-4d5e-83cb-fc8d55fb11ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4503c91-ea76-44e7-aa72-58326969c54f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb6792e8-2355-45d2-b2e6-b4bf0d6ed766">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15c372c6-0f86-47ec-ab02-2430140a0365"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5f0b86-e3e6-4ba6-8337-5a1dfe0ba185"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf1b7ac2-01d9-4c6f-b9d5-8a6f88346d85">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2109bdd-4ae7-4649-b46a-1d19661df69f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d51f13ea-e727-40f6-ac6f-0bfa9d9196eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55494656-8bb4-4ff1-81af-0beeafe00a6b">
    <rdfs:label>low hemoglobin concentration</rdfs:label>
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a79f738-0092-4a04-9296-08e213f95393">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c2d6dce-08c3-44ca-9860-9d8918b75603">
    <rdfs:label>Uridine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03ceab51-fa37-45bd-b46f-f02315b13020"/>
    <dc:identifier>DB02745</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3ecf0b2-fb55-467e-b759-3441e2cc77aa">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05a71b1-c61f-4ad4-be7f-0d8c5875c4fd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08aff1fa-2257-41b6-a07a-5ff53934847b"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc80c155-ac7c-4cf3-90de-5a3908fd59a8"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/650eea1f-4882-4ef9-95c5-b903786b6766">
    <rdfs:label>Skin papules</rdfs:label>
    <dc:identifier>HP:0200034</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8285dae-4970-4c6d-84cd-20888ebd77be"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e01af460-60d4-46cd-a050-6d7614a3387b"/>
    <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96da02a2-23dc-4836-8bba-28b074559ed6">
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>osteopenia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de6d3048-4b4f-40ff-bb56-5aeaefece42b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90a605d6-a3c0-404a-9c2f-e295cb517337"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24b24857-c8c7-468d-b775-4177f2641972"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8833bd30-8bcf-4960-a0b6-ec95a04ea7d3"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bacfa875-e7d5-4dde-9eba-05f84258c1bf">
        <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/993babc1-1608-4825-8424-79fe16fc62da"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04ab218a-bd05-4be4-b58c-beee75725945"/>
        <dc:identifier>C09CA</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbf9f2f0-54d5-42b9-91ef-f5bce1dbca89">
    <rdfs:label>Abnormal AGA processing</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcdb0b2a-7bc2-4073-95fb-d2a2bb58d4fc">
    <rdfs:label>Adalimumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1956873c-f784-4c11-907d-a39fbc46e93e"/>
    <dc:identifier>DB00051</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ecd4343-a7a1-4be5-9226-1a1d3d389f7a">
    <rdfs:label>dopamine deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012656</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6dbc0080-07b0-412b-86d9-56e6ba59024d">
    <rdfs:label>rhPBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a6b59d8-0e16-4c8a-897a-d95761af6040"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82fd5597-bbc0-44f5-b98c-8ebeed8e4dbd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d793440-c0e8-4379-a995-e4f6a2488d55"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec1debd4-85ce-4f33-a1ad-ce8a9e2f7839">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54eb4f5f-836e-4dcc-af5b-36cda3c7b163"/>
    <rdfs:label>Uridine triacetate</rdfs:label>
    <dc:identifier>DB09144</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/714aa4c5-3d50-4284-81dd-d4791025425e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d19548d-b17e-43a3-a028-a0abaa980790"/>
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49942e04-f364-4e47-8574-416e3d5981e0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f89b3f63-d5fd-4a9b-b843-22fc8584c045">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57dfd0c7-84c0-4426-a1f5-7ae0b60964ea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
    <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67aa678a-b9ce-41d9-9bb0-e791e282c925"/>
    <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e5a47c8-8547-4df3-9ffb-267e42ffadb0">
    <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0100022*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0146db9d-ecbf-4929-ad0f-623a45c0a53a">
    <dc:identifier>DB11917</dc:identifier>
    <rdfs:label>Vatiquinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53e5e5f9-3294-42aa-a96d-c8b17c2a911d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4191684a-8147-4657-b063-edaa37b78986"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b64feee7-830a-42ca-9637-081986ca3046"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd41c5df-59bd-4ece-91f0-ead1295013c3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd7b6863-ce2b-4a18-9b9e-2ad5cc9ab328"/>
    <dc:identifier>DB00477</dc:identifier>
    <rdfs:label>Chlorpromazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39e00bb0-2fe0-4661-a45e-f1db57d5713b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:label>low physical capacity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7bbe2505-4cf9-4008-b762-f884a0f9ac02">
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/116f71d7-6de4-4564-bcad-907cd83299fc">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce4a378e-3cf5-4ff8-a77e-25580845f596"/>
        <dc:provenance>https://academic.oup.com/hmg/article/22/15/3003/652530</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71dce0c7-b888-4c5c-b0dd-11ab07c0af6b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca514538-9b1f-4faa-86d0-5f02a146b3e2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dc6a930-ce0b-4b39-bd98-4da3598f8e1b"/>
    <dc:identifier>DB00158</dc:identifier>
    <rdfs:label>Folic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34b3c74e-6405-4820-a86b-e403d42b92b4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
    <dc:identifier>HP:0002156</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0efd4c2e-d5bd-442a-8629-71f8b668a8f2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd06ee52-ad84-4932-a74d-ff3159ec5f23"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d3e7d54-8f2d-40b6-b253-b332035f3c11">
    <dc:identifier>DB00564</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d89149c7-3420-43ef-b4ab-c104cdb96a9c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4d3896e-06cd-41a7-958d-97ceb2db538c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
    <rdfs:label>Carbamazepine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11fcf246-1e2f-480d-9624-78539d39911b">
    <dc:identifier>HP:0001508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>failure to thrive</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3afa243-7cab-4ac6-a748-27df14ad5095">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9808c63-5f0f-48ca-9ac3-053c2823f063"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be73579f-9653-4d67-b3c7-7647a5320420">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf4a0302-d526-4209-903a-516569180646"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/0a39950d-7089-400c-ae3b-e2dc67a28af3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a959fbeb-49cd-400c-aa7d-d05e95e7e6b2">
    <rdfs:label>photosensitivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000992</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f9f506e-b38f-498d-bdf4-e1a451d2ce3d">
    <rdfs:label>Status epilepticus</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e618bcc-c142-4068-a56b-de630926868d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/778af531-3158-4c87-9b21-c7356b4ac614"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3330b214-895f-4b26-82b3-445158efed6a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b0fc274-8958-4b5f-86fb-d6b0cc8ae24f">
    <rdfs:label>Insulin resistance</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000855</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3888bb68-7079-40c3-a95e-2dfad90a0451">
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31753db6-d6f1-4a62-9e57-a3b36f908d92">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f5db4f0-9546-4479-8b65-7ef51b92a316"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94a2be75-2639-4c75-b92f-b86e68565d8d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>D07A</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef502999-6d4f-462f-8ccf-cffce737ec7e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/488061cb-0792-4659-8aeb-2c6fa33bc886"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6ba1409-ae1e-4b24-adc9-d938ed8fdbab"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c83e4a40-8109-4010-8769-b8a3550dfc3b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1db1145e-6e99-4619-b108-49a9a4ba5355">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/367c0a28-bc75-49e4-917e-3320e3b907cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3aadc884-7315-4eb1-8595-f5766981a799"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d46a7563-95bd-4c13-be7a-a84250b3d786">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ad82a62-c450-4afb-8c1d-13299a250832"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc904b33-af09-4626-9a46-5ad82ce84a4e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f899bb2e-fb37-42fd-ad74-89785faacfab">
    <rdfs:label>immune dysfunctions</rdfs:label>
    <dc:identifier>HP:0002715</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9628ccbe-dfd6-46a9-8611-ddadfb4f731a">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78001d9e-1922-4b0b-8b01-cdaa6fcdad74"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145981"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c45f49d5-cbac-4a72-b75a-ddf48204bf34"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54bf7d6f-a1ee-4014-a253-ebd17432ae40"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a758139-b00e-4801-b201-845cdf30c9ef">
    <dc:identifier>HP:0002148</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypophosphatasia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7bd8e12e-0454-4107-b08e-69b64d2abe49">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0691b59e-c158-4f23-9f32-6ffb8723727d"/>
    <dc:identifier>DB04789</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e26177f4-ddc0-4dd0-9f2e-afcad74e93db">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8898046d-9a34-41fd-b24e-730ea9faf893"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a124d5f3-0fca-4608-be44-5ac8030a4875">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca6e5e54-bc80-46b7-b5e1-783ff15b5de0"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f171f2eb-91e2-492a-8659-652eb88b6a93"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dddc2cd1-e4da-43ba-8d36-70ab69f0395d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>low physical activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7eb8e3e0-95fb-4f54-9d19-68b86537033d">
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ba0b3af-7e14-4acc-95b6-0b90d468d11b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1baca804-7130-40cd-9e3a-94c3f2d4f823"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bbc61a8b-d094-4931-953e-e8ea16f01718">
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92b07a6c-a2d3-4e01-a6b0-0509d164ce51"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f33e5ce5-32da-492e-bb1a-e231db59911f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00083</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94d4d776-f00f-49dd-8b1e-fe2a807513b6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5b5d848-667b-4f53-b58b-ea9e6f7c3592"/>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <dc:identifier>DB08809</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fc1e4bf-f3d2-482f-ba89-d736542370be">
    <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <dc:identifier>HP:0003200</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/798b083a-6a34-4ba4-9d13-64308e5968a8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23dd5d4d-a2e8-4f6d-8a0f-f73574a0f9d5"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/040b491d-9732-4e52-8cc0-9a1a1cc7c0fb">
    <rdfs:label>Lactic acidosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <dc:identifier>HP:0003128</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/abf9e081-9f0e-47ef-90e5-54888206a2d5">
    <rdfs:label>Beta carotene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7522af18-8414-4916-b33b-b56f04445550"/>
    <dc:identifier>DB06755</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dc5963b4-77ee-4cd1-b7d7-8824c81eeea0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe804bb8-8166-460a-9cd3-341cd28a6a6a"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94c36957-45a5-4ce1-aad0-9b1c2d9ad1d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a40ca89-45da-44e4-aacd-c802d5ab02cf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9df9a50-1955-433e-8339-f1ae5e972f18">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6870673a-d36f-421f-9473-0c976ba8d23f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a7846ee-2a43-464d-a806-42752ccd450c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/593774f9-638c-4896-9228-0d153522688a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36a0b866-055e-4fe9-b39e-3268051e9dc1">
    <rdfs:label>Oprozomib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f470fb25-71b2-4f75-aada-ca8f78ae890d"/>
    <dc:identifier>DB11991</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d613f263-5152-4728-9ce3-16cbe6bf795d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/825598e1-ad58-46b7-83d8-ef088ea42a65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ce4f51-3bad-479a-b189-b87aa27827b9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa368640-515d-4ad5-8bf5-9c01ad5f269a">
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32bc8a69-e4a4-4350-b241-6ee5e6192fbb">
    <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
    <dc:identifier>HP:0001980</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a7846ee-2a43-464d-a806-42752ccd450c">
    <dc:identifier>DB04729</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9df9a50-1955-433e-8339-f1ae5e972f18"/>
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/050d26ae-7916-4684-85c1-c5da333e5070">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d44fae3-dfdb-4e2c-9574-4805ec79ff3c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c46e0d67-317d-46f8-8144-d996c63806ce">
        <rdfs:label>Kaliumbromid</rdfs:label>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
        <dc:identifier>CHEBI_32030</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/674c72ff-a044-4eb2-9063-0f97b6b6c1cd"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3320963-0cb7-448d-81fe-23e45d902686">
    <dc:identifier>DB00869</dc:identifier>
    <rdfs:label>Dorzolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3257f499-2885-4b95-963c-c4eb81a91b3e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b957bab-a09f-4fc7-b768-b232c2e0cd1b">
    <dc:identifier>A06AA</dc:identifier>
    <rdfs:label> Softeners, emollients</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25bc20ed-6534-4a02-b1ec-1be2657e1bbd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85b4334d-a355-4c5e-b4b0-760256465c36"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf4a0302-d526-4209-903a-516569180646">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3afa243-7cab-4ac6-a748-27df14ad5095"/>
    <dc:identifier>CHEBI_2786</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0054c8e9-b230-4eb3-9046-3cda0c83cda5">
    <rdfs:label>Chlorpropamide</rdfs:label>
    <dc:identifier>DB00672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5596f44-f34e-4897-bca0-96860c81ea89"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21dfd466-d651-409e-857a-58bfc983acb0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e0c7de2-d020-4b2d-ab77-c9260423388e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfe0175b-c659-439f-aead-e1e40cba8e43"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b057608-5467-418c-9cba-7828c2325817"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3de536a6-45f7-4cc6-a41c-09d531f079ac"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1697d1eb-2b2c-4d4c-a0e1-8562745fb441">
        <rdfs:label>Bone mass loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd616b85-42f0-434e-aa55-68d205b08fc6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d27a3d3-f29a-44b8-9d8d-6d0cd65da062"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7800a7ff-2b56-41c8-9f93-25253b0f0716">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdcbc546-8377-4683-aa97-862812d5e141"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe16f381-1136-4bce-9105-d70a7f26c6c2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/140b4a69-3995-47a7-b7fa-778433b68dfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c73a7a43-6efc-4a0c-b074-b52583d63f9d">
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e618bcc-c142-4068-a56b-de630926868d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <dc:identifier>DB00114</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f0011dc-ddec-42d4-98b5-6f66f3ad12e3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a579fb1d-81e4-4b8e-81ca-aec16a963271">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pseudoexon activation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3523a71-e407-4ef7-bc5f-0a907603cc89">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaec78eb-a7f2-4275-a714-976b95cc257d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88b47a90-d191-4ccb-bcd5-267bb8e76685"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/35ac6be4-650c-4b08-9542-fb48783b3544"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5637df9-bf9c-4816-9e13-682a4a4e3b2a">
        <dc:identifier>HP:0007166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9a80e12-bd4d-4954-929d-a34a049b6a2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afea946d-1beb-499f-9dd0-4195b3bdf186"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8aad4c83-2a7e-4788-91b3-ec66fa284a04">
    <rdfs:label>Flumazenil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37998eba-3ad5-4d43-bf43-5ea8f4153616"/>
    <dc:identifier>DB01205</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc515b8e-fe39-4282-8271-28987f4cf030">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd468c6c-075f-49b3-87d9-e41bfeebab66"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <dc:identifier>DB01403</dc:identifier>
    <rdfs:label>Methotrimeprazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63c4ed5d-4e67-4e15-8804-0ac3cc26cb81">
    <dc:identifier>HP:0000819</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a80542da-88d1-4afb-b015-1aa8e1b7e12f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea4a329f-cd6f-4e82-a071-7a2e83b8d643"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a34b8ffd-efc7-4a04-b24b-174b96967d14">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72971a2c-0aaf-4286-badb-53448dbca572"/>
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0691b59e-c158-4f23-9f32-6ffb8723727d"/>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2512865-d605-4a30-87b3-6a40d43452f7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f4bd841-a43e-44df-9604-67962bf85a90"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e429081b-a47d-4f7e-851d-8b6a0f52eef3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69e07741-5c0a-4754-a174-5c687cfc93e1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
    <dc:identifier>DB00608</dc:identifier>
    <rdfs:label>Chloroquine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bafb71e-6cc1-49e2-b2d0-f0d81672b5c8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <rdfs:label>High total cysteine levels</rdfs:label>
    <dc:identifier>HP:0010918</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d57be4a-cf98-4c8f-a8c7-86fd9c23127d">
    <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0031034</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66be445e-b485-4218-96c1-b62d06e88b48">
    <dc:identifier>HP:0001290</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Low muscular tone</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b55b3ee4-7256-4f58-91f6-2e4b6f08629f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <dc:identifier>HP:0003254*</dc:identifier>
    <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e88c4100-40c7-4dd9-b0b8-4ce61d04bdea">
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <dc:identifier>DB08830</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24c12953-7a18-4040-a708-c13ba4bfe9a0">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e984ebe3-d0e1-4ea4-b478-c9b88dce5bfc"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
        <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cf9c124-dc52-45f3-a836-ec60269fd21f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f96107b-83d5-4a8b-8d21-8b73e9850e4c">
    <rdfs:label>GNT0003</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aaa87744-bc85-413f-8d8b-3a49186c2bbc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75f4085c-5640-4484-9fcf-b9a9f02fe578">
    <dc:identifier>DB04844</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88ade400-ef15-4134-8596-8fb0b87fa9d7"/>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0cb3881a-0415-4ef6-8c19-4020fd020110">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d6b25bb-2e7e-4aef-bf84-c7348b20fdb3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34df49da-decb-4fe6-9d62-0867e0416958">
        <dc:identifier>HP:0001954</dc:identifier>
        <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3ab2db18-1ed2-4234-aba6-16aa5d0bc3f8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/532114a3-d1d4-4f72-998a-6438f9535133"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce4a378e-3cf5-4ff8-a77e-25580845f596">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7bbe2505-4cf9-4008-b762-f884a0f9ac02"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4dfdc92-54b0-4705-b241-d6fac154c34a">
    <dc:identifier>HP:0030098</dc:identifier>
    <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/035b6148-cd24-46d1-b7e9-17c0eeb73320">
    <dc:identifier>HP:0004918</dc:identifier>
    <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4cf845f4-b895-4f2c-819c-fe6c33db7152">
    <rdfs:label>Etanercept</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd548f26-848a-469d-a30a-cfed6b9ff7d3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <dc:identifier>DB00005</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a15778df-0cba-491f-8a60-699be0004fb2">
    <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <dc:identifier>HP:0010472</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2dffbd9-e3f3-43d1-af36-ed691a4e979e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/515a0570-36de-482b-866b-b8503c341743"/>
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d31176fa-ea59-4767-b73a-05ff48071a56">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66648191-0d56-44da-9c41-1fb2fe2efbff"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34a81ee8-9f31-4df6-9556-c54e2e4aa7d6">
    <dc:identifier>DB00682</dc:identifier>
    <rdfs:label>Warfarin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55d9914d-351f-4c5f-821b-150f28e6bbc1"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a04cf5e-6c55-4174-9f1a-035ecd11da6c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7a34661-ae56-4a9b-b8bc-53c44db40b62"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac12a0ae-b551-49a2-a253-95abadcce14a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1fda405-0c2a-4460-93a1-5bdba337989c"/>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14b6bc37-36cd-4782-ad5e-9829718ad954">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mortality</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c72d14a-e4a7-446b-9ae9-e3d8332a09f9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa632dfa-4252-4be8-bd9c-c8b95888f5ea"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/613b3dc0-4cb5-4a4d-95c6-bdc31cca55cb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93a5932d-6ab8-4245-9465-3e2a40d591cb"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be59f880-a8dd-4044-987f-57ccd4f18a41">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a04b132c-5e0c-4bd8-a127-57a8e1d822a5"/>
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e50745aa-e753-484e-ab8f-6b7be7724a07">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d28536c-1a4a-407b-b997-aff768627d07"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/65dfcc2c-2e1c-4051-97d9-4f959f437d8b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44fad141-1f90-43fc-b37e-e704f5b5e150">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/efcdce22-a1e3-4249-b8e3-6457c70a20e3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/322892c2-4132-4fe9-94f3-20b08b233bc4">
    <dc:identifier>DB04272</dc:identifier>
    <rdfs:label>Citric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0a83ddd-9491-4f34-97f8-7d2e2f9f920a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4890d35c-bc4f-4c04-a091-73e7b811c4dd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52cc001e-d5e3-47bd-9a6c-d128b442fcf8"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e939de0b-f7c0-41eb-b38c-7ce171de07e7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c4d3970-fa91-4936-b9d7-0bc3c4a00ad5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
    <dc:identifier>DB06742</dc:identifier>
    <rdfs:label>Ambroxol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/468c6852-d1e6-4d1a-a0f1-1fe88ef79925">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1572752-f160-4aa6-8b79-ceaa9e96680f"/>
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41be7b1e-0878-4956-ab85-5b86dff8ae69">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd92e643-4a06-4595-bdce-295440b2f5ba"/>
    <dc:identifier>DB06262</dc:identifier>
    <rdfs:label>Droxidopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39701c0a-0448-4f52-a016-d23ea50ed44d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54072383-9c08-4719-aae2-d0feb69f86f5"/>
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30b02f95-33ee-48ed-8421-59384bd19e8e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
    <dc:identifier>DB00053</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2678786f-2ba3-469e-b844-18cc3d6c4c9d"/>
    <rdfs:label>Imiglucerase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70667afc-22ad-4927-ac66-839c41ce9036">
    <dc:identifier>DB14151</dc:identifier>
    <rdfs:label>Phosphorus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eee0ab42-8ca8-4c85-a332-2429d7f56559"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a86d0736-7876-4f86-acf9-c2931b836385">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a23ee965-3fce-4d83-b4fc-769fb601231b"/>
    <dc:identifier>CHEBI_84293</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
    <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac1a0d6e-22a5-4e0e-8879-301b78999eef">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <dc:identifier>CHEBI_113373</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0955ea1f-49e4-4fed-9f97-60056e841021"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
    <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
    <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bf98be2c-baff-491a-a522-472fbf1e32bb"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02db4f9c-caa0-4665-a2d1-3f0e61e2409d">
    <rdfs:label>Geneticin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f02ee08-bd2f-455d-b579-d87640431a72"/>
    <dc:identifier>DB04263</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7905f83-0727-4beb-a9dd-101a429bd0d3">
    <dc:identifier>DB01041</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4bf9436-c7ae-42f2-b3b7-3d0f049881b3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <rdfs:label>Thalidomide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0cb3881a-0415-4ef6-8c19-4020fd020110"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e3e846a-86b0-48c8-a973-607b479943c0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3113bfef-d336-4564-96f1-2567c13f16b8"/>
    <rdfs:label>Digoxin</rdfs:label>
    <dc:identifier>DB00390</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/647cf890-639d-4776-bdd6-3bd9c2b845a2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/753a5b2b-3d0c-423d-b4a0-014a09755b6e">
        <rdfs:label>Pitavastatin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
        <dc:identifier>DB08860</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5060c482-6ec9-460c-bb81-ba18e8ef70f5"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b70b7f8c-040d-43f9-8c8d-ec5725ef43bf"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/859291f1-e6ed-4470-a310-2d06db95fda9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61bcbd07-d3a4-418e-900e-4317d937b3b1">
    <rdfs:label>Oxitriptan</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52521b4e-b521-47eb-82c3-3b33b3bd3409"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ad9115f-6f75-4f39-8b58-06ca4144379c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66238906-711d-4a27-9df2-52abc5ab93d5"/>
    <dc:identifier>DB02959</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/1d799582-a3a6-4d0f-ba3b-1e2197ddade5">
    <rdfs:label>functional complementatoin of a defective protein</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cb971cc-0ed1-4fe0-96d0-c522f201f200">
    <rdfs:label>Increased ROS production</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d126c424-2405-455e-9797-6f778e6f75ee">
    <rdfs:label>Furosemide</rdfs:label>
    <dc:identifier>DB00695</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c05fdd8f-84d9-435c-af24-e7dbb686f892"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3ed529f-ab83-4666-b4a8-eead194f7f12">
    <rdfs:label>low heamoglobin leval</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <dc:identifier>HP:0001903</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4516abf5-16a3-40db-9d2a-b88cb02add0e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95f29519-6756-4a4a-a04a-6beca79ac5b7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bef031e1-10a8-4620-85da-db1dc26feee5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13744bf0-2544-44df-b482-1561b23f57fa"/>
    <rdfs:label>Phenytoin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e14c21f7-47c1-405e-b717-94ae118a3332"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <dc:identifier>DB00252</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89eb12b2-1846-4a6d-bbd7-9aa58dd49d45">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa3770f2-5dc1-46c5-b4ec-73208a0b700e"/>
    <rdfs:label>Rofecoxib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
    <dc:identifier>DB00533</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/afd314ef-b0eb-40a2-b50d-76fcc4458aff">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3127fae4-ef25-4fa1-b869-d2a734377fdd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/caed1c2d-5985-4271-b7fd-bf4cdfe939db"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e3d205-8ca2-465e-bc7c-853fe8709eba"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Carglumic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <dc:identifier>DB06775</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/249793bb-b678-4a57-84a5-8ab3e6379dd1"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0b73e6e-878f-4f9d-bdad-8eb16cced690">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20f34742-b191-412e-849d-6eb1528d661c"/>
    <rdfs:label>AAV-treated βgal</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18da7944-80ba-4245-a3ec-59d4d0a2299e">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
    <dc:identifier>HP:0001266</dc:identifier>
    <rdfs:label>choreoathetosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bac64f69-133f-4748-b59d-5a92aaedfd86">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0251b4b2-eeb0-4bd6-96cf-19a3d2e69416"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a124d5f3-0fca-4608-be44-5ac8030a4875"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eec1af36-a885-4779-9247-18625f54cfd3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f9f506e-b38f-498d-bdf4-e1a451d2ce3d"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca6e5e54-bc80-46b7-b5e1-783ff15b5de0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Magnesium</rdfs:label>
    <dc:identifier>DB14513</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34c11fe3-a918-4170-a18a-2415d194dc73"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a8de991-c372-4287-a288-c4b6d8188263">
    <rdfs:label>Alprazolam</rdfs:label>
    <dc:identifier>DB00404</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8681660f-2bf3-40a1-b882-d8151e7424c0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b831fd14-05e1-4ebe-82f8-a69bda5126d9">
    <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cecec11a-b064-45be-8211-35455751eba7">
    <dc:identifier>HP:0011729</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Abnormality of joint mobility</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee5f9482-52dd-4e3a-afcd-da57263ae3bc">
    <rdfs:label>Midazolam</rdfs:label>
    <dc:identifier>DB00683</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab40f657-33ef-4886-a53f-30400a9f7f6f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/974fe5f2-ef1a-4c46-8fd2-04c93d66aec3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27f15591-54dc-4841-b66d-cc0e894921e0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <dc:identifier>DB00688</dc:identifier>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6b95738-070e-4fa0-a44f-a17e0f590fc0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
    <dc:identifier>DB09393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92218fb7-375c-430a-82c9-971668de0c7d"/>
    <rdfs:label>Amino acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ee3ee75-f39d-45cf-b27d-6aa3cdb0bf04">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36ccca8c-3578-45e0-ac19-6511b3983584"/>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <dc:identifier>DB06151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7e1cb00-35f2-46c7-aaa4-88062661280b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7199446b-e1f0-47e2-81ca-db8f1641cf96"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35b763cc-3967-4a1d-a518-82bbd5db9f26"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96bd1ee4-174c-4348-9045-d27535c3b756"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e76504e7-4342-4d17-87c1-41bc22f8230c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
    <dc:identifier>DB02691</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95ec471e-a9b4-46f2-9b1c-190c467b7199"/>
    <rdfs:label>Glycocholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bfacc159-3628-48d5-8cfd-a3bdf86c8903"/>
    <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
    <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
    <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d0c163a9-6df0-4779-b03e-2e31f2d6e91d">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b155a1a6-9255-4467-9d23-64309f95ab8d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b89da4db-e62b-46f4-a7b7-0cd7fc6d9e51"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230600"/>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10b64356-fdfc-4787-883a-9280555115a3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
    <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6237074-e071-4c90-ab0d-702d3f6fa5d9"/>
    <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/049f1be3-61cd-4240-bda8-8f60835a4b48">
    <dc:identifier>HP:0000613</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>photophobia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcb5999f-13a5-4cac-bbae-16ed916341f3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040129</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/116bf674-2963-439e-8091-c20118874836">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84aba42c-9fd3-41a4-b8a9-a86ba5507ac2"/>
    <dc:identifier>DB08909</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ccb9d0e-3324-415f-813e-fa0a1190d5b4">
    <dc:identifier>DB09105</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2222f4ed-9159-4964-b516-89a7920eb994"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18a98bf7-f11a-4505-a9bc-d3dab3e40300"/>
    <rdfs:label>Asfotase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65ca935b-3739-4898-89ee-0b07f7aaeaac">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <dc:identifier>HP:0012446</dc:identifier>
    <rdfs:label>depletion of cerebral folate</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/367c0a28-bc75-49e4-917e-3320e3b907cb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c83e4a40-8109-4010-8769-b8a3550dfc3b"/>
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d5f4c9c-6da8-49fb-beb7-6c85b6624de1">
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:label>High serum ferritin</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79230e27-81d4-4e1f-93d9-a59e8c3e2b7e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>low phosphate reabsorption</rdfs:label>
    <dc:identifier>HP:0000117</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31cd95df-be3c-40df-9653-b0684989f231">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/005d3a6d-d6f4-4418-93e0-741d49651416"/>
    <rdfs:label>Iron</rdfs:label>
    <dc:identifier>DB01592</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19aeb085-8434-4f8c-8eac-db63c29cb8c2"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e984ebe3-d0e1-4ea4-b478-c9b88dce5bfc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sulfide toxicity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b00a7185-fcbb-477a-a2e8-834e2877b31e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0f64c39-ea63-403d-96eb-bc61aeccd976"/>
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f37bfbe-4d54-450a-afd9-65ad96e5fb51">
    <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cf9c124-dc52-45f3-a836-ec60269fd21f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e88c4100-40c7-4dd9-b0b8-4ce61d04bdea"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93602d1d-23af-465c-ac0d-6d54d2134387">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003676</dc:identifier>
    <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f33e5ce5-32da-492e-bb1a-e231db59911f">
    <rdfs:label>abnormal muscular co-contraction</rdfs:label>
    <dc:identifier>HP:0001257</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dd01c09-3e9c-4437-b602-01c3d86bb7a0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0008189</dc:identifier>
    <rdfs:label>low insulin senstivity</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/094b0855-9e7f-47bc-bd9a-25607f91bb46">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1677a8f9-6391-476f-b926-0f858a08b257"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a9271d5-afc3-42f1-a85a-f42e47b59573">
    <rdfs:label>5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ade92ca8-00a1-466d-a856-260feb2df748"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/496f6406-bdfd-473c-afc4-eb99df48e75d">
    <rdfs:label>vitamine K</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e891a03-f9fa-4664-b2c9-15864ba4cdc2"/>
    <dc:identifier>CHEBI_28384</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56ac239a-7098-4666-ac4b-e7188f36e80c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/830b2c16-d5f9-4766-b0d8-9914f32b9602"/>
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b944e1f-5155-45fd-8baf-a2965b69ec50"/>
    <rdfs:label>Cinacalcet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9628ccbe-dfd6-46a9-8611-ddadfb4f731a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e553d13-8bb9-41c1-afa5-82f064b53b4d">
    <rdfs:label>Rotigotine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39dc9193-42c1-46a6-8934-784497798a75"/>
    <dc:identifier>DB05271</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/940af391-4582-41d3-a670-3b3073560244"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a9130e2-e8ed-4334-bba6-0c7550ac67e4">
    <dc:identifier>HP:0030353</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased serum IGF‐1</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d771805-cef7-4026-b51f-f60f347864d1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
    <dc:identifier>HP:0002189</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Daytime somnolence</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76e3d205-8ca2-465e-bc7c-853fe8709eba">
    <rdfs:label>acute hyperammonemia</rdfs:label>
    <dc:identifier>HP:0008281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc1df46c-5e30-4b76-a73a-0f8fdc2bca7a">
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607625"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/deaab464-f734-4409-9973-16dd1b60d06a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2955ad53-0dc3-41a5-b3aa-ac30a148223c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc22d937-cda3-446a-aa28-e5fd9cb325a8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/915a9a15-e914-4048-b3ec-ae8872c7c296"/>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c91046b-8e79-4cf9-9303-faad251e2344">
    <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b609fa61-1fb1-410e-8a6e-a4bb27e54e4a">
    <dc:identifier>HP:0000969</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>edematous</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb295284-e278-423a-aff4-464168629616">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperlactatemia</rdfs:label>
    <dc:identifier>HP:0003128</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3974bf57-9305-4ec4-a46b-dbf2d55c1fae"/>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30a0a5b6-5405-4579-b1f7-b2d70d87d309">
    <dc:identifier>DB02285</dc:identifier>
    <rdfs:label>Protoporphyrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba368dd4-9f38-4531-acb7-8b7ce98cacee"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5ed4c6e-8be2-439b-93cb-36ce6b9cf009">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:label>epileptic seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42d3d2bb-ea81-41bf-a742-ea63e62fbd5c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c95fef39-275c-46c3-a931-89fb70986579"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <rdfs:label>Mannose</rdfs:label>
    <dc:identifier>DB12907</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dac309c-19d2-4540-ae04-351049783391">
    <dc:identifier>HP:0200034</dc:identifier>
    <rdfs:label>Mucosal lesions</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6fdf1ba7-f67b-42c7-a25b-4cfd6931199c">
    <rdfs:label>Duloxetine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/772e9068-1c36-4edc-9ea1-22680c08bf28"/>
    <dc:identifier>DB00476</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01e1ab93-307d-4569-b8f1-7d7337cf069c">
    <rdfs:label>hemolytic anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
    <dc:identifier>HP:0001878</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d956b54-b839-42c2-8f49-fb11ad0afed8">
    <dc:identifier>HP:0100660</dc:identifier>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Dyskinesia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32a3297c-b2a1-4a6e-9181-817283e9b4f5">
    <dc:identifier>DB12319</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a66dd9a-2cbe-4aa5-9200-3a703557de6e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <rdfs:label>Benzbromarone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/00a6c171-5a7d-4af1-bdcf-07aaeafad53a"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8917778-2ee0-451c-bb7c-2046f09496a3">
    <dc:identifier>DB09422</dc:identifier>
    <rdfs:label>Soybean oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25264cc8-e0b8-4dd0-bf7a-309fed0c20ac"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f7e9dcd-06f8-4363-bbe5-494fa50b7e7c">
    <dc:identifier>HP:0000742</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Self-mutilation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02aeab36-8b5a-4311-be4b-6bfda79e763c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001332</dc:identifier>
    <rdfs:label>Cerebellar dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17a86540-57ed-4dd1-afce-5a31a458e6fd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <dc:identifier>DB09269</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7024c2a-cc10-4d65-9b68-6fc327bb9083"/>
    <rdfs:label>Phenylacetic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c364901-455a-4e69-a41a-eccc10afeb21">
    <rdfs:label>Pegademase</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70c5a01d-6704-43be-89aa-368106a5246b"/>
    <dc:identifier>DB00061</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/286bc6e9-eaac-4f92-a871-71c2861afcbc">
    <rdfs:label>Dexamethasone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e782ec0e-9f1a-4f40-88bc-8968ae1666bd"/>
    <dc:identifier>DB01234</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21dfd466-d651-409e-857a-58bfc983acb0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e1ed8f7-a6c6-43b8-8c09-659de9ca3ef4">
    <rdfs:label>Inflammatory myopathy</rdfs:label>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:identifier>HP:0009071</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeb9920b-5f88-4d90-9a3b-f0b514cd0038">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
    <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
    <dc:identifier>HP:0000491</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b8149b5-2cdc-4fcd-a2d8-3c3366b1a402">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7903f487-92a2-45d7-a13c-f0686301c202"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca88dcef-c15f-4c53-a68f-96cb65565699"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0e41145-5221-4421-b446-9e3734937462"/>
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a55f7668-dbbf-4568-9cd4-c2344b5d2637"/>
    <rdfs:label>Thiamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc1a9085-9d5a-4147-a9b5-f9d32b417419"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcad3147-183d-42e3-ab15-0db7b73136ec">
    <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebd85445-2ea4-45e4-9eb6-457fbde78342">
    <rdfs:label>CoCarbs + HPro</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5f58baa-9e8e-46c6-9b34-dbf3702d64ef"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6de1c1d-ff6a-49c0-9f97-983b440c850c">
    <rdfs:label>neurologic deficits</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/099b64c4-5ece-4afc-bace-cf187dee35da">
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a296600-1608-41a4-8f4c-f37a0004f45e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3078ebb4-c942-4112-9748-f2260c9943d0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/adfe6264-2f72-489c-b65e-e270061f6f0f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0000bc0-9f6c-4b6e-b573-b397f0787063"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30f57f99-b14b-43ec-a883-b0a1d970dc06"/>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08442be9-a80a-449f-b66a-6162ad6d21e4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42a994b9-b217-4672-ade6-319f79ec9e4d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Metabolic Decompensation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d71eb05-e3d0-42f0-a613-95033fcbfbfb">
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/190757ae-9544-46a9-b9ba-477cde9fc6f2">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
    <dc:identifier>CHEBI_26537</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fa61863-722a-411e-b5b5-90b0120322d9"/>
    <rdfs:label>retinoid</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f5db4f0-9546-4479-8b65-7ef51b92a316">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3888bb68-7079-40c3-a95e-2dfad90a0451"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92eb1b0d-971f-4639-9e52-94d48d610270">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001263</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Delayed Develoment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7762478-85fc-4d19-81d1-08ebe881777c">
    <rdfs:label>High serum GDF15 level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f1e2d97-f3ca-459c-88df-06a20dbdedec">
    <dc:identifier>C03D</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e7283d0-6197-4664-8398-7bb4966a824e"/>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e0753407-6349-4379-b0d3-30e0a265869b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/afea60ec-e61b-4fe1-a639-3c2b38fb859c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <dc:identifier>DB14992</dc:identifier>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb86562b-16fa-45fa-921f-083619423d3b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8ce967d-b397-4dfd-a593-e014005004a3">
    <dc:identifier>DB14098</dc:identifier>
    <rdfs:label>Cobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4b12da4-2214-4583-9d1b-d6e8ebe6572c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e8f138be-f7eb-413a-916f-b2cdce35adb2">
    <dc:identifier>DB12890</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b779172e-82d3-481b-b5d5-0e4196bfdad5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
    <rdfs:label>Dihydrexidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/140b4a69-3995-47a7-b7fa-778433b68dfe">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <dc:identifier>DB00593</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7800a7ff-2b56-41c8-9f93-25253b0f0716"/>
    <rdfs:label>Ethosuximide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a975cea0-4b10-4be3-96e8-ae93522e1df2">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
    <dc:identifier>HP:0004322</dc:identifier>
    <rdfs:label>Low height velocity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6d45f24-f2f0-4a74-8cc5-c0498d24320c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
    <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
    <dc:identifier>HP:0010438*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bb0b514-86de-423b-b67c-45b7ac7a47f6">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70b26806-28ce-4aaa-9685-7ff2a83e2dfe">
    <rdfs:label>Pargyline</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c0bcf64-51a3-4bbc-8333-f6659b4cd181"/>
    <dc:identifier>DB01626</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46e4f447-0b12-40de-81bd-df57c8e5e015">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>deambulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/674c72ff-a044-4eb2-9063-0f97b6b6c1cd">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/861569ff-c98f-4082-b201-acda22bf4f30"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d44fae3-dfdb-4e2c-9574-4805ec79ff3c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f1215d9-7876-4527-9519-1dd96d8fac11">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/62b01bcb-bb4e-4451-ac3b-76ef492b48d8"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbe90ed8-0732-45da-8e6d-5ed5764d8d32">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63109928-8d1e-4e99-9b01-472ff3b9c7ed"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ce10b4a-2b67-4abe-9058-917b161c1b8e"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b699cfc-8a3a-4ce4-9ddc-9e6ed9b68127">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1aa1e311-58e8-4560-88ab-5d33014a45a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>Involuntary movement</rdfs:label>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e58efdac-b25b-4248-9b07-7792e599e7fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7551fc3a-8223-4281-86b4-18f6cba3682c"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00e00b0d-c8ac-4d80-86ab-f8e6c9907529">
    <dc:identifier>DB09115</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a875ec8e-dcad-4f6d-a659-09a9e5217d1f"/>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c2ea9cc-b7eb-49b4-9862-935761fd4e69">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a556d70b-30d3-4526-ac2a-91858e0ab02c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ce5655f2-7a8c-430e-b183-d64533443451"/>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <dc:identifier>DB01586</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f2a1366-9fdb-48e9-ac88-44b4e9c95146">
    <rdfs:label>waxy scaling plaques</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040189*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ae8f62b-c3e7-4daf-8969-f81499592b05">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e384279-7848-4e6f-b056-1101f177e9ee"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ffa08f7-8703-4737-886f-fa74c6decbbc">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
    <dc:identifier>HP:0002877</dc:identifier>
    <rdfs:label>Nocturnal hypopnea</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0565e16e-54f5-48f9-9ba6-6d6b428386a9">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5eeaaa51-c62e-4a3b-8c36-25b9147a4d62">
    <rdfs:label>Entacapone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6279dc44-c682-4c95-88d1-507ff27de8be"/>
    <dc:identifier>DB00494</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/953bb473-ed20-4b35-8969-f7f06452ce0d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57beba64-a75e-412e-aea0-ecff467679d4"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f57243c7-d108-4f11-b620-472d4e6e5042">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0005180</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
    <rdfs:label>tricuspid regurgitation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b62a7452-578a-42a6-ba4a-42a65098961b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased LDL cholesterol</rdfs:label>
    <dc:identifier>HP:0003141</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a09ea6a4-4332-483a-a117-e1554ad5cf4a">
    <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
    <dc:identifier>HP:0004355</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a077a9ba-1777-4735-8df4-5453e9b43845">
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
    <dc:identifier>HP:0012350</dc:identifier>
    <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12422fef-374c-4209-91ec-c6c502330b3f">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79d692bb-42c4-4f70-b215-906f7066b92c">
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/385c91dd-0b6f-42b2-a016-4de9fcb42f5c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/425839ae-8ba6-4161-901c-2ac091b992c4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
    <rdfs:label>white matter abnormalities</rdfs:label>
    <dc:identifier>HP:0002500</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9249955e-2c9e-4db7-a174-50774a070152">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c67335e3-3208-4bf5-9e31-d6f69b4366d5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <dc:identifier>DB00155</dc:identifier>
    <rdfs:label>L-Citrulline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a607a17c-2dde-4a06-9381-fe8e5b3ef6e2">
    <dc:identifier>HP:0009124*</dc:identifier>
    <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dc9f268-6cab-483d-8b89-321717d068e5">
    <rdfs:label>Hypopigmented skin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
    <dc:identifier>HP:0001010</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0fca2bd-7489-4510-b133-19e5aedf20e0">
    <dc:identifier>DB00788</dc:identifier>
    <rdfs:label>Naproxen</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08c09366-b2db-41d7-9d0a-2544dc7298ee"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f94b98f2-aea2-41c6-9d74-d1ce86eee2ea"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba3bfdbd-1d75-485a-916a-8bca259f612c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/212c2f86-daea-4075-b085-ae3b8dda00e5">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2839876-e5d4-4567-b28f-d5b8acad349f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffa4715f-764f-465d-87fe-71f141b04aaa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1dd56478-54d5-4d76-adf2-1adecd62a2fd"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/588d649d-4875-4fd5-9276-0fb631fc6aee"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df72f826-1a62-4af5-8b10-27f94c1fc823"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/234500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8125c10-7128-4940-b617-ca93fc3a77a8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
    <rdfs:label>Hyperinsulinism</rdfs:label>
    <dc:identifier>HP:0000842</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b660461c-bdc6-403d-afd6-1d00b6f0f73a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70284ddb-e966-4f30-a2ca-6b7f83681da1"/>
    <dc:identifier>DB00996</dc:identifier>
    <rdfs:label>Gabapentin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/100311f6-2ea9-49f3-ac73-cf2f292dc218">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0002224</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
    <rdfs:label>Woolly hair</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6f8302c-3e45-4a49-8101-1bba99606e24">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <rdfs:label>Thiram</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a23ee965-3fce-4d83-b4fc-769fb601231b"/>
    <dc:identifier>DB13245</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3e894c3c-84b1-42a0-8342-23cf52e3463c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9015455-2997-432f-92bf-b9197284e799"/>
    <rdfs:label>AT342</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef92f84b-3982-4487-ac0d-739c20ba25c5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df6ffd17-9e50-47c4-9144-44df5876ad89"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <rdfs:label>Tempol</rdfs:label>
    <dc:identifier>DB12449</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9aabb9d8-b1c5-4750-b58b-34312e775ed4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>defected excertion of 3- MCG</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aeb7778b-0544-4f9a-a69b-ceb0f9b86f68">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca31d84e-903c-4d4d-bbb2-af201ed471bc"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed6463dc-6b45-4243-9a08-07fbcd98c6e7"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee5f9482-52dd-4e3a-afcd-da57263ae3bc"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3455b1b-c376-483c-82df-58a4ffcd680f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18e29b6b-9f02-4f8c-91f8-e15651599d1e">
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>movement disorders</rdfs:label>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bf70f20-176f-45c8-9284-e66c83428e23">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Skin lesion</rdfs:label>
    <dc:identifier>HP:0011122</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a237ce2-20f0-4b7d-a1fa-95590e7f7e37">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
    <dc:identifier>HP:0012029</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/40a5ff72-c7cd-42c3-84b9-f4c8e85ff00c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4e639fc-da95-48b0-88f0-6e80fc19ef2f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40af249a-cede-48b9-ba14-00c110cc003c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cfc769ca-7434-45d8-8171-641e8a3ace19">
    <dc:identifier>DB15146</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc1df46c-5e30-4b76-a73a-0f8fdc2bca7a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8028c2e-06db-47e3-8a86-95afaab7a09d"/>
    <rdfs:label>Adrabetadex</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea5e8dd8-4216-4c8c-beec-5a69a217a30e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5786ab17-532f-433f-98b5-cff33cca9e59">
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <rdfs:label>High plasma branched chain keto acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1355360f-d1a2-4a6a-ae95-b4c633d763de">
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high ornithine level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e65a7bca-c3b2-4751-b40e-509b92f99d17">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7369ec8-d143-4bf5-a2ea-ab53a8344f49"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cb8d6f5-54b9-473a-8a1c-4ddc2f81a8b1"/>
    <rdfs:label>Sargramostim</rdfs:label>
    <dc:identifier>DB00020</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8199d8c-29cc-450b-9638-f9d5f55f7687">
    <rdfs:label>Pathological apoptosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/469e7dcb-34fc-4015-b2c8-b6bf3f9c87be">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb48cf12-9256-416c-afac-31926d03a7ea"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc5963b4-77ee-4cd1-b7d7-8824c81eeea0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75fd871b-2ee7-45b5-8419-ca773d6be6b5"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b1f59b4-7190-4d01-a35c-3e4d4840d328"/>
    <dc:identifier>DB11599</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb0fd844-4db3-4861-ab4d-ff2d27a6c1f4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/621cf4a7-82da-4323-bef7-2744032fbbc5">
    <dc:identifier>HP:0008972*</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e97fa4a-b2e3-43d1-a633-780802b196fb">
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/341358bf-b65a-428d-b429-f0eae85cfef8"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f81bd20a-61f3-4fa6-9120-b477cb76bd8a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b31b9b1-e10f-43a6-bbdb-114a9c2bcdb9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92eb1b0d-971f-4639-9e52-94d48d610270"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b286eac-07e2-4ea6-8f7d-e39d3018b70c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34245b91-216d-4443-8647-e353c523102c"/>
    <dc:identifier>DB02659</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f741859a-8fb0-4ed9-a680-24d3997ff224"/>
    <rdfs:label>Cholic Acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/630a6f24-cb58-4e0c-8dfa-0aab7456d105">
    <rdfs:label>Abnormality of the nervous system</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/304205f1-8359-4459-a20b-4154073d4344">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d395b5a-c8a3-4512-892d-0f3ac00bbd37"/>
    <dc:identifier>DB00627</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2839876-e5d4-4567-b28f-d5b8acad349f"/>
    <rdfs:label>Niacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2e941c8-f505-4238-b1af-2771d41ee969"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48f1949d-318f-41da-8407-60736725fdc1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e24d2a9-880e-4986-9939-325b4b88a5a9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/040df56d-6865-4ea5-923d-add3f8513528">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f058e25-6fc6-4338-98a1-e3fd44b80f04"/>
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34e459e4-736f-4383-b9f0-0e79a090043b">
    <rdfs:label>Clioquinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a38581fc-4660-4c5a-a9c9-9d286ca6a15f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <dc:identifier>DB04815</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/236752a8-ee7c-4123-99c0-84b914aae337">
    <dc:identifier>HP:0012825</dc:identifier>
    <rdfs:label>Mild attack</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bbbded45-e5a7-4d98-9e55-a323a8ef18be"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d536e237-6794-480d-96ce-0185a81f563d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca9b44e6-b3e9-4605-81d5-bfadbed3fe33"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1400c793-f5dd-4768-8ac1-4eca82243f01">
    <rdfs:label>Bezafibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c225cc9-9904-4e1a-bbd5-87ae3752cf3b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04bd4b5d-7c02-42ba-bdce-4e7d7733d0f0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d24c77a2-e569-419d-abda-d20ad7e10bae"/>
    <dc:identifier>DB01393</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e8e044b-0555-440a-bb72-d508c96e0d8d"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bfd7d7d2-0ac1-438f-a9a2-d95c600e04e5">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
        <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ce0cca37-7447-4f92-a723-f83b114b5139"/>
        <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14804f8f-5524-4fd2-8971-f399fdf20a28"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2282239-ed1f-4091-a211-c6f6188aed9f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71bc9a7d-0098-44be-9fa3-8c3fa1c479eb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <dc:identifier>DB00073</dc:identifier>
    <rdfs:label>Rituximab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53861ecb-e4b1-40b5-8680-c55cb4dafbbc">
    <rdfs:label>AAV-cG6PGH</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68e5b581-34e3-46d8-8ac0-27a0e5ab39e9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2edef394-50b5-411d-aec7-7efcad902236">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/993babc1-1608-4825-8424-79fe16fc62da"/>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <dc:identifier>B01A</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b023d55-0cc2-48b7-9b99-5f59d9af1fb7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6022de8-931d-45a7-bd52-660c833943ce"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41e6024a-01b6-4b6c-bb27-79a27e961cef"/>
    <dc:identifier>DB02701</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c475fa2c-64d1-4091-9f49-0ca991b3ed67"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6db69c20-daff-42ad-97de-7be560372ae9"/>
    <rdfs:label>Nicotinamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/898f3080-1d82-407b-96d8-9f4e03883e12">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7f3bb1f-3fac-4246-8772-406819f14a9b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28a04214-df68-465f-b4f8-043b143ff087"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d8ae4b-a52b-470e-bb7b-7c162ccb0b32">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002900</dc:identifier>
    <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4574a0b3-8cee-4e73-86ff-27fef8dc460e">
    <rdfs:label>High α-ketoisocaproate level</rdfs:label>
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46668266-6007-48c7-b426-0e4234803f72">
    <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/311f7a89-1cbc-4d0b-87e4-d391d279bdfb">
    <dc:identifier>HP:0002509</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>limb hypertonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b89da4db-e62b-46f4-a7b7-0cd7fc6d9e51">
    <dc:identifier>HP:0001298</dc:identifier>
    <rdfs:label>Brain pathology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d9f3b5a-b2f8-4d52-97b8-2ff8e4ea39af">
    <rdfs:label>Eltrombopag</rdfs:label>
    <dc:identifier>DB06210</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9201a68-f0b5-4e81-9b6c-ce3cf57717a2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e49c447-72c9-4da9-9cac-650e67b3136c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40a5ff72-c7cd-42c3-84b9-f4c8e85ff00c"/>
    <rdfs:label>Topiramate</rdfs:label>
    <dc:identifier>DB00273</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52cfa7ab-e677-4ac6-93da-3750d77a4e93"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44001326-1038-4cbb-a604-6a4c64bff88c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d8a4e80-fecb-4e89-95c3-d3b3edb0c52e">
    <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7af185da-c65b-498a-b9de-b5c84e485253">
    <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aae94b20-415b-4cc1-8bf0-a55424e4e77a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1206689-1291-4c04-8ad5-e9ec968d6b48"/>
    <rdfs:label>Gene Therapy ??</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/357904aa-35ec-4515-975f-4b62d46bad99">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71cbc3b3-7367-4061-850b-b1b9d78b5bc4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f8ce8a4-f351-42c2-b2cb-6c14e44c1ed4">
    <dc:identifier>DB01611</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4460f6f8-aa08-45dc-b397-2f9d7958c15c"/>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/434275c8-72e8-490c-8f4d-eb048233694b">
    <rdfs:label>Etretinate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/349eaae9-12f4-47c0-ad3e-4d04f5ede1dd"/>
    <dc:identifier>DB00926</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8ce56d4-7b5a-4f86-88c6-3b56b8512465">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
    <dc:identifier>HP:0012130*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa80325a-7838-4e27-a629-3af43baaf297">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
    <dc:identifier>HP:0010473</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72c695c1-da17-413d-a164-829166751ac0">
    <dc:identifier>DB00742</dc:identifier>
    <rdfs:label>Mannitol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92ff6092-7f7b-4fb9-9f0f-263e88c1b31c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3a162d3-6978-4829-b7aa-ac1b2fac1ba4">
    <dc:identifier>CHEBI_15724</dc:identifier>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae614412-c78b-464d-b0fd-7f00e453bebf"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7673cae4-387f-4390-ad64-89033f26a680">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
    <rdfs:label>Abnormal circulating GH level</rdfs:label>
    <dc:identifier>HP:0032367</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53b59138-a747-46b9-b179-781bbbf01171">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19aeb085-8434-4f8c-8eac-db63c29cb8c2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/373bdf97-f8d0-46f4-a007-803282beff0e"/>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <dc:identifier>DB00115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1cdeb84-82cf-4052-8f66-57e05cfbbc0a">
    <rdfs:label>dysarthric speech</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0be20901-8de3-4ade-a0c9-fd5005795219">
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5f68eee-eda4-460d-87e0-d52783884a9c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71dce0c7-b888-4c5c-b0dd-11ab07c0af6b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Imapired muscle function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cf840c6-bc4d-44fd-8664-30892f085da1">
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12393f3b-3373-4917-bb46-0869d7d7d13d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3466f49b-e8d8-4e63-b8e6-fe3210b058c6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f5b31da-2d87-42f6-b101-3880740f10fe">
    <rdfs:label>Deferasirox</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ca63edc-d224-4163-b444-5d2bd9488db8"/>
    <dc:identifier>DB01609</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a74a7203-8414-4396-a06a-6916e7594cc7">
    <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <dc:identifier>HP:0000488</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97b62666-7b14-42d0-b5a6-d9cdfa0916d5">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0001288</dc:identifier>
    <rdfs:label>gait abnormality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5f2b59c-9859-43bb-9e90-11cc8358abe3">
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:label>Hyposthenuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48968ad7-3df7-4dae-8ef3-5139bf917304">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f70b428e-557b-46b6-9c17-4a13bf4dc35b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88085a1d-52b8-457e-93fd-583c478b06dd">
    <rdfs:label>elevation of creatine kinase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003236</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a9eac6e-4a47-40c0-ae54-5c54e436c9ef">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
    <rdfs:label>neutropenia</rdfs:label>
    <dc:identifier>HP:0001875</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb4b1ca1-7957-4644-810d-c3c036c2006a">
    <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005978*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66c3e9f4-d62c-40e5-b56f-ba82d2e40e6f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <rdfs:label>Niflumic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7f5d3d2b-c41c-46de-99ed-d067ff1ff632"/>
    <dc:identifier>DB04552</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48369725-0f66-4918-9c17-83e583e6d109">
    <rdfs:label>tissue damage</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3de019c-42a6-4a7b-9c26-642a9628cc26">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e7c75f4-4ec7-4ee2-bc10-3ee41bec78fe"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f9194f3-dbb9-40b9-a3bd-34b4fa811495">
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:label>low hb level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15c372c6-0f86-47ec-ab02-2430140a0365">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca21d37d-dfcb-4b38-b299-9f7d44507361"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <rdfs:label>Chloral hydrate</rdfs:label>
    <dc:identifier>DB01563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a60fbdc-85a0-4538-85d1-c278c0c25b49">
    <rdfs:label>Deferiprone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4732eabe-b58d-40e6-b16d-3cb0dd06c651"/>
    <dc:identifier>DB08826</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54657026-3241-49e6-b073-874e7d2e87c7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96ff9f4b-827b-41f5-8fbd-0c4323fd7f0d">
    <dc:identifier>DB00808</dc:identifier>
    <rdfs:label>Indapamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c37cc9b4-57e7-4858-bde7-a60fd6ab95af"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5c83ac7-4e88-42d6-b741-90c24d49f365">
    <dc:identifier>DB00348</dc:identifier>
    <rdfs:label>Nitisinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2edb1724-9805-4697-b61a-7825882362cf"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9315bf50-b5a3-4d0c-94cf-3bbe4680814b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c11908e-e18d-4ca1-b20f-827b206b576f">
    <rdfs:label>axial hypotonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0008936</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38cb2b1c-89e3-48a3-a030-04488ccd6f79">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0000969</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>pitting edema</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f1452d9-d411-49ef-96e2-a55b29605891">
    <rdfs:label>Fenofibric acid</rdfs:label>
    <dc:identifier>DB13873</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19cb4e7a-d6c5-4313-8f32-cb1e83108dc8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/097b9286-324a-4012-89de-81d94dcd6859"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cf386a6-6791-46e0-ad5c-b9bcbc97991d">
    <rdfs:label>Impaired nerve conduction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <dc:identifier>HP:0040129</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2ffc87f-7cf6-48de-b098-ce4fd10bdf5c">
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7309ab27-2b67-45a8-93e2-633fcc189f99"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e204a313-32f9-4737-b5d2-787f0be53eed">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74a5ccf3-9902-4bdf-8d14-c80bf34b9924"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/824a5ca8-d592-4b44-9e43-ef02b47a6438">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c8a77ab-aa11-447c-8d37-a5f7a0090833"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3012f613-cd62-4735-9581-78887ed67a7d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b6ca70f-aa4a-4db2-a3d0-66974d8756f2"/>
    <dc:identifier>DB00030</dc:identifier>
    <rdfs:label>Insulin Human</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d5f50ee-0802-4097-b9ed-90d6433afe8f">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad86a3cb-dc10-4e99-bce7-35306c7d5a02"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
    <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
    <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
    <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5ec0d32b-7895-4f5b-9607-e120a0e64ae8"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d358040-2bef-4f98-9a63-e7ce8427f08d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87c30ec1-13bd-48bb-89c4-1a5e3f86264f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d7db588-e5d6-4f5e-9244-7d9d05d14b71">
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6484e092-33d6-480a-bb63-18b40a32aae8">
    <dc:identifier>HP:0012048</dc:identifier>
    <rdfs:label>oromandibular dystonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7338adff-5692-4b1d-a36c-af16accc218c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5a62547-1e3a-443e-b583-e547c5e0d6ae"/>
    <rdfs:label>Ad-mG6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb42e556-cfc0-483f-abd5-1d54715592c9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
    <dc:identifier>HP:0100529</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3cd7b14f-ed95-4c31-8161-abc82aa6cfef">
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87d979f0-bf24-442c-8dc3-10d7101db7e9"/>
    <dc:identifier>DB03256</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/210f4e8a-e70a-4038-a1e5-760bedd58510"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ecc8d8a-f2c1-4cf0-b031-e76bd6077ff8">
    <dc:identifier>HP:0000992</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>skin photosensitivity</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53411398-b503-4a01-8009-02f7f5da8617">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>acidosis</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31fb932d-ccec-4e47-826c-92c5083115e4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/707af5af-f4c5-44ed-bb7f-db3c8aaf8bbd">
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45395689-ab14-49b7-9e43-be096b1d4a39"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01286287-ea8f-47db-a543-9f66d71debee">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <dc:identifier>DB00129</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc6f4886-0ee6-4ddb-a964-4fd17857aace"/>
    <rdfs:label>Ornithine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bebe5346-772e-4a4a-a598-f1810673373e">
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89368a4f-a9a3-48c8-a579-4a8184a90dda"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a981641-0af2-41d3-834b-3f211332ded9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3dbc1c7d-a561-4351-93b2-f6e848ee3543"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40f13438-0ae3-4861-8058-84d233d52ed8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4f45fe4-0632-4e67-9fe4-6755a19cd115"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ba5bdf8-60ae-496c-9b13-f454261fb23f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ebe3c66-a551-4940-a17f-cf4177500f94"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45fe2ba9-6997-483b-b6ae-66a19bd053cf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d05db93d-7628-47d6-86f2-1c9beb8d3bd1"/>
    <rdfs:label>Methylene blue</rdfs:label>
    <dc:identifier>DB09241</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23926b59-fde3-49d8-9957-2d1d95f0a99f">
    <dc:identifier>HP:0011031*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/806e584a-d01e-47a6-a2b0-28462f25ee5e">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <dc:identifier>HP:0002155</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33e3012a-9841-4f91-a1ee-47d73b70b43c">
    <dc:identifier>DB08875</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/152ef11d-2bc4-4cc3-b74f-07f50f5d2d6a"/>
    <rdfs:label>Cabozantinib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/487ff6d7-0653-4c0b-8165-57c145bb3fbe">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05f72ca3-494e-4abd-9184-fd102457cb39"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef345ff1-7a3e-420d-8237-4efe303938db">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e523d46a-92e7-4ba6-813b-78c33f9fa45d"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9993a36a-de05-4bbc-8276-ad1e7560fdf1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b54d425a-746a-480f-8157-9302dc167899"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ee249fd-a962-42cd-8977-4ba3c49f0c87">
    <dc:identifier>DB00028</dc:identifier>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb6438d8-6938-425b-ba83-e3addee96a2e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1938a0b7-c97f-4276-af84-43479537320a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21e40347-72c8-44cb-bdef-24a5c0216658"/>
    <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
    <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
    <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f58035b-c316-4e3b-b307-a9e312d3b767">
    <rdfs:label>Lack of energy</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <dc:identifier>HP:0012378</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7290e06-1b30-4d9e-ab08-94295da7d94d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a89b3c7d-46bb-4b76-bd57-69e563b8b088"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dc6a930-ce0b-4b39-bd98-4da3598f8e1b"/>
    <rdfs:label>Erythropoietin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <dc:identifier>DB00016</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10b64356-fdfc-4787-883a-9280555115a3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d0c163a9-6df0-4779-b03e-2e31f2d6e91d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ec5a4dd-69ae-46ed-bb0d-f479af3018b4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb79b0d5-8740-4e2d-b543-b2da99514244"/>
    <rdfs:label>Rilonacept</rdfs:label>
    <dc:identifier>DB06372</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/947ce8b3-f319-43b2-8994-54c406d1d877">
    <rdfs:label>Selenium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/402f7a7d-c0e0-456b-8f37-76d824e77a0f"/>
    <dc:identifier>DB11135</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6cbd54f1-15c0-4d37-82ab-163595825523">
    <dc:identifier>DB03485</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbddbc3f-8056-4ef4-9d06-1584dba7c5d3"/>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ed9de0d-6bc3-4e86-91f3-2a0c8593f61c">
    <rdfs:label>low exercise endurance</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7134f16d-e1ee-4691-8556-e174bb40ea58">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31a9268f-6980-4495-a981-277e41d2ae57"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28b79bfc-7671-41da-a307-9939db10811d">
    <rdfs:label>frequent hospital admission</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27e8b6d8-a63c-4cb5-b773-b68f5061e0ef">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b1028522-c742-4caf-a0d3-b8fa5965f8c3"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/254b0f28-92cb-4ec1-85e9-862f74f5660b">
    <dc:identifier>HP:0025034*</dc:identifier>
    <rdfs:label>erythroid progenitor depletion</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f8b362a-704c-4cd0-8708-6d7ee4cbc5d6">
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <dc:identifier>DB14751</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7300c2c1-0d39-4940-940e-f18713ab1a98"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4cb54174-680f-4ba3-bd75-d5cd9d14157c">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/410e777d-521c-4eb6-a758-ef84becd563c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f161b79a-291f-4a75-90f8-01b90144a3a6">
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bd210e3-fefa-454f-996f-7746beff595e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8ff800d-6e94-4c55-a029-d72cc1c5296c">
    <dc:identifier>(DB00440</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6c84218-2cac-4899-a422-9fd791bee06d"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8e84724-2189-44a0-b52e-fd7eaecb3944">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb3b14f7-d0e0-4909-a398-e1ae6e10517a"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05058665-f1e8-4328-a907-b0efd8444ddc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d5f4c9c-6da8-49fb-beb7-6c85b6624de1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca2a6be0-299e-44b1-a45e-571e24b16556">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <rdfs:label>Glutathione</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a0bb546-8d01-44f6-a179-a485254e75ed"/>
    <dc:identifier>DB00143</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdb7372c-b477-4bdd-a449-a1e18e886b43">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lipid peroxidation</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4db172a0-0b66-4e0e-96b7-6c9187c4ed29">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/daeb618d-5ea0-43d5-9137-5b11a11c4759"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccdd5eb3-d425-4819-a3e1-ad45bdff5ab2">
    <rdfs:label>Focal seizures</rdfs:label>
    <dc:identifier>HP:0007359</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3149ed75-7985-4498-b709-82668f05378a">
    <dc:identifier>HP:0001251*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22e97e22-6864-4940-8b80-8a5b2222c185">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21fe2243-f66e-4b9c-bf58-6a915c4d9fef"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/540099ae-808d-41ae-9ad0-6c6a34817700">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0774c0bf-451e-4af8-8cf1-5d01f612fc2c"/>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
    <dc:identifier>DB14933</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/efcdce22-a1e3-4249-b8e3-6457c70a20e3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e50745aa-e753-484e-ab8f-6b7be7724a07"/>
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79defd26-86c0-4b53-8564-c6713cf8720d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/971f7365-11cf-42d0-97f6-531c91afd5e2"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/253c3e50-67bd-47d9-981e-4f3c82008df0">
    <rdfs:label>defect in eye contect</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <dc:identifier>HP:0000817</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/059baf88-2b46-4abb-aa06-21d071b1906e">
    <dc:identifier>C09C</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8db3656-c3ef-4c47-9cd3-216f4e236ae8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b7f1fcc-c96b-439c-8e8f-433aa74bddee"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58ed4778-4d5c-445b-8e27-f6505cf3be3a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bacf3a2b-5290-4f58-8fb7-a4dc75cd2455">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0045082</dc:identifier>
    <rdfs:label>Low lean body mass</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0aaac067-d14f-4a6e-91e5-8e8e5384aeaf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6ffed0b-9879-444b-90e4-01c970758ee5"/>
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4870f86-2458-4efb-abd9-c22e447c5dce">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <rdfs:label>speech impairment</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0002167</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30428e82-dc5a-43dc-aaa3-cb1f418466a7">
    <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0003541</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f587e029-1f0e-4e87-a783-fa738e2e9359">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f64150f8-7a6c-452a-8fce-0412d94b3556"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/156ddb54-5dca-49a4-86e6-a15f8d32c52c">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0006530</dc:identifier>
    <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb2b47a7-c0d2-48fc-9cb0-d975e7e4d71a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c936c70a-f645-430c-b4a2-385eed945e37"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f303bc6-de43-4fde-8fe5-37771802150c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ffa9c4d0-56fa-44c4-a83a-a0880cf81b41"/>
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/38bb610f-1569-4e5e-9a31-bbc6fb8e5e2d">
    <dc:identifier>H02</dc:identifier>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b018e78-9adb-4d1c-a991-ea3e4beda783"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5ae967f-4e3b-4a54-8347-8ccb04d5aed9">
    <rdfs:label>Acidemia</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/b01f18fc-c924-47b5-9782-21279ccf83e0">
    <rdfs:label>functional complementation of a genetically defective protein+direct complementation of a genetically defective protein</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe6930a5-cd47-429e-8dee-79bab929b2f9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e26be1b8-15cc-405a-9fca-c01d0eff8f4e"/>
    <dc:identifier>DB03614</dc:identifier>
    <rdfs:label>Methylcobalamin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb7cde19-d899-4a38-8ebd-7cbb7c622b91">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <dc:identifier>HP:0002180</dc:identifier>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e3ad3d7-9d7b-4a02-bb7b-41f6bfea1d60">
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
    <dc:identifier>HP:0012363</dc:identifier>
    <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fc664ac-9c18-4ee2-bb3c-5c3f10d35e02">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84bc73fe-5adb-4fc3-9ee6-69d3b0c1abf0"/>
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
    <dc:identifier>S01BC</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ffae80b-fbcd-470a-9348-702c77ae3734">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:label>High calcium excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002150</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1b46f25-00f2-4eb8-ab4f-1d910899dd47">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97e6cc28-f8d3-4d0b-b099-de0cce802172"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7b4d948-3694-4500-824a-e7c852dfdc42">
    <rdfs:label>GNE gene lipoplex</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ca324de-6787-40de-81f5-04aa020085e6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31d10fc1-477f-4b7c-8b0d-693252c9a7ca">
    <rdfs:label>Hemin</rdfs:label>
    <dc:identifier>DB03404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f4799bd-506b-4c30-980c-ecb27361e9aa"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5803b138-d04f-45d0-8d88-66c44fa35d4c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0186e51-6ce8-4524-ad4c-011ac894dd0e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9525309-65f6-4c58-9f79-441a8119780e">
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70993780-3208-4a52-bef3-4f13ceb72672"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d4b85b2-3953-49a1-a04e-513cf996297c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/807994c1-bda1-4754-916d-1ebe332e1240"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c9cf5b2-13e3-4a26-8b51-a0f63fa69759">
    <rdfs:label>Increased total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1898fe5f-9c66-4bb5-a019-72bfc4f682ae">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc66f0ed-de35-423d-931c-179fdca15976">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4100f22b-ee85-495b-a288-fc8d6f39dce8"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac7b166a-83ea-4e85-b27d-51c4fb2478a2"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/699a8c55-bd58-486e-b14e-784dda70787d">
    <dc:identifier>DB14476</dc:identifier>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/357ef4e6-a7e1-4de3-909d-63aa873c857a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6e369d3-d141-481f-bfa4-212b194df3b1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8caa2f4a-ca5e-4417-a19a-e6e3434501f8"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
    <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
    <rdfs:label>SALLA DISEASE; SD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ce0cca37-7447-4f92-a723-f83b114b5139"/>
    <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/2cfc12e5-5806-4730-bf41-c38892776126">
    <rdfs:label>symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af07f989-695a-410c-90a5-41ae77fa1e96">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dda3f269-ecf2-4e43-9e28-d9e1336a1b5d"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6081eae1-4da3-445e-88cb-09e08389f2df">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9629ff0f-4245-4908-9821-6177c667c3ca"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6684e63e-58bd-4d13-bd5d-8d335726c8e7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/38c08611-f032-412a-935d-a6e358b66d31"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/afea946d-1beb-499f-9dd0-4195b3bdf186">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3523a71-e407-4ef7-bc5f-0a907603cc89"/>
    <rdfs:label>AAV-GLUT1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/727efb21-fb72-45ef-9cc7-01c8b5437468">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
    <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64f6bf42-ea1a-48fc-a56e-e3665f2b78da">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e32c92db-90e5-45f2-84c2-cddf08168527"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8906584e-899a-41d1-b5b9-f1f366ae7ef7">
    <rdfs:label>Estradiol</rdfs:label>
    <dc:identifier>DB00783</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/129b488c-a9e9-49b0-8567-add99f0a3074"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d46a7563-95bd-4c13-be7a-a84250b3d786"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/272b6dff-53c7-4deb-bc95-d56e6b2f9c87">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd45e18f-1f31-4714-8d92-6c6c4772544c">
    <rdfs:label>Protein oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b02d5c04-a5ee-414f-a885-a66f819e6fe4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1236c634-0010-4f5f-b240-e17387e23198"/>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7cb4e61-4e40-4c43-bf1a-ca5788bcd8a1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <dc:identifier>HP:0040129</dc:identifier>
    <rdfs:label>Defected mucle plasma membrane</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a603d56a-54df-4c45-8b8e-48fd533c5c1b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3bfd16d-e8cb-44ab-ab07-e2ee03c86b16"/>
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ddda299-1ff2-44c2-aead-67706f8e1b87">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00f713ba-3904-4923-8e43-f89a414b6947"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf028570-87f2-45da-bea8-433697a1d187">
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66897cf6-2f0d-47cc-9485-9942fdadb1fb">
    <dc:identifier>DB03904</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01676cdf-33e8-4942-873c-e666c55ad794"/>
    <rdfs:label>Urea</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/fcc48fc7-c496-4200-a53c-1a77f2c7f711">
    <rdfs:label>Functional complementation of a genetically defective protein</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3cb6a6dc-a608-4eb5-9ec2-93b1677f6f22">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fb9c390-58be-462c-a552-e63929312a7b"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e1184d4-3961-4c2b-ab86-88360bda5743">
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>decreased visual acuity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/375684ed-26e7-4aa3-9fe1-5136bf858378">
    <rdfs:label>infertility</rdfs:label>
    <dc:identifier>HP:0000789</dc:identifier>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddf21aab-e6b4-4c83-a56a-dd5b0d996d14">
    <rdfs:label>Elevated long chain fatty acids</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56baeb13-34a3-4ed1-a33d-5ff036a877c8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e771f9cd-9478-4887-b705-85c7fd39f735"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a2c48a6-ac41-4db9-b91b-8cc87abbf869">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43069fea-6a5b-44e8-9a75-d30534da85af"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca5d72c7-dd7b-4c0c-9075-21b76ca049cd">
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8563d67d-6a18-4a9b-9c72-31a014c31827"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/148377f1-66eb-4d3f-9549-8bd459adb92a">
    <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <dc:identifier>HP:0002069</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b53f80c4-d389-47c5-a7e6-0204295e71dd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/940c298b-1ad1-4c22-96fa-db64ccc2487d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d93408b-a14d-45a4-b770-30e46ac93257">
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1bd1476e-0bf0-41e0-9c96-7d42f4a52cec"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b0419f6-38fd-4c41-a8bd-749d5c322230"/>
    <dc:identifier>DB06720</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbc83946-a599-4489-b4ba-bfb95e78d242">
    <rdfs:label>Liver dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001410</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3454844b-a95d-4631-854b-ac6f0ed3b006">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c7478ad-47cc-446f-826d-5e788e27f075"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/19bc2698-af79-407b-a5cc-653688ec3892">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92218fb7-375c-430a-82c9-971668de0c7d"/>
    <rdfs:label>L-Glutamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1929261e-fa4a-4eb8-9027-5d09bb4ca6cc"/>
    <dc:identifier>DB00130</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74970341-42d1-44ee-8ce5-286314dc1a69">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <dc:identifier>DB01015)</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6c84218-2cac-4899-a422-9fd791bee06d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3d710f0-be6d-4a08-9887-3a4931a5b9bc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <dc:identifier>DB00679</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca21d37d-dfcb-4b38-b299-9f7d44507361"/>
    <rdfs:label>Thioridazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80759576-6cc3-4cb4-b506-7ec73b371c0f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfd7d7d2-0ac1-438f-a9a2-d95c600e04e5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebcfaa48-94e4-436b-9e12-cb605178cc01"/>
    <dc:identifier>DB01151</dc:identifier>
    <rdfs:label>Desipramine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/267826b3-d5c4-4003-a6f4-351ff444b82a">
    <rdfs:label>activity modification of a genetically defective protein by transcriptional or translational modification</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b217d952-f590-40d3-90f6-18116a8e04b1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebec3f6b-f3c7-439d-92bf-7b87bf7b213c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8d09e85-a690-4154-9025-0af76b2567ce">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0010472</dc:identifier>
    <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
    <dc:identifier>EC:0007121</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
  </ddiem:Evidence>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfffd107-d6dd-4f22-9a49-882416c9e9b7">
    <rdfs:label>Abdominal pain</rdfs:label>
    <dc:identifier>HP:0002027</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4983c93e-e769-4c43-a0aa-c426bb67256b">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd752ed9-e27c-4289-b327-78171a3570dc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57dfd0c7-84c0-4426-a1f5-7ae0b60964ea">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49942e04-f364-4e47-8574-416e3d5981e0"/>
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/165b6b09-fc5d-4938-97af-1769659fecee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b105fd8-1c3d-48b6-baa4-e27a7a02c7f7"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b0f8e54-60e9-4b2b-be84-c200c79e23de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c798565-ed80-483d-a892-65e56fd3f16b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7b527ba-b0a8-46b1-a246-10df229e41c6">
    <rdfs:label>Low 5‐MTHF level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa911a6a-2687-4a09-bb18-b0a46036e5b8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/162fdc69-7ffb-4d70-9991-411d53201b36"/>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ca0dfbd-ca3d-432c-a018-4ff612eaa409">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb161655-3b0b-4af6-a61b-18d6fe05e3f2"/>
    <dc:identifier>DB00700)</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f677b5a-6ca0-4461-a595-69c46966d53c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2648405a-0049-4c64-9ddf-b61ef25565ee"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2a7c57c-eab8-405e-8eb3-8412bad9118e">
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59e02844-e7e7-4c25-abed-cee78a8fd88b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e12c1b92-1abd-4aaf-b5f9-c02f69b569f1">
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b55db75-5c38-4130-b82b-913eaeeb53c6"/>
    <dc:identifier>CHEBI_25548</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/278f208d-f5c3-4ffb-93f0-041001d61ee8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42bd695b-9133-4b60-b6d3-bc07c5a0f870"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fe74d0c-aa4b-48da-9cc2-21a481143472">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6c3cf4e-bd4b-4b60-96d7-04bc2e182b22"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/962fdfe0-71bf-4f3e-89af-8cf2fa3f818d"/>
    <dc:identifier>DB00915</dc:identifier>
    <rdfs:label>Amantadine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96155a37-a01e-4b4e-b971-691923846e1c">
    <rdfs:label>GNeo-IDUA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/908ddbce-f483-4a05-8a58-9d02c42d53cb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea2da973-054d-46f4-a9b2-6d14c4b19e95">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0a8569d-6fd6-4dea-b2ee-8c315b33444c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56327c8b-c5fc-4c2d-8f5b-56b6d3303282">
    <rdfs:label>Central nervous degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007009</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91876e16-60dc-444d-91b6-b4543534f8a6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0121293a-14ec-41c1-a250-311f8e3724f2"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21086a03-de43-4c78-901b-80ca79f76073">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/111ea73d-28af-4f84-8cb8-8b811cc36cba"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/973c5339-2d59-47c6-a061-8f675756c975">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6739fb6-52cf-4fad-be4f-e64f19140adb"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/620e3aa0-8eb9-4daf-a906-b04015ea174b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17493778-1c5e-4126-a4ba-0dbb8a02e955"/>
    <rdfs:label>leucine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb675716-38e6-4bc1-b7bf-8cf764a39f63">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6eb03f68-1947-4151-9e01-7837d63f8f47"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9976154b-9d74-4e6e-bd43-a1dd1866ce03">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d04b7bb2-caf5-49b2-bf67-fae7560009fb"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e83a583-48a3-4a43-a220-19c94843cba2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a181747c-d756-4d30-b078-9339bc69e903"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95093a0b-060a-4678-bb95-c76cc8130e0c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fd8e695-282e-4dfd-bf40-caf499943019"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c84068ad-6232-44f6-a0db-0d2b90f86053">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37a488d3-be80-45f8-aae5-e8640ce6e7d8"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7de1c75-81d0-49a7-919b-6d87ed252906">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fec46c38-a6d0-472d-a9dc-f78abfb32838"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/361329f4-3e2c-411c-bfa0-599b742d5f20">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6e8c2ee-7fc5-4e96-857f-411a87a6fc73"/>
  </rdf:Alt>
</rdf:RDF>
